

Appendix A Search Strategies

OVID-Medline

June 28 2010

1. dysthm*.tw.
2. (subclinical adj2 depressi*).tw.
3. (subsyndromal adj2 depressi*).tw.
4. (subthreshold adj2 depressi*).tw.
5. (subdiagnostic adj2 depressi*).tw.
6. Depression/
7. depressive disorder/ or depressive disorder, major/ or dysthymic disorder/
8. or/1-7
9. serotonin uptake inhibitors/ or citalopram/ or fluoxetine/ or fluvoxamine/ or paroxetine/ or sertraline/
10. (citalopram or celexa or cipramil or dalsan or recital or emocal or sepram or seropram).mp.
11. (escitalopram or es citalopram or lexapro or cipralext or esertia).mp.
12. (fluoxetine or prozac or fontex or seromex or seronil or sarafem or fluctin or fluox or lovan).mp.
13. (fluvoxamine or luvox or fevarin or faverin or dumyrox or favoxil or movox).mp.
14. (paroxetine or paxil or seroxat or sereupin or aropax or deroxat or rextin or xetanor or paroxat).mp.
15. (sertraline or zoloft or lustral or serlain).mp.
16. ssri?.mp.
17. selective serotonin reuptake inhibit*.tw.
18. symbyax.mp.
19. or/9-18
20. Drug Resistance/
21. treatment failure/
22. Retreatment/
23. ((difficult or hard) adj3 treat).tw.
24. augment*.tw.
25. nonrespon*.tw.
26. non-respon*.tw.
27. switch*.tw.
28. ((insufficient or inadequate or incomplete) adj3 respon*).tw.
29. (ssri? adj3 (resist* or fail* or respon* or refractory)).tw.
30. (partial adj3 respon*).tw.
31. ((combination or adjunct*) adj3 (therap* or drug? or treat*)).tw.
32. ((treat* or therapy or drug) adj4 (resist* or fail*)).tw.
33. ((treatment resistant or refractory) adj3 depressi*).tw.
34. or/20-32
35. 8 and 34
36. 35 or 33
37. 8 and 19
38. 36 or 37

39. *depression/ or *depressive disorder/ or *depressive disorder, major/ or *dysthymic disorder/
40. or/1-5
41. 39 or 40
42. 5-Hydroxytryptophan/
43. phototherapy/
44. light therapy.tw.
45. exp Exercise/ae, th [Adverse Effects, Therapy]
46. exp Exercise Therapy/
47. exp Acupuncture Therapy/
48. exp Massage/
49. Relaxation Therapy/
50. exp vitamins/
51. Hypericum/
52. john* wort.tw.
53. deplin.tw.
54. methylfolate.tw.
55. Folic Acid/
56. S-Adenosylmethionine/
57. "SAM-e".tw.
58. exp Fatty Acids, Omega-3/
59. Cognitive Therapy/
60. Crocus/
61. Tryptophan/
62. exp Inositol/
63. or/42-62
64. 41 and 63
65. (harm? or adverse or "side effect?").tw.
66. (adjunct* or augment*).tw.
67. 65 or 66
68. 41 and 67
69. exp *antidepressive agents/ae, to [Adverse Drug Reaction, Drug Toxicity]
70. 68 or 69
71. 38 or 64 or 70
72. animals/ not (animals/ and humans/)
73. 71 not 72
74. (comment or editorial).pt.
75. 73 not 74
76. review.pt,sh.
77. 75 and 76
78. meta-analysis.pt,ti,ab,sh.
79. (meta anal\$ or metaanal\$).ti,ab,sh.
80. ((methodol\$ or systematic\$ or quantitativ\$) adj3 (review\$ or overview\$ or survey\$)).ti.
81. ((methodol\$ or systematic\$ or quantitativ\$) adj3 (review\$ or overview\$ or survey\$)).ab.
82. ((pool\$ or combined or combining) adj (data or trials or studies or results)).ti,ab.
83. (medline or embase or cochrane).ti,ab.
84. or/81-83

85. review.pt,sh.
86. 84 and 85
87. 78 or 86 or 80 or 79
88. 75 and 87
89. 77 not 88
90. 75 not 89
91. limit 90 to yr="1980 -Current"
92. limit 91 to english language
93. 91 not 92

OVID-Embase

June 28 2010

1. depression/ or agitated depression/ or atypical depression/ or dysthymia/ or endogenous depression/ or involuntional depression/ or major depression/ or masked depression/ or melancholia/ or "mixed anxiety and depression"/ or "mixed depression and dementia"/ or organic depression/ or reactive depression/ or recurrent brief depression/
2. dysthm*.tw.
3. (subclinical adj2 depressi*).tw.
4. (subsyndromal adj2 depressi*).tw.
5. (subthreshold adj2 depressi*).tw.
6. (subdiagnostic adj2 depressi*).tw.
7. or/1-6
8. serotonin uptake inhibitor/ or citalopram/ or escitalopram/ or fluoxetine/ or fluoxetine plus olanzapine/ or fluvoxamine/ or paroxetine/ or sertraline/
9. ssri?.tw.
10. selective serotonin reuptake inhibit*.tw.
11. (citalopram or celexa or cipramil or dalsan or recital or emocal or sepram or seropram).mp.
12. (escitalopram or es citalopram or lexapro or cipralext or esertia).mp.
13. (fluoxetine or prozac or fontex or seromex or seronil or sarafem or fluctin or fluox or lovan).mp.
14. (fluvoxamine or luvox or fevarin or faverin or dumyrox or favoxil or movox).mp.
15. (paroxetine or paxil or seroxat or sereupin or aropax or deroxat or rexetin or xetanor or paroxat).mp.
16. (sertraline or zoloft or lustral or serlain).mp.
17. symbyax.mp.
18. or/8-17
19. Drug Resistance/
20. exp treatment failure/
21. Retreatment/
22. ((difficult or hard) adj3 treat).tw.
23. augment*.tw.
24. non-respon*.tw.
25. nonrespon*.tw.
26. switch*.tw.
27. ((insufficient or inadequate or incomplete) adj3 response).tw.
28. (ssri? adj3 (resist* or fail* or response or refractory)).tw.

29. (partial adj3 respon*).tw.
30. ((combination or adjunct*) adj3 (therap* or drug? or treat*)).tw.
31. ((treat* or therapy or drug) adj4 (resist* or fail*)).tw.
32. ((treatment resistant or refractory) adj3 depressi*).tw.
33. or/19-31
34. 7 and 33
35. 32 or 34
36. 7 and 18
37. 35 or 36
38. *depression/ or *agitated depression/ or *atypical depression/ or *dysthymia/ or *endogenous depression/ or *involuntional depression/ or *major depression/ or *masked depression/ or *melancholia/ or *"mixed anxiety and depression"/ or *"mixed depression and dementia"/ or *organic depression/ or *reactive depression/ or *recurrent brief depression/
39. or/2-6
40. 38 or 39
41. exp *side effect/
42. (harm? or adverse or side effect?).tw.
43. 40 and 42
44. 41 or 42
45. 40 and 44
46. exp *antidepressant agent/ae, to [Adverse Drug Reaction, Drug Toxicity]
47. 45 or 46
48. 5 hydroxytryptophan/
49. exp vitamin/
50. exp Fatty Acids, Omega-3/
51. exp acupuncture/
52. exp exercise/
53. massage/
54. Relaxation Therapy/
55. phototherapy/
56. light therapy.tw.
57. Hypericum perforatum/
58. methylfolate.tw.
59. folic acid/
60. S-Adenosylmethionine/
61. SAM-e.tw.
62. (cbt or cognitive behavior?r therapy).tw.
63. cognitive behavior therapy/
64. inositol/
65. saffron/
66. crocus/
67. tryptophan/
68. exp diet therapy/
69. or/48-68
70. 40 and 69
71. (adjunct* or augment*).tw.

72. 40 and 71
73. 37 or 47 or 70 or 72
74. (editorial or note).pt.
75. 73 not 74
76. limit 75 to human
77. review.pt,sh.
78. 76 and 77
79. meta analysis/
80. meta-analysis.ti,ab.
81. (meta anal\$ or metaanal\$).ti,ab.
82. ((methodol\$ or systematic\$ or quantitativ\$) adj3 (review\$ or overview\$ or survey\$)).ti.
83. ((methodol\$ or systematic\$ or quantitativ\$) adj3 (review\$ or overview\$ or survey\$)).ab.
84. ((pool\$ or combined or combining) adj (data or trials or studies or results)).ti,ab.
85. (medline or embase or cochrane).ti,ab.
86. or/83-85
87. review.pt,sh.
88. 86 and 87
89. or/79-82
90. 89 or 88
91. 76 and 90
92. 78 not 91
93. 76 not 92
94. limit 93 to yr=1980-current
95. limit 94 to english language

Ovid-PsycINFO

June 28 2010

1. major depression/ or dysthymic disorder/ or endogenous depression/ or reactive depression/ or recurrent depression/ or atypical depression/ or "depression (emotion)"/
2. dysthm*.tw.
3. (subclinical adj2 depressi*).tw.
4. (subsyndromal adj2 depressi*).tw.
5. (subthreshold adj2 depressi*).tw.
6. (subdiagnostic adj2 depressi*).tw.
7. or/1-6
8. ((difficult or hard) adj3 treat).tw.
9. augmentation.tw.
10. nonrespon*.tw.
11. non-respon*.tw.
12. switch*.tw.
13. ((insufficient or inadequate or incomplete) adj3 response).tw.
14. (ssri? adj3 (resist* or fail* or response or refractory)).tw.
15. (partial adj3 response).tw.
16. ((combination or adjunct*) adj3 (therap* or drug? or treat*)).tw.
17. ((treat* or therapy or drug) adj4 (resist* or fail*)).tw.

18. or/8-17
19. 18 and 7
20. treatment resistant depression/
21. ((treatment resistant or refractory) adj3 depressi*).tw.
22. or/19-21
23. cognitive behavior therapy/ or cognitive therapy/
24. phototherapy/
25. "hydroxytryptophan (5-)"
26. light therapy.tw.
27. exp exercise/
28. acupuncture/
29. massage/
30. exp relaxation therapy/
31. exp vitamins/ or vitamin therapy/
32. hypericum perforatum/
33. (S-Adenosylmethionine or SAM-e).tw.
34. folic acid/
35. fatty acids/
36. saffron.tw.
37. inositol.tw.
38. exp tryptophan/
39. or/23-38
40. serotonin reuptake inhibitors/ or citalopram/ or fluoxetine/ or fluvoxamine/ or paroxetine/
41. sertraline/
42. (citalopram or celexa or cipramil or dalsan or recital or emocal or sepram or seropram).mp.
43. (escitalopram or es citalopram or lexapro or cipralex or esertia).mp.
44. (fluvoxamine or luvox or fevarin or faverin or dumyrox or favoxil or movox).mp.
45. (fluoxetine or prozac or fontex or seromex or seronil or sarafem or fluctin or fluox or lovan).mp.
46. (paroxetine or paxil or seroxat or sereupin or aropax or deroxat or rexetin or xetanor or paroxat).mp.
47. (sertraline or zoloft or lustral or serlain).mp.
48. ssri?.mp.
49. selective serotonin reuptake inhibit*.mp.
50. symbyax.mp.
51. or/40-50
52. *major depression/ or *dysthymic disorder/ or *endogenous depression/ or *reactive depression/ or *recurrent depression/ or *treatment resistant depression/ or *"depression (emotion)"/
53. or/2-6
54. 52 or 53
55. (harm? or adverse or "side effect?").tw.
56. adverse effects.id.
57. exp "side effects (treatment)"/
58. drug interactions/
59. exp toxicity/

60. (adjunct* or augment*).tw.
61. or/55-60
62. 39 or 61
63. 54 and 62
64. 7 and 51
65. 22 or 63 or 64
66. limit 65 to human
67. limit 66 to ("comment/reply" or editorial or encyclopedia entry or obituary or review-book or review-media or review-software & other)
68. 66 not 67
69. limit 68 to yr="1980 -Current"
70. limit 69 to english language

OVID-Cochrane Central Register of Controlled Trials

June 28 2010

1. dysthm*.tw.
2. (subclinical adj2 depressi*).tw.
3. (subsyndromal adj2 depressi*).tw.
4. (subthreshold adj2 depressi*).tw.
5. (subdiagnostic adj2 depressi*).tw.
6. Depression/
7. depressive disorder/ or depressive disorder, major/ or dysthymic disorder/
8. or/1-7
9. serotonin uptake inhibitors/ or citalopram/ or fluoxetine/ or fluvoxamine/ or paroxetine/ or sertraline/
10. (citalopram or celexa or cipramil or dalsan or recital or emocal or sepram or seropram).mp.
11. (escitalopram or es citalopram or lexapro or cipralex or esertia).mp.
12. (fluoxetine or prozac or fontex or seromex or seronil or sarafem or fluctin or fluox or lovan).mp.
13. (fluvoxamine or luvox or fevarin or faverin or dumyrox or favoxil or movox).mp.
14. (paroxetine or paxil or seroxat or sereupin or aropax or deroxat or rexetin or xetanor or paroxat).mp.
15. (sertraline or zoloft or lustral or serlain).mp.
16. ssri?.mp.
17. selective serotonin reuptake inhibit*.tw.
18. symbyax.mp.
19. or/9-18
20. Drug Resistance/
21. treatment failure/
22. Retreatment/
23. ((difficult or hard) adj3 treat).tw.
24. augment*.tw.
25. nonrespon*.tw.
26. non-respon*.tw.
27. switch*.tw.
28. ((insufficient or inadequate or incomplete) adj3 respon*).tw.

29. (ssri? adj3 (resist* or fail* or respon* or refractory)).tw.
30. (partial adj3 respon*).tw.
31. ((combination or adjunct*) adj3 (therap* or drug? or treat*)).tw.
32. ((treat* or therapy or drug) adj4 (resist* or fail*)).tw.
33. ((treatment resistant or refractory) adj3 depressi*).tw.
34. or/20-32
35. 8 and 34
36. 35 or 33
37. 8 and 19
38. 36 or 37
39. *depression/ or *depressive disorder/ or *depressive disorder, major/ or *dysthymic disorder/
40. or/1-5
41. 39 or 40
42. 5-Hydroxytryptophan/
43. phototherapy/
44. light therapy.tw.
45. exp Exercise/ae, th [Adverse Effects, Therapy]
46. exp Exercise Therapy/
47. exp Acupuncture Therapy/
48. exp Massage/
49. Relaxation Therapy/
50. exp vitamins/
51. Hypericum/
52. john* wort.tw.
53. deplin.tw.
54. methylfolate.tw.
55. Folic Acid/
56. S-Adenosylmethionine/
57. "SAM-e".tw.
58. exp Fatty Acids, Omega-3/
59. Cognitive Therapy/
60. Crocus/
61. Tryptophan/
62. exp Inositol/
63. or/42-62
64. 41 and 63
65. (harm? or adverse or "side effect?").tw.
66. (adjunct* or augment*).tw.
67. 65 or 66
68. 41 and 67
69. exp *antidepressive agents/ae, to [Adverse Drug Reaction, Drug Toxicity]
70. 68 or 69
71. 38 or 64 or 70
72. limit 71 to yr="1980-Current"

OVID-AMED

June 28 2010

1. depression/
2. dysthm*.tw.
3. (subclinical adj2 depressi*).tw.
4. (subsyndromal adj2 depressi*).tw.
5. (subthreshold adj2 depressi*).tw.
6. (subdiagnostic adj2 depressi*).tw.
7. or/1-6
8. antidepressive agents/
9. (citalopram or celexa or cipramil or dalsan or recital or emocal or sepram or seropram).mp.
10. (escitalopram or es citalopram or lexapro or cipralext or esertia).mp.
11. (fluvoxamine or luvox or fevarin or faverin or dumyrox or favoxil or movox).mp.
12. (fluoxetine or prozac or fontex or seromex or seronil or sarafem or fluctin or fluox or lovan).mp.
13. (paroxetine or paxil or seroxat or sereupin or aropax or deroxat or rextin or xetanor or paroxat).mp.
14. (sertraline or zoloft or lustral or serlain).mp.
15. ssri?.mp.
16. selective serotonin reuptake inhibit*.tw.
17. or/8-16
18. 7 and 17
19. ((difficult or hard) adj3 treat).tw.
20. (adjunct* or augment*).tw.
21. nonrespon*.tw.
22. non-respon*.tw.
23. switch*.tw.
24. ((insufficient or inadequate or incomplete) adj3 response).tw.
25. (ssri? adj3 (resist* or fail* or response or refractory)).tw.
26. (partial adj3 response).tw.
27. ((combination or adjunct*) adj3 (therap* or drug? or treat*)).tw.
28. ((treat* or therapy or drug) adj4 (resist* or fail*)).tw.
29. or/19-28
30. 7 and 29
31. ((treatment resistant or refractory) adj3 depressi*).tw.
32. 30 or 31
33. cognitive behavior therapy/ or cognitive therapy/
34. phototherapy/
35. hydroxytryptophan.tw.
36. light therapy.tw.
37. exp exercise therapy/
38. exp acupuncture therapy/
39. massage/
40. exp relaxation/
41. exp vitamins/
42. hypericum perforatum/
43. (S-Adenosylmethionine or SAM-e).tw.

44. exp complementary therapies/
45. folic acid/
46. exp fatty acids/
47. crocus/
48. saffron.tw.
49. inositol.tw.
50. tryptophan/
51. or/33-50
52. 7 and 51
53. (harm? or adverse or "side effect?").tw.
54. adverse effects/
55. or/53-54
56. 7 and 55
57. 18 or 32 or 52 or 56
58. limit 57 to (commentary or editorial or interview or news or notes)
59. 57 not 58
60. limit 59 to english
61. limit 60 to yr="1980 -Current"

EBSCO-CINAHL

- S2 TX Hydroxytryptophan
- S3 (MH "Therapeutic Exercise+")
- S4 (MH "Alternative Therapies+")
- S5 (MH "Massage+")
- S7 (MH "Simple Relaxation Therapy (Iowa NIC)")
- S8 (MH "St. John's Wort")
- S9 "methylfolate"
- S10 (MH "Folic Acid+")
- S11 (MH "S-Adenosylmethionine")
- S12 TX SAM-e
- S13 (MH "Fatty Acids, Omega 3+")
- S14 (MH "Cognitive Therapy")
- S15 "saffron"
- S16 (MH "Tryptophan")
- S17 (MH "Inositol")
- S18 S2 or S3 or S4 or S5 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17
- S19 (MM "Depression")
- S20 (MM "Depression, Reactive")
- S21 (MM "Dysthymic Disorder")
- S22 S19 or S20 or S21
- S23 (S19 or S20 or S21) and (S18 and S22)
- S24 Limiters - Publication Year from: 1980-2009
- S25 S23 and S24
- S26 Limiters - Publication Type: Accreditation, Advice and Referral Website, Anecdote, Audiovisual, Bibliography, Biography, Book, Book Chapter, Book Review, Cartoon, Code of

Ethics, Commentary, Computer Program, Consumer/Patient Teaching Materials, Directories, Editorial, Exam Questions, Games, Individual Testimonial Website, Interview, Listservs, Masters Thesis, Obituary, Pamphlet, Pamphlet Chapter, Poetry, Software, Teaching Materials, Tracings, Website

S27 S25 NOT S26

S28 S27 Limiters - Language: English

Grey Literature Search

The following sources were searched using sensitive searches similar to the searches in bibliographic databases

Regulatory Information

FDA

Health Canada

Authorized Medicines for EU

Clinical Trial Registries

ClinicalTrials.gov

Current Controlled Trials

Clinical Study Results

WHO Clinical Trials

Abstracts and Conference Papers

Conference Papers Index

Scopus

Grants and Federally Funded Research

NIH RePORTER (a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other research institutions)

HSRPROJ (a database providing access to ongoing grants and contracts in health services research)

Other Miscellaneous Sources

Hayes, Inc. Health Technology Assessment

NY Academy of Medicine's Grey Literature

Index

In addition, the following website were search specifically for guidelines on depression treatment

<http://www.guideline.gov/>

<http://guidance.nice.org.uk/>

<http://www.sign.ac.uk/>

<http://www.nhmrc.gov.au/publications/subjects/clinical.htm>

<http://www.nzgg.org.nz/>

<http://www.hc-sc.gc.ca/ahc-asc/legislation/guide-ld/index-eng.php>

Appendix B Forms

Title and Abstract Level I

1. Is this report in English?

No (stop)

2. Is this article a commentary/note, letter, editorial, case study, or narrative review (non-systematic review)?

Yes (stop)

No/Can't Tell

Instruction for Q2:

If the citation is a commentary/note /letter or editorial or is a non-systematic review* (i.e. a review that is not systematic) you should answer "YES" and then go on to the next citation (don't forget to click "submit" or your answers won't be recorded).

If the citation is for a PRIMARY study, a clinical practice guideline or a systematic review* (or any study type not listed above) you should answer "NO" and then continue screening.

*Look carefully for words like "systematic review", "meta analysis", "Cochrane review" or "pooling", or some description of the methods used to assemble papers: Systematic reviews generally provide detailed description of their methods that include searches that included more than 1 database (for example, MEDLINE, Embase, PsychInfo, etc) and specifies inclusion and exclusion criteria for eligible studies.

Discusses inclusion and exclusion criteria.

Do not exclude any guideline/recommendation on question 2. We will include guidelines/recommendations where they are appropriate.

3. Does this article include subjects who are 12 years of age or older?

Yes/Can't Tell

No (stop)

4. Does this article focus on the "treatment" of depression?

Yes/Can't Tell

No (stop)

5. Does this article have a "primary focus" on "subjects" who have depression (including Dysthymia & Subsyndromal)?

Please answer “no” if the type of depression focused on:

1. post-partum/puerperal Depression, 2. bipolar depression, 3. seasonal affective disorder, 4. post-operative depression, 5. premenstrual dysphoric disorder, 6. depressive psychosis, 7. dysphoria, mourning syndrome 8. pseudodementia

- Yes/Can't Tell
- No (exclude)

6. This report published before 1980?

- Yes

7. This is a guideline published before 2005?

- Yes
- No

Title & Abstract Level 2

1. What type of study is this citation?

- Primary study / Can't Tell
- Systematic Review / Meta Analysis
- Guideline/ Recommendation (stop)
- None of the above (specify & stop)

2. Is the population diagnosed as Major Depressive Disorder (MDD), Dysthymia, or Subsyndromal Depression?

- Yes
- No (stop)
- Can't Tell

3. Does the study population include subjects who have failed to respond to treatment previously (if the only treatment they receive is rTMS, or ECT please answer No and go onto Q4)?

- Yes / Can't Tell (stop-include)
- No (continue)

Instruction for Q3

We are interested in ANY articles with this group as the population or subpopulation—common terms to identify this population are:

- Treatment resistant, inadequate response; failed treatment, refractory depression

Sometimes they identify this population by the treatment commonly received after failure—common terms include:

- Augment/augmentation, switching, optimizing, changing dose,
Also respond “yes” to studies that focus on predictors of response rather than treatment efficacy/ effectiveness

4. Does this study focus primarily on the following:

- Efficacy/effectiveness of an SSRI (monotherapy)
- Efficacy/ effectiveness of a COMBINED treatment
- Efficacy/effectiveness of a NON-pharmacological treatment (monotherapy)
- Adverse events related to medications
- Other (specify in box intervention or population)
- Efficacy/ Effectiveness of Non-SSRI drug intervention

This is a relevant guideline for this SR to extract the data:

- Yes
- No

Investigators comments:

Full Text Screening, Level 3

1. What is the study design described in this study?

- RCT (randomized control trial) or CCT (clinical control trial)
- Cohort / Longitudinal
- Case-Control
- Cross-Sectional
- Interrupted time series with comparator group
- Systematic Review / Meta analysis (stop)
- Guideline / Recommendation (stop)
- Non-comparative design (before after study, case series or case report) (stop)
- Other (specify and can include qualitative studies, editorials, commentaries, etc) (stop)

2. Is the study population diagnosed primarily (>50%) with Dementia (Alzheimer's Disease, Vascular dementia, etc), Stroke (cerebrovascular accident), Parkinson's disease, Hypo-thyroidism, or Cushing's Syndrome?

- Yes (stop)
- No / Can't tell (continue)

3. Were the study subjects (diagnosed with MDD, Dysthymia, or Subsyndromal depression) recruited because they had failed to respond to an SSRI?

- YES – ALL (100%) of the subjects demonstrated an inadequate response to SSRI as a part of this study
- YES - ALL (100%) of the subjects based on history had an inadequate response to SSRI prior to the start of the current study
- YES - Some of the subjects have inadequate response to SSRI determined by history and some by demonstration in this study
- NO - All (100%) of the subjects had an inadequate response to a NON-SSRI anti-depressant determined by history or by demonstration in this study (STOP)
- NO - All (100%) of the subjects had an inadequate response to a SSRI combination therapy determined by history or by demonstration in this study (STOP)
- NO - All (100%) of the subjects had an inadequate response to a NON- SSRI combination therapy determined by history or by demonstration in this study (STOP)
- NO - All (100%) of the subjects had NOT failed to respond in this study (STOP)

- Can't tell if the subjects failed to respond to an SSRI or any other antidepressant (STOP)

Q3: INSTRUCTION

Demonstrated an inadequate response to SSRI as a part of this study means that at the start/enrolment of the study patients are given/started on an SSRI and then followed forward in time to determine who did and did not respond adequately. Those subjects who did **NOT** respond adequately, continued on in the study and were then managed with

- 1) a NEW intervention/ treatment OR
- 2) Switched to a different dose OR
- 3) Changed to a different duration of the SSRI OR
- 4) Combined the SSRI with another medication or supplement

Based on history had an inadequate response to SSRI prior to this study means:

- 1) that the subjects enter the study currently taking an SSRI and the investigators assess their response is not adequate
- 2) Subject's report their past history and indicate they were on an SSRI previously and they did not have an adequate response but they are currently not on the medication. The investigators must determine their past inadequate response from patient self-report or medical records.

4. Does the study include any of the following monotherapy interventions in the patients? (check all that apply)

- Change the dose or duration of the same SSRI
- Change/switch to another SSRI
- Change/switch to an antidepressant medication of another class
- Change to a non-pharmacological intervention (only included list of interventions)
- NONE of the above (continue)

5. Does the study include any of the following combined therapy interventions in the patients? (check all that apply)

- Adjunct therapy: addition of an augmenter (i.e. a drug that has no formal indication as monotherapy treatment for unipolar depression, or a food supplement)
- Adjunct therapy: addition of a second SSRI or antidepressant from another class
- Adjunct therapy: addition of a non-pharmacological therapy (see list)
- Combinations of any of the interventions listed above or other interventions

- None of the above (continue)
- 6. **Does this study focus on the outcomes (primary, secondary, and harm) of interest for our review?**
 - Yes
 - No
 - Other (specify)

Q6: INSTRUCTION

Other outcomes could include measures of cardiovascular disease, other biological markers.

Primary Outcomes: Partial or complete response, Remission (free of all symptoms or with few symptoms), Speed of response or remission, and Relapse

Secondary Outcomes: Quality of life, Adherence, Return to work, Global change, External service utilization

Harms: Treatment emergent symptoms as follows: Sexual dysfunction symptoms, Neuropsychiatric symptoms or sedation, Gastrointestinal disturbances, Weight gain or metabolic disturbance, Sleep, Cardiovascular system problems, Geriatric toxicity problems, Other common adverse effects (for example, headaches, orthostatic hypotension, hypertension)

7. **Investigators comments:**

8. **STARD**

- Yes (exclude)
- No (include)

9. **If this study is a STARD study, is this one of the following (all excludes).**

- An overview
- A study with only phase 1 data
- Other

10. **This is a guideline/recommendation before 2005:**

- Yes

11. **This is a guideline/recommendation that should be exclude because of:**

- focus on diagnosis or screening rather than treatment
- not a population of interest
- not a guideline

12. The following options are the result of contact to author(s) on "Some" list.:

- Responded and can't provide data
- Did not respond
- Unable to contact (wrong email address..can't find them)
- Responded but beyond our cut date
- Responded and provided data

Level 4 Data Extraction -Primary Studies (General Information)(Groupin)

- Group1
- Group2
- Group3
- Exclude

STUDY

1. **Country(s) in which study was conducted:**

2. **Funding source** (mark NR if not reported)

METHODOLOGY

3. **Study type (If it is a multicentral study, please provide the number of centers in the box)**
 - RCT
 - Non-RCT
 - Cohort/longitudinal
 - Case-Control
 - Cross-Sectional
 - Other (specify)

4. **Setting**
 - Outpatient Psychiatric
 - Inpatient Psychiatric
 - Outpatient Primary Care
 - Inpatient Primary Care
 - Other (specify)

Table No 1: Type of Intervention/treatment (List all that apply) (specify for each arm/group)

Type
Total
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7
Intervention

Table No 2: Sample characteristics

Total
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7
Total Recruited

Total Eligible Screened

Total Run- in-Phase

Sample of non-responders
RANDOMIZED or GROUPED

For each time point that have results provided (labeled as T1, T2, T3)

Total who withdrew or were lost to follow-up when study outcomes are measured

Withdrawal because of adverse Effects

Withdrawal because of loss to follow-up

Total number of subjects analyzed

POPULATION CHARACTERISTICS

Table No 3: Age

Age
Total
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7
Min

Max
Mean
SD
SEM
Median
IQR
Other
(e.g. age group)

Table No 4: Gender

Gender
Total
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7
Male (No)
Male (%)
Female (No)
Female (%)

Table No 5: Ethnicity

Ethnicity

Total

Group 1

Group 2

Group 3

Group 4

Group 5

Group 6

Group 7

White (No)

Hispanic (No)

African-American (No)

Oriental(No)

Asian (No)

Other (specify) (No)

230. List all Inclusion criteria

1

2

3

4

5

6

7

8

231. List all Exclusion criteria

1

2

3

4

5

6

7

8

232. Diagnosis (list all that apply)

- Major Depressive Disorder (MDD)
- Dysthymia
- Subsyndromal
- Other (specify)

233. Method(s) used to diagnose Depression:

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8

234. Method of determining inadequate response (click all that apply and provide as much detail as possible. e.g. proportion).

- Prospective (Screening or Run-in Phase)
- Retrospective: Medical chart
- Retrospective: Patient self report of history of failure
- Retrospective: Patient self report of history of adverse event response
- Retrospective: Currently on medication to which they have not responded
- Retrospective: Confirmation by clinician
- Other (specify)

235. Who determined previous treatment failure?

Table No 6: Length of current Episode

Length
Total
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7
Min
Max
Mean
SD
SEM
Median
IQR
Other

300. Specify units in the mean for table 6 (above table).

- Week
- Day
- Month
- Year

Table No 7: Past Mental Health History (episodes of Depression over lifetime)

No of past episode

Total

Group 1

Group 2

Group 3

Group 4

Group 5

Group 6

Group 7

Min

Max

Mean

SD

SEM

Median

IQR

Other

e.g % (specify)

Table No 8: Type and number of SSRI that had previously failed to respond (List all that apply) (specify for each arm/group)

Type/No

Total

Group 1

Group 2

Group 3

Group 4

Group 5

Group 6

Group 7

Type

No of drugs

Type not specified

INTERVENTION

389. **Were patients tapered off existing medications prior to start of the study?**

- Yes
- No
- Unclear

390. **Was a run-in phase employed?**

- Yes (specify time in weeks)
- No

391. **Was there a washout period following the run-in phase? (If yes, specify the time-interval)**

- Yes
- No
- Unclear

392. **PURPOSE OF TREATMENT**

393. **What type of patients are excluded from proceeding to the next phase of treatment (List all criteria)?**

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8

Table No 9: Dose of treatment/intervention

Dose

Total

Group 1

Group 2

Group 3

Group 4

Group 5
Group 6
Group 7
Initial
(Minimum)
Initial
(Maximum)
Final
(Minimum)
Final
(Maximum)
Other

Table No 10: Treatment interval (week) of treatment/intervention for arm1/group1

SSRI
Total
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7
Min
Max
Mean
SD
SEM
Median
IQR
Other

498. Specify units in the mean for table 10 (above table).

- Week
- Day
- Month
- Year

499. Type of treatment provider (describe in brief):

- Psychiatrist
- Family Physician
- Allied Health
- Other

RESULTS

Table No 11: Time points at which treatment discontinued (specify when outcomes were collected and the length of follow up in week(s))

Time Points

Week(s)

Note

First

Intermediate

Other

Final

Follow Up

510. Patient Compliance (Detail definition if provided) (list all methods):

1

2

3

4

5

6

7

8

Table No 12: Compliance with treatment (End Point) (indicate compliance or non-compliance in the last box)

Comply

Total

Group 1

Group 2

Group 3

Group 4

Group 5

Group 6

Group 7

Min

Max

Mean

SD

SEM

Median

IQR

Other

(e.g. number)

Note

(compliance or non-compliance)

583. Percent (%) or number of subjects declaring use of Complementary and Alternative Medicine (CAM) interventions .

- Baseline (No)
- Baseline (%)
- Concurrent (No)
- Concurrent (%)

584. Are there stratified ANALYSES for the following variables/factors (check all that apply):

- Depressive Diagnosis (MDD vs Other)
- Disease Severity
- Age
- Gender
- Race
- Socioeconomic status
- Medical comorbidities
- Psychiatric comorbidities
- Other
- Other
- Other

585. List all relevant outcomes/instruments used in this study. Place a (P) after the outcomes indicating the primary outcomes.

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8

586. Overall conclusions on efficacy from an abstract if no/short results reported :

587. Additional Comments or important notes about this study :

588. Go to Data Extraction form for Harm

- Yes
- No

589. Investigator 1 Comments:

590. Investigator 2 Comments

591. Investigator 3 Comments

592. Group

- MoCo
- MoMo
- CoCo
- STARD
- Other

1. Quality Assessment for Primary Studies Rater #1 (Grouping)

- Group 1
- Group 2
- Group 3
- Exclude

Instruction: Please read the instructions that were sent to you by email before completing this form.

2. Was the method of randomization adequate?

- Yes
- No
- Unsure

3. Was the treatment allocation concealed?

- Yes
- No
- Unsure

Was knowledge of the allocated interventions adequately prevented during the study?

4. Was the patient blinded to the intervention?

- Yes
- No
- Unsure

5. Was the care provider blinded to the intervention?

- Yes
- No
- Unsure

6. Was the outcome assessor blinded to the intervention?

- Yes
- No
- Unsure

Were incomplete outcome data adequately addressed?

7. Was the drop-out rate described and acceptable?

- Yes
- No
- Unsure

8. Were all randomized participants analysed in the group to which they were allocated?

- Yes
- No
- Unsure

9. Are reports of the study free of suggestion of selective outcome reporting?

- Yes
- No
- Unsure

Other sources of potential bias:

10. Were the groups similar at baseline regarding the most important prognostic indicators?

- Yes
- No
- Unsure

11. Were co-interventions avoided or similar?

- Yes
- No
- Unsure

12. Was the compliance acceptable in all groups?

- Yes
- No
- Unsure

13. Was the timing of the outcome assessment similar in all groups?

- Yes
- No
- Unsure

14. Is the role of the study sponsor/ funder (i.e. manufacturer of the device) appropriate?

- Yes
- No
- Unsure

15. GO to level 5

- Yes

16. Other:

1. **Data Extraction, Primary Study-Harm (Grouping)**

- Group 1
- Group 2
- Group 3
- Exclude

2. **Did the authors specify if the harms reported encompass ALL the events collected or a selected SAMPLE?**

- Yes
- No
- Unclear

3. **Were the harms PRE-DEFINED using standardized or precise definitions?**

- Yes
- No
- Unclear

4. **Were SEVERE events precisely defined?**

- Yes
- No
- Unclear

5. **Were SERIOUS events precisely defined?**

- Yes
- No
- Unclear

6. **Did the author(s) use STANDARD scale(s) or checklist(s) for harms collection?**

- Yes
- No
- Unclear

7. **Was the mode of harms collection specified as:**

- Active
- Passive
- Not Reported
- Unclear

8. **Did the study specify WHO collected the harms?**

- Yes
- No
- Unclear

9. **Did the study specify the TRAINING or BACKGROUND of who ascertained the harms (specify)?.**

- Yes
- No
- Unclear

10. **Did the study specify the TIMING and FREQUENCY of collection of the harms (specify)?**

- Yes
- No
- Unclear

11. **Did the author(s) specify the type of analyses undertaken for harms data (specify)?**

- Yes
- No
- Unclear

Table No 1: Type of Intervention/treatment, sample size , Adverse Events (AE), and Withdrawals per group

Type

Total

Group1

Group 2

Group 3

Group 4

Group 5

Group 6

Group 7
Type of
Intervention
No of Pts assigned
No of Pts Who have AE
Percent of Pts Who have AE
No of of Pts Who Withdrew due to AE
Percent of Pts Who Withdrew

Table No 2: Identify Number (%) of Patients Who Had Severe or Serious Adverse Events (AE) per group

Sevier AD
Total
Group1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7
Suicidality
Bleeding
Low Sodium
Death
Other 1
Other 2:
Other 3:
Other 4:
Other 5:

Table No 3: Identify Number (%) of Patients Who Had Adverse Events (AE) per group

Adverse
Events
Total
Group1
Group 2
Group 3
Group 4
Group 5
Group 6
Group 7

Sexual Dysfunction
Anxiety
Sedation
Gastrointestinal disturbance
(nausea, vomiting, diarrhea)
Weight Loss
Weight gain
Change in triglycerides
Change in glucose
Sleep disorder
(insomnia or hypersomnia)
Cardiovascular problems
(Hypotension, tachycardia, bradycardia)
Toxicity Problems:
Headaches
Other 1:
Other 2:
Other 3:
Other 4:
Other 5:

278. Data extractor/Reviewer:

279. Comments:

280. First Reviewer:

281. First Reviewer comments:

282. Second Reviewer:

283. Second Reviewer Comments:

284. Investigators Comments:

285. Go to outcome form

- Yes
- No

286. New Question

287. Group

- MoCo

- MoMo
- CoCo
- STARD
- Other

Level 4 - Data Extraction Guidelines & Recommendations

- 1. Is publication date of this guideline 2004 and forward?**
 - Yes
 - No
- 2. What organization sponsored this Guideline?**
- 3. In which country is this guideline applied?**
- 4. What is the scope and purpose of this Guideline/Recommendation?**
(List all that apply)
 - Treatment
 - Diagnosis
 - Prognosis
 - Others (specify)
- 5. Who are the Intended Users (check all that apply)**
 - Primary Care Physicians (e.g. General practitioners)
 - Mental Health Specialist (Psychiatrists)
Allied Mental Health Professionals (Social Workers, Mental Health Nurses,
Occupational Therapists)
 - Patients
Other (specify)
- 6. What is the setting for use of this Guideline? (check all that apply)**
 - Primary Care
 - Mental Health Out Patient Setting
 - Mental Health Inpatient Setting
 - Other (specify)
- 7. What is the target population on this Guideline? (check all that apply)**

- Adult MDD
- Adult Dysthymia
- Adult Subsyndromal
Adolescent MDD
- Adolescent Dysthymia
- Adolescent Subsyndromal
- None of the above (stop)

8. Does this guideline have a specific recommendation (course of action) for patients who do not respond to the intervention(s)?

- Yes
- No
- Not Sure

9. What is the definition of AND method of establishing “inadequate/unsatisfactory” response?

Recommendation #1 for populations who failed to respond to previous antidepressants;

10. Specify Recommendation #1 for populations who failed to respond to previous antidepressants. (Please type in the exact wording)

11. Does the recommendation identify or stratify actions or suggestions based on the specific TYPE of antidepressant medication that subjects had not respond to adequately?

- NO: they do NOT specify previous type of antidepressant (go to Q13)
- YES: they specify the type of antidepressant

12. Specify the type/class of DRUG intervention (check all that apply)

- SSRI (specify)
- SNRI (specify)
- SSNRI (specify)
- Other second generation antidepressants (specify)
- None Pharmacological (specify)

13. What type of system was used to grade or evaluate the strength of evidence (i.e. GRADE, or some association specific system)?

14. **Grading of the recommendation #1: (i.e. strong recommendation)**
15. **Rating of quality of evidence for Recommendation #1 :** (i.e. evidence at high risk of bias, or level I (indicating RCT design))
16. **For the evidence that is cited to support the recommendation, please list the number and type of studies included:** (i.e. 4 RCTs, and 2 Observational studies)
17. **Does the recommendation ONLY specify actions/ suggestions to switch to the use of MONOTHERAPY that are generic (not specific to drug or intervention)?** (Please type in the exact wording)
18. **Does the recommendation specify any of the following for MONOTHERAPY treatment changes?**(specify exact wording)
- ONLY specify actions/ suggestions to switch but is non-specific (Specify exact wording)
 - Indicates to change the DOSE of the current SSRI or antidepressant
 - Indicates to change the DURATION of the current SSRI or antidepressant
 - Indicates a switch from one SSRI to another SSRI OR from one Non-SSRI antidepressant to another within the SAME drug class
 - Indicates a switch from an SSRI to another non-SSRI antidepressant of a different class
 - Indicates a switch from an SSRI or non-SSRI anti-depressant to a non-pharmacological treatment
19. **Does the recommendation specify any of the following for COMBINED THERAPY treatment changes:** (specify exact wording)
- ONLY specify actions/ suggestions to combine therapies but is non-specific
 - Indicates to combine therapies with Augmenters (drugs or food supplements)
 - Indicates to combine one SSRI or non-SSRI antidepressant with another SSRI or non-SSRI antidepressant of the SAME class
 - Indicates to combine one SSRI with another non-SSRI antidepressant
 - Indicates to combine an SSRI or antidepressant with a non-pharmacological intervention
 - Indicates to combine an SSRI or antidepressant with multiple combinations (any intervention previously listed)

Recommendation #2 for populations who failed to respond to previous antidepressants;

20. **Specify Recommendation #2 for populations who failed to respond to previous antidepressants. (Please type in the exact wording)**
21. **Does the recommendation identify or stratify actions or suggestions based on the specific TYPE of antidepressant medication that subjects had not respond to adequately?**
- NO: they do NOT specify previous type of antidepressant (go to Q23)
 - YES: they specify the type of antidepressant
22. **Specify the type/class of DRUG intervention (check all that apply)**
- SSRI (specify)
 - SNRI (specify)
 - SSNRI (specify)
 - Other second generation antidepressants (specify)
 - None Pharmacological (specify)
23. **What type of system was used to grade or evaluate the strength of evidence (i.e. GRADE, or some association specific system?)**
24. **Grading of the recommendation #2:** (i.e. strong recommendation)
25. **Rating of quality of evidence for Recommendation #2 :** (i.e. evidence at high risk of bias, or level I (indicating RCT design)
26. **For the evidence that is cited to support the recommendation, please list the number and type of studies included:** (i.e. 4 RCTs, and 2 Observational studies)
27. **Does the recommendation ONLY specify actions/ suggestions to switch to the use of MONOTHERAPY that are generic (not specific to drug or intervention?) (Please type in the exact wording)**
28. **Does the recommendation specify any of the following for MONOTHERAPY treatment changes?(specify exact wording)**
- ONLY specify actions/ suggestions to switch but is non-specific (Specify exact wording)
 - Indicates to change the DOSE of the current SSRI or antidepressant
 - Indicates to change the DURATION of the current SSRI or antidepressant
 - Indicates a switch from one SSRI to another SSRI OR from one Non-SSRI antidepressant to another within the SAME drug class

- Indicates a switch from an SSRI to another non-SSRI antidepressant of a different class
- Indicates a switch from an SSRI or non-SSRI anti-depressant to a non-pharmacological treatment

29. Does the recommendation specify any of the following for COMBINED THERAPY treatment changes: (specify exact wording)

- ONLY specify actions/ suggestions to combine therapies but is non-specific
- Indicates to combine therapies with Augmenters (drugs or food supplements)
- Indicates to combine one SSRI or non-SSRI antidepressant with another SSRI or non-SSRI antidepressant of the SAME class
- Indicates to combine one SSRI with another non-SSRI antidepressant
- Indicates to combine an SSRI or antidepressant with a non-pharmacological intervention
- Indicates to combine an SSRI or antidepressant with multiple combinations (any intervention previously listed)

Recommendation #3 for populations who failed to respond to previous antidepressants;

30. Does the recommendation identify or stratify actions or suggestions based on the specific TYPE of antidepressant medication that subjects had not respond to adequately?

- NO: they do NOT specify previous type of antidepressant (go to Q33)
- YES: they specify the type of antidepressant

31. Does the recommendation identify or stratify actions or suggestions based on the specific TYPE of antidepressant medication that subjects had not respond to adequately?

- NO: they do NOT specify previous type of antidepressant (go to Q33)
- YES: they specify the type of antidepressant

32. Specify the type/class of DRUG intervention (check all that apply)

- SSRI (specify)
- SNRI (specify)
- SSNRI (specify)
- Other second generation antidepressants (specify)
- None Pharmacological (specify)

33. **What type of system was used to grade or evaluate the strength of evidence (i.e. GRADE, or some association specific system?)**
34. **Grading of the recommendation #3:** (i.e. strong recommendation)
35. **Rating of quality of evidence for Recommendation #3 :** (i.e. evidence at high risk of bias, or level I (indicating RCT design))
36. **For the evidence that is cited to support the recommendation, please list the number and type of studies included:** (i.e. 4 RCTs, and 2 Observational studies)
37. **Does the recommendation ONLY specify actions/ suggestions to switch to the use of MONOTHERAPY that are generic (not specific to drug or intervention?)** (Please type in the exact wording)
38. **Does the recommendation specify any of the following for MONOTHERAPY treatment changes?**(specify exact wording)
- ONLY specify actions/ suggestions to switch but is non-specific (Specify exact wording)
 - Indicates to change the DOSE of the current SSRI or antidepressant
 - Indicates to change the DURATION of the current SSRI or antidepressant
 - Indicates a switch from one SSRI to another SSRI OR from one Non-SSRI antidepressant to another within the SAME drug class
 - Indicates a switch from an SSRI to another non-SSRI antidepressant of a different class
 - Indicates a switch from an SSRI or non-SSRI anti-depressant to a non-pharmacological treatment
39. **Does the recommendation specify any of the following for COMBINED THERAPY treatment changes:** (specify exact wording)
- ONLY specify actions/ suggestions to combine therapies but is non-specific
 - Indicates to combine therapies with Augmenters (drugs or food supplements)
 - Indicates to combine one SSRI or non-SSRI antidepressant with another SSRI or non-SSRI antidepressant of the SAME class

- Indicates to combine one SSRI with another non-SSRI antidepressant
- Indicates to combine an SSRI or antidepressant with a non-pharmacological intervention
- Indicates to combine an SSRI or antidepressant with multiple combinations (any intervention previously listed)

Recommendation #4 for populations who failed to respond to previous antidepressants;

40. Specify Recommendation #4 for populations who failed to respond to previous antidepressants. (Please type in the exact wording)

41. Does the recommendation identify or stratify actions or suggestions based on the specific TYPE of antidepressant medication that subjects had not respond to adequately?

- NO: they do NOT specify previous type of antidepressant (go to Q43)
- YES: they specify the type of antidepressant

42. Specify the type/class of DRUG intervention (check all that apply)

- SSRI (specify)
- SNRI (specify)
- SSNRI (specify)
- Other second generation antidepressants (specify)
- None Pharmacological (specify)

43. What type of system was used to grade or evaluate the strength of evidence (i.e. GRADE, or some association specific system?)

44. Grading of the recommendation #4: (i.e. strong recommendation)

45. Rating of quality of evidence for Recommendation #4 : (i.e. evidence at high risk of bias, or level I (indicating RCT design)

46. For the evidence that is cited to support the recommendation, please list the number and type of studies included: (i.e. 4 RCTs, and 2 Observational studies)

47. Does the recommendation ONLY specify actions/ suggestions to switch to the use of MONOTHERAPY that are generic (not specific to drug or intervention)? (Please type in the exact wording)

48. Does the recommendation specify any of the following for MONOTHERAPY treatment changes?(specify exact wording)

- ONLY specify actions/ suggestions to switch but is non-specific (Specify exact wording)
- Indicates to change the DOSE of the current SSRI or antidepressant
- Indicates to change the DURATION of the current SSRI or antidepressant
- Indicates a switch from one SSRI to another SSRI OR from one Non-SSRI antidepressant to another within the SAME drug class
- Indicates a switch from an SSRI to another non-SSRI antidepressant of a different class
- Indicates a switch from an SSRI or non-SSRI anti-depressant to a non-pharmacological treatment

49. Does the recommendation specify any of the following for COMBINED THERAPY treatment changes: (specify exact wording)

- ONLY specify actions/ suggestions to combine therapies but is non-specific
- Indicates to combine therapies with Augmenters (drugs or food supplements)
- Indicates to combine one SSRI or non-SSRI antidepressant with another SSRI or non-SSRI antidepressant of the SAME class
- Indicates to combine one SSRI with another non-SSRI antidepressant
- Indicates to combine an SSRI or antidepressant with a non-pharmacological intervention
- Indicates to combine an SSRI or antidepressant with multiple combinations (any intervention previously listed)

50. Data Extractor/Reviewer:

51. Second Reviewer:

**Level 5: Quality Assessment Tools for Guidelines and Recommendations:
AGREE II instrument for Guidelines:**

General Instruction, Rating Scale:

All AGREE II items are rated on the following 7-point scale:

Score of 1 (Strongly Disagree). A score of 1 should be given when there is no information that is

relevant to the AGREE II item or if the concept is very poorly reported.

Score of 7 (Strongly Agree). A score of 7 should be given if the quality of reporting is exceptional and where the full criteria and considerations articulated in the User's Manual have been met.

Scores Between 2 and 6. A score between 2 and 6 is assigned when the reporting of the AGREE II item does not meet the full criteria or considerations. A score is assigned depending on the completeness and quality of reporting. Scores increase as more criteria are met and considerations addressed. The "How to Rate" section for each item includes details about assessment criteria and considerations specific to the item. (see instruction)

1. The overall objective(s) of the guideline is (are) specifically described.

1 2 3 4 5 6 7

2. The health question(s) covered by the guideline is (are) specifically described.

1 2 3 4 5 6 7

3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.

1 2 3 4 5 6 7

4. The guideline development group includes individuals from all the relevant professional groups.

1 2 3 4 5 6 7

5. The views and preferences of the target population (patients, public, etc.) have been sought.

1 2 3 4 5 6 7

6. The target users of the guideline are clearly defined.

1 2 3 4 5 6 7

7. Systematic methods were used to search for evidence.

1 2 3 4 5 6 7

8. The criteria for selecting the evidence are clearly described.

1 2 3 4 5 6 7

9. The strengths and limitations of the body of evidence are clearly described.

1 2 3 4 5 6 7

10. The methods used for formulating the recommendations are clearly described.

1 2 3 4 5 6 7

11. The health benefits, side effects and risks have been considered in formulating the recommendations.

1 2 3 4 5 6 7

12. There is an explicit link between the recommendations and the supporting evidence.

1 2 3 4 5 6 7

13. The guideline has been externally reviewed by experts prior to its publication.

1 2 3 4 5 6 7

14. A procedure for updating the guideline is provided.

1 2 3 4 5 6 7

15. The recommendations are specific and unambiguous.

1 2 3 4 5 6 7

16. The different options for management of the condition or health issue are clearly presented.

1 2 3 4 5 6 7

17. Key recommendations are easily identifiable.

1 2 3 4 5 6 7

18. The guideline describes facilitators and barriers to its application.

1 2 3 4 5 6 7

19. The guideline provides advice and/or tools on how the recommendations can be put into practice .

1 2 3 4 5 6 7

20. The potential resource implications of applying the recommendations have been considered.

1 2 3 4 5 6 7

21. The guideline presents monitoring and/ or auditing criteria.

1 2 3 4 5 6 7

22. The views of the funding body have not influenced the content of the guideline.

1 2 3 4 5 6 7

23. Competing interests of guideline development group members have been recorded and addressed.

1 2 3 4 5 6 7

24. Overall Assessment:

Would you recommend these guidelines for use in practice?

- Strongly recommend
- Recommend (with provisos alteration)
- Would not recommend
- Unsure

25. Comments:

26. Appraiser 1:

- Catherine
- Sara
- Homa
- Lina
- other (specify)

Appendix C - Table 2. Strength of evidence

Quality assessment							Summary of findings				Importance
							No of patients		Effect	Quality	
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Mono 1 Combo 1	Mono 2 Combo 2	Relative Risk (95% CI)		
Monotherapy versus Monotherapy (Pharmacological and Non-Pharmacological)											
Outcome Response											
7 ¹⁻⁸	RCT/CCT	Study limitations	N/A	Indirect	Imprecise		1058	1124	0.27 vs 1.06	Low	Critical
Outcome Remission											
5 ^{1-4,6,7}	RCT/CCT	Study limitations	N/A	Indirect	Imprecise		1042	1011	0.27 vs 1.06	Low	Critical
Combined Therapy versus Combined Therapy (Pharmacological and non-pharmacological)											
Outcome Response											
6 ^{2,3,9-14}	RCT/ CCT	Study limitations -2	N/A	Indirect	Imprecise		434	377	0.37 – 1.36	Low	Critical
Outcome Remission											
1 ^{3,15}	RCT/ CCT	Study limitations	N/A	Indirect	Imprecise		344	286	0.69 – 1.0	Low	Critical

* For the STAR*D trial monotherapy medications (n=86) was added to the monotherapy 2 group.

^ For the STAR*D trial combined medications (n=117) was added to combined therapy 2

Reference List

1. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. *Psychopharmacol* 2002;161(2):143-51.
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. *N Engl J Med* 2006;354(12):1231-42.
3. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. *Am J Psychiatry* 2007;164(5):739-52.
4. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. *Journal of Clinical Psychiatry* 2007;68(2):224-36.
5. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. *Am J Psychiatry* 2001;158(1):131-4.
6. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. *Acta Psychiatr Scand* 2001;103(1):66-72.
7. Perahia DG, Quail D, Desai D, et al. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. *J Clin Psychiatry* 2008;69(1):95-105.
8. Bondolfi G, Aubry JM, Golaz J, et al. A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. *Swiss Med Wkly* 2006;136(5-6):78-85.
9. Altamura AC, Dell'Osso B, Buoli M, et al. Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: a short-term, low dose, randomized, placebo-controlled study. *J Clin Psychopharmacol* 2008;28(4):406-10.
10. Altamura AC, Dell'Osso B, Buoli M, et al. Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study. *Int Clin Psychopharmacol* 2008;23(4):198-202.
11. Dinan TG. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. *Acta Psychiatr Scand* 1993;88(4):300-1.
12. Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. *J Clin Psychiatr* 2007;68(7):1071-7.
13. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. *J Clin Psychopharmacol* 2002;22(4):379-87.

14. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. *The American journal of psychiatry* 1994;151(9):1372-4.
15. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression.[see comment]. *N Engl J Med* 2006;354(12):1243-52.

Appendix C - Table 1. Strength of evidence

Quality assessment							Summary of findings				
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No of patients		Effect	Quality	Importance
							Combined Therapy	Mono therapy	Relative Risk (95% CI)		
Monotherapy vs Combined Therapy (maintaining SSRI or Switching AD and adding any Augmenting agents)											
Outcome Response											
18 ¹⁻¹⁹	RCT/CCT	Study limitations	N/A	Indirect (pop/int)	Imprecise -2	12 different agents considered	1137	1904	0.40 – 13.0	Insufficient	Critical
Outcome Remission											
8 ^{3,5,8-10,16,18,20,21}	RCT/CCT	Study limitations	N/A	Indirect	Imprecise -2	7 different agents considered	1679	951	0.72 – 4.74	Insufficient	Critical
Monotherapy vs Combined Therapy (Maintaining SSRI and adding Atypical Antipsychotics agents)*											
Outcome Response											
3 ^{3,7,8}	RCT	Study Limitations	N/A	Indirect	Imprecise -0		290	492	1.37 – 13.0	Low	Critical
Outcome Remission											
3 ^{3,8,21}	RCT	Study Limitations	N/A	Indirect	Imprecise -0		327	496	1.63 -4.74	Moderate	Critical
Monotherapy versus Combined Therapy (Maintaining SSRI and Adding Bupirone)											
Outcome Response											
2 ^{11,12}	RCT	Study Limitations + 1	N/A	Indirect	Imprecise -0	108	108	111	1.06 – 1.09	Insufficient	Critical
Outcome Remission											
0											Critical
Monotherapy versus Combined Therapy (switching AD and Adding Bupirone)											
Outcome Response											
1 ^{9,10}	RCT	Study Limitations	N/A	Indirect	Imprecise -0	STAR*D Equipoise	286	727	0.96 – 1.02	Low	Critical
Outcome Remission											
1 ^{9,10}	RCT	Study Limitations	N/A	Indirect	Imprecise -0	STAR*D Equipoise	286	727	1.21 – 1.70	Low	Critical

Appendix C - Table 1. (Cont'd) Strength of evidence

Quality assessment							Summary of findings				
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	No of patients		Effect	Quality	Importance
							Combined Therapy	Mono therapy	Relative Risk (95% CI)		
Monotherapy versus Combined Therapy (MAINTAINING SSRI and Adding Lithium agents)											
Outcome Response											
3 ^{13,15,16}	RCT	Study Limitations	N/A	Indirect	Imprecise -2		67	81	0.40 -4.20	Insufficient	Critical
Outcome Remission											
1 ¹⁶	RCT	Study Limitations	N/A	Indirect	Imprecise -2		9	32	N/A	Insufficient	Critical
Monotherapy versus Combined Therapy (MAINTAINING SSRI and Adding Mianserin agents)											
Outcome Response											
2 ^{18,19}	RCT	Study Limitations	N/A	Indirect	Imprecise -2		130	269	0.97 – 1.70	Insufficient	Critical
Outcome Remission											
1 ¹⁸	RCT	Study Limitations	N/A	Indirect	Imprecise -2	STAR*D Equipoise	98	197	1.17 – 1.54	Insufficient	Critical
Monotherapy versus Combined Therapy (MAINTAINING SSRI and Adding Other Augmenting agents)											
Outcome Response											
6 ^{1,2,4-6,17}	RCT	Study Limitations	N/A	Indirect	Imprecise -2		235	227	0.23 – 4.55	INSUFFICIENT	Critical
Outcome Remission											
2 ^{5,20}	RCT	Study Limitations	N/A	Indirect	Imprecise -2		230	227	1.06 – 1.20	INSUFFICIENT	Critical
Monotherapy versus Combined Therapy (MAINTAINING SSRI and Adding another treatment (Non-SSRI, SSRI and non-pharmacological)											
Outcome Response											
4 ^{13,14,23-25}	RCT	Study limitations	N/A	Indirect	Imprecise -2	3 different interventions	74	76	0.47-19.00	INSUFFICIENT	Critical
Outcome Remission											
1 ²⁶	RCT	Study limitations	N/A	Indirect	Imprecise		20	12	1.20	INSUFFICIENT	Critical

Appendix Table 1. (Cont'd) Strength of evidence

Quality assessment							Summary of findings				
							No of patients		Effect	Quality	Importance
No of studies	Design	Limitations	Inconsistency	Indirectness	Imprecision	Other considerations	Combined Therapy	Mono therapy	Relative Risk (95% CI)		
Monotherapy versus Combined Therapy (SWITCHING monotherapy versus adding another treatment (Non-SSRI, SSRI, and non-pharmacological))											
Outcome of Response											
2 ^{9,10,16,22}	RCT/CCT		N/A	Indirect	Imprecise -1		353	776	0.4 -1.02	LOW	Critical
Outcome Remission											
1 ²⁶	RCT/CCT		N/A	Indirect	Imprecise	STAR*D Equipoise	344	763	1.21-1.70	LOW	Critical

Reference List

1. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. *J Clin Psychopharmacol* 2008;28(6):631-7.
2. George TP, Sacco KA, Vessicchio JC, et al. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. *J Clin Psychopharmacol* 2008;28(3):340-4.
3. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. *J Clin Psychiatry* 2007;68(2):224-36.
4. Shapira B, Nemets B, Trachtenberg A, et al. Phenytoin as an augmentation for SSRI failures: a small controlled study. *J Affect Disord* 2006;96(1-2):123-6.
5. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. *J Clin Psychiatry* 2005;66(1):85-93.
6. Dunner DL, Amsterdam JD, Shelton RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. *J Clin Psychiatry* 2007;68(7):1071-7.
7. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. *Am J Psychiatry* 2001;158(1):131-4.
8. Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. *Ann Intern Med* 2007;147(9):593-602.
9. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.[see comment]. *N Engl J Med* 2006;354(12):1231-42.
10. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression.[see comment]. *N Engl J Med* 2006;354(12):1243-52.
11. Appelberg BG, Syvalahti EK, Koskinen TE, et al. Patients with severe depression may benefit from bupirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. *J Clin Psychiatry* 2001;62(6):448-52.
12. Landén M, Björling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of bupirone in combination with an SSRI in patients with treatment-refractory depression. *J Clin Psychiatry* 1998;59(12):664-8.

13. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. *Am J Psychiatry* 1994;151(9):1372-4.
14. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. *J Clin Psychopharmacol* 2002;22(4):379-87.
15. Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. *J Clin Psychopharmacol* 1996;16(4):307-14.
16. Bondolfi G, Aubry JM, Golaz J, et al. A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. *Swiss Med Wkly* 2006;136(5-6):78-85.
17. Perry EB, Berman RM, Sanacora G, et al. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. *J Clin Psychiatry* 2004;65(2):238-43.
18. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. *Psychopharmacology* 2002;161(2):143-51.
19. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. *Acta Psychiatr Scand* 2001;103(1):66-72.
20. Michelson D, Adler LA, Amsterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2007;68(4):582-7.
21. Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. *J Psychiatr Res* 2009;43(3):205-14.
22. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. *Am J Psychiatry* 2007;164(5):739-52.
23. Wiles NJ, Hollinghurst S, Mason V, et al. A randomized controlled trial of cognitive behavioural therapy as an adjunct to pharmacotherapy in primary care based patients with treatment resistant depression: A pilot study. *Behav Cogn Psychother* 2008;36(1):21-33.
24. Altamura AC, Dell'Osso B, Buoli M, et al. Intravenous augmentative citalopram versus clomipramine in partial/nonresponder depressed patients: a short-term, low dose, randomized, placebo-controlled study. *J Clin Psychopharmacol* 2008;28(4):406-10.

25. Altamura AC, Dell'Osso B, Buoli M, et al. Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study. *Int Clin Psychopharmacol* 2008;23(4):198-202.
26. Lynch TR, Cheavens JS, Cukrowicz KC, et al. Treatment of older adults with co-morbid personality disorder and depression: A dialectical behavior therapy approach. *Int J Geriatr Psychiatry* 2007;22(2):131-43.

Appendix D - Excluded Studies

APA issues practice guideline for major depressive disorder in adults. *Am Fam Physician* 1993;48(7):1312-3.

Exclude: For Guideline published before 2005, OVID-Embase.

Augmenting standard antidepressant treatment may help recovery in elderly. *Brown University Geriatric Psychopharmacol Update* 2007;11(8):1

Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.

Cognitive behavioral therapy + alternative selective serotonin reuptake inhibitor better than alternative SSRI alone in adolescent depression. *J Natl Med Assoc* 2008;100(6):762-3.

Exclude: For study design, OVID-Embase.

Do omega-3 fatty acids help in depression? *Drug Ther Bull* 2007;45(2):9-12. **Exclude:** For study design, EBSCO-CINAHL.

Effect of *Hypericum perforatum* (St John's wort) in major depressive disorder: A randomized controlled trial. *JAMA* 2002;287(14):1807-14.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Electroconvulsive therapy. *JAMA* 1985;254(15):2103-8.

Exclude: For Guideline published before 2005, OVID-Embase

Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression: Treatment for Adolescents With Depression Study (TADS) Randomized Controlled Trial. *JAMA* 2004;292(7):807-20.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology. *J Psychopharmacol* 1993;7(1):19-23.

Exclude: For Guideline published before 2005, OVID-PsycINFO.

Omissions in acknowledgments in: "The treatment for adolescents with depression study (TADS): Long-term effectiveness and safety outcomes". *Arch Gen Psychiatry* 2008;65(1):101

Exclude: For study design, OVID-PsycINFO.

POEMs. CBT plus alternative SSRI is better than alternative SSRI alone in adolescent depression. *J Am Acad Physician Assist* 2008;21(5):58

Exclude: For study design, EBSCO-CINAHL.

Practice guideline for major depressive disorder in adults. *American Psychiatric Association. Am J Psychiatry* 1993;150(4:Suppl):Suppl-26
PMID:8465906

Exclude: For Guideline published before 2005, OVID-Medline.

Separate and combined anxiolytic and anti-depressant treatment of mixed anxiety/depression. A double-blind, placebo controlled comparison. *Sussex Clinical Trials Group. Acta Psychiatr Scand* 1985;72(1):81-8.
PMID:2863922

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

St John's wort = SSRI for moderate-severe depression. *South African Fam Pract* 2005;47(4):18

Exclude: For study design, OVID-Embase.

Switching antidepressants plus CBT best for treatment-resistant depression in teens. *cognitive behavioral therapy. Brown University Child & Adolescent Psychopharmacol Update* 2008;10(5):1-3.

Exclude: For study design, EBSCO-CINAHL.

TADS results show fluoxetine plus CBT safer and more effective for teen depression. *Cognitive-behavioral therapy; Treatment for Adolescents with Depression Study. Brown University Child & Adolescent Psychopharmacol Update* 2007;9(1):1-4.

Exclude: For study design, EBSCO-CINAHL.

The Treatment for Adolescents With Depression Study (TADS): Long-term effectiveness and safety outcomes. *Arch Gen Psychiatry* 2007;64(10):1132-44.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Treating depression with comorbid personality disorder: meds, CT or both?..Cognitive therapy. *Brown University Psychopharmacol Update* 2008;19(4):1 **Exclude:** For study design, EBSCO-CINAHL.

Aan Het Rot MCD, Mathew S. Intravenous ketamine for treatment-resistant major depressive disorder. *Prim Psychiatry* 2008;15(4):39-47.

Exclude: For study design, Wiley-CCTR.

Aarsland D, Larsen JP, Lim NG, et al. Citalopram plus mianserin in patients with Parkinson's disease and depression: An open-label study. *Nord J Psychiatry* 1998;52(2):115-6.

Exclude: For population/diagnosis, OVID-Embase.

Abbass AA. Intensive short-term dynamic psychotherapy of treatment-resistant depression: A pilot study. *Depress Anxiety* 2006;23(7):449-52.

Exclude: For study design, OVID-Embase.

Aberg-Wistedt A. Comparison between zimelidine and desipramine in endogenous depression. A cross-over study. *Acta Psychiatrica* 1982;66(2):129-38.
PMID:6215831

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Aberg A. Controlled cross-over study of a 5-HT uptake inhibiting and an NA uptake inhibiting

- antidepressant. *Acta Psychiatr Scand, Supplementum* 1981;290:244-55. PMID:6452794
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Abraham G, Milev R, Lawson JS. T3 augmentation of SSRI resistant depression. *J Affect Disord* 2006;91(2-3):211-5.
Exclude: For study design, OVID-PsycINFO.
- Abraham IL, Neundorfer MM, Currie LJ. Effects of group interventions on cognition and depression in nursing home residents. *Nurs Res* 1992;41(4):196-202. PMID:1383947
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Abt KL. The effects of a group exercise intervention in the adjunctive treatment of depression *Medicine & Science in Sports & Exercise* 2006;38(5): S99
Exclude: For study design, OVID-PsycINFO.
- Ackermann RT, Williams JW, Jr. Rational treatment choices for non-major depressions in primary care: an evidence-based review. *J Gen Intern Med* 2002;17(4):293-301. PMID:11972726
Exclude: For systematic review before 2005, OVID-Medline.
- Adlersberg S, Toren P, Mester R, et al. Verapamil is not an antidepressant in patients resistant to tricyclic antidepressants. *Clin Neuropharmacol* 1994;17(3):294-7. PMID:9316675
Exclude: For study design, OVID-Medline.
- Adli M, Berghofer A, Linden M, et al. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. *J Clin Psychiatry* 2002;63(9):782-90. PMID:12363118
Exclude: For study design, OVID-Medline.
- Adli M, Pilhatsch M, Bauer M, et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. *Pharmacopsychiatry* 2008;41(6):252-7. PMID:19067263
Exclude: For study design, OVID-Medline.
- Adli M, Berghofer A, Linden M, et al. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: Results of a 2-year observational algorithm study. *J Clin Psychiatry* 2002;63(9):782-90.
Exclude: For study design, OVID-PsycINFO.
- Adson DE, Kushner MG, Eiben KM, et al. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. *Depress Anxiety* 2004;19(2):121-6.
Exclude: For study design, OVID-Embase.
- Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. *J Affect Disord* 2005;86(1):99-104. PMID:15820277
Exclude: For study design, OVID-Medline.
- Agid O, Lerer B. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. *Int J Neuropsychopharmacol* 2003;6(1):41-9. PMID:12899735
Exclude: For study design, OVID-Medline.
- Agnoli A, Martucci N, Manna V. On the antidepressant effect of SAME: Clinical and pharmac-EEG study with SAME alone and in association with a beta-2 stimulant drug, phenoterole. *J de Psychiatrie Biolog Therap* 20: 4-8, 1985
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
- Agosti V. One year clinical and psychosocial outcomes of early-onset chronic depression. *J Affect Disord* 1999;54(1-2):171-5. PMID:10403160
Exclude: For study design, OVID-Medline.
- Agosti V, Ocepek-Welikson K. The efficacy of imipramine and psychotherapy in early-onset chronic depression: A reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program. *J Affect Disord* 1997;43(3):181-6.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Agosti V, Ocepek-Welikson K. The efficacy of imipramine and psychotherapy in early-onset chronic depression: A reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program. *J Affect Disord* 1997;43(3):181-6.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Agricola R, Dalla VG, Urani R, et al. S-adenosyl-L-methionine in the treatment of major depression complicating chronic alcoholism. *Curr Ther Res Clin Exp* 1994;55(1):83-92.
Exclude: For study design, OVID-Embase.
- Ahmed SH, Zaheeruddin. Early experience with fluoxetine. *JPMA* 1991;41(11):275-7. PMID:1766070
Exclude: For study design, OVID-Medline.
- Aikens JE, Kroenke K, Swindle RW, et al. Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care. *Gen Hosp Psychiatry* 2005;27(4):229-36. PMID:15993253
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Ajel K, Bhogal K, Baldwin D. Prescribing of the antidepressant duloxetine: Can local clinical audit findings facilitate medicines management decisions? *Int J Psychiatry Clin Pract* 2008;12(2):156-9.
Exclude: For study design, OVID-Embase.
- Akhondzadeh BA, Moshiri E, Noorbala AA, et al. Comparison of petal of *Crocus sativus* L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31(2):439-42. PMID:17174460
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Akhondzadeh BA, Moshiri E, Noorbala AA, et al. Comparison of petal of *Crocus sativus* L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31(2):439-42.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Akhondzadeh S, Fallah-Pour H, Afkham K, et al. A comparative trial of *Crocus sativus* L. (saffron) and imipramine in mild to moderate depression. *Focus on Alternative and Complementary Therapies* 2005;10(1):22-3.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. *Depress Anxiety* 2009;26(7):607-11.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Akhondzadeh S, Fallah-Pour H, Afkham K, et al. Comparison of *Crocus sativus* L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial. 2004;4:12 PMID:15341662
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Akhondzadeh S, Kashani L, Fotouhi A, et al. Comparison of *Lavandula angustifolia* Mill. tincture and imipramine in the treatment of mild to moderate depression: A double-blind, randomized trial. *Progress in Neuro-Prog Neuropsychopharmacol Biol Psychiatry* 2003;27(1):123-7.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Akhondzadeh S, Kashani L, Fotouhi A, et al. Comparison of *Lavandula angustifolia* Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2003;27(1):123-7.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. *Crocus sativus* L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. *Phytother res* 2005;19(2):148-51. PMID:15852492
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, et al. *Crocus sativus* L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. *Phytotherapy research* 2005;19(2):148-51.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Akhondzadeh S, Jafar S, Rais F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. *Depress Anxiety* 2009;26(7):607-11.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Akizuki N, Okamura H, Akechi T, et al. Clinical experience of the pharmacological treatment algorithm for major depression in advanced cancer patients: Preliminary study. *Int J Psychiatry Clin Pract* 2002;6(2):83-9.
Exclude: For study design,
- Alamo C, Lopez-Munoz F, Rubio G, et al. Combined treatment with reboxetine in depressed patients with no response to venlafaxine: A 6-week follow-up study. *Acta Neuropsychiatrica* 2007;19(5):291-6.
Exclude: For study design, OVID-Embase.
- Alamo C, Lopez-Munoz F, Rubio G, et al. Combined treatment with reboxetine in depressed patients with no response to venlafaxine: A 6-week follow-up study. *Acta Neuropsychiatrica* 2007;19(5):291-6.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Albanese MJ, Clodfelter RC, Jr., Khantzian EJ. Divalproex sodium in substance abusers with mood disorder. *J Clin Psychiatry* 2000;61(12):916-21. PMID:11206596
Exclude: For study design, OVID-Medline.
- Albin, J.I. A study measuring the effectiveness of cognitive/psychosocial intervention with a life-threatening illness: My thoughts, my illness, my life. 1998
Exclude: For study design, OVID-PsycINFO.
- Alderman CP. Pindolol augmentation of antidepressant therapy. *Australian J Hosp Pharm* 1999;29(3):146-8.
Exclude: For systematic review before 2005, OVID-Embase.
- Alexopoulos GS, Sirey JA, Raue PJ, et al. Outcomes of depressed patients undergoing inpatient pulmonary rehabilitation. *Am J Geriatr Psychiatry* 2006;14(5):466-75. PMID:16670251
Exclude: For study design, OVID-Medline.
- Alexopoulos GS, Raue P, Arean P. Problem-solving therapy versus supportive therapy in geriatric major depression with executive dysfunction. *Am J Geriatr Psychiatry* 2003;11(1):46-52. PMID:12527539
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Alexopoulos GS, Raue P, Areán P. Problem-solving therapy versus supportive therapy in geriatric major depression with executive dysfunction. *Am J Geriatr Psychiatry* 2003;11(1):46-52.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Alladin A, Alibhai A. Cognitive hypnotherapy for depression: an empirical investigation. *Int J Clin Exp Hypnosis* 2007;55(2):147-66. PMID:17365072
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Allart-van Dam E, Hosman CM, Hoogduin CA, et al. Prevention of depression in subclinically depressed

- adults: follow-up effects on the 'Coping with Depression' course. *J Affect Disord* 2007;97(1-3):219-28. PMID:16860874
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Allart-van Dam E, Hosman CMH, Hoogduin CAL, et al. The Coping With Depression course: Short-term outcomes and mediating effects of a randomized controlled trial in the treatment of subclinical depression. *Behav Ther* 2003;34(3):381-96.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Allen JJB. Depression and acupuncture: a controlled clinical trial. *Psychiatr Times* 2000;17(3):-6p
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Allen JJB, Schnyer RN, Hitt SK. The efficacy of acupuncture in the treatment of major depression in women. *Psychol Sci* 1998;9(5):397-401.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Alpert JE, Mischoulon D, Rubenstein GE, et al. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. *Ann Clin Psychiatry* 2002;14(1):33-8. PMID:12046638
Exclude: For study design, OVID-Medline.
- Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-L-methionine (SAME) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. *J Clin Psychopharm* 2004;24(6):661-4. PMID:15538131
Exclude: For study design, OVID-Medline.
- Altshuler LL, Cohen LS, Moline ML, et al. Expert consensus guidelines for the treatment of depression in women: A new treatment tool. *Economics of Neuroscience* 2001;3(6):48-61.
Exclude: For Guideline published before 2005, OVID-Embase.
- Altshuler LL, Cohen LS, Moline ML, et al. Treatment of depression in women: A summary of the expert consensus guidelines. *J Psychiatr Pract* 2001;7(3):185-208.
Exclude: For Guideline published before 2005, OVID-PsycINFO.
- Alvarez E, Perez-Sola V, Perez-Blanco J, et al. Predicting outcome of lithium added to antidepressants in resistant depression. *J Affect Disord* 1997;42(2-3):179-86. PMID:9105959
Exclude: For study design, OVID-Medline.
- Amsterdam J, Garcia-Espana F, Fawcett J, et al. Fluoxetine efficacy in menopausal women with and without estrogen replacement. *J Affect Disord* 1999;55(1):11-7. PMID:10512601
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Amsterdam JD, Garcia-Espana F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. *Depress Anxiety* 1997;5(2):84-90. PMID:9262938
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Amsterdam JD, Berwisch NJ. High dose tranylcypromine therapy for refractory depression. *Pharmacopsychiatry* 1989;22(1):21-5. PMID:2710808
Exclude: For study design, OVID-Medline.
- Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study. *J Affect Disord* 2005;89(1-3):183-8. PMID:16213594
Exclude: For study design, OVID-Medline.
- Amsterdam JD, Williams D, Michelson D, et al. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. *Neuropsychobiology* 2009;59(4):227-33. PMID:19571597
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Amsterdam JD, Berwisch N. Treatment of refractory depression with combination reserpine and tricyclic antidepressant therapy. *J Clin Psychopharm* 1987;7(4):238-42.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression--a retrospective study. *J Affect Disord* 2005;89(1-3):183-8.
Exclude: For study design, OVID-PsycINFO.
- Anderson IM, Sarsfield A, Haddad PM. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: An open-label, pilot study. *J Affect Disord* 2009;117(1-2):116-9.
Exclude: For study design, OVID-Embase.
- Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. *J Psychopharmacol* 2000;14(1):3-20.
Exclude: For Guideline published before 2005, OVID-Embase.
- Anderson T, Watson M, Davidson R. The use of cognitive behavioural therapy techniques for anxiety and depression in hospice patients: a feasibility study. *PALLIAT MED* 2008;22(7):814-21. PMID:18755828
Exclude: For study design, OVID-Medline.
- Andrade C, Aswath A, Chaturvedi SK, et al. GS-02 for dysthymic disorder: results of a preliminary, open study. *J Herb Pharmacother* 2002;2(1):49-55.
Exclude: For study design, EBSCO-CINAHL.
- Andruskevicius S. Parameters of the spectral analysis of the heart rate variability in treating depression. *Medicina (Kaunas, Lithuania)* 2009;45(3):214-20. PMID:19357451
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Angheliescu IG, Kohnen R, Szegedi A, et al. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results

- from a randomized multicenter study. *Pharmacopsychiatry* 2006;39(6):213-9. PMID:17124643
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Angst J. Severity of depression and benzodiazepine co-medication in relationship to efficacy of antidepressants in acute trials: A meta-analysis of moclobemide trials. *Hum Psychopharmacol* 1993;8(6):401-7.
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Annesi JJ. Changes in Depressed Mood Associated With 10 Weeks of Moderate Cardiovascular Exercise in Formerly Sedentary Adults. *Psychol Rep* 2005;96(3):855-62.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Anseau M, Pitchot W, Gonzalez MA, et al. Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperature. *Human Psychopharm* 1993;8(4):279-83.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Anseau M, Pitchot W, Gonzalez Moreno A, et al. Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperature. *Hum Psychopharmacol* 1993;8(4):279-83.
Exclude: For study design, OVID-PsycINFO.
- Antikainen R, Lehtonen J, Koponen HJ, et al. The effect of hospital treatment on depression and anxiety in patients with borderline personality organization. *Nord J Psychiatry* 1992;46(6):399-405.
Exclude: For study design, OVID-PsycINFO.
- Antonuccio DO, Thomas M, Danton WG. A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (Prozac) in the treatment of depression. *Behav Ther* 1997;28(2):187-210.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Antonuccio DO, Akins WT, Chatham PM, et al. An exploratory study: the psychoeducational group treatment of drug-refractory unipolar depression. *Journal of Behav Ther & Experimental Psychiatry* 1984;15(4):309-13. PMID:6396319
Exclude: For study design, OVID-Medline.
- Antunes HKM, Stella SG, Santos RF, et al. Depression, anxiety and quality of life scores in seniors after an endurance exercise program. *Revista Brasileira de Psiquiatria* 2005;27(4):266-71.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Appelhof BC, Brouwer JP, van Dyck R, et al. Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. *Journal of Clinical Endocrinology & Metabolism* 2004;89(12):6271-6. PMID:15579788
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Araya R, Flynn T, Rojas G, et al. Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. *Am J Psychiatry* 2006;163(8):1379-87.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Arean PA, Gum A, McCulloch CE, et al. Treatment of depression in low-income older adults. *Psychol Aging* 2005;20(4):601-9. PMID:16420135
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Arean PA, Gum A, McCulloch CE, et al. Treatment of depression in low-income older adults. *Psychol Aging* 2005;20(4):601-9.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Areán PA, Gum A, McCulloch CE, et al. Treatment of depression in low-income older adults. *Psychol Aging* 2005;20(4):601-9.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Arnold LM, Meyers AL, Sunderajan P, et al. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. *Ann Clin Psychiatry* 2008;20(4):187-93.
Exclude: For study design, Wiley-CCTR.
- Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: A meta-analysis. *Arch Gen Psychiatry* 1996;53(9):842-8.
Exclude: For systematic review before 2005, OVID-Embase.
- Arsland D, Larsen JP, Neh GL, et al. alpha₂-adrenoreceptor antagonism and serotonin reuptake inhibition in patients with Parkinson disease and depression. *Nord J Psychiatry* 2000;54(6):411-5.
Exclude: For study design, OVID-Embase.
- Artigas F, Pérez V, Alvarez E, et al. Neurobiological differences between responders and non-responders to SSRI treatments. Evidence from pindolol augmentation. *Eur Neuropsychopharmacol* 1999;9(Suppl 5):S177
Exclude: For study design, Wiley-CCTR.
- Artigas F, Romero L, de Montigny C, et al. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. *Trends Neurosci* 1996;19(9):378-83.
Exclude: For study design, OVID-PsycINFO.
- Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. *Arch Gen Psychiatry* 1994;51(3):248-51.
Exclude: For study design, OVID-PsycINFO.
- Asarnow JR, Scott CV, Mintz J. A combined cognitive-behavioral family education intervention for depression in children: A treatment development study. *Cogn Ther Res* 2002;26(2):221-9.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

- Asarnow JR, Jaycox LH, Tang L, et al. Long-term benefits of short-term quality improvement interventions for depressed youths in primary care. *Am J Psychiatry* 2009;166(9):1002-10. PMID:19651711
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Asarnow JR, Scott CV, Mintz J. A combined cognitive-behavioral family education intervention for depression in children: A treatment development study. *Cogn Ther Res* 2002;26(2):221-9.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Asarnow JR, Jaycox LH, Duan N, et al. Effectiveness of a Quality Improvement Intervention for Adolescent Depression in Primary Care Clinics: A Randomized Controlled Trial. *JAMA* 2005;293(3):311-9.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Asheyckik R, Jackson T, Baker H, et al. The efficacy of L-tryptophan in the reduction of sleep disturbance and depressive state in alcoholic patients. *Journal of Studies on Alcohol* 1989;50(6):525-32. PMID:2685471
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Atlantis E, Chow C-M, Kirby A, et al. An effective exercise-based intervention for improving mental health and quality of life measures: A randomized controlled trial. *PREV MED* 2004;39(2):424-34.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Atmaca M, Kuloglu M, Tezcan E, et al. Switching to tianeptine in patients with antidepressant-induced sexual dysfunction. *Hum Psychopharmacol* 2003;18(4):277-80.
Exclude: For study design, OVID-PsycINFO.
- Austin MP, Souza FG, Goodwin GM. Lithium augmentation in antidepressant-resistant patients. A quantitative analysis. *Br J Psychiatry* 1991;159:510-4. PMID:1836411
Exclude: For systematic review before 2005, OVID-Medline.
- Azhar MZ, Varma SL. Religious psychotherapy in depressive patients. *Psychother Psychosom* 1995;63(3-4):165-8. PMID:7624461
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. *Psychosom Med* 2000;62(5):633-8. PMID:11020092
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Baca BE, Giner UJ, Leal CC, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. *Depress Anxiety* 2005;22(2):68-76.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.
- Baghai TC, Marcuse A, Brosch M, et al. The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. *World J Biol Psychiatry* 2006;7(2):82-90. PMID:16684680
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bailey, H.A. Coue revisited: An internet-based investigation of repetition and positive self-statements on depression, self-esteem, and automatic thoughts. Bailey. 2004
Exclude: For study design, OVID-PsycINFO.
- Baker AL, Wilson PH. Cognitive-behavior therapy for depression: The effects of booster sessions on relapse. *Behav Ther* 1985;16(4):335-44.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
- OVID-Embase.
- Bakish D, Hooper CL, Thornton MD, et al. Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. *Int Clin Psychopharmacol* 1997;12(2):91-7. PMID:9219044
Exclude: For study design, OVID-Medline.
- Bakish D, Hooper CL, West DL, et al. Moclobemide and specific serotonin re-uptake inhibitor combination treatment of resistant anxiety and depressive disorders. *Hum Psychopharmacol* 1995;10(2):105-9.
Exclude: For study design, OVID-Embase.
- Baldree, B.F. The self-statement: Cognitive mediation in affective disorder intervention strategies. Baldree. 1996
Exclude: For study design, OVID-PsycINFO.
- Baldwin D, Hawley C, Szabadi E, et al. Reboxetine in the treatment of depression: Early clinical experience in the UK. *Int J Psychiatry Clin Pract* 1998;2(3):195-201.
Exclude: For study design, OVID-Embase.
- Baldwin RC, Jeffries S, Jackson A, et al. Treatment response in late-onset depression: Relationship to neuropsychological, neuroradiological and vascular risk factors. *Psychol Med* 2004;34(1):125-36.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.
- Ball C, Rice F, Thapar A. Childhood depression. *Current Paediatrics* 2000;10(4):259-63.
Exclude: For study design, OVID-Embase.
- Ball J, Kearney B, Wilhelm K, et al. Cognitive behaviour therapy and assertion training groups for patients with depression and comorbid personality disorders. *Behav Cogn Psychother* 2000;28(1):71-85.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: A meta-analysis of early and late outcomes from randomised controlled trials. *J Affect Disord* 2004;79(1-3):137-

47.

Exclude: For systematic review before 2005, OVID-PsycINFO.

Balyk, E.D. An analysis of rational emotive hypnotherapy in the treatment of depression: A pilot study Balyk. 2004

Exclude: For study design, OVID-PsycINFO.

Bano M, Iqbal F, Irshad E. Treatment of depression: Different approaches. . Journal of Personality and Clinical Studies 2003;19(1):63-9.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Bar-Sela G, Atid L, Danos S, et al. Art therapy improved depression and influenced fatigue levels in cancer patients on chemotherapy. *Psycho Oncol* 2007;16(11):980-4. **Exclude:** For study design, EBSCO-CINAHL.

Barak Y, Olmer A, Aizenberg D. Antidepressants reduce the risk of suicide among elderly depressed patients. *Neuropsychopharmacol* 2006;31(1):178-81. PMID:16123751

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Barak Y, Stein D, Levine J, et al. Thyroxine augmentation of fluoxetine treatment for resistant depression in the elderly: An open trial. *Hum Psychopharmacol* 1996;11(6):463-7.

Exclude: For study design, OVID-Embase.

Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. *Ann Clin Psychiatry* 2004;16(4):189-94. PMID:15702566

Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. *J Clin Psychiatry* 2002;63(8):737-41. PMID:12197456

Exclude: For study design, OVID-Medline.

Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. *J Clin Psychiatry* 2004;65(7):975-81. PMID:15291687

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Barbisoni P, Bertozzi B, Franzoni S, et al. Mood improvement in elderly women after in-hospital physical rehabilitation. *Arch Phys Med Rehabil* 1996;77(4):346-9.

Exclude: For study design, OVID-Embase.

Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. *J Clin Psychiatry* 2003;64(4):403-7. PMID:12716240

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Bares M, Brunovsky M, Kopecek M, et al. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment

resistant depressive disorder: a pilot study. *J Psychiatr Res* 2007;41(3-4):319-25. PMID:16889798

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Bares M, Brunovsky M, Kopecek M, et al. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. *Eur Psychiatry* 2008;23(5):350-5. PMID:18450430

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Bares M, Kopecek M, Novak T, et al. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: A double-blind, single-centre, randomized study. *J Affect Disord* 2009;118(1-3):94-100.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Barker WA, Scott J, Eccleston D. The Newcastle chronic depression study: results of a treatment regime. *Int Clin Psychopharmacol* 1987;2(3):261-72. PMID:3121718

Exclude: For study design, OVID-Medline.

Barkham M, Mooney J, Davis G. Cognitive-behavioural therapy in two-plus-one sessions: a pilot field trial. *Behav Psychother* 1992;20(2):147-54.

Exclude: For population/not failed to respond to an SSRI, OVID-AMED.

Barkham M, Rees A, Shapiro DA, et al. Outcomes of time-limited psychotherapy in applied settings: replicating the Second Sheffield Psychotherapy Project. *J Consult Clin Psychol* 1996;64(5):1079-85. **Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.

Barkham M, Shapiro DA, Hardy GE, et al. Psychotherapy in two-plus-one sessions: outcomes of a randomized controlled trial of cognitive-behavioral and psychodynamic-interpersonal therapy for subsyndromal depression. *J Consult Clin Psychol* 1999;67(2):201-11. PMID:10224730

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Barkham M, Shapiro DA. Brief psychotherapeutic interventions for job-related distress: A pilot study of Prescriptive and Exploratory therapy. *Counselling Psychology Quarterly* 1990;3(2):133-47.

Exclude: For study design, OVID-PsycINFO.

Barkham M, Rees A, Shapiro DA, et al. Outcomes of time-limited psychotherapy in applied settings: Replicating the Second Sheffield Psychotherapy Project. . *J Consult Clin Psychol* 1996;64(5):1079-85.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Barkham M, Shapiro DA, Hardy GE, et al. Psychotherapy in two-plus-one sessions: Outcomes of a randomized controlled trial of cognitive-behavioral and psychodynamic-interpersonal therapy for subsyndromal depression. . *J Consult Clin Psychol*

1999;67(2):201-11.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Barlow J, Coren E, Stewart-Brown S. Parent-training programmes for improving maternal psychosocial health. In Cochrane 2003. **Exclude:** For systematic review before 2005, Wiley-CDSR.

Barnhofer T, Crane C, Hargus E, et al. Mindfulness-based cognitive therapy as a treatment for chronic depression: A preliminary study. *Beh Res Ther* 2009;47(5):366-73.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Barrett JE, Williams J, Oxman TE, et al. The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: Background and research plan. *Gen Hosp Psychiatry* 1999;21(4):260-73.

Exclude: For study design, OVID-Embase.

Barrett JE, Williams JW, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. *The J Fam Prac* 2001;50(5):405-12.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Barrett PM, Farrell LJ, Ollendick TH, et al. Long-term outcomes of an Australian universal prevention trial of anxiety and depression symptoms in children and youth: an evaluation of the friends program. *J Clin Child Adolesc Psychol* 2006;35(3):403-11. PMID:16836477

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Barsevick AM, Sweeney C, Haney E, et al. A systematic qualitative analysis of psychoeducational interventions for depression in patients with cancer. *Oncol Nurs Forum* 2002;29(1):73-84.

Exclude: For systematic review before 2005, OVID-AMED.

Bartholomew JB, Morrison D, Ciccolo JT. Effects of acute exercise on mood and well-being in patients with major depressive disorder. *Med Sci Sports Exerc* 2005;37(12):2032-7.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Basoglu C, Ates MA, Algul A, et al. Adjuvant folate with escitalopram treatment and homocystein, folate, vitamin B-12 levels in patients with major depressive disorder. *Klinik Psikofarmakoloji Bulteni* 2009;19(2):135-42.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Basti AA, Moshiri E, Noorbala AA, et al. Comparison of petal of *Crocus sativus* L. and fluoxetine in the treatment of depressed outpatients: A pilot double-blind randomized trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31(2):439-42.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Bastiaens L. Adolescents' response to antidepressant treatment in a community mental health center. *Community Ment Health J* 2005;41(1):77-84. PMID:15932054

Exclude: For study design, OVID-Medline.

Bastiaens L. Response to antidepressant treatment in a community mental health center. *Community Ment Health J* 2004;40(6):561-7. PMID:15672694

Exclude: For study design, OVID-Medline.

Bauer M, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. *Am J Psychiatry* 2000;157(9):1429-35. PMID:10964859

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Bauer M, Baur H, Berghofer A, et al. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. *J Affect Disord* 2002;68(2-3):285-94. PMID:12063156

Exclude: For study design, OVID-Medline.

Bauer M, Pfennig A, Linden M, et al. Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. *J Clin Psychopharm* 2009;29(4):327-33. PMID:19593170

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. *J Clin Psychiatry* 2009;70(4):540-9. PMID:19358791

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. [erratum appears in *J Clin Psychopharmacol*. 2000 Apr;20(2):287; PMID:10770484]. *J Clin Psychopharm* 1999;19(5):427-34. PMID:10505584

Exclude: For systematic review before 2005, OVID-Medline.

Bauer M, Adli M, Baethge C, et al. Lithium Augmentation Therapy in Refractory Depression: Clinical Evidence and Neurobiological Mechanisms. *Canadian Journal of Psychiatry* 2003;48(7):440-8.

Exclude: For systematic review before 2005, OVID-Embase.

Bauer M, Forsthoff A, Baethge C, et al. Lithium augmentation therapy in refractory depression-update 2002. *Eur Arch Psychiatry Clin Neurosci* 2003;253(3):132-9. PMID:12904977

Exclude: For systematic review before 2005, OVID-Medline.

Bauer M, Zaninelli R, Muller-Oerlinghausen B, et al. Paroxetine and amitriptyline augmentation of lithium

- in the treatment of major depression: a double-blind study. *J Clin Psychopharm* 1999;19(2):164-71. PMID:10211918
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bauer M, Berghofer A, Bschor T, et al. Supraphysiological doses of L-Thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. *Neuropsychopharmacol* 2002;27(4):620-8.
Exclude: For study design,
- Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biol Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. *World J Biol Psychiatry* 2002;3(1):5-43. PMID:12479086
Exclude: For Guideline published before 2005, OVID-Medline.
- Bauer M, Hellweg R, Graf KJ, et al. 3rd International Conference on Refractory Depression (1995, October 18-21, Napa, CA, US) & 149th Annual Meeting of the American Psychiatric Association (1996, May 4-9, New York, NY, US). *Neuropsychopharmacol* 1998;18(6):444-55.
Exclude: For study design, OVID-PsycINFO.
- Bauer M, Dopfmer S. Correction by authors to "Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies.". *J Clin Psychopharm* 2000;20(2):287
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Bauer M, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. *Am J Psychiatry* 2000;157(9):1429-35.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Bauer M, Baur H, Berghofer A, et al. Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders. *J Affect Disord* 2002;68(2-3):285-94.
Exclude: For study design, OVID-PsycINFO.
- Baumann P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation. *J Clin Psychopharm* 1996;16(4):307-14.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-PsycINFO.
- Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. *Hum Psychopharmacol* 2007;22(1):1-9. PMID:17191266
Exclude: For study design, OVID-Medline.
- Baxter J, Liston EH, Schwartz JM. Prolongation of the antidepressant response to partial sleep deprivation by lithium. *Psychiatry Res* 1986;19(1):17-23.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
- Baxter LR, Liston EH, Schwartz JM, et al. Prolongation of the antidepressant response to partial sleep deprivation by lithium. *Psychiatry Res* 1986;19(1):17-23.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Beach SRH, O'Leary KD. Treating depression in the context of marital discord: Outcome and predictors of response of marital therapy versus cognitive therapy. *Behav Ther* 1992;23(4):507-28.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Beach SR, O'Leary KD. The treatment of depression occurring in the context of marital discord. *Behav Ther* 1986;17(1):43-9.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Beardslee WR, Salt P, Versage EM, et al. Sustained change in parents receiving preventive interventions for families with depression. *Am J Psychiatry* 1997;154(4):510-5.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Bearn J, Franey C, Arendt J, et al. A study of the effects of desipramine treatment alone and in combination with L-triiodothyronine on 6-sulphatoxymelatonin excretion in depressed patients. *Br J Psychiatry* 1989;155:341-7. PMID:2611544
Exclude: For study design, OVID-Medline.
- Beasley CM, Jr., Sayler ME, Cunningham GE, et al. Fluoxetine in tricyclic refractory major depressive disorder. *J Affect Disord* 1990;20(3):193-200. PMID:2148340
Exclude: For study design, OVID-Medline.
- Beauchemin KM, Hays P. Phototherapy is a useful adjunct in the treatment of depressed in-patients. *Acta Psychiatr Scand* 1997;95(5):424-7. PMID:9197908
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Beauchemin KM, Hays P. Sunny hospital rooms expedite recovery from severe and refractory depressions. *J Affect Disord* 1996;40(1-2):49-51. PMID:8882914
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Beck AT, Hollon SD, Young JE. Treatment of depression with cognitive therapy and amitriptyline. *Arch Gen Psychiatry* 1985;42(2):142-8.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
- Beckman SE, Sommi RW, Switzer J. Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability. *Pharmacotherapy* 2000;20(5):568-74. PMID:10809344

- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Bedi N, Chilvers C, Churchill R, et al. Assessing effectiveness of treatment of depression in primary care. *Br J Psychiatry* 2000;177(4):312-8.
- Exclude:** For population/not failed to respond to an SSRI, OVID-AMED.
- Behnke K, Jensen GS, Graubaum HJ, et al. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. *Advances in Therapy* 2002;19(1):43-52. PMID:12008860
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Bell IR, Edman JS, Morrow FD, et al. Brief communication. Vitamin B1, B2, and B6 augmentation of tricyclic antidepressant treatment in geriatric depression with cognitive dysfunction. *J Am Coll Nutr* 1992;11(2):159-63. PMID:1578091
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Bell KM, Plon L, Bunney WE, Jr., et al. S-adenosylmethionine treatment of depression: a controlled clinical trial. *Am J Psychiatry* 1988;145(9):1110-4. PMID:3046382
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Bell KM, Potkin SG, Carreon D, et al. S-adenosylmethionine blood levels in major depression: changes with drug treatment. *Acta Neurologica Scandinavica* 1994;Supplementum.:154-8. PMID:7941961
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. *Int J Clin Pharmacol Res* 1990;10(6):355-60. PMID:2099360
- Exclude:** For population/diagnosis, OVID-Medline.
- Bellino S, Zizza M, Rinaldi C, et al. Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. *Can J Psychiatry* 2007;52(11):718-25. PMID:18399039
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Bellino S, Zizza M, Rinaldi C, et al. Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy. *Can J Psychiatry* 2006;51(7):453-60. PMID:16838827
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Belsher G, Wilkes TCR, Rush AJ. An open, multisite pilot study of cognitive therapy for depressed adolescents. *Journal of Psychother Pract Res* 1995;4(1):52-66.
- Exclude:** For study design, OVID-Embase.
- Benedetti F, Colombo C, Pontiggia A, et al. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. *J Clin Psychiatry* 2003;64(6):648-53. PMID:12823078
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Benkert O, Szegedi A, Wetzel H, et al. Dose escalation vs continued doses of paroxetine and maprotiline: A prospective study in depressed outpatients with inadequate treatment response. *Acta Psychiatr Scand* 1997;95(4):288-96.
- Exclude:** For Mixed antidepressants; some failed on SSRI, OVID-PsycINFO.
- Bennett, C.F. Treatment effects of acupuncture on anxiety and depression in working women University of South Carolina. 1997
- Exclude:** For study design, EBSCO-CINAHL.
- Bennett JA, Hirschowitz J, Zemlan F, et al. Combined thioridazine and desipramine: early antidepressant response. *Psychopharmacology* 1984;82(3):263-5.
- Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.
- Bennett JA. Combined thioridazine and desipramine: Early antidepressant response. *Psychopharmacology* 1984;82(3):263-5.
- Exclude:** For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Berger M, Gastpar M. Trimipramine: A challenge to current concepts on antidepressives. *Eur Arch Psychiatry Clin Neurosci* 1996;246(5):235-9.
- Exclude:** For systematic review before 2005, OVID-PsycINFO.
- Berger S, Schad T, Von W, V, et al. Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. *AIDS* 2008;22(6):767-75.
- Exclude:** For population/not failed to respond to an SSRI, OVID-Embase.
- Berkman LF, Blumenthal J, Burg M, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICH) Randomized Trial. *JAMA* 2003;289(23):3106-16. PMID:12813116
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. *J Affect Disord* 1995;34(3):187-92. PMID:7560546
- Exclude:** For study design, OVID-Medline.
- Berlanga C, Ortega-Soto HA, Ontiveros M, et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. *Psychiatry Res* 1992;44(3):257-62. PMID:1289923
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Berlanga C, Mendieta D, Alva G, et al. Failure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depression. *J Womens Health* 2003;12(1):33-9. PMID:12639367
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.

- Berlanga C, Ortega-Soto HA, Ontiveros M, et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. *Psychiatry Res* 1992;44(3):257-62.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Berlanga C, Mendieta D, Alva G, et al. Failure of Tibolone to Potentiate the Pharmacological Effect of Fluoxetine in Postmenopausal Major Depression. *J Womens Health* 2003;12(1):33-9.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Berlim MT, Pargendler J, Brenner J, et al. Significant improvement in the quality of life of Brazilian depressed outpatients 12 weeks following the start of antidepressants. *Psychiatry Res* 2007;153(3):253-9.
Exclude: For study design, OVID-Embase.
- Berman RM, Fava M, Thase ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. *Cns Spectrums* 2009;14(4):197-206. PMID:19407731
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. *Am J Psychiatry* 1997;154(1):37-43. PMID:8988956
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2007;68(6):843-53. PMID:17592907
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Berman RM, Anand A, Capiello A, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. *Biol Psychiatry* 1999;45(9):1170-7. PMID:10331109
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Bernstein GA, Borchardt CM, Perwien AR, et al. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. *J Am Acad Child Adolesc Psychiatry* 2000;39(3):276-83.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Berstrom J, Hollandare F, Carlbring P, et al. Treatment of depression via the Internet: A randomized trial of a self-help programme. *J Telemed Telecare* 2003;9(Suppl2):85
Exclude: For study design, OVID-PsycINFO.
- Bertschy G, Ragama-Pardos E, Ait-Ameur A, et al. Lithium augmentation in venlafaxine non-responders: an open study. *Eur Psychiatry* 2003;18(6):314-7. PMID:14611927
Exclude: For study design, OVID-Medline.
- Beusterien KM, Buesching DP, Robison RN, et al. Evaluation of an information exchange program for primary care patients with depression. *Disease Management* 2000;3(1):1-9.
Exclude: For study design, OVID-Embase.
- Beutler LE, Scogin F, Kirkish P, et al. Group cognitive therapy and alprazolam in the treatment of depression in older adults. *J Consult Clin Psychol* 1987;55(4):550-6.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Beutler LE, Machado PP, Engle D, et al. Differential patient treatment maintenance among cognitive, experiential, and self-directed psychotherapies. *Journal of Psychotherapy Integration* 1993;3(1):15-31.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Bhar SS, Gelfand LA, Schmid SP, et al. Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. *J Affect Disord* 2008;110(1-2):161-6. PMID:18276017
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bichescu D, Neuner F, Schauer M, et al. Narrative exposure therapy for political imprisonment-related chronic posttraumatic stress disorder and depression. *Behav Res Ther* 2007;45(9):2212-20. PMID:17288990
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bidzinski A, Swiecicki L, Tonderska A, et al. Effects of phototherapy on the activities of MAO, DBH, pseudocholinesterase and upon choline transport in erythrocytes of patients with seasonal and non-seasonal depression. *New Trends in Experimental and Clinical Psychiatry* 1996;12(3):175-8.
Exclude: For study design, OVID-Embase.
- Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. *British Journal of Clinical Pharmacology* 2008;65(4):558-64. PMID:18070221
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bilich LL, Deane FP, Phipps AB, et al. Effectiveness of bibliotherapy self-help for depression with varying levels of telephone helpline support. *Clinical Psychology & Psychotherapy* 2008;15(2):61-74. PMID:19115429
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bindemann S, Soukop M, Kaye SB. Randomised controlled study of relaxation training. *Eur J Cancer* 1991;27(2):170-4.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Bird D, Haddad PM, Dursun SM. An overview of the definition and management of treatment-resistant

depression. . Klinik Psikofarmakoloji Bulteni 2002;12(2):92-101.

Exclude: For systematic review before 2005, OVID-PsycINFO.

Birkenhager TK, Vegt M, Nolen WA. An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression. *Pharmacopsychiatry* 1997;30(1):23-6. PMID:9065966

Exclude: For study design, OVID-Medline.

Birkenhager TK, Moleman P, Nolen WA. Benzodiazepines for depression? A review of the literature. *Int Clin Psychopharmacol* 1995;10(3):181-95.

Exclude: For systematic review before 2005, OVID-PsycINFO.

Birkenhager TK, van den Broek WW, Mulder PG, et al. Efficacy and tolerability of tranlycypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. *J Clin Psychiatry* 2004;65(11):1505-10. PMID:15554763

Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Medline.

Birkenhager TK, van den Broek WW, Moleman P, et al. Outcome of a 4-step treatment algorithm for depressed inpatients. *J Clin Psychiatry* 2006;67(8):1266-71. PMID:16965206

Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Medline.

Birmaher B, Brent DA, Kolko D, et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. *Arch Gen Psychiatry* 2000;57(1):29-36. PMID:10632230

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Birmaher B, Waterman GS, Ryan ND, et al. Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression. *J Am Acad Child Adolesc Psychiatry* 1998;37(5):527-35. PMID:9585655

Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Medline.

Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: A review of the past 10 years, Part II. *J Am Acad Child Adolesc Psychiatry* 1996;35(12):1575-83.

Exclude: For systematic review before 2005, OVID-PsycINFO.

Birmaher B, Waterman GS, Ryan ND, et al. Randomized, controlled trial of amitriptyline versus placebo for adolescents with "treatment-resistant" major depression. *J Am Acad Child Adolesc Psychiatry* 1998;37(5):527-35.

Exclude: For Mixed antidepressants; some failed on SSRI , OVID-PsycINFO.

Bjerkenstedt L, Edman GV, Alken RG, et al. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. *Eur Arch Psychiatry Clin Neurosci* 2005;255(1):40-7.

PMID:15538592

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. *J Affect Disord* 1986;10(1):67-75.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Blackburn IM, Bishop S. Changes in cognition with pharmacotherapy and cognitive therapy. *Br J Psychiatry* 1983;143:609-17. PMID:6661604

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. *Br J Psychiatry* 1997;171:328-34. PMID:9373420

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Blackburn IM, Bishop S, Glen AI, et al. The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. *Br J Psychiatry* 1981;139:181-9. PMID:7317698

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Blanch J, Rousaud A, Hautzinger M, et al. Assessment of the efficacy of a cognitive-behavioural group psychotherapy programme for HIV-infected patients referred to a consultation-liaison psychiatry department. *Psychother Psychosom* 2002;71(2):77-84. PMID:11844943

Exclude: For study design, OVID-Medline.

Blenkiron P. Coping with depression: A pilot study to assess the efficacy of a self-help audio cassette. *British Journal of General Practice* 2001;51(466):366-70.

Exclude: For study design, OVID-Embase.

Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. . *J Clin Psychopharm* 1995;15(3):217-22. PMID:7636000

Exclude: For study design, OVID-Medline.

Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. *European Neuropsychopharmacol* 2009;19(7):457-65. PMID:19345072

Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Medline.

Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. *J Clin Psychopharm* 1995;15(3):217-22.

Exclude: For study design, OVID-PsycINFO.

- Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. *Neuropsychopharmacol* 1997;16(5):333-8.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Blitzer LE, Atchison-Nevel DJ, Kenny MC. Using acupuncture to treat major depressive disorder: A pilot investigation. *Clinical Acupuncture and Oriental Medicine* 2003;4(4):144-7.
Exclude: For study design, OVID-Embase.
- Bloch M, Schwartzman Y, Bonne O, et al. Concurrent treatment of nonresistant major depression with desipramine and lithium: a double-blind, placebo-controlled study. *J Clin Psychopharm* 1997;17(1):44-8. PMID:9004056
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bloch M, Schwartzman Y, Bonne O, et al. Concurrent treatment of nonresistant major depression with desipramine and lithium: A double-blind, placebo-controlled study. *J Clin Psychopharm* 1997;17(1):44-8.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Blom MB, Jonker K, Dusseldorp E, et al. Combination treatment for acute depression is superior only when psychotherapy is added to medication. *Psychother Psychosom* 2007;76(5):289-97. PMID:17700049
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Blumenthal JA, Babyak MA, Moore KA, et al. Effects of exercise training on older patients with major depression. *Arch Intern Med* 1999;159(19):2349-56. PMID:10547175
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. *Psychosom Med* 2007;69(7):587-96. PMID:17846259
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Blumenthal JA, Emery CF, Rejeski WJ. The effects of exercise training on psychosocial functioning after myocardial infarction. *J Cardiopulm Rehabil* 1988;8(5):183-93.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Blumer D. Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. *J Clin Psychiatry* 1997;58(1):3-11.
Exclude: For study design, OVID-PsycINFO.
- Bockting CL, Schene AH, Spinhoven P, et al. Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. *J Consult Clin Psychol* 2005;73(4):647-57. PMID:16173852
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bodenmann G, Plancherel B, Beach SRH, et al. Effects of Coping-Oriented Couples Therapy on Depression: A Randomized Clinical Trial. *J Consult Clin Psychol* 2008;76(6):944-54.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Bodin T, Martinsen EW. Mood and Self-Efficacy During Acute Exercise in Clinical Depression. A Randomized, Controlled Study. *Journal of Sport & Exercise Psychology* 2004;26(4):623-33.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression. *J Clin Psychopharm* 1995;15(1):49-57. PMID:7714228
Exclude: For study design, OVID-Medline.
- Bodkin JA, Lasser RA, Wines JD, Jr., et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. *J Clin Psychiatry* 1997;58(4):137-45. PMID:9164423
Exclude: For study design, OVID-Medline.
- Bogner HR, Morales KH, Post EP, et al. Diabetes, depression, and death: A randomized controlled trial of a depression treatment program for older adults based in primary care (PROSPECT). *Diabetes Care* 2007;30(12):3005-10.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Bond M, Perry JC. Psychotropic medication use, personality disorder and improvement in long-term dynamic psychotherapy. *J NERV MENT DIS* 2006;194(1):21-6. PMID:16462551
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bondolfi G, Lissner C, Kosel M, et al. Fluoxetine augmentation in citalopram non-responders: Pharmacokinetic and clinical consequences. *Int J Neuropsychopharmacol* 2000;3(1):55-60.
Exclude: For study design, OVID-Embase.
- Bonnet, L.H. Effects of aerobic exercise in combination with Cognitive Therapy on self-reported depression Bonnet. 2006
Exclude: For study design, OVID-PsycINFO.
- Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. *Revue de Recherche et d'Experimentation Psychopharmacologique*. *Am J Psychiatry* 1998;155(10):1346-51. PMID:9766765
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Borgherini G, Conforti D, Cognolato S, et al. Efficacy and tolerability of venlafaxine in patients hospitalized with moderate to severe depression: An open-label pilot study. *Curr Ther Res Clin Exp* 1999;60(12):672-80.
Exclude: For study design, OVID-Embase.

- Bornstein S. Cross-over trial comparing the antidepressant effects of amineptine and maprotiline. *Current Medical Research and Opinion* 1979;6(2):107-10.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Borup C, Unden M. Combined fluoxetine and disulfiram treatment of alcoholism with comorbid affective disorders. A naturalistic outcome study, including quality of life measurements. *Eur Psychiatry* 1994;9(2):83-9.
Exclude: For study design, OVID-Embase.
- Bosmans JE, Hermens MLM, de Bruijne MC, et al. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression. *J Affect Disord* 2008;111(1):106-12.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Bosscher RJ. Running and mixed physical exercises with depressed psychiatric patients. *Int J Sport Psychol* 1993;24(2):170-84.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Bosworth HB, Hays JC, George LK, et al. Psychosocial and clinical predictors of unipolar depression outcome in older adults. *Int J Geriatr Psychiatry* 2002;17(3):238-46.
Exclude: For study design,
- Bottlender R, Rudolf D, Jager M, et al. Are bipolar I depressive patients less responsive to treatment with antidepressants than unipolar depressive patients? Results from a case control study. *Eur Psychiatry* 2002;17(4):200-5.
Exclude: For study design,
- Bouckoms A, Mangini L. Pergolide: An antidepressant adjuvant for mood disorders? *Psychopharmacol Bull* 1993;29(2):207-11.
Exclude: For study design, OVID-PsycINFO.
- Boury M, Treadwell T, Kumar VK. Integrating psychodrama and cognitive therapy--an exploratory study. *International Journal of Action Methods: Psychodrama, Skill Training, and Role Playing* 2001;54(1):13-37.
Exclude: For study design, OVID-PsycINFO.
- Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. *South African Medical Journal* 540;Suid-Afrikaanse(4 Suppl):534-7. PMID:9180827
Exclude: For study design, OVID-Medline.
- Bower P, Byford S, Sibbald B, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. II: cost effectiveness. *BMJ* 2000;321(7273):1389-92. PMID:11099285
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bower P, Richards D, Lovell K. The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: A systematic review. *British Journal of General Practice* 2001;51(471):838-45.
Exclude: For systematic review before 2005, OVID-Embase.
- Bower P, Rowland N, Hardy R. The clinical effectiveness of counselling in primary care: A systematic review and meta-analysis. *Psychol Med* 2003;33(2):203-15.
Exclude: For systematic review before 2005, OVID-Embase.
- Bowers WA. Treatment of depressed in-patients. Cognitive therapy plus medication, relaxation plus medication, and medication alone. *Br J Psychiatry* 1990;156:73-8. PMID:2404539
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bowman D, Scogin F, Lyrene B. The efficacy of self-examination therapy and cognitive bibliotherapy in the treatment of mild to moderate depression. *Psychotherapy Research* 1995;5(2):131-40.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Bowman V, Ward LC, Bowman D, et al. Self-examination therapy as an adjunct treatment for depressive symptoms in substance abusing patients. *ADDICT BEHAV* 1996;21(1):129-33. PMID:8729714
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Boyd, G.M. Effects of group therapy on levels of depression of family caregivers of patients with dementia residing in nursing homes Boyd. 2006
Exclude: For study design, OVID-PsycINFO.
- Bradley RH, Barkin RL, Jerome J, et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. *American Journal of Therapeutics* 2003;10(5):318-23. PMID:12975715
Exclude: For study design, OVID-Medline.
- Brajkovic L, Jevtovic S, Bilic V, et al. The efficacy of a brief supportive psychodynamic therapy in treating anxious-depressive disorder in Daily Hospital. *Collegium Antropologicum* 2009;33(1):245-51. PMID:19408633
Exclude: For study design, OVID-Medline.
- Bramesfeld A, Adler G, Brassens S, et al. Day-clinic treatment of late-life depression. *Int J Geriatr Psychiatry* 2001;16(1):82-7. PMID:11180490
Exclude: For study design, OVID-Medline.
- Bransfield RC. Potential uses of modafinil in psychiatric disorders. *Journal of Applied Research* 2004;4(2):198-207.
Exclude: For study design, OVID-Embase.
- Brattstrom A. Long-term effects of St. John's wort (*Hypericum perforatum*) treatment: a 1-year safety study in mild to moderate depression. *Phytomedicine* 2009;16(4):277-83. PMID:19299116
Exclude: For study design, OVID-Medline.

- Brenes GA, Williamson JD, Messier SP, et al. Treatment of minor depression in older adults: a pilot study comparing sertraline and exercise. *AGING MENT HEALTH* 2007;11(1):61-8. PMID:17164159
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. *Clinical Therapeutics* 2000;22(4):411-9. PMID:10823363
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Brent D, Onorato M, Enrile A and others. Treatment of resistant depression in adolescents (TORDIA). In 2004. **Exclude:** For Guideline published before 2005, Wiley-CCTR.
- Brent DA, Holder D, Kolko D, et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. *Arch Gen Psychiatry* 1997;54(9):877-85. PMID:9294380
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Brent DA, Birmaher B. Adolescent depression. *N ENGL J MED* 2002;347(9):667-71.
Exclude: For Guideline published before 2005,
- Bressa GM. S-adenosyl-l-methionine (SAmE) as antidepressant: meta-analysis of clinical studies. *Acta Neurologica Scandinavica* 1994;Supplementum.:154-14. PMID:7941964
Exclude: For systematic review before 2005, OVID-Medline.
- Bricker JB, Russo J, Stein MB, et al. Does occasional cannabis use impact anxiety and depression treatment outcomes?: Results from a randomized effectiveness trial. *Depress Anxiety* 2007;24(6):392-8. PMID:17096386
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Bridge LR, Benson P, Pietroni PC, et al. Relaxation and imagery in the treatment of breast cancer. *BMJ (Clinical research ed)* 1988;297(6657):1169-72.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Bristow M, Bright J. Group cognitive therapy in chronic depression: Results from two intervention studies. *Behav Cogn Psychother* 1995;23(4):373-80.
Exclude: For study design, OVID-Embase.
- Brittle N, Patel S, Wright C, et al. An exploratory cluster randomized controlled trial of group exercise on mobility and depression in care home residents. *CLIN REHABIL* 2009;23(2):146-54. PMID:19164402
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Brockman B, Poynton A, Ryle A, et al. Effectiveness of time-limited therapy carried out by trainees: Comparison of two methods. *Br J Psychiatry* 1987;151:602-10.
Exclude: For study design, OVID-PsycINFO.
- Brodie NH, McGhie RL, O'Hara H, et al. Once daily administration of a fluphenazine/nortriptyline preparation in the treatment of mixed anxiety/depressive states. *Current Medical Research and Opinion* 1976;4(5):346-52.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Brody BL, Roch-Levecq AC, Kaplan RM, et al. Age-Related Macular Degeneration: Self-Management and Reduction of Depressive Symptoms in a Randomized, Controlled Study. *J AM GERIATR SOC* 2006;54(10):1557-62.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Brolhier C, Hamrick N, Jacobson B. Aerobic exercise: A potential occupational therapy modality for adolescents with depression. *OCCUP THER MENT HEALTH* 1993;12(4):19-29.
Exclude: For study design, OVID-Embase.
- Broota A, Dhir R. Efficacy of two relaxation techniques in depression. *Journal of Personality and Clinical Studies* 1990;6(1):83-90.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Brown ES, Gan V, Jeffress J, et al. Antidepressant treatment of caregivers of children with asthma. *Psychosomatics* 2008;49(5):420-5. PMID:18794511
Exclude: For study design, OVID-Medline.
- Brown JS, Elliott SA, Boardman J, et al. Can the effects of a 1-day CBT psychoeducational workshop on self-confidence be maintained after 2 years? A naturalistic study. *Depress Anxiety* 2008;25(7):632-40. PMID:17941095
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Brown JSL, Elliott SA, Boardman J, et al. Meeting the unmet need for depression services with psychoeducational self-confidence workshops: Preliminary report. *Br J Psychiatry* 2004;185(6):511-5.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Brown M, Goldstein-Shirley J, Robinson J, et al. The effects of a multi-modal intervention trial of light, exercise, and vitamins on women's mood. *WOMEN HEALTH* 2001;34(3):93-112. **Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Brown MA, Shirley JL. Enhancing women's mood and energy: a research-based program for subthreshold depression using light, exercise, and vitamins. *Holistic Nurs Pract* 2005;19(6):278-84. PMID:16269947
Exclude: For study design, OVID-Medline.
- Brown MA, Goldstein-Shirley J, Robinson J, et al. The effects of a multi-modal intervention trial of light, exercise, and vitamins on women's mood. *WOMEN HEALTH* 2001;34(3):93-112. PMID:11708689

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Brown MA, Munford A. Rehabilitation of post MI depression and psychological invalidism: A pilot study. *Int J Psychiatry Med* 1983;13(4):291-8.

Exclude: For study design, OVID-PsycINFO.

Brown RA, Evans DM, Miller IW, et al. Cognitive-behavioral treatment for depression in alcoholism. *J Consult Clin Psychol* 1997;65(5):715-26.

PMID:9337490

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Brown RP, Frances A, Kocsis JH, et al. Psychotic vs. nonpsychotic depression: comparison of treatment response. *J NERV MENT DIS* 1982;170(10):635-7.

PMID:6125562

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Brown RA, Lewinsohn PM. A psychoeducational approach to the treatment of depression: Comparison of group, individual, and minimal contact procedures. *J Consult Clin Psychol* 1984;52(5):774-83.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Brown RA, Evans DM, Miller IW, et al. Cognitive-behavioral treatment for depression in alcoholism. *J Consult Clin Psychol* 1997;65(5):715-26.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Brown SA, Glasner-Edwards SV, Tate SR, et al. Integrated cognitive behavioral therapy versus twelve-step facilitation therapy for substance-dependent adults with depressive disorders. *Journal of Psychoactive Drugs* 2006;38(4):449-60.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Brown, W.H.J. A cognitive-behavioral intervention to decrease symptoms of depression, anxiety and somatic complaints in adults diagnosed with Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) Brown. 2003

Exclude: For study design, OVID-PsycINFO.

Browne G, Steiner M, Roberts J, et al. Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs. *J Affect Disord* 2002;68(2-3):317-30. PMID:12063159

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Browne M, Lapierre YD, Hrdina PD, et al. Lithium as an adjunct in the treatment of major depression. *Int Clin Psychopharmacol* 1990;5(2):103-10.

PMID:2116474

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Bruce ML, Ten Have TR, Reynolds CF, III, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. *JAMA* 2004;291(9):1081-91.

PMID:14996777

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Bruijn JA, Moleman P, Mulder PG, et al. Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. *J Clin Psychiatry* 1998;59(12):657-63. PMID:9921699

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Bschor T, Berghöfer A, Ströhle A, et al. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. *J Clin Psychopharm* 2002;22(4):427-30.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Bschor T, Baethge C, Adli M, et al. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. *Depress Anxiety* 2003;17(1):43-8.

Exclude: For study design, OVID-Embase.

Bschor T, Baethge C, Adli M, et al. Association between responses to lithium augmentation and the combined DEX/CRH test in major depressive disorder. *J Psychiatr Res* 2003;37(2):135-43.

Exclude: For study design, OVID-PsycINFO.

Bschor T, Berghofer A, Strohle A, et al. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. *J Clin Psychopharm* 2002;22(4):427-30.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Bschor T, Adli M, Baethge C, et al. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. *Neuropsychopharmacol* 2002;27(3):470-8.

Exclude: For study design, OVID-PsycINFO.

Bschor T, Baethge C, Adli M, et al. Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. *Depress Anxiety* 2003;17(1):43-8.

Exclude: For study design, OVID-PsycINFO.

Bulloch AG, Patten SB. Non-remission of depression in the general population as assessed by the HAMD-7 scale. *Depress Anxiety* 2008;25(5):393-7.

PMID:17948276

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Bump GM, Reynolds CF, III, Smith G, et al. Accelerating response in geriatric depression: a pilot study combining sleep deprivation and paroxetine. *Depress Anxiety* 1997;6(3):113-8. PMID:9442985

Exclude: For study design, OVID-Medline.

Bump GM, Mulsant BH, Pollock BG, et al. Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly.

- Depress Anxiety 2001;13(1):38-44. PMID:11233459
Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Burbach FR. The efficacy of physical activity interventions within mental health services: Anxiety and depressive disorders. J MENT HEALTH 1997;6(6):543-66.
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Burnand Y, Andreoli A, Kolatte E, et al. Psychodynamic psychotherapy and clomipramine in the treatment of major depression. Psychiatr Serv 2002;53(5):585-90. PMID:11986508
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Burton E, Stice E, Bearman SK, et al. Experimental test of the affect-regulation theory of bulimic symptoms and substance use: a randomized trial. INT J EAT DISORD 2007;40(1):27-36. PMID:16958129
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Butler LD, Waelde LC, Hastings TA, et al. Mediation with Yoga, group therapy with hypnosis, and psychoeducation for long-term depressed mood: A randomized pilot trial. J Clin Psych 2008;64(7):806-20.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Buysse DJ, Reynolds CF, III, Houck PR, et al. Does lorazepam impair the antidepressant response to nortriptyline and psychotherapy? J Clin Psychiatry 1997;58(10):426-32. PMID:9375592
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Byford S, Barrett B, Roberts C, et al. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression. Br J Psychiatry 2007;191:521-7. PMID:18055956
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Cabiya JJ, Padilla-Cotto L, Gonzalez K, et al. Effectiveness of a cognitive-behavioral intervention for Puerto Rican children. Revista Interamericana de Psicologia 2008;42(2):195-202.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Cahill J, Barkham M, Hardy G, et al. Outcomes of patients completing and not completing cognitive therapy for depression. BR J CLIN PSYCHOL 2003;42(Pt:2):2-43. PMID:12828803
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? J Clin Psychiatry 1992;53(8):272-7. PMID:1500403
Exclude: For study design, OVID-Medline.
- Calabrese C, Londborg P.D., Shelton MD, et al. Citalopram treatment of paroxetine-intolerant depressed patients. J Clin Psychiatry 2003;64:564-7.
Exclude: For study design,
- Calabrese C, Gregory WL, Leo M, et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med 2008;14(6):707-13. PMID:18611150
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Calabrese JR, Londborg PD, Shelton MD, et al. Citalopram treatment of fluoxetine-intolerant depressed patients. J Clin Psychiatry 2003;64(5):562-7. PMID:12755660
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Calabrese JR, Londborg PD, Shelton MD, et al. Citalopram treatment of fluoxetine-intolerant depressed patients. J Clin Psychiatry 2003;64(5):562-7.
Exclude: For study design, OVID-PsycINFO.
- Calcedo Ordonez A, Arosamene X, Otero Perez FJ, et al. Clomipramine/benzazepam combination in the treatment of major depressive disorders. Hum Psychopharmacol 1992;7(2):115-22.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Caliyurt O, Guducu F. Partial sleep deprivation therapy combined with sertraline induces more rapid improvements in quality of life items in major depressive disorder. J Affect Disord 2005;88(1):75-8. PMID:15967511
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Campbell JM. Treating depression in well older adults: use of diaries in cognitive therapy. Issues Ment Health Nurs 1992;13(1):19-29. PMID:1737700
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Canna, M.A. Controlled evaluation of the effects of expressive writing on subsequent cognitive behavioral group treatment with an anxious/depressed sample Canna. 2006
Exclude: For study design, OVID-PsycINFO.
- Cappiello A, McDougale CJ, Delgado PL, et al. Lithium and desipramine versus desipramine alone in the treatment of severe major depression: a preliminary study. Int Clin Psychopharmacol 1998;13(5):191-8. PMID:9817623
Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Cappiello A, McDougale CJ, Malison RT, et al. Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Biol Psychiatry 1995;38(11):765-7.
Exclude: For study design, Wiley-CCTR.
- Cappiello A, McDougale CJ, Malison RT, et al. Yohimbine augmentation of fluvoxamine in refractory

depression: A single-blind study. *Biol Psychiatry* 1995;38(11):765-7.
Exclude: For study design, OVID-PsycINFO.

Carney CE, Segal ZV, Edinger JD, et al. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. *J Clin Psychiatry* 2007;68(2):254-60. PMID:17335324
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Carney MW, Edeh J, Bottiglieri T, et al. Affective illness and S-adenosyl methionine: a preliminary report. *Clin Neuropharmacol* 1986;9(4):379-85. PMID:2425961
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Carney RM, Templeton B, Hong BA, et al. Exercise training reduces depression and increases the performance of pleasant activities in hemodialysis patients. *Nephron* 1987;47(3):194-8. PMID:3317091
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Carney RM, Freedland KE, Rubin EH, et al. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. *JAMA* 2009;302(15):1651-7. PMID:19843899
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Carney RM, McKeivitt PM, Goldberg AP. Psychological effects of exercise training in hemodialysis patients. *Nephron* 1983;33(3):179-81.
Exclude: For study design, OVID-Embase

OVID-Embase.

Carpenter KM, Aharonovich E, Smith JL, et al. Behavior therapy for depression in drug dependence (BTDD): results of a stage Ia therapy development pilot. *Am J Drug Alcohol Abuse* 2006;32(4):541-8. PMID:17127541
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Carpenter KM, Smith JL, Aharonovich E, et al. Developing therapies for depression in drug dependence: results of a stage I therapy study. *Am J Drug Alcohol Abuse* 2008;34(5):642-52. PMID:18821458
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Carpenter L L, Yasmin S, Price L H. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory depression. In 2000. **Exclude:** For study design, Wiley-CCTR.

Carpenter L L, Yasmin S, Price L H. A double-blind, placebo-controlled study of mirtazapine augmentation for refractory major depression: preliminary findings. In 2000. **Exclude:** For study design, Wiley-CCTR.

Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. *Biol Psychiatry* 2002;51(2):183-8. PMID:11822997
Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Medline.

Carpenter LL, Milosavljevic N, Schechter JM, et al. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. *J Clin Psychiatry* 2005;66(10):1234-8. PMID:16259536
Exclude: For study design, OVID-Medline.

Carpenter LL, Bayat L, Moreno F, et al. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. *Psychiatry Res* 2008;157(1-3):123-9. PMID:17976740
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Carpenter LL, Leon Z, Yasmin S, et al. Do obese depressed patients respond to topiramate? A retrospective chart review. *J Affect Disord* 2002;69(1-3):251-5. PMID:12103474
Exclude: For study design, OVID-Medline.

Carpenter LL, Jovic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. *J Clin Psychiatry* 1999;60(1):45-9.
Exclude: For study design, OVID-Embase.

Carpenter LL, Jovic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. *J Clin Psychiatry* 1999;60(1):45-9.
Exclude: For study design, OVID-PsycINFO.

Carrico AW, Antoni MH, Weaver KE, et al. Cognitive-behavioural stress management with HIV-positive homosexual men: mechanisms of sustained reductions in depressive symptoms. *CHRONIC ILLN* 2005;1(3):207-15. PMID:17152183
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Carrico AW, Antoni MH, Duran RE, et al. Reductions in depressed mood and denial coping during cognitive behavioral stress management with HIV-positive gay men treated with HAART. *Annals of Behavioral Medicine* 2006;31(2):155-64.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Carrico AW, Antoni MH, Weaver KE, et al. Cognitive-behavioural stress management with HIV-positive homosexual men: Mechanisms of sustained reductions in depressive symptoms. . *CHRONIC ILLN* 2005;1(3):207-15.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Carrico AW, Antoni MH, Duran RE, et al. Reductions in depressed mood and denial coping during cognitive behavioral stress management with HIV-positive gay men treated with HAART. . *Annals of Behavioral Medicine* 2006;31(2):155-1164.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Carrieri PB, Indaco A, Gentile S, et al. S-Adenosylmethionine treatment of depression in patients with Parkinson's disease. A double-blind,

- crossover study versus placebo. *Curr Ther Res Clin Exp* 1990;48(1):154-60.
Exclude: For population/diagnosis, OVID-Embase OVID-Embase.
- Carroll BJ, Mowbray RM, Davies B. Sequential comparison of L-tryptophan with E.C.T. in severe depression. *Lancet* 1970;1(7654):967-9.
Exclude: For study design, Wiley-CCTR.
- Carroll KM, Nich C, Rounsaville BJ. Differential symptom reduction in depressed cocaine abusers treated with psychotherapy and pharmacotherapy. *J NERV MENT DIS* 1995;183(4):251-9.
 PMID:7714514
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Carta MG, Zairo F, Mellino G, et al. Add-on quetiapine in the treatment of major depressive disorder in elderly patients with cerebrovascular damage. *Clin Pract Epidemiol Ment Health* 2007;3, 2007. Article Number: 28. Date of Publication: 26 Nov 2007.:
Exclude: For study design, OVID-Embase.
- Carta MG, Hardoy MC, Pilu A, et al. Improving physical quality of life with group physical activity in the adjunctive treatment of major depressive disorder. *Clin Pract Epidemiol Ment Health* 2008;4, 2008. Article Number: 1. Date of Publication: 26 Jan 2008.:
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.
- Carta MG, Zairo F, Mellino G, et al. Add-on quetiapine in the treatment of major depressive disorder in elderly patients with cerebrovascular damage. *Clin Pract Epidemiol Ment Health* 2007;3:ArtID
Exclude: For study design, OVID-PscINFO.
- Caruso I, Fumagalli M, Boccassini L, et al. Treatment of depression in rheumatoid arthritic patients. A comparison of S-adenosylmethionine (Samyr) and placebo in a double-blind study. *Clinical Trials Journal* 1987;24(4):305-10.
Exclude: For study design, OVID-Embase.
- Casacalenda N, Perry JC, Looper K. Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. [Review] [48 refs]. *Am J Psychiatry* 2002;159(8):1354-60. PMID:12153828
Exclude: For systematic review before 2005, OVID-Medline.
- Casciano R, Arikian SR, Tarride J-E, et al. Antidepressant selection for major depressive disorder: The budgetary impact on managed care. *Drug Benefit Trends* 2000;12(5):6BH-17BH.
Exclude: For study design, OVID-Embase.
- Case, S.C. The effects of group therapy and exercise on depression and self-esteem in college students. *Case*. 2003
Exclude: For study design, OVID-PscINFO.
- Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: an extended follow-up. *Depress Anxiety* 2004;20(3):131-8.
 PMID:15549689
Exclude: For study design, OVID-Medline.
- Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. *Can J Psychiatry* 2005;50(6):357-60.
 PMID:15999953
Exclude: For study design, OVID-Medline.
- Castonguay LG, Schut AJ, Aikens DE, et al. Integrative Cognitive Therapy for Depression: A Preliminary Investigation. *Journal of Psychotherapy Integration* 2004;14(1):4-20.
Exclude: For study design, OVID-PscINFO.
- Cavanagh K, Shapiro DA. Computer treatment for common mental health problems. [Review] [73 refs]. *J Clin Psych* 2004;60(3):239-51. PMID:14981789
Exclude: For systematic review before 2005, OVID-Medline.
- Cavanagh K, Shapiro DA, Van Den BS, et al. The effectiveness of computerized cognitive behavioural therapy in routine care. *BR J CLIN PSYCHOL* 2006;45(Pt:4):4-514. PMID:17076960
Exclude: For study design, OVID-Medline.
- Ceskova E, Nahunek K, Rysanek R, et al. Clinical experience with parenteral clomipramine and desipramine in the treatment of drug-resistant endogenous depression. *Act Nerv Super* 1981;23(3):212-4.
Exclude: For population/not failed to respond to an SSRI, OVID-PscINFO.
- Cevasco AM, Kennedy R, Generally NR. Comparison of movement-to-music, rhythm activities, and competitive games on depression, stress, anxiety, and anger of females in substance abuse rehabilitation. *Journal of Music Therapy* 2005;42(1):64-80.
 PMID:15839734
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Chan, E.K.-H. Efficacy of cognitive-behavioral, pharmacological, and combined treatments of depression: A meta-analysis. *Chan*. 2006
Exclude: For study design, OVID-PscINFO.
- Chan I, Kong P, Leung P, et al. Cognitive-behavioral group program for Chinese heterosexual HIV-infected men in Hong Kong. *PATIENT EDUC COUNS* 2005;56(1):78-84. PMID:15590226
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Chan MF, Chan EA, Mok E, et al. Effect of music on depression levels and physiological responses in community-based older adults. *International Journal of Mental Health Nursing* 2009;18(4):285-94.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Chang M, Chen C, Huang K. Effects of music therapy on psychological health of women during pregnancy. *J CLIN NURS* 2008;17(19):2580-7.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Chaput Y, Magnan A, Gendron A. The co-administration of quetiapine or placebo to cognitive-

behavior therapy in treatment refractory depression: a preliminary trial. *BMC Psychiatry* 2008;8:73

Exclude: For Mixed antidepressants; some failed on SSRI, Wiley-CCTR.

Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. *Arch Gen Psychiatry* 1986;43(12):1155-61. PMID:3022664

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression: Implications for the beta-adrenergic receptor hypothesis of antidepressant action. *Arch Gen Psychiatry* 1986;43(12):1155-61.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Chaudhry HR, Najam N, Naqvi A. The value of amineptine in depressed patients treated with cognitive behavioural psychotherapy. *Hum Psychopharmacol* 1998;13(6):419-24.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Chen K, Chen M, Chao H, et al. Sleep quality, depression state, and health status of older adults after silver yoga exercises: cluster randomized trial. *INT J NURS STUD* 2009;46(2):154-63.

Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.

Chen T, Lu R, Chang A, et al. The evaluation of cognitive-behavioral group therapy on patient depression and self-esteem. *Arch Psychiatr Nurs* 2006;20(1):3-11.

Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.

Chen TH, Lu RB, Chang AJ, et al. The evaluation of cognitive-behavioral group therapy on patient depression and self-esteem. *Arch Psychiatr Nurs* 2006;20(1):3-11. PMID:16442469

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Cherkezova M, Toteva S. Acupuncture in the treatment of alcoholics with a depressive syndrome. *Journal of Russian & East Eur Psychiatry* 1993;26(1):28-30.

Exclude: For study design, OVID-PsycINFO.

Cho YC, Tsay SL. The effect of acupressure with massage on fatigue and depression in patients with end-stage renal disease. *J Nurs Res* 2004;12(1):51-9. PMID:15136963

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Choi AN, Lee MS, Lim HJ. Effects of group music intervention on depression, anxiety, and relationships in psychiatric patients: a pilot study. *J Altern Complement Med* 2008;14(5):567-70.

Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.

Chouinard G, Saxena BM, Nair NP, et al.

Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. *Clin Neuropharmacol* 1993;16:Suppl-4 PMID:8313397

Exclude: For systematic review before 2005, OVID-Medline.

Chouinard G, Young SN, Annable L, et al. Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study. *Acta Psychiatr Scand* 1979;59(4):395-414.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Christensen H, Griffiths KM, Korten AE, et al. A comparison of changes in anxiety and depression symptoms of spontaneous users and trial participants of a cognitive behavior therapy website. *J Med Internet Res* 2004;6(4):e46 PMID:15631970

Exclude: For study design, OVID-Medline.

Christensen H, Griffiths KM, Jorm AF. Delivering interventions for depression by using the internet: randomised controlled trial. *BMJ* 2004;328(7434):265 PMID:14742346

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Christensen H, Griffiths KM, Mackinnon AJ, et al. Online randomized controlled trial of brief and full cognitive behaviour therapy for depression. *Psychol Med* 2006;36(12):1737-46. PMID:16938144

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Christensen H, Griffiths KM, Korten A. Web-based cognitive behavior therapy: analysis of site usage and changes in depression and anxiety scores. *J Med Internet Res* 4(1):e3-Mar PMID:11956035

Exclude: For study design, OVID-Medline.

Christensen H, Griffiths KM, Jorm AF. Delivering interventions for depression by using the internet: Randomised controlled trial. *BMJ* 2004;328(7434):265-9.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Chronis AM, Gamble SA, Roberts JE, et al. Cognitive-behavioral depression treatment for mothers of children with attention-deficit/hyperactivity disorder. *Behav Ther* 2006;37(2):143-58. PMID:16942968

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Chu I-H, Buckworth J, Kirby TE, et al. Effect of exercise intensity on depressive symptoms in women. *Mental Health and Physical Activity* 2009;2(1):37-43.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Chu, I.H. Effect of exercise intensity during aerobic training on depressive symptoms in initially sedentary depressed women Chu. 2008

Exclude: For study design, OVID-PsycINFO.

Chun, D.S. An assessment of support group participation on depression and adherence in veterans

- with hepatitis C Chun. 2002
Exclude: For study design, OVID-PsycINFO.
- Church J. The application of cognitive-behavioural therapy for depression to people with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). *Psycho Oncol* 1998;7(2):78-88. **Exclude:** For study design, EBSCO-CINAHL.
- Churchill R, Hunot V, Corney R, et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. *HEALTH TECHNOL ASSESS* 2001;5(35):
Exclude: For systematic review before 2005, OVID-Embbase.
- Cipher DJ, Clifford PA, Roper KD. The effectiveness of geropsychological treatment in improving pain, depression, behavioral disturbances, functional disability, and health care utilization in long-term care. *CLIN GERONTOL* 2007;30(3):23-40.
Exclude: For population/diagnosis, OVID-Embbase.
- Clarke G, DeBar L, Lynch F, et al. A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. *J Am Acad Child Adolesc Psychiatry* 2005;44(9):888-98. PMID:16113617
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Clarke G, DeBar L, Lynch F, et al. A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. *J Am Acad Child Adolesc Psychiatry* 2005;44(9):888-98.
Exclude: For population/not failed to respond to an SSRI, OVID-Embbase.
- Clarke G, Reid E, Eubanks D, et al. Overcoming depression on the Internet (ODIN): a randomized controlled trial of an Internet depression skills intervention program. *J Med Internet Res* 2002;4(3):E14 PMID:12554545
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Clarke G, Eubanks D, Reid E, et al. Overcoming Depression on the Internet (ODIN) (2): a randomized trial of a self-help depression skills program with reminders. *J Med Internet Res* 2005;7(2):e16 PMID:15998607
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Clarke GN, Hornbrook M, Lynch F, et al. A randomized trial of a group cognitive intervention for preventing depression in adolescent offspring of depressed parents. *Arch Gen Psychiatry* 2001;58(12):1127-34. PMID:11735841
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Clarke GN, Rohde P, Lewinsohn PM, et al. Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. *J Am Acad Child Adolesc Psychiatry* 1999;38(3):272-9. PMID:10087688
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Clarke GN, Hornbrook M, Lynch F, et al. Group cognitive-behavioral treatment for depressed adolescent offspring of depressed parents in a health maintenance organization. *J Am Acad Child Adolesc Psychiatry* 2002;41(3):305-13. PMID:11886025
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Clarke GN, Hawkins W, Murphy M, et al. Targeted prevention of unipolar depressive disorder in an at-risk sample of high school adolescents: a randomized trial of a group cognitive intervention. *J Am Acad Child Adolesc Psychiatry* 1995;34(3):312-21. PMID:7896672
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Clunie F. Double blind randomised controlled trial comparing moclobemide and phenelzine in treatment resistant depression. In 2001. **Exclude:** For study design, Wiley-CCTR.
- Cocker KI, Bell DR, Kidman AD. Cognitive behaviour therapy with advanced breast cancer patients: A brief report of a pilot study. *Psycho Oncol* 1994;3(3):233-7.
Exclude: For study design, OVID-Embbase.
- Cockram A, McCall L, Judd F, et al. The development and pilot testing of a Focused Education and Psychotherapy Program (FEPP) for treatment of depression in general practice. *AUSTRALAS PSYCHIATRY* 2002;10(3):268-74.
Exclude: For study design,
- Cohen AJ. Treatment of anergic depression in Hashimoto's thyroiditis with fluoxetine and d-amphetamine. *Depression* 1993;1(2):110-4.
Exclude: For study design, OVID-PsycINFO.
- Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. *JAMA* 2006;295(5):499-507.
Exclude: For population/not failed to respond to an SSRI, OVID-Embbase.
- Cole BS. Spiritually-focused psychotherapy for people diagnosed with cancer: A pilot outcome study. *Mental Health, Religion and Culture* 2005;8(3):217-26.
Exclude: For population/not failed to respond to an SSRI, OVID-Embbase.
- Cole MG, Elie LM, McCusker J, et al. Feasibility and effectiveness of treatments for depression in elderly medical inpatients: a systematic review. *INT PSYCHOGERIATR* 2000;12(4):453-61. PMID:11263712
Exclude: For systematic review before 2005, OVID-Medline.
- Cole MG, McCusker J, Elie M, et al. Systematic detection and multidisciplinary care of depression in older medical inpatients: a randomized trial. *CMAJ* 2006;174(1):38-44. PMID:16330624

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Coleman E, Cesnik J, Moore AM, et al. An exploratory study of the role of psychotropic medications in the treatment of sex offenders. *Journal of Offender Rehabilitation* 1992;18(3-4):75-88.

Exclude: For study design, OVID-PsycINFO.

Collet L, Cottraux J, Ladouceur R. Cognitive therapy of depression and counterdemand effects: A pilot study. *Psychol Rep* 1987;60(2):555-60.

Exclude: For study design, OVID-PsycINFO.

Collins J, Abou SMT. Risperidone: A new concept for the treatment of tricyclic resistant depression. *J Drug Dev* 1992;5(2):65-70.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Collins,R.W. The treatment of depression: An integrative psychotherapy model Collins. 1997

Exclude: For study design, OVID-PsycINFO.

Comas-Diaz L. Effects of cognitive and behavioral group treatment on the depressive symptomatology of Puerto Rican women. *J Consult Clin Psychol* 1981;49(5):627-32.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Comas DL. Effects of cognitive and behavioral group treatment on the depressive symptomatology of Puerto Rican women. *J Consult Clin Psychol* 1981;49(5):627-32.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Comer EW. Integrating the health and mental health needs of the chronically ill: a group for individuals with depression and sickle cell disease. *Social Work in Health Care* 2004;38(4):57-76. PMID:15149906

Exclude: For study design, OVID-Medline.

Compton SN, March JS, Brent D, et al. Cognitive-Behavioral Psychotherapy for Anxiety and Depressive Disorders in Children and Adolescents: An Evidence-Based Medicine Review. *J Am Acad Child Adolesc Psychiatry* 2004;43(8):930-59.

Exclude: For systematic review before 2005, OVID-PsycINFO.

Congleton,A.B. The effect of a cognitive-behavioral group intervention on the locus of control, attributional style, and depressive symptoms of middle school students Congleton. 1996

Exclude: For study design, OVID-PsycINFO.

Conn DK, Clarke D, van Reekum R. Depression in Holocaust survivors: Profile and treatment outcome in a geriatric day hospital program. *Int J Geriatr Psychiatry* 2000;15(4):331-7.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Conn DK, Steingart AB. Diagnosis and management of late life depression: A guide for the primary care physician. *Int J Psychiatry Med* 1997;27(3):269-81.

Exclude: For Guideline published before 2005, OVID-PsycINFO.

Connerley,R.C. Distant intercessory prayer as an adjunct to psychotherapy with depressed outpatients: A small-scale investigation Connerley. 2003

Exclude: For study design, OVID-PsycINFO.

Conradi HJ, de Jonge P, Ormel J. Cognitive-behavioural therapy v. usual care in recurrent depression. *Br J Psychiatry* 2008;193(6):505-6. PMID:19043158

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Conradi HJ, de Jonge P, Kluiters H, et al. Enhanced treatment for depression in primary care: long-term outcomes of a psycho-educational prevention program alone and enriched with psychiatric consultation or cognitive behavioral therapy. *Psychol Med* 2007;37(6):849-62. PMID:17376257

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Conradi HJ, de Jonge P, Kluiters H, et al. Enhanced treatment for depression in primary care: Long-term outcomes of a psycho-educational prevention program alone and enriched with psychiatric consultation or cognitive behavioral therapy. *Psychol Med* 2007;37(6):849-62.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Constantino MJ, Marnell ME, Haile AJ, et al. Integrative cognitive therapy for depression: A randomized pilot comparison. *Psychotherapy* 2008;45(2):122-34.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Cook JW, Spring B, McChargue DE, et al. Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. *Psychopharmacology* 2004;173(1-2):153-9. PMID:14727000

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Cooke RG, Joffe RT, Levitt AJ. T3 augmentation of antidepressant treatment in T4-replaced thyroid patients. *J Clin Psychiatry* 1992;53(1):16-8. PMID:1737734

Exclude: For study design, OVID-Medline.

Cooke RG, Joffe RT, Levitt AJ. T3 augmentation of antidepressant treatment in T4-replaced thyroid patients. *J Clin Psychiatry* 1992;53(1):16-8.

Exclude: For study design, OVID-PsycINFO.

Coon DW, Thompson L, Steffen A, et al. Anger and depression management: psychoeducational skill training interventions for women caregivers of a relative with dementia. *Gerontologist* 2003;43(5):678-89. PMID:14570964

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Cooper-Kazaz R, Apter JT, Cohen R, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-

- controlled trial. *Arch Gen Psychiatry* 2007;64(6):679-88. PMID:17548749
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Cooper AJ, Datta SR. A placebo controlled evaluation of L-tryptophan in depression in the elderly. *Can J Psychiatry* 1980;25(5):386-90. PMID:7407745
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Cooper AJ, Datta SR. A placebo controlled evaluation of L-tryptophan in depression in the elderly. *The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie* 1980;25(5):386-90.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. *J Affect Disord* 2000;60(2):121-30. PMID:10967371
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Coppen A, Abou-Saleh MT. Lithium therapy: from clinical trials to practical management. *Acta Psychiatr Scand* 1988;78(6):754-62. PMID:3146892
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Coppen A, Whybrow PC, Noguera R, et al. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. *Arch Gen Psychiatry* 1972;26(3):234-41.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Corey-Lisle PK, Birnbaum H, Greenberg P, et al. Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study. *Psychopharmacol Bull* 2003;37(3):90-8. PMID:14608242
Exclude: For study design, OVID-Medline.
- Corey-Lisle PK, Nash R, Stang P, et al. Response, partial response, and nonresponse in primary care treatment of depression. *Arch Intern Med* 2004;164(11):1197-204. PMID:15197045
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Corrado P, Gottlieb H. Alternative medicine. The effect of biofeedback and relaxation training on depression in chronic pain patients. *American Journal of Pain Management* 1999;9(1):18-21. **Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Corya SA, Andersen SW, Detke HC, et al. Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.[erratum appears in *J Clin Psychiatry*. 2004 Feb;65(2):279]. *J Clin Psychiatry* 2003;64(11):1349-56. PMID:14658950
Exclude: For study design, OVID-Medline.
- Costa e Silva. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. *J Clin Psychiatry* 1998;59(7):352-7. PMID:9714263
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Costa Miranda V, Trufelli DC, Santos J, et al. Effectiveness of guarana (*Paullinia cupana*) for postradiation fatigue and depression: Results of a pilot double-blind randomized study. *The J Altern Complement Med* 2009;15(4):431-3.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Courbasson CM, de Sorkin AA, Dullerud B, et al. Acupuncture treatment for women with concurrent substance use and anxiety/depression: an effective alternative therapy? *FAM COMMUNITY HEALTH* 2007;30(2):112-20. PMID:19241647
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Covi L, Roth D, Lipman RS. Cognitive group psychotherapy of depression: The close-ended group. *American Journal of Psychotherapy* 1982;36(4):459-69.
Exclude: For study design, OVID-PsycINFO.
- Cowen PJ, McCance SL, Cohen PR, et al. Lithium increases 5-HT-mediated neuroendocrine responses in tricyclic resistant depression. *Psychopharmacology* 1989;99(2):230-2. PMID:2508159
Exclude: For study design, OVID-Medline.
- Cox AA. A description of a behavioral group treatment for depression. *Journal for Specialists in Group Work* 1984;9(2):85-92.
Exclude: For study design, OVID-PsycINFO.
- Cox,J.G. Is exercise an evidence-based intervention for clinical depression in older adults: A meta-analysis of randomized studies 2000-2006 Cox. 2008
Exclude: For study design, OVID-PsycINFO.
- Craft LL, Freund KM, Culpepper L, et al. Intervention study of exercise for depressive symptoms in women. *J Womens Health* 2007;16(10):1499-509.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Craft LL. Exercise and clinical depression: Examining two psychological mechanisms. *Psychology of Sport and Exercise* 2005;6(2):151-71.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Craft LL, Landers DM. The effect of exercise on clinical depression and depression resulting from mental illness: A meta-analysis. *Journal of Sport & Exercise Psychology* 1998;20(4):339-57.
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Craft,L.L. Exercise and clinical depression: Examining psychological mechanisms Craft. 2003
Exclude: For study design, OVID-PsycINFO.
- Craig AR, Hancock K, Chang E, et al. Immunizing against depression and anxiety after spinal cord injury. *Arch Phys Med Rehabil* 1998;79(4):375-7.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Craigie MA, Nathan P. A nonrandomized effectiveness comparison of broad-spectrum group CBT to individual CBT for depressed outpatients in a community mental health setting. *Behav Ther* 2009;40(3):302-14. PMID:19647531

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Creed F, Guthrie E, Ratcliffe J, et al. Does psychological treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder? *Aust NZ J Psychiatry* 2005;39(9):807-15. PMID:16168039

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Criconia AM, Araquistain JM, Daffina N, et al. Results of treatment with s-adenosyl-l-methionine in patients with major depression and internal illnesses. *Curr Ther Res Clin Exp* 1994;55(6):666-74.

Exclude: For study design, OVID-Embase.

Crismon ML, Trivedi M, Pigott TA, et al. The Texas medication algorithm project: Report of the Texas consensus conference panel on medication treatment of major depressive disorder. *J Clin Psychiatry* 1999;60(3):142-56.

Exclude: For Guideline published before 2005, OVID-Embase.

Crowley JJ, Lipsky RH, Lucki I, et al. Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome. *Psychiatric Genetics* 2008;18(5):248-51. PMID:18797399

Exclude: For guideline, not a population of interest, OVID-Medline.

Cruciani RA, Dvorkin E, Homel P, et al. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. *Annals of the New York Academy of Sciences* 2004;1033:168-76. PMID:15591014

Exclude: For study design, OVID-Medline.

Cruess S, Antoni MH, Hayes A, et al. Changes in mood and depressive symptoms and related change processes during cognitive-behavioral stress management in HIV-infected men. *Cogn Ther Res* 2002;26(3):373-92.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Cuijpers P. Bibliotherapy in unipolar depression: A meta-analysis. *J Behav Ther and Experimental Psychiatry* 1997;28(2):139-47.

Exclude: For systematic review before 2005, OVID-Embase.

Cuijpers P, van Lier PA, van Straten A, et al. Examining differential effects of psychological treatment of depressive disorder: an application of trajectory analyses. *J Affect Disord* 2005;89(1-3):137-46. PMID:16274750

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Cuijpers P, Smit F, Voordouw I, et al. Outcome of cognitive behaviour therapy for minor depression in routine practice. *Psychology & Psychotherapy: Theory, Research & Practice* 2005;78(Pt:2):2-88. PMID:16004697

Exclude: For study design, OVID-Medline.

Cuijpers P. Prevention of depression in chronic general medical disorders: a pilot study. *Psychol Rep* 1998;82(3:Pt 1):t-8 PMID:9676483

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Cuijpers P. Psychological outreach programmes for the depressed elderly: a meta-analysis of effects and dropout. *Int J Geriatr Psychiatry* 1998;13(1):41-8. PMID:9489580

Exclude: For systematic review before 2005, OVID-Medline.

Cuijpers P. A psychoeducational approach to the treatment of depression: A meta-analysis of Lewinsohn's "Coping with Depression" course. *Behav Ther* 1998;29(3):521-33.

Exclude: For systematic review before 2005, OVID-PsycINFO.

Cukrowicz KC, Joiner J. Computer-based intervention for anxious and depressive symptoms in a non-clinical population. *Cogn Ther Res* 2007;31(5):677-93.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Cukrowicz, K.C. Prevention of anxiety and depression Cukrowicz. 2008

Exclude: For study design, OVID-PsycINFO.

Cullen, J.M. Testing the effectiveness of behavioral activation therapy in the treatment of acute unipolar depression Cullen. 2003

Exclude: For study design, OVID-PsycINFO.

Cullen M, Mitchell P, Brodaty H, et al. Carbamazepine for treatment-resistant melancholia. *J Clin Psychiatry* 1991;52(11):472-6. PMID:1744065

Exclude: For study design, OVID-Medline.

Cunningham, J. The effects of exercise and relaxation training upon psychological variables in coronary heart patients Cunningham. 1980

Exclude: For study design, OVID-PsycINFO.

Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. *Ann Clin Psychiatry* 1997;9(3):157-64. PMID:9339881

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Curry JF, Wells KC, Lochman JE, et al. Cognitive-behavioral intervention for depressed, substance-abusing adolescents: development and pilot testing. *J Am Acad Child Adolesc Psychiatry* 2003;42(6):656-65. PMID:12921473

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Cyranowski JM, Frank E, Shear MK, et al. Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study. *Depress Anxiety* 2005;21(3):140-2. PMID:15965998
Exclude: For study design, OVID-Medline.
- d'Elia G, Hallstrom T, Nystrom C, et al. Zimelidine vs maprotiline in depressed outpatients. A preliminary report. *Acta Psychiatrica Scandinavica, Supplementum* 1981;290:225-35. PMID:6452793
Exclude:For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- da Silva TM, Munhoz RP, Alvarez C, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. *J Affect Disord* 2008;111(2-3):351-9. PMID:18485485
Exclude: For population/diagnosis, OVID-Medline.
- da CM, V, Trufelli DC, Santos J, et al. Effectiveness of guarana (*Paullinia cupana*) for postradiation fatigue and depression: results of a pilot double-blind randomized study. *J Altern Complement Med* 2009;15(4):431-3. PMID:19388866
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- da CM, V, Trufelli DC, Santos J, et al. Effectiveness of guarana (*Paullinia cupana*) for postradiation fatigue and depression: Results of a pilot double-blind randomized study. *J Altern Complement Med* 2009;15(4):431-3.
Exclude: For population/not failed to respond to an SSRI, OVID-Embse.
- Dadkhan A, Raoufi MG. A Japanese treatment used in major depressive disorder in adolescence. *PERCEPT MOTOR SKILLS* 2007;105(2):531-8.
Exclude: For study design, EBSCO-CINAHL.
- Dai Y, Zhang S, Yamamoto J, et al. Cognitive behavioral therapy of minor depressive symptoms in elderly Chinese Americans: a pilot study. *Community Ment Health J* 1999;35(6):537-42. PMID:10863990
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dallal A, Fontaine R, Ontiveros A, et al. Lithium carbonate augmentation of desipramine in refractory depression. *Can J Psychiatry* 1990;35(7):608-11. PMID:2125237
Exclude: For study design, OVID-Medline.
- Dalton EJ, Rotondi D, Levitan RD, et al. Use of slow-release melatonin in treatment-resistant depression. *J Psychiatry Neurosci* 2000;25(1):48-52. PMID:10721684
Exclude: For study design, OVID-Medline.
- Dam J, Ryde L, Svejsjo J, et al. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. *Pharmacopsychiatry* 1998;31(2):48-54. PMID:9562208
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dana, E.C. A cognitive-behavioral intervention for conduct-disordered and concurrently conduct-disordered and depressed children Dana. 1998
Exclude: For study design, OVID-PsycINFO.
- Dannowski U, Baune BT, Bockermann I, et al. Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. *Hum Psychopharmacol* 2008;23(7):587-93. PMID:18663773
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Darbinyan V, Aslanyan G, Amroyan E, et al. Clinical trial of *Rhodiola rosea* L. extract SHR-5 in the treatment of mild to moderate depression.[erratum appears in *Nord J Psychiatry*. 2007;61(6):503]. *Nord J Psychiatry* 2007;61(5):343-8. PMID:17990195
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Darbinyan V, Aslanyan G, Amroyan E, et al. Erratum: Clinical trial of *Rhodiola rosea* L. extract SHR-5 in the treatment of mild to moderate depression. *Nord J Psychiatry* 2007;61(6):503
Exclude: For study design, OVID-PsycINFO.
- Daughters SB, Braun AR, Sargeant MN, et al. Effectiveness of a brief behavioral treatment for inner-city illicit drug users with elevated depressive symptoms: the life enhancement treatment for substance use (LETS Act!). *J Clin Psychiatry* 2008;69(1):122-9. PMID:18312046
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- David D, Szentagotai A, Lupu V, et al. Rational emotive behavior therapy, cognitive therapy, and medication in the treatment of major depressive disorder: a randomized clinical trial, posttreatment outcomes, and six-month follow-up. *J Clin Psych* 2008;64(6):728-46. PMID:18473339
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- David D, Szentagotai A, Lupu V, et al. Rational emotive behavior therapy, cognitive therapy, and medication in the treatment of major depressive disorder: A randomized clinical trial, posttreatment outcomes, and six-month follow-up. *J Clin Psych* 2008;64(6):728-46.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Davidson JR, Abraham K, Connor KM, et al. Effectiveness of chromium in atypical depression: a placebo-controlled trial. *Biol Psychiatry* 2003;53(3):261-4.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Davidson JR, Morrison RM, Shore J, et al. Homeopathic treatment of depression and anxiety. *Altern Ther Health Med* 1997;3(1):46-9. PMID:8997804
Exclude: For study design, OVID-Medline.
- Davidson JRT, Gadde KM, Fairbank JA, et al. Effect of *Hypericum perforatum* (St John's wort) in major depressive disorder: A randomized controlled trial.

JAMA 2002;287(14):1807-14.

Exclude: For population/not failed to respond to an SSRI,

Davidson O, King M, Sharpe D, et al. A pilot randomized trial evaluating GP registrar management of major depression following brief training in cognitive behaviour therapy. *Education for General Practice* 1999;10(4):485-8.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Davis GR, Armstrong HE, Donovan DM, et al. Cognitive-behavioral treatment of depressed affect among epileptics: Preliminary findings. *J Clin Psych* 1984;40(4):930-5.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Dawson MY, Michalak EE, Waraich P, et al. Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis. *BMC Family Practice* 2004;5, 2004. Date of Publication: 07 Sep 2004.:

Exclude: For systematic review before 2005, OVID-Embase.

de Carvalho MR, Sato EI, Tebexreni AS, et al. Effects of Supervised Cardiovascular Training Program on Exercise Tolerance, Aerobic Capacity, and Quality of Life in Patients With Systemic Lupus Erythematosus. *Arthritis & Rheumatism: Arthritis Care & Research* 2005;53(6):838-44.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

De Cuyper S, Timbremont B, Braet C, et al. Treating depressive symptoms in schoolchildren: a pilot study. *EUR CHILD ADOLESC PSYCHIATRY* 2004;13(2):105-14. PMID:15103536

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

de Godoy DV, de Godoy RF. A randomized controlled trial of the effect of psychotherapy on anxiety and depression in chronic obstructive pulmonary disease. *ARCH PHYS MED REHABIL* 2003;84(8):1154-7. PMID:12917854

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

de Graaf LE, Gerhards SA, Evers SM, et al. Clinical and cost-effectiveness of computerised cognitive behavioural therapy for depression in primary care: design of a randomised trial. *BMC Public Health* 2008;8:224 PMID:18590518

Exclude: For study design, OVID-Medline.

de Graaf LE, Huibers MJ, Riper H, et al. Use and acceptability of unsupported online computerized cognitive behavioral therapy for depression and associations with clinical outcome. *J Affect Disord* 2009;116(3):227-31. PMID:19167094

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

de Groot MH, Nolen WA, Huijsman AM, et al. Lateralized neuropsychological functioning in depressive patients before and after drug therapy. *Biol Psychiatry* 1996;40(12):1282-7.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

de Jonghe F, Kool S, van Aalst G, et al. Combining psychotherapy and antidepressants in the treatment of depression. *J Affect Disord* 2001;64(2-3):217-29. PMID:11313088

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

de Jonghe F, Hendricksen M, van Aalst G, et al. Psychotherapy alone and combined with pharmacotherapy in the treatment of depression. *Br J Psychiatry* 2004;185:37-45. PMID:15231554

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

De Leo D. S-adenosyl-L-methionine (SAME) in clinical practice: Preliminary report on 75 minor depressives. *Curr Ther Res Clin Exp* 1985;37(4):658-61.

Exclude: For study design, OVID-Embase

OVID-Embase.

De Leo D. S-Adenosylmethionine as an antidepressant. A double-blind trial versus placebo. *Curr Ther Res Clin Exp* 1987;41(6):865-70.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

de Leo D. S-adenosylmethionine as an antidepressant: A double-blind trial versus placebo. **Curr Ther Res** 1987;41(6):865-70.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

de Montigny C, Courmoyer G, Morissette R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. *Arch Gen Psychiatry* 1983;40(12):1327-34.

Exclude: For study design, Wiley-CCTR.

de Montigny C, Grunberg F, Mayer A, et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. *Br J Psychiatry* 1981;138:252-6. PMID:7272619

Exclude: For study design, OVID-Medline.

de Montigny C, Elie R, Caille G. Rapid response to the addition of lithium in iprindole-resistant unipolar depression: a pilot study. *Am J Psychiatry* 1985;142(2):220-3. PMID:3918468

Exclude: For study design, OVID-Medline.

de Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. *J Clin Psychopharm* 1999;19(5):401-6. PMID:10505581

Exclude: For study design, OVID-Medline.

de Montigny C, Elie R, Caille G. Rapid response to the addition of lithium in iprindole-resistant unipolar depression: A pilot study. *Am J Psychiatry* 1985;142(2):220-3.

Exclude: For study design, OVID-PsycINFO.

de Piano FA, de Piano LC, Carter W, et al. Physical fitness training: Adjunctive treatment for the

- depressed, low self esteem and muscular tense patient. *Psychotherapy in Private Practice* 1984;2(3):75-83.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression. *Curr Ther Res Clin Exp* 1992;52(3):478-85.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- de Zwaan M, Schonbeck G, Nutzinger D, et al. Fluvoxamine and behavior therapy in the treatment of depressed obese. *Pharmacopsychiatry* 1989;22(5):223
Exclude: For study design, OVID-Embase.
- Deas D, Randall CL, Roberts JS, et al. A double-blind, placebo-controlled trial of sertraline in depressed adolescent alcoholics: A pilot study. *Hum Psychopharmacol* 2000;15(6):461-9.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. *J Clin Psychopharm* 2003;23(1):27-30. PMID:12544372
Exclude: For study design, OVID-Medline.
- DeBattista C, Lembke A, Solvason HB, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. *J Clin Psychopharm* 2004;24(1):87-90. PMID:14709953
Exclude: For study design, OVID-Medline.
- DeBattista C, Solomon A, Arnow B, et al. The efficacy of divalproex sodium in the treatment of agitation associated with major depression. *J Clin Psychopharm* 2005;25(5):476-9. PMID:16160625
Exclude: For study design, OVID-Medline.
- DeBattista C, Solvason HB, Poirier J, et al. A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. *J Clin Psychopharm* 2003;23(1):27-30.
Exclude: For study design, OVID-PsycINFO.
- Deberry S, Davis S, Reinhard KE. A comparison of meditation-relaxation and cognitive/behavioral techniques for reducing anxiety and depression in a geriatric population. *Journal of Geriatric Psychiatry* 1989;22(2):231-47. PMID:2701175
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- DeBerry S. The effects of meditation-relaxation on anxiety and depression in a geriatric population. *Psychotherapy: Theory, Research & Practice* 1982;19(4):512-21.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Dekker J, Molenaar PJ, Kool S, et al. Dose-effect relations in time-limited combined psychopharmacological treatment for depression. *Psychol Med* 2005;35(1):47-58. PMID:15842028
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Del Vecchio M, Amati A, Vacca L, et al. Monitoring S-adenosyl-methionine blood levels and antidepressant effect. *Acta Neurologica* 1980;2(6):488-95. PMID:7027755
Exclude: For study design, OVID-Medline.
- DelBello MP, Adler CM, Whitsel RM, et al. A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. *J Clin Psychiatry* 2007;68(5):789-95.
Exclude: For study design, OVID-Embase.
- Delgado PL, Price LH, Charney DS, et al. Efficacy of fluvoxamine in treatment-refractory depression. *J Affect Disord* 1988;15(1):55-60. PMID:2970493
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Delle Chiaie R, Pancheri P, Scapicchio P. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAME) in the treatment of major depression: comparison with imipramine in 2 multicenter studies... S-Adenosylmethionine (SAME): From Molecular Mechanism to Clinical Implication: proceedings of a symposium held at the Oxygen Club of California 2001 World Congress, Santa Barbara, CA, March 7-10, 2001. *AM J CLIN NUTR* 2002;76(5):1172S-1176.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Deltito JA, Moline M, Pollak C, et al. Effects of phototherapy on non-seasonal unipolar and bipolar depressive spectrum disorders. *J Affect Disord* 1991;23(4):231-7. PMID:1791269
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- den Boer PC, Wiersma D, Ten V, I, et al. Cognitive self-therapy for chronic depression and anxiety: a multi-centre randomized controlled study. *Psychol Med* 2007;37(3):329-39. PMID:17076917
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- DeRubeis RJ, Hollon SD, Evans MD, et al. Can psychotherapies for depression be discriminated? A systematic investigation of cognitive therapy and interpersonal therapy. *J Consult Clin Psychol* 1982;50(5):744-56.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- OVID-Embase.
- DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. *Arch Gen Psychiatry* 2005;62(4):409-16. PMID:15809408
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- DeRubeis RJ, Gelfand LA, Tang TZ, et al. Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. *Am J Psychiatry*

- 1999;156(7):1007-13. PMID:10401443
Exclude: For systematic review before 2005, OVID-Medline.
- DeRubeis RJ, Gelfand LA, Tang TZ, et al. Medications versus cognitive behavior therapy for severely depressed outpatients: Mega-analysis of four randomized comparisons. . Am J Psychiatry 1999;156(7):1007-13.
Exclude: For systematic review before 2005, OVID-PscINFO.
- Deshmukh AD, Sarvaiya AA, Nayak AS. Effect of Indian classical music on quality of sleep in depressed patients: a randomized controlled trial. Nordic J Music Ther 2009;18(1):70-8.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Dessauer M, Goetze U, Tolle R. Periodic sleep deprivation in drug-refractory depression. Neuropsychobiology 1985;13(3):111-6. PMID:3900797
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dessaules A, Johnson SM, Denton WH. Emotion-focused therapy for couples in the treatment of depression: A pilot study. American Journal of Family Therapy 2003;31(5):345-53.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Dew MA, Reynolds CF, III, Mulsant B, et al. Initial recovery patterns may predict which maintenance therapies for depression will keep older adults well. J Affect Disord 2001;65(2):155-66. PMID:11356239
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dew MA, Whyte EM, Lenze EJ, et al. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. . Am J Psychiatry 2007;164(6):892-9. PMID:17541048
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Di Palma C, Urani R, Agricola R, et al. Is methylfolate effective in relieving major depression in geriatric alcoholics? A hypothesis of treatment. Curr Ther Res Clin Exp 1994;55(5):559-68.
Exclude: For study design, OVID-Embase.
- Di Rocco A, Rogers JD, Brown R, et al. S-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Movement Disorders 2000;15(6):1225-9. PMID:11104210
Exclude: For study design, OVID-Medline.
- Diamond S, Baltes BJ. The office treatment of mixed anxiety and depression with combination therapy. Psychosomatics 1969;10(6):360-5.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Dias RS, Kerr-Correa F, Moreno RA, et al. Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. . Menopause (10723714) 2006;13(2):202-11. PMID:16645534
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Diaz A, Fouilloux C, Ortiz S. Open trial study of a combined antidepressant (amitriptyline, perphenazine, diazepam) versus fluoxetine or imipramine in ambulatory depressed patients. Proceedings of the Western Pharmacology Society 2002;45:154-5. PMID:12434564
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20(1):57-71. PMID:8861177
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dietrich DE, Bode L, Spannhuth CW, et al. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disorders 2000;2(1):65-70. PMID:11254023
Exclude: For study design, OVID-Medline.
- Dietz LJ, Mufson L, Irvine H, et al. Family-based interpersonal psychotherapy for depressed preadolescents: An open-treatment trial. Early Intervention in Psychiatry 2008;2(3):154-61.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- DiMascio A, Weissman MM, Prusoff BA, et al. Differential symptom reduction by drugs and psychotherapy in acute depression. Arch Gen Psychiatry 1979;36(13):1450-6.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Dimeo F, Bauer M, Varahram I, et al. Benefits from aerobic exercise in patients with major depression: a pilot study. BR J SPORTS MED 2001;35(2):114-7. PMID:11273973
Exclude: For study design, OVID-Medline.
- Dimidjian S, Hollon SD, Dobson KS, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006;74(4):658-70. PMID:16881773
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dimidjian,S. Behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of major depression Dimidjian. 2005
Exclude: For study design, OVID-PscINFO.
- Dimitriou EC, Logothetis JA, Paschalidou M. A double blind comparative study of mianserin and a fixed combination of amitriptyline plus chlordiazepoxide. Adv Biochem Psychopharmacol 1982;32:213-22. PMID:7046365
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. *J Clin Psychopharm* 1998;18(6):465-9. PMID:9864079
Exclude: For study design, OVID-Medline.
- Dinan TG, Barry S. A comparison of electroconvulsive therapy with a combined lithium and tricyclic combination among depressed tricyclic nonresponders. *Acta Psychiatr Scand* 1989;80(1):97-100. PMID:2504034
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dinan TG, Lavelle E, Cooney J, et al. Dexamethasone augmentation in treatment-resistant depression. *Acta Psychiatr Scand* 1997;95(1):58-61. PMID:9051162
Exclude: For study design, OVID-Medline.
- Dinan TG, Scott LV. Does pindolol induce a rapid improvement in depressed patients resistant to serotonin reuptake inhibitors? *Journal of Serotonin Research* 1996;3(3):119-21.
Exclude: For study design, OVID-Embase.
- Dinan TG, Lavelle E, Cooney J, et al. Dexamethasone augmentation in treatment-resistant depression. *Acta Psychiatr Scand* 1997;95(1):58-61.
Exclude: For study design, OVID-PsycINFO.
- Ditzler K, Gessner B, Schatton WFH, et al. Clinical trial on Neurapas versus placebo in patients with mild to moderate depressive symptoms: A placebo-controlled, randomised double-blind study. Phase IV: Clinical trial. *COMPLEMENT THER MED* 1994;2(1):5-13.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Dixon M. Does 'healing' benefit patients with chronic symptoms? A quasi-randomized trial in general practice. *Journal of the Royal Society of Medicine* 1998;91(4):183-8. PMID:9659302
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dixon R, Cohen J. Steady state plasma concentration profiles and therapeutic response in anxious-depressed outpatients after administration of a chlordiazepoxide-amitriptyline combination. *J Clin Psychopharm* 1983;3(2):107-9.
Exclude: For study design, OVID-Embase
- OVID-Embase.
- Dobbin A, Maxwell M, Elton R. A benchmarked feasibility study of a self-hypnosis treatment for depression in primary care. *Int J Clin Exp Hypnosis* 2009;57(3):293-318. PMID:19459090
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dobia B, McMurray NE. Applicability of learned helplessness to depressed women undergoing assertion training. *Australian Journal of Psychology* 1985;37(1):71-80.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Dobkin RD, Allen LA, Alloy LB, et al. Adaptive Inferential Feedback Partner Training for Depression: A Pilot Study. *Cognitive and Behavioral Practice* 2007;14(4):350-63.
Exclude: For study design, OVID-Embase.
- Dobkin RD, Menza M, Marin H, et al. Bupropion improves sexual functioning in depressed minority women: an open-label switch study. *J Clin Psychopharm* 2006;26(1):21-6. PMID:16415700
Exclude: For study design, OVID-Medline.
- Dobkin RD, Allen LA, Menza M. Cognitive-behavioral therapy for depression in Parkinson's disease: A pilot study. *Movement Disorders* 2007;22(7):946-52.
Exclude: For study design, OVID-Embase.
- Dobson KS. A meta-analysis of the efficacy of cognitive therapy for depression. *J Consult Clin Psychol* 1989;57(3):414-9.
Exclude: For systematic review before 2005, OVID-Embase.
- Dobson KS, Hollon SD, Dimidjian S, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. *J Consult Clin Psychol* 2008;76(3):468-77. PMID:18540740
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dobson KS. A meta-analysis of the efficacy of cognitive therapy for depression. *J Consult Clin Psychol* 1989;57(3):414-9.
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Docherty JP, Sack DA, Roffman M, et al. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. *J Psychiatr Pract* 2005;11(5):302-14.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Doggrell SA. Fluoxetine - Do the benefits outweigh the risks in adolescent major depression? *Expert Opinion on Pharmacotherapy* 2005;6(1):147-50.
Exclude: For study design, OVID-Embase.
- Dolezal-Wood S, Belar CD, Snibbe J. A comparison of computer-assisted psychotherapy and cognitive-behavioral therapy in groups. *J Clin Psych in Medical Settings* 1998;5(1):103-15.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Dombrovski AY, Lenze EJ, Dew MA, et al. Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy. *J AM GERIATR SOC* 2007;55(9):1325-32. PMID:17767673
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dombrovski AY, Lenze EJ, Dew MA, et al. Maintenance treatment for old-age depression preserves health-related quality of life: A randomized, controlled trial of paroxetine and interpersonal

psychotherapy. . J AM GERIATR SOC
2007;55(9):1325-32.

Exclude: For Mixed antidepressants; some failed on
SSRI , OVID-PsycINFO.

Dominguez RA, Jacobson AF, Goldstein BJ, et al.
Comparison of triazolam and placebo in the treatment
of insomnia in depressed patients. *Curr Ther Res Clin
Exp*1984;36(5 I):856-65.

Exclude: For population/not failed to respond to an
SSRI, OVID-Embase

OVID-Embase.

Domino ME, Burns BJ, Silva SG, et al. Cost-
effectiveness of treatments for adolescent depression:
results from TADS. . *Am J Psychiatry*
2008;165(5):588-96. PMID:18413703

Exclude: For population/not failed to respond to an
SSRI, OVID-Medline.

Domino ME, Foster EM, Vitiello B, et al. Relative
cost-effectiveness of treatments for adolescent
depression: 36-week results from the TADS
randomized trial. *J Am Acad Child Adolesc
Psychiatry* 2009;48(7):711-20. PMID:19465880

Exclude: For population/not failed to respond to an
SSRI, OVID-Medline.

Domino ME, Burns BJ, Silva SG, et al. Cost-
effectiveness of treatments for adolescent depression:
Results from TADS. . *Am J Psychiatry*
2008;165(5):588-96.

Exclude: For population/not failed to respond to an
SSRI, OVID-PsycINFO.

Domino ME, Foster EM, Vitiello B, et al. Relative
cost-effectiveness of treatments for adolescent
depression: 36-week results from the TADS
randomized trial. . *J Am Acad Child Adolesc
Psychiatry* 2009;48(7):711-20.

Exclude: For population/not failed to respond to an
SSRI, OVID-PsycINFO.

Dong JT. Research on the reduction of anxiety and
depression with acupuncture. *American Journal of
Acupuncture* 1993;21(4):327-30.

Exclude: For study design, OVID-Embase.

Doree J-P, Des RJ, Lew V, et al. Quetiapine
augmentation of treatment-resistant depression: A
comparison with lithium. *Current Medical Research
and Opinion* 2007;23(2):333-41.

Exclude: For Mixed antidepressants; some failed on
SSRI , OVID-Embase.

Doree J P, Tourjman S V, Kunicki S and others.
Comparison of quetiapine versus lithium treatment of
resistant depression. In 2004. **Exclude:** For study
design, Wiley-CCTR.

Dorée JP, Des RJ, Lew V, et al. Quetiapine
augmentation of treatment-resistant depression: a
comparison with lithium. *Current Medical Research
and Opinion* 2007;23(2):333-41.

Exclude: For Mixed antidepressants; some failed on
SSRI , Wiley-CCTR.

Dornseif BE, Dunlop SR, Potvin JH, et al. Effect of
dose escalation after low-dose fluoxetine therapy.

Psychopharmacol Bull 1989;25(1):71-9.

PMID:2672072

Exclude: For Mixed antidepressants; some failed on
SSRI , OVID-Medline.

Doyne EJ, Ossip-Klein DJ, Bowman ED, et al.
Running versus weight lifting in the treatment of
depression. *J Consult Clin Psychol* 1987;55(5):748-
54. PMID:3454786

Exclude: For population/not failed to respond to an
SSRI, OVID-Medline.

Doyne EJ, Ossip-Klein DJ, Bowman ED, et al.
Running versus weight lifting in the treatment of
depression. . *J Consult Clin Psychol* 1987;55(5):748-
54.

Exclude: For population/not failed to respond to an
SSRI, OVID-PsycINFO.

Drago F, Motta A, Grossi E. Intravenous maprotiline
in severe and resistant primary depression: a double-
blind comparison with clomipramine. *The Journal of
international medical research* 1983;11(2):78-84.

Exclude: For population/not failed to respond to an
SSRI, Wiley-CCTR.

Driessen E, Van HL, Schoevers RA, et al. Cognitive
Behavioral Therapy versus Short Psychodynamic
Supportive Psychotherapy in the outpatient treatment
of depression: a randomized controlled trial. *BMC
Psychiatry* 2007;7:58 PMID:17963493

Exclude: For study design, OVID-Medline.

Driscoll HC, Basinski J, Mulsant BH, et al. Late-
onset major depression: clinical and treatment-
response variability. *Int J Geriatr Psychiatry*
2005;20(7):661-7. PMID:16021664

Exclude: For study design, OVID-Medline.

Driver S, Ede A. Impact of physical activity on mood
after TBI. *Brain Inj* 2009;23(3):203-12.

Exclude: For population/not failed to respond to an
SSRI, OVID-Embase.

Duarte PS, Miyazaki MC, Blay SL, et al. Cognitive-
behavioral group therapy is an effective treatment for
major depression in hemodialysis patients. *KIDNEY
INT* 2009;76(4):414-21.

Exclude: For population/not failed to respond to an
SSRI, OVID-Embase.

Dube S, Dube S, Andersen S W and others.
Olanzapine-fluoxetine for treatment-resistant
depression. In 2002. **Exclude:** For study design,
Wiley-CCTR.

Dube S, ersen S W, Paul S and others. Meta-analysis
of olanzapine-fluoxetine in treatment-resistant
depression. In 2002. **Exclude:** For study design,
Wiley-CCTR.

Dubovsky SL, Buzan R, Thomas M, et al.
Nicardipine improves the antidepressant action of
ECT but does not improve cognition. *Journal of ECT*
2001;17(1):3-10. PMID:11281512

Exclude: For population/not failed to respond to an
SSRI, OVID-Medline.

Dudley DL, Volberding N, Loebel P. Intravenous
chlorimipramine and refractory depression. *Gen Hosp*

- Psychiatry 1980;2(1):61-4. PMID:7380252
Exclude: For study design, OVID-Medline.
- Duffy SA, Ronis DL, Valenstein M, et al. A tailored smoking, alcohol, and depression intervention for head and neck cancer patients. *Cancer Epidemiology, Biomarkers & Prevention* 2006;15(11):2203-8. PMID:17119047
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dufresne RL, Kass DJ, Becker RE. Bupropion and thiothixene versus placebo and thiothixene in the treatment of depression in schizophrenia. *Drug Development Research* 1988;12(3-4):259-66.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Dujovne V.F. Comparison of cognitive-behavioral to pharmacological treatment of depression in prepubertal children Dujovne. 1994
Exclude: For study design, OVID-PsycINFO.
- Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. *J Clin Psychopharm* 2007;27(6):614-9. PMID:18004129
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dunn AL, Trivedi MH, Kampert JB, et al. Exercise treatment for depression: efficacy and dose response. *American Journal of Preventive Medicine* 2005;28(1):1-8. PMID:15626549
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dunn AL, Trivedi MH, O'Neal HA. Physical activity dose-response effects on outcomes of depression and anxiety. [Review] [55 refs]. *MED SCI SPORTS EXERC* 33(6:Suppl):Suppl-97 PMID:11427783
Exclude: For systematic review before 2005, OVID-Medline.
- Dunn AL, Trivedi MH, Kampert JB, et al. The DOSE study: A clinical trial to examine efficacy and dose response of exercise as treatment for depression. *Controlled Clinical Trials* 2002;23(5):584-603.
Exclude: For study design,
- Dunn NJ, Rehm LP, Schillaci J, et al. A randomized trial of self-management and psychoeducational group therapies for comorbid chronic posttraumatic stress disorder and depressive disorder. *Journal of Traumatic Stress* 2007;20(3):221-37.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Dunner DL, Schmalting KB, Hendrickson H, et al. Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. *Depression* 1996;4(1):34-41. PMID:9160652
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Dunner DL, Blier P, Keller MB, et al. Preventing recurrent depression: Long-term treatment for major depressive disorder. *Primary Care Companion to the J Clin Psychiatry* 2007;9(3):214-23.
Exclude: For study design, OVID-Embase.
- Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. *J Clin Psychiatry* 2006;67(5):688-95. PMID:16841617
Exclude: For study design, OVID-Medline.
- Dursun SM, Devarajan S, Kutcher S. The 'dalhousie serotonin cocktail' for treatment-resistant major depressive disorder. *J Psychopharmacol* 2001;15(2):136-8. PMID:11448087
Exclude: For study design, OVID-Medline.
- Dyson R, Baldwin DS, Mayers AG, et al. The reported use and effectiveness of Hypericum (St John's wort) on affective symptoms in a depression self-help group. *Primary Care Psychiatry* 2002;8(3):99-102.
Exclude: For systematic review before 2005, OVID-Embase.
- Echeburua E, Salaberria K, De Corral P, et al. Treatment of mixed anxiety-depression disorder: Long-term outcome. *Behav Cogn Psychother* 2006;34(1):95-101.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Eckshtain D. Combined cognitive behavioral treatment plus caregiver sessions for childhood depression Eckshtain. 2009
Exclude: For study design, OVID-PsycINFO.
- Edwards N, Gardiner M, Ritchie DM, et al. Effect of exercise on negative affect in residents in special care units with moderate to severe dementia. *Alzheimer Disease & Associated Disorders* 2008;22(4):362-8. PMID:18978600
Exclude: For study design, OVID-Medline.
- Ehrensing RH, Kastin AJ, Wurzlów GF, et al. Improvement in major depression after low subcutaneous doses of MIF-1. *J Affect Disord* 1994;31(4):227-33.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-PsycINFO.
- Eidelson JJ. Cognitive group therapy for depression: 'Why and what'. *International Journal of Mental Health* 1985;13(3-4):54-66.
Exclude: For study design, OVID-Embase
- OVID-Embase.
- Ekers D, Lovell K. Self-help for anxiety and depression in primary care: an audit of a pilot clinic. *Clinical Effectiveness in Nursing* 2002;6(3-4):129-33.
Exclude: For study design, EBSCO-CINAHL.
- Eksi A, Braun KL. Over-time changes in PTSD and depression among children surviving the 1999 Istanbul earthquake. *European Child and Adolescent Psychiatry* 2009;18(6):384-91.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

- Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. *Arch Gen Psychiatry* 1983;46(11):971-82. PMID:2684085
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: General effectiveness of treatments. *Arch Gen Psychiatry* 1989;46(11):971-82.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Eller T, Vasar V, Shlik J, et al. Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder. *J Psychopharmacol* 2009;23(7):854-8. PMID:18562403
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Elliott TR, Kennedy P. Treatment of Depression Following Spinal Cord Injury: An Evidence-Based Review. *REHABIL PSYCHOL* 2004;49(2):134-9.
Exclude: For systematic review before 2005, OVID-Embase.
- Ellis PM, Smith DAR. Treating depression: The beyondblue guidelines for treating depression in primary care: "Not so much what you do but that you keep doing it". *Medical Journal of Australia* 2002;176(SUPPL.):S77-S83
Exclude: For Guideline published before 2005,
- Ellis PM, Hickie IB, Smith DAR. Summary of guideline for the treatment of depression. *AUSTRALAS PSYCHIATRY* 2003;11(1):34-8.
Exclude: For Guideline published before 2005, OVID-PsycINFO.
- Elsenga S, van den Hoofdakker RH. Clinical effects of sleep deprivation and clomipramine in endogenous depression. *J Psychiatr Res* 1982;17(4):361-74.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Emanuel-Zuurveen L, Emmelkamp PM. Individual behavioural-cognitive therapy v. marital therapy for depression in maritally distressed couples. *Br J Psychiatry* 1996;169(2):181-8. PMID:8871794
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Emanuel-Zuurveen L, Emmelkamp PM. Spouse-aided therapy with depressed patients. *BEHAV MODIF* 1997;21(1):62-77. PMID:8995042
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Embling S. The effectiveness of cognitive behavioural therapy in depression. *NURS STAND* 2002;17(14-15):33-41. PMID:12567797
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Emrich HM, Berger M, Riemann D, et al. Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. *Pharmacopsychiatry* 1987;20(2):60-3. PMID:3108909
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Engels GI, Vermey M. Efficacy of nonmedical treatments of depression in elders: A quantitative analysis. *Journal of Clinical Geropsychology* 1997;3(1):17-35.
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Enns MW, Cox BJ, Pidlubny SR. Group cognitive behaviour therapy for residual depression: Effectiveness and predictors of response. *Cognitive Behaviour Therapy* 2002;31(1):31-40.
Exclude: For study design, OVID-Embase.
- Erfurth A, Ackenheil M, Moller HJ. Effects of Pindolol in Hastening Response to Serotonergic Antidepressants: An Open Study in Severely Depressed In-Patients. *Clinical Neuropsychiatry: Journal of Treatment Evaluation* 2004;1(3):196-201.
Exclude: For study design, OVID-PsycINFO.
- Erlen JA, Mellors MP, Sereika SM, et al. The use of life review to enhance quality of life of people living with AIDS: a feasibility study. *Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation* 2001;10(5):453-64.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Ernst E, Rand JL, Stevinson C. Complementary therapies for depression: an overview. *Arch Gen Psychiatry* 1998;55(11):1026-32.
Exclude: For systematic review before 2005, OVID-AMED.
- Eskin M, Ertekin K, Demir H. Efficacy of a problem-solving therapy for depression and suicide potential in adolescents and young adults. *Cogn Ther Res* 2008;32(2):227-45.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Ettelson, R.G. The treatment of adolescent depression Ettelson. 2003
Exclude: For study design, OVID-PsycINFO.
- Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. *Genetics in Medicine* 2007;9(12):819-25. PMID:18091431
Exclude: For Guideline focus on diagnosis or screening rather than treatment, OVID-Medline.
- Evans MD, Hollon SD, DeRubeis RJ, et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. *Arch Gen Psychiatry* 1992;49(10):802-8. PMID:1417433
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Evans ME. Depression in elderly physically ill inpatients: a 12-month prospective study. *Int Clin Psychopharmacol* 1993;8(4):333-6. PMID:8277159
Exclude: For study design, OVID-Medline.
- Evans MD, Hollon SD, DeRubeis RJ, et al. Differential relapse following cognitive therapy and pharmacotherapy for depression. *Arch Gen Psychiatry* 1992;49(10):802-8.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Evins AE, Culhane MA, Alpert JE, et al. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. *J Clin Psychopharm* 2008;28(6):660-6. PMID:19011435
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fabbri S, Fava GA, Rafanelli C, et al. Family intervention approach to loss of clinical effect during long-term antidepressant treatment: a pilot study. *J Clin Psychiatry* 2007;68(9):1348-51. PMID:17915972
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fahlén T, Agren H, Edström A and others. Buspirone in SSRI-refractory depression. In 1996. **Exclude:** For study design, Wiley-CCTR.
- Fahndrich E. Effects of sleep deprivation on depressed patients of different nosological groups. *Psychiatry Res* 1981;5(3):277-85. PMID:6948310
Exclude: For study design, OVID-Medline.
- Fahy TJ. Side effects of moclobemide in depressed patients refractory to other treatments. *IR J PSYCHOL MED* 1993;10(1):24-7.
Exclude: For study design, OVID-Embase.
- Fakhoury TA, Miller JM, Hammer AE, et al. Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study. *DRUGS AGING* 2008;25(11):955-62. PMID:18947263
Exclude: For study design, OVID-Medline.
- Falconnier L. Socioeconomic status in the treatment of depression. *American Journal of Orthopsychiatry* 2009;79(2):148-58. PMID:19485632
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Faramarzi M, Kheirkhah F, Esmaelzadeh S, et al. Is psychotherapy a reliable alternative to pharmacotherapy to promote the mental health of infertile women? A randomized clinical trial. *European Journal of Obstetrics, Gynecology, & Reproductive Biology* 2008;141(1):49-53. PMID:18848381
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Faramarzi M, Alipor A, Esmaelzadeh S, et al. Treatment of depression and anxiety in infertile women: cognitive behavioral therapy versus fluoxetine. *J Affect Disord* 2008;108(1-2):159-64. PMID:17936366
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Faravelli C, Albanesi G, Sessarego A. Viquiline in resistant depression: a double-blind, placebo-controlled trial. *Neuropsychobiology* 1988;20(2):78-81. PMID:3075725
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Farid FF, Wenger TL, Tsai SY, et al. Use of bupropion in patients who exhibit orthostatic hypotension on tricyclic antidepressants. *J Clin Psychiatry* 1983;44(5:Pt 2):t-3 PMID:6406451
Exclude: For study design, OVID-Medline.
- Fasullo S, Vinci GG. Treatment of resistant depression with TRH. *Psichiatria e Psicoterapia Analitica* 1991;10(3):241-6.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Fava GA, Savron G, Grandi S, et al. Cognitive-behavioral management of drug-resistant major depressive disorder. *J Clin Psychiatry* 283;58(6):278-82. PMID:9228899
Exclude: For study design, OVID-Medline.
- Fava GA, Ruini C, Rafanelli C, et al. Cognitive behavior approach to loss of clinical effect during long-term antidepressant treatment: a pilot study. *Am J Psychiatry* 2002;159(12):2094-5. PMID:12450962
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fava GA, Grandi S, Zielesny M, et al. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. *Am J Psychiatry* 1994;151(9):1295-9. PMID:8067483
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fava GA, Grandi S, Zielesny M, et al. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression. *Am J Psychiatry* 1996;153(7):945-7. PMID:8659620
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. *Arch Gen Psychiatry* 1998;55(9):816-20. PMID:9736008
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fava GA, Rafanelli C, Grandi S, et al. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. *Am J Psychiatry* 1998;155(10):1443-5. PMID:9766780
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fava GA, Ruini C, Rafanelli C, et al. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. *Am J Psychiatry* 2004;161(10):1872-6.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

- Fava GA, Rafanelli C, Cazzaro M, et al. Well-being therapy. A novel psychotherapeutic approach for residual symptoms of affective disorders. *Psychol Med* 1998;28(2):475-80. PMID:9572104
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fava M, Alpert J, Nierenberg AA, et al. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. *J Clin Psychopharm* 2005;25(5):441-7. PMID:16160619
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. *Biol Psychiatry* 2006;59(11):1052-60. PMID:16581036
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fava M, Rosenbaum JF, Cohen L, et al. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. *J Affect Disord* 1992;25(4):229-34. PMID:1430659
Exclude: For study design, OVID-Medline.
- Fava M, Giannelli A, Rapisarda V, et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. *Psychiatry Res* 1995;56(3):295-7. PMID:7568552
Exclude: For study design, OVID-Medline.
- Fava M, Papakostas GI, Petersen T, et al. Switching to bupropion in fluoxetine-resistant major depressive disorder. *Ann Clin Psychiatry* 2003;15(1):17-22. PMID:12839429
Exclude: For study design, OVID-Medline.
- Fava M, McGrath PJ, Sheu WP, et al. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. *J Clin Psychopharm* 2003;23(4):365-9. PMID:12920412
Exclude: For study design, OVID-Medline.
- Fava M, Alpert J, Nierenberg AA, et al. A Double-blind, Randomized Trial of St John's Wort, Fluoxetine, and Placebo in Major Depressive Disorder. *J Clin Psychopharm* 2005;25(5):441-7.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Fawcett J, Edwards JH, Kravitz HM, et al. Alprazolam: an antidepressant? Alprazolam, desipramine, and an alprazolam-desipramine combination in the treatment of adult depressed outpatients. *J Clin Psychopharm* 1987;7(5):295-310. PMID:3316312
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. *J Clin Psychopharm* 1991;11(2):127-32. PMID:2056139
Exclude: For study design, OVID-Medline.
- Feet PO, Larsen S, Robak OH. A double blind study in out-patients with primary non-agitated depression treated with imipramine in combination with placebo, diazepam or dixyrazine. *Acta Psychiatr Scand* 1985;72(4):334-40.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Feighner JP, Brauzer B, Gelenberg AJ, et al. A placebo-controlled multicenter trial of Limbitrol versus its components (amitriptyline and chlordiazepoxide) in the symptomatic treatment of depressive illness. *Psychopharmacology* 1979;61(2):217-25.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Feighner JP, Boyer WF, Tyler DL, et al. Adverse consequences of fluoxetine-MAOI combination therapy. *J Clin Psychiatry* 1990;51(6):222-5. PMID:2347858
Exclude: For study design, OVID-Medline.
- Feighner JP, Sverdlov L, Hlavka J, et al. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients. *Int Clin Psychopharmacol* 2008;23(1):29-35. PMID:18090505
Exclude: For study design, OVID-Medline.
- Feighner JP, Sverdlov L, Nicolau G, et al. Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment. *Int J Neuropsychopharmacol* 2003;6(3):207-13. PMID:12974986
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. [Review] [44 refs]. *J Clin Psychiatry* 2004;65(11):1520-4. PMID:15554766
Exclude: For systematic review before 2005, OVID-Medline.
- Feldman G, Harley R, Kerrigan M, et al. Change in emotional processing during a dialectical behavior therapy-based skills group for major depressive disorder. *Beh Res Ther* 2009;47(4):316-21.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Fenton L, Fasula M, Ostroff R, et al. Can cognitive behavioral therapy reduce relapse rates of depression after ECT? a preliminary study. *Journal of ECT* 2006;22(3):196-8. PMID:16957536
Exclude: For study design, OVID-Medline.
- Ferguson J, Cunningham L, Merideth C, et al. Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. *Ann Clin Psychiatry* 1994;6(3):153-60. PMID:7881495
Exclude: For study design, OVID-Medline.
- Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. *Clin Neuropharmacol* 2007;30(3):136-44.

PMID:17545748

Exclude: For study design, OVID-Medline.

Ferrucci R, Bortolomasi M, Vergari M, et al. Transcranial direct current stimulation in severe, drug-resistant major depression. *J Affect Disord* 2009;118(1-3):215-9.

Exclude: For study design, OVID-Embase.

Fetsch RJ, Sprinkle RL. Effects of running on depressed adults. *American Mental Health Counselors Association Journal* 1983;5(2):75-84.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Field T, Hernandez-Reif M, Hart S, et al. Effects of sexual abuse are lessened by massage therapy. *Journal of Bodywork and Movement Therapies* 1997;1(2):65-9.

Exclude: For population/not failed to respond to an SSRI, OVID-AMED.

Finch E, Katona CLE. Lithium augmentation in the treatment of refractory depression in old age. *Int J Geriatr Psychiatry* 1989;4(1):41-6.

Exclude: For study design, OVID-Embase.

Findling RL, Lingler J, Rowles BM, et al. A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. *Journal of Child & Adolescent Psychopharmacology* 2008;18(6):615-21. PMID:19108666

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Findling RL, McNamara NK, O'Riordan MA, et al. An open-label pilot study of St. John's wort in juvenile depression. *J Am Acad Child Adolesc Psychiatry* 2003;42(8):908-14. PMID:12874492

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Finkelstein FO, Watnick S, Finkelstein SH, et al. The treatment of depression in patients maintained on dialysis. *J Psychosom Res* 2002;53(4):957-60.

Exclude: For study design, OVID-Embase.

Finucane A, Mercer SW. An exploratory mixed methods study of the acceptability and effectiveness of Mindfulness-Based Cognitive Therapy for patients with active depression and anxiety in primary care. *BMC Psychiatry* 2006;6:14 PMID:16603060

Exclude: For study design, OVID-Medline.

Firth-Cozens J, Brewin CR. Attributional change during psychotherapy. *BR J CLIN PSYCHOL* 1988;27(1):47-54.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Fischer P, Tauscher J, Kufferle B, et al. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. *Int Clin Psychopharmacol* 1998;13(2):83-6. PMID:9669189

Exclude: For study design, OVID-Medline.

Flaughner M. The intervention of music on perceptions of chronic pain, depression, and anxiety in ambulatory individuals with cancer University of Alabama at

Birmingham. 2002

Exclude: For study design, EBSCO-CINAHL.

Fleischhauer J, Glauser G, Hofstetter P. The influence of light therapy in depressive patients. *Pharmacopsychiatry* 1988;21(6):414-5.

PMID:3244780

Exclude: For study design, OVID-Medline.

Flint AJ, Rifat SL. A prospective study of lithium augmentation in antidepressant-resistant geriatric depression. *J Clin Psychopharm* 1994;14(5):353-6.

PMID:7806693

Exclude: For study design, OVID-Medline.

Flint AJ, Rifat SL. Anxious depression in elderly patients. Response to antidepressant treatment. *Am J Geriatr Psychiatry* 1997;5(2):107-15. PMID:9106374

Exclude: For study design, OVID-Medline.

Flint AJ, Rifat SL. Maintenance treatment for recurrent depression in late life. A four-year outcome study. *Am J Geriatr Psychiatry* 2000;8(2):112-6.

PMID:10804071

Exclude: For study design, OVID-Medline.

Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. *J Affect Disord* 1996;36(3-4):95-105. PMID:8821312

Exclude: For study design, OVID-Medline.

Flint AJ, Rifat SL. The effect of treatment on the two-year course of late-life depression. *Br J Psychiatry* 1997;170(MAR.):268-72.

Exclude: For study design, OVID-Embase.

Floyd M, Scogin F, McKendree-Smith NL, et al. Cognitive therapy for depression: a comparison of individual psychotherapy and bibliotherapy for depressed older adults. *BEHAV MODIF* 2004;28(2):297-318. PMID:14997954

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Floyd M, Rohen N, Shackelford JA, et al. Two-year follow-up of bibliotherapy and individual cognitive therapy for depressed older adults. *BEHAV MODIF* 2006;30(3):281-94. PMID:16574815

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Fontaine R, Ontiveros A, Elie R, et al. Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression. [erratum appears in *Biol Psychiatry* 1992 Feb 1;31(3):322]. *Biol Psychiatry* 1991;29(9):946-8. PMID:1904782

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Fontaine R, Ontiveros A, Elie R, et al. "Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression": Correction. *Biol Psychiatry* 1992;31(3):322

Exclude: For study design, OVID-PsycINFO.

Forman EM, Herbert JD, Moitra E, et al. A randomized controlled effectiveness trial of acceptance and commitment therapy and cognitive therapy for anxiety and depression. *BEHAV MODIF* 2007;31(6):772-99. PMID:17932235

- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Forstmeier S, Rueddel H. Improving volitional competence is crucial for the efficacy of psychosomatic therapy: a controlled clinical trial. *Psychother Psychosom* 2007;76(2):89-96.
- Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.
- Foster MA, Ragsdale K, Dunne B, et al. Detection and treatment of depression in a VA primary care clinic. *Psychiatr Serv* 1999;50(11):1494-5.
- Exclude:** For study design, OVID-Embase.
- Foster RP. Treating depression in vulnerable urban women: a feasibility study of clinical outcomes in community service settings. *American Journal of Orthopsychiatry* 2007;77(3):443-53. PMID:17696673
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Fountoulakis KN, Nimatoudis I, Iacovides A, et al. Off-label indications for atypical antipsychotics: A systematic review. *Annals of General Hospital Psychiatry* 2004;3, 2004. Date of Publication: 18 Feb 2004.:
- Exclude:** For systematic review before 2005, OVID-Embase.
- Fournier JC, DeRubeis RJ, Shelton RC, et al. Antidepressant medications v. cognitive therapy in people with depression with or without personality disorder. *Br J Psychiatry* 2008;192(2):124-9. PMID:18245030
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Fowler JC, Ackerman SJ, Speanburg S, et al. Personality and symptom change in treatment-refractory inpatients: evaluation of the phase model of change using Rorschach,TAT, and DSM-IV Axis V. *Journal of Personality Assessment* 2004;83(3):306-22. PMID:15548467
- Exclude:** For study design, OVID-Medline.
- Franchini L, Bongiorno F, Spagnolo C, et al. Psychoeducational group intervention in addition to antidepressant therapy as relapse preventive strategy in unipolar patients. *Clinical Neuropsychiatry* 2006;3(4):282-5.
- Exclude:** For population/not failed to respond to an SSRI, OVID-Embase.
- Frank E, Grochocinski VJ, Spanier CA, et al. Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression. *J Clin Psychiatry* 2000;61(1):51-7. PMID:10695647
- Exclude:** For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Frank E, Kupfer DJ, Buysse DJ, et al. Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. *Am J Psychiatry* 2007;164(5):761-7. PMID:17475735
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. *Arch Gen Psychiatry* 1990;47(12):1093-9.
- Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.
- Frank, Ellen, Kupfer, David J., Levenson, Janet. Continuation therapy for unipolar depression: The case for combined treatment. 1990:135-49. 1990.
- Exclude:** For study design, OVID-PsycINFO.
- Frank E, Stewart BD. Treating depression in victims of rape. *Clinical Psychologist* 1983;36(4):95-8.
- Exclude:** For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Frankenburg,J.B. The effects of three experimental phenomenological techniques in treating dysthymic depression Frankenburg. 1996
- Exclude:** For study design, OVID-PsycINFO.
- Franzblau SH, Echevarria S, Smith M, et al. A preliminary investigation of the effects of giving testimony and learning yogic breathing techniques on battered women's feelings of depression. *Journal of Interpersonal Violence* 2008;23(12):1800-8.
- Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Frederick C. Pools and wellings: the resolution of refractory intermittent depressive symptoms with ego-state therapy. *Hypnos* 1993;20(4):221-7.
- Exclude:** For study design, OVID-AMED.
- Free ML, Oei TP, Sanders MR. Treatment outcome of a group cognitive therapy program for depression. *International Journal of Group Psychotherapy* 1991;41(4):533-47. PMID:1938020
- Exclude:** For study design, OVID-Medline.
- Freedland KE, Skala JA, Carney RM, et al. Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. *Arch Gen Psychiatry* 2009;66(4):387-96. PMID:19349308
- Exclude:** For population/diagnosis, OVID-Medline.
- Freeman MP, Hibbeln JR, Wisner KL, et al. An open trial of Omega-3 fatty acids for depression in pregnancy. *Acta Neuropsychiatrica* 2006;18(1):21-4.
- Exclude:** For study design, OVID-Embase.
- Fremont J, Wilcoxon CL. Aerobic exercise and cognitive therapy in the treatment of dysphoric moods. *Cogn Ther Res* 1987;11(2):241-51.
- Exclude:** For population/not failed to respond to an SSRI, OVID-Embase.
- Freudenstein U, Jagger C, Arthur A, et al. Treatments for late life depression in primary care - A systematic review. *Family Practice* 2001;18(3):321-7.
- Exclude:** For systematic review before 2005, OVID-Embase.
- Friedberg F, Krupp LB. A comparison of cognitive behavioral treatment for chronic fatigue syndrome and primary depression. *Clinical Infectious Diseases* 1994;18:Suppl-10 PMID:8148435
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.

- Friedberg RD, McClure JM, Wilding L, et al. A Cognitive-Behavioral Skills Training Group for Children Experiencing Anxious and Depressive Symptoms: A Clinical Report with Accompanying Descriptive Data. *Journal of Contemporary Psychotherapy* 2003;33(3):157-75.
Exclude: For study design, OVID-Embase.
- Friedberg RD, McClure JM, Wilding L, et al. A Cognitive-Behavioral Skills Training Group for Children Experiencing Anxious and Depressive Symptoms: A Clinical Report with Accompanying Descriptive Data. *Journal of Contemporary Psychotherapy* 2003;33(3):157-75.
Exclude: For study design, OVID-PsycINFO.
- Friede M, Henneicke von Zepelin HH, Freudenstein J. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort. *Pharmacopsychiatry* 2001;34:Suppl-41
PMID:11518073
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Friedman AS. Interaction of drug therapy with marital therapy in depressive patients. *Arch Gen Psychiatry* 1975;32(5):619-37.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Friedman ES, Wisniewski SR, Gilmer W, et al. Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: Results of the NIMH star*D trial. *Depress Anxiety* 2009;26(7):612-21.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.
- Friedman ES, Thase ME, Wisniewski SR, et al. Cognitive therapy augmentation versus CT switch treatment: A STAR*D report. *International Journal of Cognitive Therapy* 2009;2(1):66-87.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-PsycINFO.
- Friedman MA, Detweiler-Bedell JB, Leventhal HE, et al. Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder. *Clinical Psychology: Science and Practice* 2004;11(1):47-68.
Exclude: For systematic review before 2005, OVID-Embase.
- Friedman MA, Cardemil EV, Uebelacker LA, et al. The GIFT program for major depression: Integrating group, individual, and family treatment. *Journal of Psychotherapy Integration* 2005;15(2):147-68.
Exclude: For study design, OVID-Embase.
- Fristad MA, Verducci JS, Walters K, et al. Impact of multifamily psychoeducational psychotherapy in treating children aged 8 to 12 years with mood disorders. *Arch Gen Psychiatry* 2009;66(9):1013-21.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Frothingham, S.S. The effects of an optimism-based cognitive behavioral intervention on mood and functioning in cardiac patients Frothingham. 2006
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. *J Clin Psychopharm* 2000;20(6):607-14.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Fu Keung WD. Cognitive and health-related outcomes of group cognitive behavioural treatment for people with depressive symptoms in Hong Kong: Randomized wait-list control study. *Aust N Z J Psychiatry* 2008;42(8):702-11.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Fu WB, Fan L, Zhu XP, et al. Depressive neurosis treated by acupuncture for regulating the liver--a report of 176 cases. *J Tradit Chin Med* 2009;29(2):83-6. PMID:19663089
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Fukunishi I, Hosaka T, Matsumoto T, et al. Liaison psychiatry and HIV infection (II): Application of relaxation in HIV positive patients. *Psychiatry and Clinical Neurosciences* 1997;51(1):5-8.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Furtado CP, Maller JJ, Fitzgerald PB. A magnetic resonance imaging study of the entorhinal cortex in treatment-resistant depression. *Psychiatry Res* 2008;163(2):133-42. PMID:18511243
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Furukawa T, Streiner DL, Young LT. Antidepressant plus benzodiazepine for major depression. [update in Cochrane Database Syst Rev. 2001;(2):CD001026; PMID: 11405972]. [Review] [87 refs]. *Cochrane Database of Systematic Reviews* 2000;(4):CD001026
PMID:11034696
Exclude: For systematic review before 2005, OVID-Medline.
- Furukawa T, Streiner DL, Young LT. Review: Antidepressants plus benzodiazepines lead to fewer drop outs and less depression severity in major depression. *Evidence-Based Medicine* 2001;6(6):184
Exclude: For systematic review before 2005, OVID-Embase.
- Furukawa TA, Streiner DL, Young LT. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. *J Affect Disord* 2001;65(2):173-7. PMID:11356241
Exclude: For systematic review before 2005, OVID-Medline.
- Gabelic I, Moll E. Moclobemide (Ro 11-1163) versus desipramine in the treatment of endogenous depression. *Acta Psychiatrica Scandinavica, Supplementum* 1990;360:44-5. PMID:2248068
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Gabelic I, Kuhn B. Moclobemide (Ro 11-1163) versus tranlycypromine in the treatment of endogenous depression. *Acta Psychiatrica Scandinavica, Supplement* 1990;82(360):63
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
 OVID-Embase.
- Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. *Depress Anxiety* 2006;23(8):485-8. PMID:16845646
Exclude: For study design, OVID-Medline.
- Gagiano CA, Muller PG, Fourie J, et al. The therapeutic efficacy of paroxetine: (a) an open study in patients with major depression not responding to antidepressants; (b) a double-blind comparison with amitriptyline in depressed outpatients. *Acta Psychiatrica Scandinavica, Supplementum* 1989;350:130-1. PMID:2530765
Exclude: For study design, OVID-Medline.
- Gaik, F.V. Merging east and west: A preliminary study applying spring forest qigong to depression as an alternative and complementary treatment Gaik. 2003
Exclude: For study design, OVID-PsycINFO.
- Galecki P, Szemraj J, Bienkiewicz M, et al. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. *Hum Psychopharmacol* 2009;24(4):277-86. PMID:19319921
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Gallagher-Thompson D, Gray HL, Dupart T, et al. Effectiveness of cognitive/behavioral small group intervention for reduction of depression and stress in non-Hispanic White and Hispanic/Latino women dementia family caregivers: Outcomes and mediators of change. *Journal of Rational-Emotive & Cognitive Behav Ther* 2008;26(4):286-303.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Gallagher-Thompson D, Gray HL, Tang PC, et al. Impact of in-home behavioral management versus telephone support to reduce depressive symptoms and perceived stress in Chinese caregivers: results of a pilot study. *Am J Geriatr Psychiatry* 2007;15(5):425-34. PMID:17463192
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Gallagher-Thompson D, Hanley-Peterson P, Thompson LW. Maintenance of gains versus relapse following brief psychotherapy for depression. *J Consult Clin Psychol* 1990;58(3):371-4.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
 OVID-Embase.
- Gallagher DE, Thompson LW. Effectiveness of psychotherapy for both endogenous and nonendogenous depression in older adult outpatients. *Journal of Gerontology* 1983;38(6):707-12.
Exclude: For study design, OVID-PsycINFO.
- Gallagher DE, Thompson LW. Treatment of major depressive disorder in older adult outpatients with brief psychotherapies. *Psychotherapy: Theory, Research & Practice* 1982;19(4):482-90.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Gallagher SM, Allen JJ, Hitt SK, et al. Six-month depression relapse rates among women treated with acupuncture. *COMPLEMENT THER MED* 2001;9(4):216-8. PMID:12184348
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Ganster DC, Mayes BT, Sime WE, et al. Managing organizational stress: A field experiment. *Journal of Applied Psychology* 1982;67(5):533-42.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Garakani A, Martinez JM, Marcus S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. *Int Clin Psychopharmacol* 2008;23(5):269-75. PMID:18703936
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Garcia-Toro M, Segura C, Gonzalez A, et al. Inefficacy of burst-suppression anesthesia in medication-resistant major depression: a controlled trial. *Journal of ECT* 2001;17(4):284-8. PMID:11731731
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Gardner EA. Long-term preventive care in depression: the use of bupropion in patients intolerant of other antidepressants. *J Clin Psychiatry* 1983;44(5:Pt 2):t-62 PMID:6406449
Exclude: For study design, OVID-Medline.
- Gariballa S, Forster S. Effects of dietary supplements on depressive symptoms in older patients: a randomised double-blind placebo-controlled trial. *CLIN NUTR* 2007;26(5):545-51. PMID:17662509
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Garriock HA, Delgado P, Kling MA, et al. Number of risk genotypes is a risk factor for major depressive disorder: A case control study. *Behavioral and Brain Functions* 2006;2, 2006. Article Number: 24. Date of Publication: 05 Jul 2006.:
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.
- Garvey MJ, DeRubeis RJ, Hollon SD, et al. Response of depression to very high plasma levels of imipramine plus desipramine. *Biol Psychiatry* 1991;30(1):57-62.
Exclude: For study design, OVID-PsycINFO.
- Gary RA, Sueta CA, Dougherty M, et al. Home-based exercise improves functional performance and quality of life in women with diastolic heart failure. *Heart & lung : the journal of critical care* 2004;33(4):210-8.

- Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.
- Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. *Drugs Under Experimental & Clinical Research* 1990;16(2):101-6. PMID:2205455
Exclude: For population/diagnosis, OVID-Medline.
- Gastpar M, Singer A, Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. *Pharmacopsychiatry* 2006;39(2):66-75. PMID:16555167
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Gastpar M, Singer A, Zeller K. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. *Pharmacopsychiatry* 2005;38(2):78-86. PMID:15744631
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Gatz M, Fiske A, Fox LS, et al. Empirically validated psychological treatments for older adults. *Prof Psychol Res Pr* 1998;4(1):9-39.
Exclude: For systematic review before 2005, OVID-Embase.
- Gayle RC, Spittler DL, Karper WB, et al. Psychological changes in exercising COPD patients. *INT J REHABIL RES* 1988;11(4):335-42.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Gaynes BN, Rush AJ, Trivedi MH, et al. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. *J Gen Intern Med* 2008;23(5):551-60. PMID:18247097
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Gaynor ST, Lawrence PS. Complementing CBT for depressed adolescents with Learning through In-Vivo Experience (LIVE): Conceptual analysis, treatment description, and feasibility study. *Behav Cogn Psychother* 2002;30(1):79-101.
Exclude: For study design, OVID-Embase.
- Gecele M, Francesetti G, Meluzzi A. Acetyl-L-carnitine in aged subjects with major depression: Clinical efficacy and effects on the circadian rhythm of cortisol. *Dementia* 1991;2(6):333-7.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Gelenberg AJ, Shelton RC, Crits-Christoph P, et al. The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. *J Clin Psychiatry* 2004;65(8):1114-9. PMID:15323598
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Gelhart RP, Hand-Ronga N, King HL. Group cognitive-behavioral treatment of depression and the interaction of demographic variables. *Journal of Cognitive Psychotherapy: An International Quarterly* 2002;16(4):469-86.
Exclude: For study design, OVID-Embase.
- Gelhart RP, King HL. The influence of comorbid risk factors on the effectiveness of cognitive-behavioral treatment of depression. *Cognitive and Behavioral Practice* 2001;8(1):18-28.
Exclude: For study design, OVID-Embase.
- Geller B, Cooper TB, Graham DL, et al. Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design. *Psychopharmacol Bull* 1990;26(1):85-90.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
OVID-Embase.
- Gelman CR, Lopez M, Foster RP. Evaluating the impact of a cognitive-behavioral intervention with depressed Latinas: a preliminary report. *SOC WORK MENT HEALTH* 2005;4(2):1-16.
Exclude: For study design, EBSCO-CINAHL.
- Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo-controlled pilot study. *Depress Anxiety* 2007;24(7):487-94.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.
- Genthner GC, Friedman HL, Studley CF. Improvement in depression following reduction of upper cervical vertebral subluxation using orthospinology technique. *Journal of Vertebral Subluxation Research (JVSR)* 2005;1-4. **Exclude:** For study design, EBSCO-CINAHL.
- George T, Theodoros MT, Chiu E, et al. An open study of sertraline in patients with major depression who failed to respond to moclobemide. *Aust NZ J Psychiatry* 1999;33(6):889-95. PMID:10619217
Exclude: For study design, OVID-Medline.
- Georgotas A, Friedman E, McCarthy M, et al. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. *Biol Psychiatry* 1983;18(2):195-205. PMID:6830930
Exclude: For study design, OVID-Medline.
- Geretsegger C, Bitterlich W, Stelzig R, et al. Paroxetine with pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients. *European Neuropsychopharmacol* 2008;18(2):141-6. PMID:18054209
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Gerson S, Belin TR, Kaufman A, et al. Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings. *Harvard Review of Psychiatry* 1999;7(1):1-28. PMID:10439302

Exclude: For systematic review before 2005, OVID-Medline.

Gervasoni N, Aubry JM, Gex-Fabry M, et al. Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression? *Pharmacological Research* 2009;59(3):202-6.

PMID:19073260

Exclude: For study design, OVID-Medline.

Ghaemi SN, Cherry EL, Katzow JA, et al. Does olanzapine have antidepressant properties? A retrospective preliminary study. *Bipolar Disorders* 2000;2(3:Pt 1):t-9 PMID:11256687

Exclude: For study design, OVID-Medline.

Ghaemi SN, Katzow JJ, Desai SP, et al. Gabapentin treatment of mood disorders: a preliminary study. *J Clin Psychiatry* 1998;59(8):426-9. PMID:9721823

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Ghaziuddin N, Naylor MW, King CA. Fluoxetine in tricyclic refractory depression in adolescents. *Depression* 1995;2(6):287-91.

Exclude: For study design, OVID-Embase.

Ghaziuddin N, Kutcher SP, Knapp P, et al. Summary of the practice parameter for the use of electroconvulsive therapy with adolescents. *J Am Acad Child Adolesc Psychiatry* 2004;43(1):119-22. PMID:14691369

Exclude: For Guideline focus on diagnosis or screening rather than treatment, OVID-Medline.

Giannelli A, Rabboni M, Zarattini F, et al. A combination of hypothalamic phospholipid liposomes with trazodone for treatment of depression. An open controlled study. *Acta Psychiatr Scand* 1989;79(1):52-8. PMID:2648767

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Gilbert G. Adults with both anxiety and depression respond poorly to treatment. *J Natl Med Assoc* 2008;100(7):870-1.

Exclude: For study design, OVID-Embase.

Gilbert J, Strong J. Dysfunctional attitudes in patients with depression: A study of patients admitted to a private psychiatric hospital. *British Journal of Occupational Therapy* 1994;57(1):15-9.

Exclude: For study design, OVID-PsycINFO.

Gillham JE, Hamilton J, Freres DR, et al. Preventing depression among early adolescents in the primary care setting: a randomized controlled study of the Penn Resiliency Program.[erratum appears in *J Abnorm Child Psychol*. 2008 Feb;36(2):297-8]. *Journal of Abnormal Child Psychology* 2006;34(2):203-19. PMID:16741684

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Gilmer WS, Gollan JK, Wisniewski SR, et al. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. *J Clin Psychiatry* 2008;69(8):1246-56. PMID:18681756

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Ginsberg DL. Adjunctive Ropinirole for Treatment-Resistant Depression. *Prim Psychiatry* 2005;12(8):26-7.

Exclude: For study design, OVID-PsycINFO.

Ginsberg DL. Atomoxetine Augmentation of Antidepressants. *Prim Psychiatry* 2005;12(3):19

Exclude: For study design, OVID-PsycINFO.

Ginsberg DL. Chromium picolinate treatment of atypical depression. *Prim Psychiatry* 2003;10(4):23-4.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Gitlin MJ, Weiner H, Fairbanks L, et al. Failure of T3 to potentiate tricyclic antidepressant response. *J Affect Disord* 1987;13(3):267-72. PMID:2960719

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Given C, Given B, Rahbar M, et al. Does a symptom management intervention affect depression among cancer patients: results from a clinical trial. *Psycho Oncol* 2004;13(11):818-30. PMID:15386790

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Glassman AH, Platman SR. Potentiation of a monoamine oxidase inhibitor by tryptophan. *J Psychiatr Res* 1969;7(2):83-8.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Gloaguen V, Cottraux J, Cucherat M, et al. A meta-analysis of the effects of cognitive therapy in depressed patients. *J Affect Disord* 1998;49(1):59-72. PMID:9574861

Exclude: For systematic review before 2005, OVID-Medline.

Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. *Lancet* 1990;336(8712):392-5. PMID:1974941

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Goel N, Etwaroo GR. Bright light, negative air ions and auditory stimuli produce rapid mood changes in a student population: a placebo-controlled study. *Psychol Med* 2006;36(9):1253-63. PMID:16756690

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Goel N, Terman M, Terman JS, et al. Controlled trial of bright light and negative air ions for chronic depression. *Psychol Med* 2005;35(7):945-55. PMID:16045061

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Goldberg B. Psychotropic drugs in children: A guide for the family physician. *CAN FAM PHYSICIAN* 1989;35(DEC.):2459-63.

Exclude: For Guideline published before 2005, OVID-Embase.

- Gonul AS, Oguz A, Yabanoglu I, et al. Buspiron and pindolol in augmentation therapy of treatment-resistant depression. *European Neuropsychopharmacol* 1999;9(Suppl 5):215
Exclude: For Mixed antidepressants; some failed on SSRI, Wiley-CCTR.
- Gonul, Ali Saffet, Doksat, Kerem, Eker, Cagdas et al. Managing Treatment-Resistant Depression: Focusing on Increasing Serotonergic Transmission. . 2005:1-27. 2005.
Exclude: For study design, OVID-PsycINFO.
- Gonzalez-Pinto A, Gutierrez M, Gonzalez N, et al. Efficacy and safety of venlafaxine-ECT combination in treatment-resistant depression. *Journal of Neuropsychiatry & Clinical Neurosciences* 2002;14(2):206-9. PMID:11983797
Exclude: For study design, OVID-Medline.
- Gonzalez GM, Munoz RF, Perez-Arce P, et al. Depression and HIV disease in injection drug users: A Spanish language feasibility study. . *Psychology of Addictive Behaviors* 1993;7(3):149-54.
Exclude: For study design, OVID-PsycINFO.
- Goodwin FK, Prange AJ, Jr., Post RM, et al. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. *Am J Psychiatry* 1982;139(1):34-8. PMID:7055275
Exclude: For study design, OVID-Medline.
- Goodwin GM. Evidence-based guidelines for treating bipolar disorder: Recommendations from the British Association for Psychopharmacology. *J Psychopharmacol* 2003;17(2):149-73.
Exclude: For Guideline published before 2005, OVID-Embase.
- Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. . *BMJ* 2007;335(7611):142 PMID:17556431
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Goodyer IM, Dubicka B, Wilkinson P, et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. *Health Technology Assessment (Winchester, England)* 60 B.C.;12(14):iii-iiiv PMID:18462573
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Gordijn MCM, Beersma DGM, Korte HJ, et al. Testing the hypothesis of a circadian phase disturbance underlying depressive mood in nonseasonal depression. *Journal of Biological Rhythms* 1998;13(2):132-47.
Exclude: For study design, OVID-PsycINFO.
- Gordon VC, Matwychuk AC, Sachs EG, et al. A 3-yr follow-up of a cognitive-behavioral therapy intervention. *Arch Psychiatr Nurs* 1988;2(4):218-26.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Gorgulu Y, Caliyurt O. Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. *Brain Research Bulletin* 2009;80(3):158-62. PMID:19576267
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Gortner ET, Gollan JK, Dobson KS, et al. Cognitive-behavioral treatment for depression: relapse prevention. *J Consult Clin Psychol* 1998;66(2):377-84. PMID:9583341
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Gosney MA, Hammond MF, Shenkin A, et al. Effect of micronutrient supplementation on mood in nursing home residents. *Gerontology* 2008;54(5):292-9. PMID:18463429
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Graf MC, Gaudiano BA, Geller PA. Written emotional disclosure: a controlled study of the benefits of expressive writing homework in outpatient psychotherapy. *Psychotherapy Research* 2008;18(4):389-99. PMID:18815991
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Gram LF, Rasmussen NA, Andersen PM, et al. Acute and continuation therapy in unipolar depression: Observations from the run-in phase of a maintenance trial. *Acta Psychiatr Scand* 2008;118(2):123-9.
Exclude: For study design, OVID-Embase.
- Grant GM, Salcedo V, Hynan LS, et al. Effectiveness of quality of life therapy for depression. *Psychol Rep* 1995;76(3:Pt 2):t-8 PMID:7480486
Exclude: For study design, OVID-Medline.
- Gravem A, Amthor KF, Astrup C, et al. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. *Acta Psychiatr Scand* 1987;75(5):478-86. PMID:3300171
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Greden JF, Pande AC. Treatment of resistant depression with 5-HT uptake inhibitors. *Clin Neuropharmacol* 1992;15:Suppl-443A PMID:1498908
Exclude: For study design, OVID-Medline.
- Green BL, Krupnick JL, Chung J, et al. Impact of PTSD comorbidity on one-year outcomes in a depression trial. *J Clin Psych* 2006;62(7):815-35. PMID:16703602
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Green TD, Reynolds CF, III, Mulsant BH, et al. Accelerating antidepressant response in geriatric depression: a post hoc comparison of combined sleep deprivation and paroxetine versus monotherapy with paroxetine, nortriptyline, or placebo. *J Geriatr Psychiatry Neurol* 1999;12(2):67-71. PMID:10483927
Exclude: For study design, OVID-Medline.

- Gregory RJ, Schwer Canning S, Lee TW, et al. Cognitive Bibliotherapy for Depression: A Meta-Analysis. *Prof Psychol Res Pr* 2004;35(3):275-80. **Exclude:** For systematic review before 2005, OVID-PsycINFO.
- Gregory RJ, Jimerson DC, Walton BE, et al. Pharmacotherapy of depression in the medically ill: Directions for future research. *Gen Hosp Psychiatry* 1992;14(1):36-42. **Exclude:** For systematic review before 2005, OVID-PsycINFO.
- Grenyer BF, Crowe T, Meyer B, et al. Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31(7):1393-6. **Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.
- Griffiths L, Blignault I, Yellowlees P. Telemedicine as a means of delivering cognitive-behavioural therapy to rural and remote mental health clients. *Journal of Telemedicine & Telecare* 2006;12(3):136-40. PMID:16638234 **Exclude:** For study design, OVID-Medline.
- Grigoriadis S, Kennedy S H, Srinivasan J and others. SSRI augmentation with raloxifene for treatment-resistant depression. In 2001. **Exclude:** For study design, Wiley-CCTR.
- Grime PR. Computerized cognitive behavioural therapy at work: a randomized controlled trial in employees with recent stress-related absenteeism. *Occupational medicine (Oxford, England)* 2004;54(5):353-9. **Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.
- Grof P, Joffe R, Kennedy S, et al. An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression. *Int Clin Psychopharmacol* 1993;8(3):167-72. PMID:8263314 **Exclude:** For study design, OVID-Medline.
- Grunhaus L, Hirschman S, Dolberg OT, et al. Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT. *Journal of ECT* 2001;17(2):124-8. PMID:11417923 **Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Grunhaus L J, Hirschmann S, Dolberg O T. MELATONIN AND FLUOXETINE IN THE PREVENTION OF DEPRESSIVE RELAPSES AFTER SUCCESSFUL ECT TREATMENT CONFERENCE ABSTRACT. In 1997; 1997. **Exclude:** For study design, Wiley-CCTR.
- Guelfi J D, Troy S. Sertraline in depressed patients resistant and/or intolerant to a previous treatment. In 1999 May 15; 1999. **Exclude:** For study design, Wiley-CCTR.
- Guirguis-Younger M, Cappeliez P, Younger A. A community-based intervention for treating depression in seniors. *CAN J Nurs Res* 2008;40(1):61-79. PMID:18459272 **Exclude:** For study design, OVID-Medline.
- Gum AM, Arean PA, Bostrom A. Low-income depressed older adults with psychiatric comorbidity: secondary analyses of response to psychotherapy and case management. *Int J Geriatr Psychiatry* 2007;22(2):124-30. PMID:17096464 **Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Gusi N, Reyes MC, Gonzalez-Guerrero JL, et al. Cost-utility of a walking programme for moderately depressed, obese, or overweight elderly women in primary care: a randomised controlled trial. *BMC Public Health* 2008;8:231 PMID:18611277 **Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Gutierrez MA, Stimmel GL, Aiso JY. Venlafaxine: a 2003 update. [Review] [75 refs]. *Clinical Therapeutics* 2003;25(8):2138-54. PMID:14512125 **Exclude:** For systematic review before 2005, OVID-Medline.
- Gutierrez RL, McKercher R, Galea J, et al. Lamotrigine augmentation strategy for patients with treatment-resistant depression. *Cns Spectrums* 2005;10(10):800-5. **Exclude:** For study design, OVID-Embase.
- Gwirtsman HE, Szuba MP, Toren L, et al. The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. *Psychopharmacol Bull* 1994;30(2):157-64. PMID:7831449 **Exclude:** For study design, OVID-Medline.
- Gyulai L, Bauer M, Garcia-Espana F, et al. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. *J Affect Disord* 2001;66(2-3):185-91. PMID:11578671 **Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Ha EH, Oh KJ. Effects of cognitive-behavioral group therapy for depressive mothers of children with behavior problems. *Child & Family Behav Ther* 2006;28(2):1-13. **Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Habib D, Seif ED. Effectiveness of cognitive behaviour therapy in schoolchildren with depressive symptoms in Alexandria, Egypt. *EAST MEDITERRANEAN HEALTH J* 2007;13(3):615-24. PMID:17687835 **Exclude:** For study design, OVID-Medline.
- Haby MM, Tonge B, Littlefield L, et al. Cost-effectiveness of cognitive behavioural therapy and selective serotonin reuptake inhibitors for major depression in children and adolescents. *Aust NZ J Psychiatry* 2004;38(8):579-91. PMID:15298580 **Exclude:** For systematic review before 2005, OVID-Medline.
- Hackett ML, Anderson CS, House AO. Interventions for treating depression after stroke.[update in Cochrane Database Syst Rev. 2008;(4):CD003437;

- PMID: 18843644]. [Review] [155 refs]. Cochrane Database of Systematic Reviews 2004;(3):CD003437
PMID:15266484
Exclude: For systematic review before 2005, OVID-Medline.
- Hagen R, Nordahl HM, Kristiansen L, et al. A randomized trial of cognitive group therapy vs. waiting list for patients with co-morbid psychiatric disorders: Effect of cognitive group therapy after treatment and six and twelve months follow-up. *Behav Cogn Psychother* 2005;33(1):33-44.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Hagen R, Nordahl HM, Grawe RW. Cognitive-behavioural group treatment of depression in patients with psychotic disorders. *Clinical Psychology and Psychotherapy* 2005;12(6):465-74.
Exclude: For study design, OVID-Embase.
- Hakkaart-Van Roijen L, van Straten A, Al M, et al. Cost-utility of brief psychological treatment for depression and anxiety. *Br J Psychiatry* 2006;188(4):323-9.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Halford WK. Cognitive behavioural treatment of adjustment disorder with depressed mood following marital breakdown. *Behav Change* 1987;4(1):28-33.
Exclude: For study design, OVID-Embase.
- Hallert C, Astrom J, Walan A. Reversal of psychopathology in adult coeliac disease with the aid of pyridoxine (vitamin B6). *Scandinavian Journal of Gastroenterology* 1983;18(2):299-304.
PMID:6369511
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hamamci Z. Integrating psychodrama and cognitive behavioral therapy to treat moderate depression. *Arts in Psychotherapy* 2006;33(3):199-207.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Hamdan-Mansour AM, Puskar K, Bandak AG. Effectiveness of cognitive-behavioral therapy on depressive symptomatology, stress and coping strategies among Jordanian university students. *Issues Ment Health Nurs* 2009;30(3):188-96.
PMID:19291496
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hamre HJ, Witt CM, Glockmann A, et al. Anthroposophic therapy for chronic depression: a four-year prospective cohort study. *BMC Psychiatry* 2006;6:57 PMID:17173663
Exclude: For study design, OVID-Medline.
- Hamre HJ, Witt CM, Glockmann A, et al. Eurythmy therapy in chronic disease: A four-year prospective cohort study. *BMC Public Health* 2007;7, 2007. Article Number: 61. Date of Publication: 2007.:
Exclude: For study design, OVID-Embase.
- Hamre HJ, Witt CM, Glockmann A, et al. Rhythmical massage therapy in chronic disease: a 4-year prospective cohort study. *J Altern Complement Med* 2007;13(6):635-42. PMID:17718646
Exclude: For study design, OVID-Medline.
- Han C, Li X, Luo H, et al. Clinical study on electroacupuncture treatment for 30 cases of mental depression. *J Tradit Chin Med* 2004;24(3):172-6.
PMID:15510791
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hannaford CP, Harrell EH, Cox K. Psychophysiological effects of a running program on depression and anxiety in a psychiatric population. *Psychol Rec* 1988;38(1):37-48.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Hannan N, Hamzah Z, Akinpeloye HO, et al. Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness.[erratum appears in *J Psychopharmacol*. 2008 Aug;22(6):698]. *J Psychopharmacol* 2007;21(2):161-4. PMID:17329295
Exclude: For study design, OVID-Medline.
- Hansgen K-D, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160. *Journal of Geriatric Psychiatry and Neurology* 1994;7(SUPPL. 1):S15-S18
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Hanson, L.M. The efficacy of three treatments for depression: Morita psychotherapy, dietary brain-chemistry treatment, and the combination of morita psychotherapy/brain-chemistry treatment as compared to no-treatment control Hanson. 2002
Exclude: For study design, OVID-PsycINFO.
- Hansson M, Bodlund O, Chotai J. Patient education and group counselling to improve the treatment of depression in primary care: A randomized controlled trial. *J Affect Disord* 2008;105(1-3):235-40.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Hantouche EG, Akiskal HS, Lancrenon S, et al. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study. *J Affect Disord* 2005;84(2-3):243-9. PMID:15708422
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Harden, J.A.T. Effect of movement group therapy on depression, morale and self-esteem in aged women UNIVERSITY OF TEXAS AT AUSTIN. 1989
Exclude: For study design, EBSCO-CINAHL.
- Hardy GE, Cahill J, Stiles WB, et al. Sudden gains in cognitive therapy for depression: a replication and extension. *J Consult Clin Psychol* 2005;73(1):59-67.
PMID:15709832
Exclude: For study design, OVID-Medline.
- Hare HP. Comparison of chlorthalidone-amitriptyline combination with amitriptyline alone in anxiety-depressive states. *The Journal of clinical pharmacology and new drugs* 1971;11(6):456-60.

- Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.
- Harley R, Sprich S, Safren S, et al. Adaptation of dialectical behavior therapy skills training group for treatment-resistant depression. *J Nerv Ment Dis* 2008;196(2):136-43.
- Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.
- Harrer G, Schmidt U, Kuhn U, et al. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. *Arzneimittel-Forschung* 1999;49(4):289-96. PMID:10337446
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Harrer G, Hubner WD, Podzuweit H. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. *J Geriatr Psychiatry Neurol* 1994;7:Suppl-8 PMID:7857503
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Harrington R, Whittaker J, Shoebridge P, et al. Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder. *BMJ* 1998;316(7144):1559-63. PMID:9596592
- Exclude:** For systematic review before 2005, OVID-Medline.
- Harris T, Brown GW, Robinson R. Befriending as an intervention for chronic depression among women in an inner city. 1: Randomised controlled trial. *Br J Psychiatry* 1999;174:219-24. PMID:10448446
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Hart S, Fonareva I, Merluzzi N, et al. Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. *Quality of Life Research* 2005;14(3):695-703. PMID:16022063
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Hartley DE, Elsabagh S, File SE. Gincosan (a combination of Ginkgo biloba and Panax ginseng): the effects on mood and cognition of 6 and 12 weeks' treatment in post-menopausal women. *Nutritional Neuroscience* 2004;7(5-6):325-33.
- Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.
- Harvey AT, Silkey BS, Kornstein SG, et al. Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. *J Clin Psychiatry* 2007;68(6):951-8. PMID:17592923
- Exclude:** For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Hauenstein EJ. Testing innovative nursing care: home intervention with depressed rural women. *Issues Ment Health Nurs* 1996;17(1):33-50.
- Exclude:** For study design, EBSCO-CINAHL.
- Hautzinger, Martin, Jong-Meyer, Renate. Cognitive-behavioural therapy versus pharmacotherapy in depression. 1996:329-40. 1996.
- Exclude:** For study design, OVID-PsycINFO.
- Hawkins WE, Latkin C, Green DL. Depression therapy with injection drug users: results of a pilot study. *Am J Drug Alcohol Abuse* 2005;31(2):243-51. PMID:15912714
- Exclude:** For study design, OVID-Medline.
- Hawley C, Sivakumaran T, Huber TJ, et al. Combination therapy with nefazodone and lithium: Safety and tolerability in fourteen patients. *Int J Psychiatry Clin Pract* 1998;2(4):251-4.
- Exclude:** For study design, OVID-Embase.
- Hawley CJ, Pattinson HA, Quick SJ, et al. A protocol for the pharmacologic treatment of major depression. A field test of a potential prototype. *J Affect Disord* 1998;47(1-3):87-96. PMID:9476748
- Exclude:** For Guideline published before 2005, OVID-Medline.
- Hawley CJ, Quick SJ, Ratnam S, et al. Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. *Int Clin Psychopharmacol* 1996;11(3):187-91. PMID:8923097
- Exclude:** For study design, OVID-Medline.
- Hayward LM, Sullivan AC, Libonati JR. Group exercise reduces depression in obese women without weight loss. *PERCEPT MOTOR SKILLS* 2000;90(1):204-8. PMID:10769900
- Exclude:** For study design, OVID-Medline.
- Hänsgen KD, Vesper J, Ploch M. Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract LI 160. *Journal of Geriatric Psychiatry and Neurology* 1994;7 Suppl 1:S15-S18
- Exclude:** For population/not failed to respond to an SSRI, Wiley-CCTR.
- He Q, Zhang J, Tang Y. A controlled study on treatment of mental depression by acupuncture plus TCM medication. *J Tradit Chin Med* 2007;27(3):166-9. PMID:17955648
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Hebenstreit GF, Fellerer K, Zochling R, et al. A pharmacokinetic dose titration study in adult and elderly depressed patients. *Acta Psychiatrica Scandinavica, Supplementum* 1989;350:81-4. PMID:2530795
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Hejazi S, Ashayeri H, Mahmoodi M, et al. Effects of music on depression in students of Iran University of Medical Sciences, Tehran 2004. *SBMU Faculty of Nursing & Midwifery Quarterly* 2005;14(47):56
- Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Hellerstein DJ, Little SA, Samstag LW, et al. Adding group psychotherapy to medication treatment in dysthymia: a randomized prospective pilot study. *Journal of Psychotherapy Practice & Research* 2001;10(2):93-103. PMID:11264333

- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Hellerstein DJ, Batchelder S, Hyler S, et al. Aripiprazole as an adjunctive treatment for refractory unipolar depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2008;32(3):744-50. PMID:18164528
Exclude: For study design, OVID-Medline.
- Hellerstein D J, Little S, Batchelder S and others. Dysthymia: An Outcome Study of Combined Group Therapy and Medication Treatment Versus Medication Treatment Alone CONFERENCE ABSTRACT. In 1997; 1997. **Exclude:** For study design, Wiley-CCTR.
- Hemmeter U, Hatzinger M, Brand S, et al. Effect of flumazenil-augmentation on microsleep and mood in depressed patients during partial sleep deprivation. *J Psychiatr Res* 2007;41(10):876-84. PMID:16978648
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hendrickx B, Floris M. A controlled pilot study of the combination of fluvoxamine and lithium. *Curr Ther Res Clin Exp*1991;49(1):106-10.
Exclude: For study design, OVID-Embase OVID-Embase.
- Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment. An effective prescription for treatment-refractory depression. *Arch Gen Psychiatry* 1983;40(12):1335-42.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Hennings JM, Owashit T, Binder EB, et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients - findings from the Munich Antidepressant Response Signature (MARS) project. *J Psychiatr Res* 2009;43(3):215-29. PMID:18586274
Exclude: For study design, OVID-Medline.
- Hensley PL, Nadiga D, Uhlenhuth EH. Long-Term Effectiveness of Cognitive Therapy in Major Depressive Disorder. *Depress Anxiety* 2004;20(1):1-7.
Exclude: For systematic review before 2005, OVID-PscINFO.
- Heresco-Levy U, Javitt DC, Gelfin Y, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. *J Affect Disord* 2006;93(1-3):239-43. PMID:16677714
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hermens ML, van Hout HP, Terluin B, et al. Clinical effectiveness of usual care with or without antidepressant medication for primary care patients with minor or mild-major depression: a randomized equivalence trial. *BMC Medicine* 2007;5:36 PMID:18067659
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hernandez-Avila CA, Modesto-Lowe V, Feinn R, et al. Nefazodone Treatment of Comorbid Alcohol Dependence and Major Depression. *Alcoholism: Clinical and Experimental Research* 2004;28(3):433-40.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Hernandez-Reif M, Ironson G, Field T, et al. Breast cancer patients have improved immune and neuroendocrine functions following massage therapy. *J Psychosom Res* 2004;57(1):45-52. PMID:15256294
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Herrington RN, Bruce A, Johnstone EC, et al. Comparative trial of L-tryptophan and amitriptyline in depressive illness. *Psychol Med* 1976;6(4):673-8.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Herwig U, Fallgatter AJ, Hoppner J, et al. Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial. *Br J Psychiatry* 2007;191:441-8. PMID:17978325
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hewett K, Chrzanowski W, Schmitz M, et al. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. *J Psychopharmacol* 2009;23(5):531-8. PMID:18635695
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hickman SE, Barrick AL, Williams CS, et al. The effect of ambient bright light therapy on depressive symptoms in persons with dementia. *J AM GERIATR SOC* 2007;55(11):1817-24. PMID:17944896
Exclude: For population/diagnosis, OVID-Medline.
- Hilsenroth MJ, Ackerman SJ, Blagys MD, et al. Short-term psychodynamic psychotherapy for depression: an examination of statistical, clinically significant, and technique-specific change. *J NERV MENT DIS* 2003;191(6):349-57. PMID:12826915
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hinkle JS. Aerobic running behavior and psychotherapeutics: Implications for sports counseling and psychology. *Journal of Sport Behavior* 1992;15(4):263-77.
Exclude: For systematic review before 2005, OVID-PscINFO.
- Hirose S, Ashby CR, Jr. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. *J Clin Psychiatry* 2002;63(8):733-6. PMID:12197455
Exclude: For study design, OVID-Medline.
- Hirsch C, Jolley S, Williams R. A study of outcome in a clinical psychology service and preliminary evaluation of cognitive-behavioural therapy in real practice. *J MENT HEALTH* 2000;9(5):537-49.
Exclude: For study design, EBSCO-CINAHL.
- Hirschfeld RM, Dunner DL, Keitner G, et al. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone,

- psychotherapy, and their combination. *Biol Psychiatry* 2002;51(2):123-33. PMID:11822991
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hirschfeld RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. [Review] [58 refs]. *J Clin Psychiatry* 1999;60(5):326-35. PMID:10362442
Exclude: For systematic review before 2005, OVID-Medline.
- Hirschfeld RMA, Nemeroff CB, Dunner DL, et al. Guidelines for the long-term treatment of depression. *J Clin Psychiatry* 1994;55(12 SUPPL.):61-9.
Exclude: For Guideline published before 2005, OVID-Embase.
- Hitt, R.A. An evidence-based group treatment for depressed female adolescents and their mothers Hitt. 2006
Exclude: For study design, OVID-PsycINFO.
- Hobi V, Gastpar M, Gastpar G, et al. Driving ability of depressive patients under antidepressants. *J Int Med Res* 1982;10(2):65-81. PMID:6121737
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hodgkiss AD, McCarthy PT, Sulke AN, et al. High dose tertiary amine tricyclic antidepressants in the treatment of severe refractory depression: The central role of plasma concentration estimations. *Hum Psychopharmacol* 1995;10(5):407-15.
Exclude: For study design, OVID-Embase.
- Hoencamp E, Haffmans J, Dijken WA, et al. Lithium augmentation of venlafaxine: an open-label trial. *J Clin Psychopharm* 2000;20(5):538-43. PMID:11001238
Exclude: For study design, OVID-Medline.
- Hoffman BM, Babyak MA, Sherwood A, et al. Effects of aerobic exercise on sexual functioning in depressed adults. *Mental Health and Physical Activity* 2009;2(1):23-8.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Hogg JA, Deffenbacher JL. A comparison of cognitive and interpersonal-process group therapies in the treatment of depression among college students. *Journal of Counseling Psychology* 1988;35(3):304-10.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Hollister LE, Overall JE, Shelton J, et al. Drug therapy of depression. Amitriptyline, perphenazine, and their combination in different syndromes. *Arch Gen Psychiatry* 1967;17(4):486-93.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Hollon SD, DeRubeis RJ, Evans MD, et al. Cognitive therapy and pharmacotherapy for depression. Singly and in combination. *Arch Gen Psychiatry* 1992;49(10):774-81. PMID:1417429
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. *Arch Gen Psychiatry* 2005;62(4):417-22. PMID:15809409
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hollon SD, Shelton RC. Treatment guidelines for major depressive disorder. *Behav Ther* 2001;32(2):235-58.
Exclude: For Guideline published before 2005, OVID-PsycINFO.
- Holroyd S, Durgee J. Venlafaxine in treatment refractory geriatric depression. *CLIN GERONTOL* 1998;18(3):39-50.
Exclude: For study design, OVID-Embase.
- Holtzheimer III PE, Meeks TW, Kelley ME, et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. *Int J Geriatr Psychiatry* 2008;23(6):625-31.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Honore P, Moller SE, Jorgensen A. Lithium + L-tryptophan compared with amitriptyline in endogenous depression. *J Affect Disord* 1982;4(1):79-82. PMID:6461690
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Hopko DR, Bell JL, Armento M, et al. Cognitive-behavior therapy for depressed cancer patients in a medical care setting. *Behav Ther* 2008;39(2):126-36. PMID:18502246
Exclude: For study design, OVID-Medline.
- Hopwood SE, Bogle S, Wildgust HJ. The combination of fluoxetine and lithium in clinical practice. *Int Clin Psychopharmacol* 1993;8(4):325-7. PMID:8277157
Exclude: For study design, OVID-Medline.
- Hornig-Rohan M, Amsterdam JD. Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2002;26(3):585-9. PMID:11999912
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Horowitz A, Reinhardt JP, Boerner K. The effect of rehabilitation on depression among visually disabled older adults. *Aging and Mental Health* 2005;9(6):563-70.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Hosaka T, Sugiyama Y. Structured intervention in family caregivers of the demented elderly and changes in their immune function. *Psychiatry and Clinical Neurosciences* 2003;57(2):147-51.
Exclude: For study design, OVID-Embase.
- Hou Y-M, Kang B, Lin J-D, et al. Combined cognitive therapy with fluoxetine hydrochloride on patients with senile depressive neurosis in open wards: A randomized controlled study. *Chinese Journal of Clinical Rehabilitation* 2003;7(30):4105-7.
Exclude: For population/diagnosis, OVID-Embase.

Houghton S, Curran J, Saxon D. An uncontrolled evaluation of group behavioural activation for depression. *Behav Cogn Psychother* 2008;36(2):235-9.

Exclude: For study design, OVID-Embase.

Howell CA, Turnbull DA, Beilby JJ, et al. Preventing relapse of depression in primary care: a pilot study of the "Keeping the blues away" program. *Medical Journal of Australia* 2008;188(12:Suppl):Suppl-41 PMID:18558915

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Høstmaelingen HJ, Asskilt O, Austad SG, et al. Primary care treatment of depression in the elderly: a double-blind, multi-centre study of flupenthixol ('Fluanxol') and sustained-release amitriptyline. *Current Medical Research and Opinion* 1989;11(9):593-9.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Hsieh HF, Wang JJ. Effect of reminiscence therapy on depression in older adults: A systematic review. *INT J NURS STUD* 2003;40(4):335-45.

Exclude: For systematic review before 2005, OVID-PsycINFO.

Hsu W, Lai H. Effects of music on major depression in psychiatric inpatients. *Arch Psychiatr Nurs* 2004;18(5):193-9.

Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.

Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. *Arch Gen Psychiatry* 2007;64(7):783-92. PMID:17606812

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Huang Y, Chen J, Zou J. Effect of scalp electroacupuncture on post-stroke depression. *Chinese Journal of Clinical Rehabilitation* 2005;9(40):172-3.

Exclude: For population/diagnosis, OVID-Embase.

Hubner WD, Lande S, Podzuweit H. Hypericum treatment of mild depressions with somatic symptoms. *J Geriatr Psychiatry Neurol* 1994;7:Suppl-4 PMID:7857500

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Hughes CW, Emslie GJ, Lynn CM, et al. The Texas children's medication algorithm project: Report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder. *J Am Acad Child Adolesc Psychiatry* 1999;38(11):1442-54.

Exclude: For Guideline published before 2005, OVID-Embase.

Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. *Archives of Family Medicine* 2000;9(8):700-8.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Huskamp HA, Busch AB, Domino ME, et al. Antidepressant reformulations: who uses them, and what are the benefits? *Health Affairs* 2009;28(3):734-45. PMID:19414882

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Huskamp HA, Azzone V, Frank RG. Carve-outs, women, and the treatment of depression. *Women's Health Issues* 1998;8(5):267-82.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Hübner WD, Lande S, Podzuweit H. Hypericum treatment of mild depressions with somatic symptoms. *Journal of Geriatric Psychiatry and Neurology* 1994;7 Suppl 1:S12-S14

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Hvas AM, Juul S, Lauritzen L, et al. No effect of vitamin B-12 treatment on cognitive function and depression: a randomized placebo controlled study. *J Affect Disord* 2004;81(3):269-73. PMID:15337331

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Hyer L, Yeager CA, Hilton N, et al. Group, individual, and staff therapy: an efficient and effective cognitive behavioral therapy in long-term care. *American Journal of Alzheimer's Disease & Other Dementias* 2008;23(6):528-39. PMID:19001352

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. *JAMA* 2002;287(14):1807-14. PMID:11939866

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Hyun M, Chung HC, Lee Y. The effect of cognitive-behavioral group therapy on the self-esteem, depression, and self-efficacy of runaway adolescents in a shelter in South Korea. *APPL Nurs Res* 2005;18(3):160-6. **Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.

Ianniello A, Ostuni PA, Sfriso P, et al. S-adenosyl-L-methionine in Sjogren's syndrome and fibromyalgia. *Curr Ther Res* 1994;55(6):699-706.

Exclude: For study design, OVID-PsycINFO.

Ilhan YL, Corapcioglu A, Kocabasoglu N, et al. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. *Int J Psychiatry Clin Pract* 2004;8(4):205-11.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Ille R, Spona J, Zickl M, et al. "Add-On"-therapy with an individualized preparation consisting of free amino acids for patients with a major depression. *Eur Arch Psychiatry Clin Neurosci* 2007;257(4):222-9.

PMID:17401733

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Inoue T, Nakagawa S, Kitaichi Y, et al. Long-term outcome of antidepressant-refractory depression: the relevance of unrecognized bipolarity. *J Affect Disord* 2006;95(1-3):61-7. PMID:16797078

Exclude: For study design, OVID-Medline.

Inoue T, Tsuchiya K, Miura J, et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. *Biol Psychiatry* 1996;40(2):151-3.

Exclude: For study design, OVID-PsycINFO.

Interian A, Allen LA, Gara MA, et al. A Pilot Study of Culturally Adapted Cognitive Behav Ther for Hispanics with Major Depression. *Cognitive and Behavioral Practice* 2008;15(1):67-75.

Exclude: For study design, OVID-Embase.

Iosifescu DV, Nierenberg AA, Mischoulon D, et al. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. *J Clin Psychiatry* 2005;66(8):1038-42. PMID:16086620

Exclude: For study design, OVID-Medline.

Iosifescu DV, Bolo NR, Nierenberg AA, et al. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. *Biol Psychiatry* 2008;63(12):1127-34. PMID:18206856

Exclude: For study design, OVID-Medline.

Iqbal S, Bassett M. Evaluation of perceived usefulness of activity scheduling in an inpatient depression group. *J PSYCHIATR MENT HEALTH NURS* 2008;15(5):393-8. PMID:18454825

Exclude: For study design, OVID-Medline.

Isaac MT, Isaac MB, Gallo F, et al. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency. *Hum Psychopharmacol* 2003;18(8):595-601. PMID:14696018

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. *Arch Gen Psychiatry* 2009;66(9):966-75. PMID:19736353

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Itil TM, Michael ST, Baccari S. Antidepressant effects of fluotracen, a long-acting potent thymoleptic (a double-blind controlled trial). *Curr Ther Res Clin Exp* 1984;35(6):1014-32.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Ivkovic M, Damjanovic A, Jovanovic A, et al. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability. *Psychiatria Danubina* 2009;21(2):187-93. PMID:19556947

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Izumi T, Inoue T, Kitagawa N, et al. Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. *J Affect Disord* 2000;61(1-2):127-32. PMID:11099751

Exclude: For study design, OVID-Medline.

Jacobsen FM. Possible augmentation of antidepressant response by buspirone. *J Clin Psychiatry* 1991;52(5):217-20. PMID:2033029

Exclude: For study design, OVID-Medline.

Jacobson AF. Doctor-patient concordance in a placebo-controlled trial of limbitrol versus its components [proceedings]. *Psychopharmacol Bull* 1978;14(3):61-3.

Exclude: For study design, Wiley-CCTR.

Jacobson NS, Fruzzetti AE, Dobson K, et al. Couple therapy as a treatment for depression: II. The effects of relationship quality and therapy on depressive relapse. *J Consult Clin Psychol* 1993;61(3):516-9. PMID:8326054

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Jacobson NS, Dobson K, Fruzzetti AE, et al. Marital therapy as a treatment for depression. *J Consult Clin Psychol* 1991;59(4):547-57. PMID:1918559

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Jahn H, Schick M, Kiefer F, et al. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. *Arch Gen Psychiatry* 2004;61(12):1235-44. PMID:15583115

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Jahn H, Schick M, Kiefer F, et al. Metyrapone as Additive Treatment in Major Depression: A Double-blind and Placebo-Controlled Trial. *Arch Gen Psychiatry* 2004;61(12):1235-44.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

James RT, Dean BC. A comparison of a single night-time and a divided daily dosage regimen of a chlordiazepoxide/amitriptyline combination. *Current Medical Research and Opinion* 1980;6(8):573-5.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

James RT, Dean BC. Comparison of limbitrol (chlordiazepoxide/amitriptyline) and amitriptyline alone as a single night-time dose for the treatment of depression with anxiety. *J Int Med Res* 1985;13(2):84-7. PMID:3888730

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Jamison C, Scogin F. The outcome of cognitive bibliotherapy with depressed adults. *J Consult Clin Psychol* 1995;63(4):644-50. PMID:7673542

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Jamison,C.S. Outcome, process, and client variables in cognitive bibliotherapy with depressed adults

- Jamison. 1994
Exclude: For study design, OVID-PsycINFO.
- Janakiramaiah N, Gangadhar BN, Naga Venkatesha Murthy PJ, et al. Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: a randomized comparison with electroconvulsive therapy (ECT) and imipramine. *J Affect Disord* 2000;57(1-3):255-9. PMID:10708840
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Janakiramaiah N, Gangadhar BN, Murthy PJN, et al. Therapeutic efficacy of Sudarshan Kriya Yoga (SKY) in dysthymic disorder. *Nimhans Journal* 1998;16(1):21-8.
Exclude: For study design, OVID-PsycINFO.
- Janicak PG, Lipinski J, Davis JM, et al. S-adenosylmethionine in depression. A literature review and preliminary report. [Review] [21 refs]. *Alabama Journal of Medical Sciences* 1988;25(3):306-13. PMID:3052139
Exclude: For systematic review before 2005, OVID-Medline.
- Jansen IH, Olde Rikkert MG, Hulsbos HA, et al. Toward individualized evidence-based medicine: five "N of 1" trials of methylphenidate in geriatric patients. *J AM GERIATR SOC* 2001;49(4):474-6. PMID:11347795
Exclude: For study design, OVID-Medline.
- Januel D, Poirier MF, D'alche-Biree F, et al. Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. *J Affect Disord* 2003;76(1-3):191-200.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Januel D, Galinowski A, Poirier MF, et al. Prospective study of antidepressants combined with lithium in unipolar depression: Preliminary results. *Lithium* 1994;5(4):253-7.
Exclude: For study design, OVID-PsycINFO.
- Jarrett RB, Basco MR, Risser R, et al. Is there a role for continuation phase cognitive therapy for depressed outpatients? *J Consult Clin Psychol* 1998;66(6):1036-40. PMID:9874918
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Jarrett RB, Kraft D, Doyle J, et al. Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. *Arch Gen Psychiatry* 2001;58(4):381-8. PMID:11296099
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Jarrett RB, Schaffer M, McIntire D, et al. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. *Arch Gen Psychiatry* 1999;56(5):431-7. PMID:10232298
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Javnbakht M, Kenari RH, Ghasemi M. Effects of yoga on depression and anxiety of women. *COMPLEMENT THER CLIN PRACT* 2009;15(2):102-4.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Jazayeri S, Tehrani-Doost M, Keshavarz SA, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. *Aust NZ J Psychiatry* 2008;42(3):192-8. PMID:18247193
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Jefferson JW. Treating affective disorders in the presence of cardiovascular disease. *PSYCHIATR CLIN NORTH AM* 1983;6(1):141-55. PMID:6889170
Exclude: For study design, OVID-Medline.
- Jensen C. Psychosocial treatment of depression in women: Nine single-subject evaluations. *Research on Social Work Practice* 1994;4(3):267-82.
Exclude: For study design, OVID-PsycINFO.
- Jiahui Z, Peng S. Clinical observation on acupuncture treatment of depressive neurosis in 30 cases. *J Tradit Chin Med* 2006;26(3):191-2. PMID:17078447
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Joanne L, Jim M, Constance L, et al. Cognitive-behavioral and psychodynamic group psychotherapy in treatment of geriatric depression. *J Consult Clin Psychol* 1984;52(2):180-9.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Joffe H, Groninger H, Soares C, et al. An open trial of mirtazapine in menopausal women with depression unresponsive to estrogen replacement therapy. *Journal of Women's Health and Gender-Based Medicine* 2001;10(10):999-1004.
Exclude: For study design, OVID-Embase.
- Joffe H, Petrillo LF, Viguera AC, et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. *J Clin Psychiatry* 2007;68(12):1954-62. PMID:18162029
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Joffe R, Sokolov S, Streiner D. Antidepressant treatment of depression: A metaanalysis. *Canadian Journal of Psychiatry* 1996;41(10):613-6.
Exclude: For systematic review before 2005, OVID-Embase.
- Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. *Psychiatry Res* 1990;32(3):241-51. PMID:2201988
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. *Arch Gen Psychiatry* 1993;50(5):387-93.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. *J Clin Psychiatry* 1993;54(7):269-71. PMID:8335654
Exclude: For study design, OVID-Medline.
- Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. *J Clin Psychiatry* 1994;55(1):24-5. PMID:8294388
Exclude: For study design, OVID-Medline.
- Joffe RT, Sawka AM, Marriott MJ, et al. Does substitution of T4 with T3 plus T4 for T4 replacement improve depressive symptoms in patients with hypothyroidism? *Annals of the New York Academy of Sciences* 2004;1032:287-8.
Exclude: For population/diagnosis, Wiley-CCTR.
- Joffe RT, Sokolov ST, Levitt AJ. Lithium and triiodothyronine augmentation of antidepressants. *Can J Psychiatry* 2006;51(12):791-3. PMID:17168254
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Joffe RT, Levitt AJ. Relationship between antidepressant partial and nonresponse and subsequent response to antidepressant augmentation. *J Affect Disord* 1999;52(1-3):257-9. PMID:10357043
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Joffe RT, Levitt AJ, Sokolov ST, et al. Response to an open trial of a second SSRI in major depression. *J Clin Psychiatry* 1996;57(3):114-5. PMID:8617695
Exclude: For study design, OVID-Medline.
- Joffe RT, Singer W. Thyroid hormone use to enhance the effects of drugs. *Clin Neuropharmacol* 1992;15 Suppl 1 Pt A:389A-90A.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. *Psychiatry Res* 1990;32(3):241-51.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. *Arch Gen Psychiatry* 1993;50(5):387-93.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Johnson GFS, Wilson P. The management of depression: A review of pharmacological and non-pharmacological treatments. *Medical Journal of Australia* 1989;151(7):397-406.
Exclude: For systematic review before 2005, OVID-Embase.
- Johnson JE, Zlotnick C. A pilot study of group interpersonal psychotherapy for depression in substance-abusing female prisoners. *Journal of Substance Abuse Treatment* 2008;34(4):371-7.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Johnston GA. Megavitamins and psychotherapy: Effective, economical and time-saving treatment: A three year study. *Journal of Orthomolecular Medicine* 1993;8(2):104-20.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. *J Clin Psychiatry* 1991;52(11):450-6.
Exclude: For study design, OVID-PsycINFO.
- Johnstone EC, Owens DG, Lambert MT, et al. Combination tricyclic antidepressant and lithium maintenance medication in unipolar and bipolar depressed patients. *J Affect Disord* 1990;20(4):225-33. PMID:2149728
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Joliat MJ, Brown EB, Miner CM. Changes in Energy After Switching From Daily Citalopram, Paroxetine, or Sertraline to Once-Weekly Fluoxetine. *J Clin Psychopharm* 2004;24(4):464-7.
Exclude: For study design, OVID-PsycINFO.
- Jones ID, Karapiperis V, Bowman L, et al. Does formal psychoeducational support influence anxiety and depression levels in cardiac patients and their relatives? A pilot study. *J Cardiopulm Rehabil* 2006;26(3):172-5.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Joo JH, Lenze EJ, Mulsant BH, et al. Risk factor for falls during treatment of late-life depression. *J Clin Psychiatry* 2002;63(10):936-41.
Exclude: For study design,
- Jorde R, Sneve M, Figenschau Y, et al. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. *Journal of Internal Medicine* 2008;264(6):599-609. PMID:18793245
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Jorm AF, Christensen H, Griffiths KM, et al. Effectiveness of complementary and self-help treatments for depression. [Review] [130 refs]. *Medical Journal of Australia* 2002;176:Suppl-96 PMID:12065003
Exclude: For systematic review before 2005, OVID-Medline.
- Judd FK, Piterman L, Cockram AM, et al. A comparative study of venlafaxine with a focused education and psychotherapy program versus venlafaxine alone in the treatment of depression in general practice. *Hum Psychopharmacol* 2001;16(5):423-8.

- Exclude:** For population/not failed to respond to an SSRI, OVID-Embase.
- Jungkunz G, Nedopil N, Ruther E. Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 on depressive symptoms. *Pharmacopsychiatria* 1983;16(3):90-2. PMID:6351118
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Juruena MF, Pariante CM, Papadopoulos AS, et al. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. *Br J Psychiatry* 2009;194(4):342-9. PMID:19336786
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kaas MJ, Lewis ML. Cognitive behavioral group therapy for residents in assisted-living facilities. *J Psychosoc Nurs Ment Health Serv* 1999;37(10):9-15. PMID:10529958
Exclude: For study design, OVID-Medline.
- Kagan BL, Sultzer DL, Rosenlicht N, et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. *Am J Psychiatry* 1990;147(5):591-5. PMID:2183633
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kahan JS, Mitchell JM, Kemp BJ, et al. The results of a 6-month treatment for depression on symptoms, life satisfaction, and community activities among individuals aging with a disability. *REHABIL PSYCHOL* 2006;51(1):13-22.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kahn JS, Kehle TJ, Jenson WR, et al. Comparison of cognitive-behavioral, relaxation, and self-modeling interventions for depression among middle-school students. *School Psychology Review* 1990;19(2):196-211.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial. *Pharmacopsychiatria* 2001;34(3):96-103. PMID:11434406
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kaltenthaler E, Shackley P, Stevens K, et al. A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. [Review] [91 refs]. *Health Technology Assessment (Winchester, England)* 2002;6(22):1-89. PMID:12433315
Exclude: For systematic review before 2005, OVID-Medline.
- Kaltenthaler E, Brazier J, De Nigris E, et al. Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. [Review] [156 refs]. *Health Technology Assessment (Winchester, England)* 2001;10(33):iii-xiv. PMID:16959169
Exclude: For systematic review before 2005, OVID-Medline.
- Kamlet MS, Paul N, Greenhouse J, et al. Cost utility analysis of maintenance treatment for recurrent depression. *Controlled Clinical Trials* 1995;16(1):17-40. PMID:7743786
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kane JM, Quitkin FM, Rifkin A, et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. *Arch Gen Psychiatry* 1982;39(9):1065-9.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Kang HS, Sok SR, Kang JS. Effects of Meridian acupuncture for stroke patients in Korea. *J CLIN NURS* 2009;18(15):2145-52. PMID:19583646
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kannappan R, Lakshmi Bai R. Cognitive behaviour therapy as an adjunct to drug therapy in the treatment of dysthymic disorder. *Journal of the Indian Academy of Applied Psychology* 2007;33(2):195-200.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Kannappan R. Intervention as an adjunct to drug therapy for childhood depression. *Journal of the Indian Academy of Applied Psychology* 2009;35(1):57-62.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Kantor D, McNevin S, Leichner P, et al. The benefit of lithium carbonate adjunct in refractory depression--fact or fiction? *Canadian Journal of Psychiatry* 1986;31(5):416-8.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: An open-label, uncontrolled study. *Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy* 2002;24(7):1194-200.
Exclude: For study design, OVID-PsycINFO.
- Kaplan K, Mendelson LB, Ploener DM. The effect of a jogging program on psychiatric inpatients with symptoms of depression. *Occupational Therapy Journal of Research* 1983;3(3):173-5.
Exclude: For study design, OVID-Embase.
- OVID-Embase.
- Karavidas MK, Lehrer PM, Vaschillo E, et al. Preliminary results of an open label study of heart rate variability biofeedback for the treatment of major depression. *Applied Psychophysiology & Biofeedback* 2007;32(1):19-30. PMID:17333315
Exclude: For study design, OVID-Medline.

- Karp JF, Whyte EM, Lenze EJ, et al. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability. *J Clin Psychiatry* 2008;69(3):457-63. PMID:18251622
Exclude: For study design, OVID-Medline.
- Kasckow JW, Mohamed S, Thallasinos A, et al. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. *Int J Geriatr Psychiatry* 2001;16(12):1163-7. PMID:11748776
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kashner TM, Henley SS, Golden RM, et al. Assessing the preventive effects of cognitive therapy following relief of depression: A methodological innovation. *J Affect Disord* 2007;104(1-3):251-61. PMID:17509693
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials. *Psychopharmacology* 2002;164(3):301-8. PMID:12424554
Exclude: For systematic review before 2005, OVID-Medline.
- Kasper S, Angheliescu IG, Szegedi A, et al. Placebo controlled continuation treatment with Hypericum extract WS 5570 after recovery from a mild or moderate depressive episode. *Wiener Medizinische Wochenschrift* 2007;157(13-14):362-6. PMID:17704988
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kasper S, Voll G, Vieira A, et al. Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression--results of a double-blind study. *Pharmacopsychiatry* 1990;23(3):135-42. PMID:2115680
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kasper S, Yieira A. Stimulation with dl-fenfluramine and antidepressive medication in major depressed inpatients. *Pharmacopsychiatry* 1989;22(5):201
Exclude: For study design, OVID-Embase.
- Kasper S, Angheliescu IG, Szegedi A, et al. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN7277298]. *BMC Medicine* 2006;4:14 PMID:16796730
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kataoka SH, Stein BD, Jaycox LH, et al. A school-based mental health program for traumatized Latino immigrant children. *J Am Acad Child Adolesc Psychiatry* 2003;42(3):311-8.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Katona CL, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. [erratum appears in *Br J Psychiatry* 1995 Apr;166(4):544]. *Br J Psychiatry* 1995;166(1):80-6. PMID:7894881
Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Katzelnick DJ, Simon GE, Pearson SD, et al. Randomized trial of a depression management program in high utilizers of medical care. *Archives of Family Medicine* 2000;9(4):345-51. PMID:10776363
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kaufmann MW, Cassem NH, Murray GB, et al. Use of psychostimulants in medically ill patients with neurological disease and major depression. *Can J Psychiatry* 1984;29(1):46-9. PMID:6704886
Exclude: For study design, OVID-Medline.
- Kay-Lambkin FJ, Baker AL, Lewin TJ, et al. Computer-based psychological treatment for comorbid depression and problematic alcohol and/or cannabis use: a randomized controlled trial of clinical efficacy. *Addiction* 2009;104(3):378-88. PMID:19207345
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kaye VG. An innovative treatment modality for elderly residents of a nursing home. *Clinical Gerontologist: The Journal of Aging and Mental Health* 1985;3(4):45-51.
Exclude: For study design, OVID-PsycINFO.
- Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. *J Psychiatr Res* 2009;43(3):205-14. PMID:18586273
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Keitner GI, Garlow SJ, Ryan CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. *J Psychiatr Res* 2009;43(3):205-14.
Exclude:For Mixed antidepressants; some failed on SSRI , OVID-PsycINFO.
- Keller M. Cross-over Study of Sertraline Versus Imipramine in Chronic Depression CONFERENCE ABSTRACT. In 1996; 1996. **Exclude:** For study design, Wiley-CCTR.
- Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. [erratum appears in *N Engl J Med* 2001 Jul 19;345(3):232]. *N ENGL J MED* 2000;342(20):1462-70. PMID:10816183
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: A multisite study from the consortium for research in electroconvulsive therapy (CORE). *Arch Gen Psychiatry* 2006;63(12):1337-44.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kelly AC, Zuroff DC, Shapira LB. Soothing oneself and resisting self-attacks: The treatment of two intrapersonal deficits in depression vulnerability. *Cogn Ther Res* 2009;33(3):301-13.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kelly JA, Murphy DA, Bahr GR, et al. Outcome of cognitive-behavioral and support group brief therapies for depressed, HIV-infected persons. *Am J Psychiatry* 1993;150(11):1679-86. PMID:8214177
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kelly TF, Lieberman DZ. Long term augmentation with T3 in refractory major depression. *J Affect Disord* 2009;115(1-2):230-3. PMID:19108898
Exclude: For study design, OVID-Medline.
- Kemp BJ, Kahan JS, Krause JS, et al. Treatment of major depression in individuals with spinal cord injury. *J SPINAL CORD MED* 2004;27(1):22-8. PMID:15156933
Exclude: For study design, OVID-Medline.
- Kemp BJ, Corgiat M, Gill C. Effects of brief cognitive-behavioral group psychotherapy on older persons with and without disabling illness. *Behavior, Health, & Aging* 1991;2(1):21-8.
Exclude: For study design, OVID-PsycINFO.
- Kendrick T, Simons L, Mynors-Wallis L, et al. A trial of problem-solving by community mental health nurses for anxiety, depression and life difficulties among general practice patients. The CPN-GP study. *HEALTH TECHNOL ASSESS* 2005;9(37):iii-59
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kendrick T, Chatwin J, Dowrick C, et al. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: The THREAD (THREShold for AntiDepressant response) study. *HEALTH TECHNOL ASSESS* 2009;13(22):1-159.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). *J Am Acad Child Adolesc Psychiatry* 2006;45(12):1404-11. PMID:17135985
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kennard BD, Silva SG, Mayes TL, et al. Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. *Am J Psychiatry* 2009;166(3):337-44. PMID:19147693
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kennard BD, Emslie GJ, Mayes TL, et al. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder. *J Am Acad Child Adolesc Psychiatry* 2008;47(12):1395-404. PMID:18978634
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kennard BD, Stewart SM, Hughes JL, et al. Developing Cognitive Behavioral Therapy to Prevent Depressive Relapse in Youth. *Cognitive and Behavioral Practice* 2008;15(4):387-99.
Exclude: For study design, OVID-Embase.
- Kennard BD, Silva SG, Tonev S, et al. Remission and recovery in the treatment for adolescents with depression study (TADS): Acute and long-term outcomes. *J Am Acad Child Adolesc Psychiatry* 2009;48(2):186-95.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kennedy N, Paykel ES. Treatment and response in refractory depression: results from a specialist affective disorders service. *J Affect Disord* 2004;81(1):49-53. PMID:15183599
Exclude: For study design, OVID-Medline.
- Kennedy P, Duff J, Evans M, et al. Coping effectiveness training reduces depression and anxiety following traumatic spinal cord injuries. *BR J CLIN PSYCHOL* 2003;42(1):41-52.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kennedy SH, Eisfeld BS, Meyer JH, et al. Antidepressants in clinical practice: Limitations of assessment methods and drug response. *Hum Psychopharmacol* 2001;16(1):105-14.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kennedy SH, Milev R, Giacobbe P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. *J Affect Disord* 2009;117(SUPPL. 1):S44-S53
Exclude: For Guideline focus on diagnosis or screening rather than treatment, OVID-Embase.
- Kennedy SH, Lam RW, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. [Review] [167 refs]. *Can J Psychiatry* 2001;46:Suppl-58S. PMID:11441771
Exclude: For Guideline published before 2005, OVID-Medline.
- Kennedy SH, Lam RW, Morris B. Clinical guidelines for depressive disorders: Summary of recommendations relevant to family physicians. *CAN FAM PHYSICIAN* 2003;49(APR.):489-91.

- Exclude:** For Guideline published before 2005, OVID-Embase.
- Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: A preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. *J Clin Psychiatry* 2002;63(3):181-6.
Exclude: For Mixed antidepressants; some failed on SSRI ,
- Kennedy SH, Cohen NL, Lam RW, et al. Combining psychotherapy and pharmacotherapy. *Canadian Journal of Psychiatry* 2001;46(SUPPL. 1):59S-62S.
Exclude: For Guideline published before 2005, OVID-Embase.
- Kennedy SH, Konarski JZ, Segal ZV, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. . *Am J Psychiatry* 2007;164(5):778-88. PMID:17475737
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kennedy SH, Segal ZV, Cohen NL, et al. Lithium carbonate versus cognitive therapy as sequential combination treatment strategies in partial responders to antidepressant medication: an exploratory trial. *J Clin Psychiatry* 2003;64(4):439-44. PMID:12716247
Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Kennedy SH, Lam RW, Cohen NL, et al. Medications and other biological treatments. *Canadian Journal of Psychiatry* 2001;46(SUPPL. 1):38S-58S.
Exclude: For Guideline published before 2005, OVID-Embase.
- Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. *European Neuropsychopharmacol* 2006;16(2):93-100.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kennedy SH, Lam RW, Cohen NL, et al. Reboxetine: a preliminary report on its use through the Special Access Program. *J Psychiatry Neurosci* 2002;27(6):418-22. PMID:12491574
Exclude: For study design, OVID-Medline.
- Kennedy S H, Srinivasan J, Fulton K. Ssri augmentation with raxoxifene for treatment-resistant depression sophie grigoriadis. In 2001. **Exclude:** For study design, Wiley-CCTR.
- Kenny MA, Williams JM. Treatment-resistant depressed patients show a good response to Mindfulness-based Cognitive Therapy. *Behav Res Ther* 2007;45(3):617-25. PMID:16797486
Exclude: For study design, OVID-Medline.
- Kerfoot M, Harrington R, Harrington V, et al. A step too far? Randomized trial of cognitive-behaviour therapy delivered by social workers to depressed adolescents. *EUR CHILD ADOLESC PSYCHIATRY* 2004;13(2):92-9. PMID:15103534
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kerr J, Calfas KJ, Caparosa S, et al. A pilot study to assess the feasibility and acceptability of a community based physical activity intervention (involving internet, telephone, and pedometer support), integrated with medication and mood management for depressed patients. *Mental Health and Physical Activity* 2008;1(1):40-5.
Exclude: For study design, OVID-Embase.
- Kessler D, Lewis G, Kaur S, et al. Therapist-delivered Internet psychotherapy for depression in primary care: a randomised controlled trial. . *Lancet* 2009;374(9690):628-34. PMID:19700005
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Ketter TA, Post RM, Parekh PI, et al. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. *J Clin Psychiatry* 1995;56(10):471-5.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Khandker RK, Kruzikas DT, McLaughlin TP. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. . *Journal of Managed Care Pharmacy* 2008;14(5):426-41. PMID:18597572
Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Khumar SS, Kaur P, Kaur S. Effectiveness of Shavasana on depression among university students. *Indian J Clin Psychol* 1993;20(2):82-7.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Kiloh LG, Moore G. An open trial of zimelidine in patients with endogenous depression. *International Pharmacopsychiatry* 1982;17(1):28-35. PMID:6211416
Exclude: For study design, OVID-Medline.
- Kim HL, Streltzer J, Goebert D. St. John's wort for depression: a meta-analysis of well-defined clinical trials. *J NERV MENT DIS* 1999;187(9):532-8. PMID:10496508
Exclude: For systematic review before 2005, OVID-Medline.
- Kim HR, Delva NJ, Lawson JS. Prophylactic medication for unipolar depressive illness: the place of lithium carbonate in combination with antidepressant medication. *Can J Psychiatry* 1990;35(2):107-14. PMID:2138503
Exclude: For systematic review before 2005, OVID-Medline.
- Kim KB, Cohen SM, Oh HK, et al. The effects of meridian exercise on anxiety, depression, and self-esteem of female college students in Korea. *Holistic Nurs Pract* 2004;18(5):230-4.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Kim SW, Shin IS, Kim JM, et al. Amisulpride versus risperidone in the treatment of depression in patients

with schizophrenia: a randomized, open-label, controlled trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2007;31(7):1504-9. PMID:17692448
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kim Y, Bowers J. Efficacy of acupuncture for treating depression. *Alternative Therapies in Women's Health* 2007;9(7):49-53.
Exclude: For study design, EBSCO-CINAHL.

Kinder LS, Katon WJ, Ludman E, et al. Improving depression care in patients with diabetes and multiple complications. *J Gen Intern Med* 2006;21(10):1036-41. PMID:16836628
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

King C, Kennedy P. Coping effectiveness training for people with spinal cord injury: preliminary results of a controlled trial. *The British journal of clinical psychology / the British Psychological Society* 1999;38 (Pt 1):5-14.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

King DJ. Drug management of depression. *Irish Medical Journal* 1983;76(1):44-50.
Exclude: For study design, OVID-Embase

OVID-Embase.

King M, Sibbald B, Ward E, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. *Health Technology Assessment (Winchester, England)* 2000;4(19):1-83. PMID:11086269
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kingston T, Dooley B, Bates A, et al. Mindfulness-based cognitive therapy for residual depressive symptoms. *Psychology & Psychotherapy: Theory, Research & Practice* 2007;80(Pt.2):2-203. PMID:17535594
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kinzie JD, Leung P. Clonidine in Cambodian patients with posttraumatic stress disorder. *J NERV MENT DIS* 1989;177(9):546-50. PMID:2769247
Exclude: For study design, OVID-Medline.

Kirkham MA. Two-year follow-up of skills training with mothers of children with disabilities. *American Journal on Mental Retardation* 1993;97(5):509-20.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Kirstein L. Neuroendocrine dysfunction and response to tricyclic antidepressants. *J Clin Psychiatry* 1984;45(9):385-6. PMID:6432772
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial

outcome from a randomized controlled trial. *Psycho Oncol* 2007;16(4):277-86. PMID:17385190
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kitsumban V, Thapinta D, Sirindharo PB, et al. Effect of cognitive mindfulness practice program on depression among elderly Thai women. *Thai Journal of Nursing Research* 2009;13(2):95-107.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.

Klaiber EL, Broverman DM, Vogel W, et al. Estrogen therapy for severe persistent depressions in women. *Arch Gen Psychiatry* 1979;36(5):550-4.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Klausner EJ, Clarkin JF, Spielman L, et al. Late-life depression and functional disability: the role of goal-focused group psychotherapy. *Int J Geriatr Psychiatry* 1998;13(10):707-16. PMID:9818307
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Kleber HD, Weissman MM, Rounsaville BJ, et al. Imipramine as treatment for depression in addicts. *Arch Gen Psychiatry* 1983;40(6):649-53. PMID:6342564
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Klein DN, Santiago NJ, Vivian D, et al. Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. *J Consult Clin Psychol* 2004;72(4):681-8. PMID:15301653
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Klein DN, Arnow BA, Barkin JL, et al. Early adversity in chronic depression: Clinical correlates and response to pharmacotherapy. *Depress Anxiety* 2009;26(8):701-10.
Exclude: For study design, OVID-Embase.

Klein MH, Greist JH, Gurman AS. A comparative outcome study of group psychotherapy vs. exercise treatments for depression. *International Journal of Mental Health* 1985;13(3-4):148-77.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Klein, R.A. Expectancy enhancement as a precursor to cognitive therapy for depression: A pilot investigation Klein. 2009
Exclude: For study design, OVID-PsycINFO.

Klieser E, Lehmann E. Experimental comparison between the effect of standardized trazodone-amitriptyline and placebo treatment in vitalized depressive patients. *Psychopharmacology* 1988;95:Suppl-5 PMID:3133710
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Knapen J, Van d, V, van Coppenolle H, et al. Comparison of changes in physical self-concept,

- global self-esteem, depression and anxiety following two different psychomotor therapy programs in nonpsychotic psychiatric inpatients. *Psychother Psychosom* 2005;74(6):353-61.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Knapen J, Sommerijns E, Vancampfort D, et al. State anxiety and subjective well-being responses to acute bouts of aerobic exercise in patients with depressive and anxiety disorders. *BR J SPORTS MED* 2009;43(10):756-9.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Knowlton L. Investigating SAM-e for depression. *Psychiatr Times* 2001;18(5):-10
Exclude: For study design, EBSCO-CINAHL.
- Knubben K, Reischies FM, Adli M, et al. A randomised, controlled study on the effects of a short-term endurance training programme in patients with major depression. *BR J SPORTS MED* 2007;41(1):29-33. PMID:17062659
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kobayashi N, Sawamura T, Yoshida T, et al. The effectiveness of lithium augmentation of milnacipran: preliminary data using the modified Japanese Psychopharmacology Algorithm. *Nihon Shinkei Seishin Yakurigaku Zasshi* 2004;24(5):279-81. PMID:15658504
Exclude: For study design, OVID-Medline.
- Koch JM, Hinze-Selch D, Stingele K, et al. Changes in CREB phosphorylation and BDNF plasma levels during psychotherapy of depression. *Psychother Psychosom* 2009;78(3):187-92. PMID:19321972
Exclude: For study design, OVID-Medline.
- Kocsis JH, Rush AJ, Markowitz JC, et al. Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. *Psychopharmacol Bull* 2003;37(4):73-87. PMID:15131518
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kocsis JH, Friedman RA, Markowitz JC, et al. Maintenance therapy for chronic depression: A controlled clinical trial of desipramine. *Arch Gen Psychiatry* 1996;53(9):769-76.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Koertge J, Janszky I, Sundin O, et al. Effects of a stress management program on vital exhaustion and depression in women with coronary heart disease: a randomized controlled intervention study. *Journal of Internal Medicine* 2008;263(3):281-93. PMID:18067552
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kohlenberg RH, Kanter JW, Bolling MY, et al. Enhancing cognitive therapy for depression with functional analytic psychotherapy: Treatment guidelines and empirical findings. *Cognitive and Behavioral Practice* 2002;9(3):213-29.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Kohler WK, Pelzer A, Schmidt K-P, et al. Bright light and dim light in the therapy of depression: effects on the circadian system and clinical results. *Pharmacopsychiatry* 1989;22(5):202
Exclude: For study design, OVID-Embase.
- Kohn-Wood, Laura, Hudson, Glenetta, Graham, Erin T. Ethnic minorities. *2008:351-72. 2008.*
Exclude: For study design, OVID-PsycINFO.
- Kohn CS, Petrucci RJ, Baessler C, et al. The effect of psychological intervention on patients' long-term adjustment to the ICD: a prospective study. *Pacing & Clinical Electrophysiology* 2000;23(4:Pt 1):t-6 PMID:10793433
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Koike K, Ohno S, Takahashi N, et al. Efficacy of the herbal medicine Unkei-to as an adjunctive treatment to hormone replacement therapy for postmenopausal women with depressive symptoms. *Clin Neuropharmacol* 2004;27(4):157-62. PMID:15319700
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kok RM, Vink D, Heeren TJ, et al. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial. *The Journal of clinical psychiatry* 2007;68(8):1177-85.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Kok RM, Nolen WA, Heeren TJ. Outcome of late-life depression after 3 years of sequential treatment. *Acta Psychiatr Scand* 2009;119(4):274-81. PMID:19053970
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Konarski JZ, Kennedy SH, Segal ZV, et al. Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. *J Psychiatry Neurosci* 2009;34(3):175-80. PMID:19448846
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kong S. Day treatment programme for patients with eating disorders: randomized controlled trial. *J ADV NURS* 2005;51(1):5-14.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Koniak-Griffin D. Aerobic exercise, psychological well-being, and physical discomforts during adolescent pregnancy. *Research in Nursing & Health* 1994;17(4):253-63.
Exclude: For study design, OVID-PsycINFO.
- Konig F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.

- Pharmacopsychiatry 1997;30(3):93-6. PMID:9211570
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Konuk N, Atasoy N, Atik L, et al. Open-label study of adjunct modafinil for the treatment of patients with fatigue, sleepiness, and major depression treated with selective serotonin reuptake inhibitors. *Advances in Therapy* 2006;23(4):646-54. PMID:17050507
Exclude: For study design, OVID-Medline.
- Koo JR, Yoon JY, Joo MH, et al. Treatment of depression and effect of antidepressant treatment on nutritional status in chronic hemodialysis patients. *American Journal of the Medical Sciences* 2005;329(1):1-5. PMID:15654172
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kool S, Dekker J, Duijsens IJ, et al. Changes in personality pathology after pharmacotherapy and combined therapy for depressed patients. *Journal of Personality Disorders* 2003;17(1):60-72. PMID:12659547
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kool S, Dekker J, Duijsens IJ, et al. Efficacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders. *Harvard Review of Psychiatry* 2003;11(3):133-41. PMID:12893503
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kopecek M, Bares M, Svarc J, et al. Hyperprolactinemia after low dose of amisulpride. *Neuroendocrinology Letters* 2004;25(6):419-22. PMID:15665803
Exclude: For study design, OVID-Medline.
- Kopecek M, Bares M, Horacek J, et al. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. *Neuroendocrinology Letters* 2006;27(6):803-6. PMID:17187006
Exclude: For study design, OVID-Medline.
- Koran LM, Aboujaoude EN, Gamel NN. Duloxetine treatment of dysthymia and double depression: an open-label trial. *J Clin Psychiatry* 2007;68(5):761-5. PMID:17503986
Exclude: For study design, OVID-Medline.
- Korn L, Logsdon RG, Polissar NL, et al. A randomized trial of a cam therapy for stress reduction in American Indian and Alaskan native family caregivers. *Gerontologist* 2009;49(3):368-77.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kornstein SG, Dunner DL, Meyers AL, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. *J Clin Psychiatry* 2008;69(9):1383-92. PMID:19193339
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Koszycki D, Lafontaine S, Frasur-Smith N, et al. An open-label trial of interpersonal psychotherapy in depressed patients with coronary disease. *Psychosomatics* 2004;45(4):319-24.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Kovac SH, Range LM. Does writing about suicidal thoughts and feelings reduce them? *Suicide & life threatening behavior* 2002;32(4):428-40.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Kovach-Anta, C.M. The effects of physical activity on levels of depression, anxiety, and hypochondriasis in the elderly Kovach-Anta. 1998
Exclude: For study design, OVID-PsycINFO.
- Kowalenko N, Rapee RM, Simmons J, et al. Short-term effectiveness of a school-based early intervention program for adolescent depression. *CLIN CHILD PSYCHOL PSYCHIATRY* 2005;10(4):493-507.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. *Arch Gen Psychiatry* 1989;46(10):922-8. PMID:2679483
Exclude: For population/diagnosis, OVID-Medline.
- Kramer, M.M. The effects of exercise on psychological well-being in women recovering from breast cancer Kramer. 1996
Exclude: For study design, OVID-PsycINFO.
- Kramlinger KG, Post RM. The addition of lithium to carbamazepine. Antidepressant efficacy in treatment-resistant depression. *Arch Gen Psychiatry* 1989;46(9):794-800.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Kramlinger KG, Post RM. The addition of lithium to carbamazepine: Antidepressant efficacy in treatment-resistant depression. *Arch Gen Psychiatry* 1989;46(9):794-800.
Exclude: For study design, OVID-PsycINFO.
- Kranzler HR, Bursleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. *Am J Psychiatry* 1995;152(3):391-7. PMID:7864265
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kratochvil C, Emslie G, Silva S, et al. Acute time to response in the Treatment for Adolescents with Depression Study (TADS). *J Am Acad Child Adolesc Psychiatry* 2006;45(12):1412-8. PMID:17135986
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. *J Am Acad Child Adolesc Psychiatry* 2005;44(9):915-24. PMID:16113620

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kraus RP, Diaz P, McEachran A. Managing rapid metabolizers of antidepressants. *Depress Anxiety* 1996;4(6):320-7. PMID:9166660

Exclude: For study design, OVID-Medline.

Kravitz HM, Sabelli HC, Fawcett J. Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders. *J Am Osteopath Assoc* 1984;84(1 SUPPL.):119-23.

Exclude: For study design, OVID-Embase

OVID-Embase.

Kripke DF, Mullaney DJ, Klauber MR, et al.

Controlled trial of bright light for nonseasonal major depressive disorders. *Biol Psychiatry* 1992;31(2):119-34. PMID:1737074

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Krishnamurthy MN, Telles S. Assessing depression following two ancient Indian interventions. *J GERONTOL NURS* 2007;33(2):17-23.

Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.

Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. *JAMA* 2009;301(20):2099-110. PMID:19470987

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kroenke K, Bair MJ, Damush TM, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. *JAMA : the journal of the American Medical Association* 2009;301(20):2099-110.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Krogh J, Saltin B, Gluud C, et al. The DEMO trial: a randomized, parallel-group, observer-blinded clinical trial of strength versus aerobic versus relaxation training for patients with mild to moderate depression. *J Clin Psychiatry* 2009;70(6):790-800. PMID:19573478

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kroll L, Harrington R, Jayson D, et al. Pilot study of continuation cognitive-behavioral therapy for major depression in adolescent psychiatric patients. *J Am Acad Child Adolesc Psychiatry* 1996;35(9):1156-61. PMID:8824059

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kronsnoble, K.M. Psychological effects of habitual aerobic exercise on cardiac patients Kronsnoble. 1996

Exclude: For study design, OVID-PsycINFO.

Krystal A, Fava M, Rubens R, et al. Evaluation of eszopiclone discontinuation after cotherapy with

fluoxetine for insomnia with coexisting depression. *Journal of Clinical Sleep Medicine* 2007;3(1):48-55. PMID:17557453

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kudoh A, Ishihara H, Matsuki A. Effect of carbamazepine on pain scores of unipolar depressed patients with chronic pain: a trial of off-on-off-on design. *The Clinical Journal of Pain* 1998;14(1):61-5.

Exclude: For study design, Wiley-CCTR.

Kuehner C. An evaluation of the 'Coping with Depression Course' for relapse prevention with unipolar depressed patients. *Psychother Psychosom* 2005;74(4):254-9. PMID:15947516

Exclude: For study design, OVID-Medline.

Kufferle B, Grunberger J. Early clinical double-blind study with S-adenosyl-L-methionine: a new potential antidepressant. *Adv Biochem Psychopharmacol* 1982;32:175-80. PMID:7046363

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Kugler J, Seelbach H, Kruskemper GM. Effects of rehabilitation exercise programmes on anxiety and depression in coronary patients: a meta-analysis. *BR J CLIN PSYCHOL* 1994;33(Pt 3):401-10. PMID:7994226

Exclude: For systematic review before 2005, OVID-Medline.

Kuhner C, Angermeyer MC, Veiel HOF. Cognitive-behavioral group intervention as a means of tertiary prevention in depressed patients: Acceptance and short-term efficacy. *Cogn Ther Res* 1996;20(4):391-409.

Exclude: For study design, OVID-PsycINFO.

Kuhs H, Färber D, Borgstädt S, et al. Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. *J Affect Disord* 1996;37(1):31-41.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Kuhs H, Kemper B, Lippe-Neubauer U, et al. Repeated sleep deprivation once versus twice a week in combination with amitriptyline. *J Affect Disord* 1998;47(1-3):97-103.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Kulcu DG, Kurtais Y, Tur BS, et al. The effect of cardiac rehabilitation on quality of life, anxiety and depression in patients with congestive heart failure. A randomized controlled trial, short-term results. *Europa Medicophysica* 2007;43(4):489-97.

Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.

Kumagai R, Ichimiya Y. Efficacy of blonanserin in combination therapy for treatment-resistant depression. *Psychiatry & Clinical Neurosciences* 2009;63(4):593-4. PMID:19659567

Exclude: For study design, OVID-Medline.

Kundermann B, Hemmeter-Spernal J, Huber MT, et al. Effects of total sleep deprivation in major

- depression: overnight improvement of mood is accompanied by increased pain sensitivity and augmented pain complaints. *Psychosom Med* 2008;70(1):92-101. PMID:18158380
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kundermann B, Strate P, Hemmeter-Spernal J, et al. Mid-term effects of serial sleep deprivation therapy implemented in cognitive-behavioral treatment on the neuroendocrine response to clomipramine in patients with major depression. *J Psychiatr Res* 2009;43(7):711-20. PMID:18930473
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kunik ME, Pollock BG, Perel JM, et al. Clomipramine in the elderly: tolerance and plasma levels. *J Geriatr Psychiatry Neurol*1994;7(3):139-43. PMID:7916936
Exclude: For study design, OVID-Medline.
- Kunik ME, Veazey C, Cully JA, et al. COPD education and cognitive behavioral therapy group treatment for clinically significant symptoms of depression and anxiety in COPD patients: a randomized controlled trial. *Psychol Med* 2008;38(3):385-96. PMID:17922939
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kunik ME, Braun U, Stanley MA, et al. One session cognitive behavioural therapy for elderly patients with chronic obstructive pulmonary disease. *Psychol Med* 2001;31(4):717-23. PMID:11352373
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kupfer DJ, Perel JM, Frank E. Adequate treatment with imipramine in continuation treatment. *J Clin Psychiatry* 1989;50(7):250-5. PMID:2661546
Exclude: For study design, OVID-Medline.
- Kupfer DJ, Spiker DG. Refractory depression: prediction of non-response by clinical indicators. *J Clin Psychiatry* 1981;42(8):307-12. PMID:7251567
Exclude: For study design, OVID-Medline.
- Kurland AA, Nagaraju A. Viloxazine and the depressed schizophrenic--methodological issues. *J CLIN PHARMACOL* 1981;21(1):37-41. PMID:7012190
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kush FR, Fleming LM. An innovative approach to short-term group cognitive therapy in the combined treatment of anxiety and depression. *Group Dynamics* 2000;4(2):176-83.
Exclude: For study design, OVID-Embase.
- Kutcher S, LeBlanc J, Maclaren C, et al. A randomized trial of a specific adherence enhancement program in setraline-treated adults with major depressive disorder in a primary care setting. *Prog Neuropsychopharmacol Biol Psychiatry* 2002;26(3):591-6.
Exclude: For Mixed antidepressants; some failed on SSRI , OVID-PsycINFO.
- Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. *J Consult Clin Psychol* 2008;76(6):966-78. PMID:19045965
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. *J Consult Clin Psychol* 2008;76(6):966-78.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Kvist J, Kirkegaard C. Effect of repeated sleep deprivation on clinical symptoms and the TRH test in endogenous depression. *Acta Psychiatr Scand* 1980;62(5):494-502. PMID:6782834
Exclude: For study design, OVID-Medline.
- Kwamie Y, Persad E, Stancer H. The use of carbamazepine as an adjunctive medication in the treatment of affective disorders: a clinical report. *Can J Psychiatry* 1984;29(7):605-8. PMID:6150757
Exclude: For study design, OVID-Medline.
- Laakmann G, Schule C, Baghai T, et al. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. *Pharmacopsychiatry* 1998;31:Suppl-9 PMID:9684948
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Labbé EE, Welsh MC, Delaney D. Effects of consistent aerobic exercise on the psychological functioning of women. *Perceptual and Motor Skills* 1988;67(3):919-25.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Lafferman J, Solomon K, Ruskin P. Lithium augmentation for treatment-resistant depression in the elderly. *J Geriatr Psychiatry Neurol*1988;1(1):49-52. PMID:3150926
Exclude: For study design, OVID-Medline.
- Lai SM, Studenski S, Richards L, et al. Therapeutic exercise and depressive symptoms after stroke. *J AM GERIATR SOC* 2006;54(2):240-7. PMID:16460374
Exclude: For population/diagnosis, OVID-Medline.
- Lai Y. Effects of music listening on depressed women in Taiwan. *Issues Ment Health Nurs* 1999;20(3):229-46.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Laidlaw K, Davidson K, Toner H, et al. A randomised controlled trial of cognitive behaviour therapy vs treatment as usual in the treatment of mild to moderate late life depression. *Int J Geriatr Psychiatry* 2008;23(8):843-50. PMID:18311844
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. *Am J Psychiatry* 2007;164(10):1530-8. PMID:17898344

Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Medline.

Lam RW, Hossie H, Solomons K, et al. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. *J Clin Psychiatry* 2004;65(3):337-40. PMID:15096072

Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Medline.

Lam RW, Wan DD, Cohen NL, et al. Combining antidepressants for treatment-resistant depression: a review. [Review] [52 refs]. *J Clin Psychiatry* 2002;63(8):685-93. PMID:12197448

Exclude: For systematic review before 2005, OVID-Medline.

Lam RW, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. [Review] [69 refs]. *Can J Psychiatry* 2004;49(3:Suppl 1):Suppl-26S PMID:15147033

Exclude: For systematic review before 2005, OVID-Medline.

Lancet,R. The effect of aerobic exercise on obsessive compulsive disorder, anxiety, and depression *Lancet*. 2005

Exclude: For study design, OVID-PsycINFO.

Landaas,J.A. The effect of aerobic exercise on self-efficacy perceptions body-esteem, anxiety and depression *Landaas*. 2006

Exclude: For study design, OVID-PsycINFO.

Landreville P. Cognitive bibliotherapy for depression in older adults with a disability. *CLIN GERONTOL* 1998;19(3):69-75.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Landreville P, Bissonnette L. Effects of cognitive bibliotherapy for depressed older adults with a disability. *Clinical Gerontologist: The Journal of Aging and Mental Health* 1997;17(4):35-55.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Lane AM, Lovejoy DJ. The effects of exercise on mood changes: The moderating effect of depressed mood. *Journal of Sports Medicine and Physical Fitness* 2001;41(4):539-45.

Exclude: For study design, OVID-Embase.

Langer G, Karazman R, Neumark J, et al. Isoflurane narcotherapy in depressive patients refractory to conventional antidepressant drug treatment. A double-blind comparison with electroconvulsive treatment. *Neuropsychobiology* 1995;31(4):182-94. PMID:7659199

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Lantz JE. Depression and social interest tasks. *Journal of Individual Psychology* 1981;37(1):113-6.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Laperriere A, Ironson GH, Antoni MH, et al. Decreased depression up to one year following CBSM+ intervention in depressed women with AIDS:

the smart/EST women's project. *J HEALTH PSYCHOL* 2005;10(2):223-31. PMID:15723892

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Lapierre Y, Bentkover J, Schainbaum S, et al. Direct cost of depression: analysis of treatment costs of paroxetine versus Imipramine in Canada. *Can J Psychiatry* 1995;40(7):370-7. PMID:8548716

Exclude: For systematic review before 2005, OVID-Medline.

Larcombe NA, Wilson PH. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. *Br J Psychiatry* 1984;145(OCT.):366-71.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Larsen JK, Rafaelsen OJ. Long-term treatment of depression with isocarboxazide. *Acta Psychiatr Scand* 1980;62(5):456-63. PMID:7211430

Exclude: For study design, OVID-Medline.

Larsen JK, Rafaelsen OJ. Long-term treatment of depression with isocarboxazide. *Acta Psychiatr Scand* 1980;62(5):456-63.

Exclude: For study design, OVID-PsycINFO.

Latour D, Cappeliez P. Pretherapy training for group cognitive therapy with depressed older adults. *Canadian Journal on Aging* 1994;13(2):221-35.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Lattanzi L, Dell'Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. *Bipolar Disorders* 2002;4(5):307-14. PMID:12479663

Exclude: For study design, OVID-Medline.

Lauritzen L, Clemmesen L, Klysner R, et al. Combined treatment with imipramine and mianserin. A controlled pilot study. *Pharmacopsychiatry* 1992;25(4):182-6. PMID:1528957

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Lauritzen L, Bendsen BB, Vilmar T, et al. Post-stroke depression: combined treatment with imipramine or desipramine and mianserin. A controlled clinical study. *Psychopharmacology* 1994;114(1):119-22. PMID:7846193

Exclude: For population/diagnosis, OVID-Medline.

Lauterbach E, Felber W, Muller-Oerlinghausen B, et al. Adjunctive lithium treatment in the prevention of suicidal behaviour in depressive disorders: a randomised, placebo-controlled, 1-year trial. *Acta Psychiatr Scand* 2008;118(6):469-79. PMID:18808400

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Laux G, Koenig W, Pfaff G. Antidepressant combination therapy of endogenous depressions with benzodiazepines or neuroleptics--a study comparing adjuvant treatment with oxazolam versus

- chlorprothixene. *Pharmacopsychiatry* 1988;21(2):87-92. PMID:2899329
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lave JR, Frank RG, Schulberg HC, et al. Cost-effectiveness of treatments for major depression in primary care practice. *Arch Gen Psychiatry* 1998;55(7):645-51. PMID:9672056
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lavertue NE, Kumar VK, Pekala RJ. The effectiveness of a hypnotic ego-strengthening procedure for improving self-esteem and depression. *Australian Journal of Clinical and Experimental Hypnosis* 2002;30(1):1-23.
Exclude: For population/not failed to respond to an SSRI,
- Lavie CJ, Milani RV, Cassidy MM, et al. Effects of cardiac rehabilitation and exercise training programs in women with depression. *American Journal of Cardiology* 1999;83(10):1480-3.
Exclude: For study design, OVID-Embase.
- Lavretsky H, Kim MD, Kumar A, et al. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. *J Clin Psychiatry* 2003;64(12):1410-4. PMID:14728100
Exclude: For study design, OVID-Medline.
- Lavretsky H, Park S, Siddarth P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. *Am J Geriatr Psychiatry* 2006;14(2):181-5. PMID:16473984
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. *The Am J Geriatr Psychiatry* 2001;9(3):298-303.
Exclude: For study design, OVID-PscINFO.
- Lawlor DA, Hopker SW. The effectiveness of exercise as an intervention in the management of depression: systematic review and meta-regression analysis of randomised controlled trials. *BMJ* 2001;322(7289):763-7. PMID:11282860
Exclude: For systematic review before 2005, OVID-Medline.
- Layne CM, Saltzman WR, Poppleton L, et al. Effectiveness of a school-based group psychotherapy program for war-exposed adolescents: A randomized controlled trial. *J Am Acad Child Adolesc Psychiatry* 2008;47(9):1048-62.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Learmonth D, Rai S. Taking computerized CBT beyond primary care. *BR J CLIN PSYCHOL* 2008;47(Pt:1):1-8. PMID:17939879
Exclude: For study design, OVID-Medline.
- Learmonth D, Trosh J, Rai S, et al. The role of computer-aided psychotherapy within an NHS CBT specialist service. *Counsel Psychother Res* 2008;8(2):117-23.
Exclude: For study design, EBSCO-CINAHL.
- Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: Consensus statement update. *JAMA* 1997;278(14):1186-90.
Exclude: For Guideline published before 2005, OVID-Embase.
- Lecrubier Y, Clerc G, Didi R, et al. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. *Am J Psychiatry* 2002;159(8):1361-6. PMID:12153829
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lecrubier Y. Pharmacological interventions in dysthymia. *Eur Psychiatry* 1996;11(Suppl 3):1996, pp-1996133s.
Exclude: For systematic review before 2005, OVID-PscINFO.
- Lee MR, Cohen L, Hadley SW, et al. Cognitive-behavioral group therapy with medication for depressed gay men with AIDS or symptomatic HIV infection. *Psychiatr Serv* 1999;50(7):948-52. PMID:10402618
Exclude: For study design, OVID-Medline.
- Lee MS, Jang J, Jang H, et al. Effects of Qi-therapy on blood pressure, pain and psychological symptoms in the elderly: a randomized controlled pilot trial. *COMPLEMENT THER MED* 2003;11(3):159-64.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Leff J, Vearnals S, Brewin CR, et al. The London depression intervention trial. Randomised controlled trial of antidepressants v. couple therapy in the treatment and maintenance of people with depression living with a partner: Clinical outcome and costs. *Br J Psychiatry* 2000;177(AUG.):95-100.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Legrand F, Heuze JP. Antidepressant effects associated with different exercise conditions in participants with depression: A pilot study. *Journal of Sport & Exercise Psychology* 2007;29(3):348-64.
Exclude: For population/not failed to respond to an SSRI, OVID-PscINFO.
- Leibenluft E, Moul DE, Schwartz PJ, et al. A clinical trial of sleep deprivation in combination with antidepressant medication. *Psychiatry Res* 1993;46(3):213-27.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.
- Leichsenring F. Comparative effects of short-term psychodynamic psychotherapy and cognitive-behavioral therapy in depression: a meta-analytic approach. *Clinical Psychology Review* 2001;21(3):401-19. PMID:11288607
Exclude: For systematic review before 2005, OVID-Medline.

- Leinonen E, Niemi H. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study. *Nord J Psychiatry* 2007;61(2):109-14. PMID:17454725
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. *Biol Psychiatry* 2008;63(12):1103-10. PMID:18191112
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Lemmens GM, Eisler I, Buysse A, et al. The effects on mood of adjunctive single-family and multi-family group therapy in the treatment of hospitalized patients with major depression. A 15-month follow-up study. *Psychother Psychosom* 2009;78(2):98-105. PMID:19218828
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lemon K. An assessment of treating depression and anxiety with aromatherapy. *International Journal of Aromatherapy* 2004;14(2):63-9.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Lenoir S, Degenring FH, Saller R. A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of *Hypericum perforatum* L. *Phytomedicine* 1999;6(3):141-6. PMID:10439477
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lenze EJ, Dew MA, Mazumdar S, et al. Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: effects on social adjustment. *Am J Psychiatry* 2002;159(3):466-8. PMID:11870013
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lenze EJ, Sheffrin M, Driscoll HC, et al. Incomplete response in late-life depression: Getting to remission. *Dialogues in Clinical Neuroscience* 2008;10(4):419-30.
Exclude: For study design, OVID-Embase.
- Lenze EJ, Dew MA, Mazumdar S, et al. Combined pharmacotherapy and psychotherapy as maintenance treatment for late-life depression: Effects on social adjustment. *Am J Psychiatry* 2002;159(3):466-8.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Leppamaki S, Haukka J, Lonnqvist J, et al. Drop-out and mood improvement: a randomised controlled trial with light exposure and physical exercise [ISRCTN36478292]. *BMC Psychiatry* 2004;4:22. PMID:15306031
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lerber-Good WF. Neurotransmitter precursor therapies in affective disorders. *International Journal for Vitamin and Nutrition Research* 1986;56(SUPPL. 29):69-82.
Exclude: For study design, OVID-Embase
- OVID-Embase.
- Lesperance F, Frasere-Smith N, Koszycki D, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. [erratum appears in JAMA. 2007 Jul 4;298(1):40]. *JAMA* 2007;297(4):367-79. PMID:17244833
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Leucht S, Hackl HJ, Steimer W, et al. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. *Psychopharmacology* 2000;147(4):378-83. PMID:10672631
Exclude: For study design, OVID-Medline.
- Leuchter AF, Lesser IM, Trivedi MH, et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. *J Psychiatr Pract* 2008;14(5):271-80. PMID:18832958
Exclude: For study design, OVID-Medline.
- Leung SN, Orrell MW. A brief cognitive behavioural therapy group for the elderly: Who benefits? *Int J Geriatr Psychiatry* 1993;8(7):593-8.
Exclude: For study design, OVID-PsycINFO.
- Levendoglu F, Altintepe L, Okudan N, et al. A twelve week exercise program improves the psychological status, quality of life and work capacity in hemodialysis patients. *Journal of Nephrology* 2004;17(6):826-32.
Exclude: For study design, OVID-Embase.
- Levesque M, Savard J, Simard S, et al. Efficacy of cognitive therapy for depression among women with metastatic cancer: a single-case experimental study. *Journal of Behav Ther & Experimental Psychiatry* 2004;35(4):287-305. PMID:15530844
Exclude: For study design, OVID-Medline.
- Levin A, Schlebusch L. Mianserin is better tolerated and more effective in depression than a nomifensine-clobazam combination: a double-blind study. *Acta Psychiatrica Scandinavica, Supplementum* 1985;320:75-80. PMID:3863470
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Levine J, Mishori A, Susnosky M, et al. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. *Biol Psychiatry* 1999;45(3):270-3. PMID:10023500
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Levine J. Controlled trials of inositol in psychiatry. *European Neuropsychopharmacol* 1997;7(2):147-55.
Exclude: For study design, OVID-Embase.
- Levine J, Gonsalves M, Babur I, et al. Inositol 6 g daily may be effective in depression but not in schizophrenia. *Hum Psychopharmacol* 1993;8(1):49-53.
Exclude: For study design, OVID-Embase.
- Levitan RD, Shen JH, Jindal R, et al. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.[erratum appears in *J Psychiatry Neurosci* 2000 Nov;25(5):439]. *J Psychiatry Neurosci* 2000;25(4):337-46. PMID:11022398
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Levitt AJ, Joffe RT, Kennedy SH. Bright light augmentation in antidepressant nonresponders. *J Clin Psychiatry* 1991;52(8):336-7. PMID:1869495
Exclude: For study design, OVID-Medline.
- Lewinsohn PM, Clarke GN, Hops H, et al. Cognitive-behavioral treatment for depressed adolescents. *Behav Ther* 1990;21(4):385-401.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
OVID-Embase.
- Lewinsohn PM, Clarke GN. Psychosocial treatments for adolescent depression. *Clinical Psychology Review* 1999;19(3):329-42.
Exclude: For systematic review before 2005, OVID-Embase.
- Lewis CC, Simons AD, Silva SG, et al. The role of readiness to change in response to treatment of adolescent depression. *J Consult Clin Psychol* 2009;77(3):422-8. PMID:19485584
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lewis FM, Cochrane BB, Fletcher KA, et al. Helping Her Heal: a pilot study of an educational counseling intervention for spouses of women with breast cancer. *Psycho Oncol* 2008;17(2):131-7. PMID:17429834
Exclude: For study design, OVID-Medline.
- Leykin Y, Amsterdam JD, DeRubeis RJ, et al. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. *J Consult Clin Psychol* 2007;75(2):267-76. PMID:17469884
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Li L, Wang S, Ge H, et al. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. *J Altern Complement Med* 2008;14(7):841-6.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Li LT, Wang SH, Ge HY, et al. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. *J Altern Complement Med* 2008;14(7):841-6. PMID:18721085
Exclude: For population/diagnosis, OVID-Medline.
- Li LT, Wang SH, Ge HY, et al. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetine on post-stroke depression. *J Altern Complement Med* 2008;14(7):841-6.
Exclude: For population/diagnosis, OVID-PsycINFO.
- Lieber AL, Newbury ND. Diagnosis, treatment, and outcome in refractory depression. *Ann Clin Psychiatry* 1991;3(2):119-24.
Exclude: For study design, OVID-Embase
OVID-Embase.
- Lieverse R, Nielen MMA, Veltman DJ, et al. Bright light in elderly subjects with nonseasonal major depressive disorder: A double blind randomised clinical trial using early morning bright blue light comparing dim red light treatment. *Trials* 2008;9, 2008. Article Number: 48. Date of Publication: 31 Jul 2008.:
Exclude: For study design, OVID-Embase.
- Lii YC, Tsay SL, Wang TJ. Group intervention to improve quality of life in haemodialysis patients. *J CLIN NURS* 2007;16(11C):268-75. PMID:17931320
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lim HJ, Moon YI, Lee MS. Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. *Rheumatology International* 2005;25(3):225-9. PMID:15650833
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Limosin F, Loze JY, Zylberman-Bouhassira M, et al. The Course of Depressive Illness in General Practice. *The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie* 2004;49(2):119-23.
Exclude: For study design, OVID-PsycINFO.
- Lincoln NB, Flannaghan T. Cognitive behavioral psychotherapy for depression following stroke: a randomized controlled trial. *Stroke* (00392499) 2003;34(1):111-5. PMID:12511760
Exclude: For population/diagnosis, OVID-Medline.
- Lincoln NB, Flannaghan T, Sutcliffe L, et al. Evaluation of cognitive behavioural treatment for depression after stroke: a pilot study. *CLIN REHABIL* 1997;11(2):114-22. PMID:9199863
Exclude: For study design, OVID-Medline.
- Lindberg D, Ahlfors UG, Dencker SJ, et al. Symptom reduction in depression after treatment with L-tryptophan or imipramine. Item analysis of Hamilton rating scale for depression. *Acta Psychiatr Scand* 1979;60(3):287-94.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. *BMJ* 1996;313(7052):253-8. PMID:8704532
Exclude: For systematic review before 2005, OVID-Medline.

- Linde K, ter Riet G, Hondras M, et al. Systematic reviews of complementary therapies - An annotated bibliography. Part 2: Herbal medicine. *BMC Complementary and Alternative Medicine* 2001;1, 2001. Date of Publication: 20 Jul 2001.:
Exclude: For systematic review before 2005, OVID-Embase.
- Lingjaerde O, Bratfos O, Bratlid T, et al. A double-blind comparison of zimelidine and desipramine in endogenous depression. *Acta Psychiatr Scand* 1983;68(1):22-30. PMID:6225313
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Lingjaerde O, Edlund AH, Gormsen CA, et al. The effects of lithium carbonate in combination with tricyclic antidepressants in endogenous depression. A double-blind, multicenter trial. *Acta Psychiatr Scand* 1974;50(2):233-42.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Liou CP, Her JR. The effectiveness of psychotherapies on hospitalized depressive patients. *Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal* 1996;58(3):163-70. PMID:8940787
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lipinski JF, Cohen BM, Frankenburg F, et al. Open trial of S-adenosylmethionine for treatment of depression. *Am J Psychiatry* 1984;141(3):448-50. PMID:6367496
Exclude: For study design, OVID-Medline.
- Listman PJ. Cognitive therapy is effective in diabetic patients with depression. *Am Fam Physician* 1997;56(2):566
Exclude: For study design, OVID-Embase.
- Liu C-F, Hedrick SC, Chaney EF, et al. Cost-effectiveness of collaborative care for depression in a primary care veteran population. *Psychiatr Serv* 2003;54(5):698-704.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Liu ETH, Chen W-L, Li Y-H, et al. Exploring the efficacy of cognitive bibliotherapy and a potential mechanism of change in the treatment of depressive symptoms among the Chinese: A randomized controlled trial. *Cogn Ther Res* 2009;33(5):449-61.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Liu P, He FF, Bai WP, et al. Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine. *Chinese Medical Journal* 2004;117(2):189-94. PMID:14975200
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Liu S-J, Lin C-J, Chen Y-M, et al. The effects of reminiscence group therapy on self-esteem, depression, loneliness and life satisfaction of elderly people living alone. *Mid-Taiwan Journal of Medicine* 2007;12(3):133-42.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Lobstein DD, Rasmussen CL. Decreases in resting plasma beta-endorphin and depression scores after endurance training. *Journal of Sports Medicine and Physical Fitness* 1991;31(4):543-51.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Locca J-F, Bula CJ, Zumbach S, et al. Pharmacological Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) in Nursing Homes: Development of Practice Recommendations in a Swiss Canton (DOI:10.1016/j.jamda.2008.04.003). *J AM MED DIR ASSOC* 2008;9(8):611
Exclude: For guideline, not a population of interest, OVID-Embase.
- Lockwood C, Page T, Conroy-Hiller T. Comparing the effectiveness of cognitive behaviour therapy using individual or group therapy in the treatment of depression. *INT J EVID BASED HEALTHC* 2004;2(5):185-206.
Exclude: For systematic review before 2005, OVID-PscINFO.
- Lojko D, Rybakowski JK. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. *J Affect Disord* 2007;103(1-3):253-6. PMID:17289154
Exclude: For study design, OVID-Medline.
- Lolak S, Connors GL, Sheridan MJ, et al. Effects of progressive muscle relaxation training on anxiety and depression in patients enrolled in an outpatient pulmonary rehabilitation program. *Psychother Psychosom* 2008;77(2):119-25.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Lombardo NBE, Dresser MVB, Malivert M, et al. Acupuncture as treatment for anxiety and depression in persons with dementia: results of a feasibility and effectiveness study. *Alzheimer's Care Quarterly* 2001;2(4):28-41. **Exclude:** For study design, EBSCO-CINAHL.
- Londborg PD, Smith WT, Glaudin V, et al. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. *J Affect Disord* 2000;61(1-2):73-9. PMID:11099743
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Louis M, Kowalski SD. Use of aromatherapy with hospice patients to decrease pain, anxiety, and depression and to promote an increased sense of well-being. *American Journal of Hospice & Palliative Care* 2002;19(6):381-6.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Louis M, Kowalski SD. Use of aromatherapy with hospice patients to decrease pain, anxiety, and depression and to promote an increased sense of well-being. *American Journal of Hospice and Palliative*

- Care 2002;19(6):381-6.
Exclude: For study design, OVID-AMED.
- Loving RT, Kripke DF, Knickerbocker NC, et al. Bright green light treatment of depression for older adults [ISRCTN69400161]. *BMC Psychiatry* 2005;5:42 PMID:16283926
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Loving RT, Kripke DF, Shuchter SR. Bright light augments antidepressant effects of medication and wake therapy. *Depress Anxiety* 2002;16(1):1-3. PMID:12203667
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- López J, Crespo M. Analysis of the efficacy of a psychotherapeutic program to improve the emotional status of caregivers of elderly dependent relatives. *AGING MENT HEALTH* 2008;12(4):451-61.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Lucas M, Asselin G, Merette C, et al. Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. *AM J CLIN NUTR* 2009;89(2):641-51. PMID:19116322
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Luciano, J.S., Jr. Neural network modeling of unipolar depression: Patterns of recovery and prediction of outcome Luciano. 1996
Exclude: For study design, OVID-PsycINFO.
- Ludman EJ, Simon GE, Grothaus LC, et al. A pilot study of telephone care management and structured disease self-management groups for chronic depression. *Psychiatr Serv* 2007;58(8):1065-72. PMID:17664517
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Ludman EJ, Simon GE, Tutty S, et al. A Randomized Trial of Telephone Psychotherapy and Pharmacotherapy for Depression: Continuation and Durability of Effects. *J Consult Clin Psychol* 2007;75(2):257-66.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Luo H, Meng F, Jia Y, et al. Clinical research on the therapeutic effect of the electro-acupuncture treatment in patients with depression. *Psychiatry & Clinical Neurosciences* 1998;52:Suppl-40 PMID:9895187
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Luo HC, Jia YK, Li Z. Electro-acupuncture vs. amitriptyline in the treatment of depressive states. *J Tradit Chin Med* 1985;5(1):3-8. PMID:3849629
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lustman PJ, Griffith LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. *Ann Intern Med* 1998;129(8):613-21. PMID:9786808
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lustman PJ, Griffith LS, Freedland KE, et al. The course of major depression in diabetes. *Gen Hosp Psychiatry* 1997;19(2):138-43.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Luty SE, Carter JD, McKenzie JM, et al. Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioural therapy for depression. *Br J Psychiatry* 2007;190:496-502. PMID:17541109
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Lykouras L, Avgoustides D, Papakostas Y, et al. Medication response to ECT-resistant melancholic patients. *Acta Psychiatrica Belgica* 1995;95(3):113-21. PMID:8525854
Exclude: For study design, OVID-Medline.
- Lynch DJ, Tamburrino MB, Nagel R. Telephone counseling for patients with minor depression: preliminary findings in a family practice setting. *The J Fam Prac* 1997;44(3):293-8.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Lynch TR, Morse JQ, Mendelson T, et al. Dialectical behavior therapy for depressed older adults: a randomized pilot study. *Am J Geriatr Psychiatry* 2003;11(1):33-45. PMID:12527538
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. *J Consult Clin Psychol* 2004;72(1):31-40. PMID:14756612
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Maag, John W., Swearer, Susan M., Toland, Michael D. Cognitive-behavioral interventions for depression in children and adolescents: Meta-analysis, promising programs, and implications for school personnel. 2009:235-65. 2009.
Exclude: For study design, OVID-PsycINFO.
- MacEwan GW, Remick RA. Treatment resistant depression: a clinical perspective. *Can J Psychiatry* 1988;33(9):788-92. PMID:3214826
Exclude: For study design, OVID-Medline.
- Mackert A, Volz H-P, Stieglitz R-D, et al. Light treatment of non-seasonal affective disorder. *Pharmacopsychiatry* 1989;22(5):206
Exclude: For study design, OVID-Embase.
- Mackert A, Volz HP, Stieglitz RD, et al. Phototherapy in nonseasonal depression. *Biol Psychiatry* 1991;30(3):257-68. PMID:1912117
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mackinnon A, Griffiths KM, Christensen H. Comparative randomised trial of online cognitive-behavioural therapy and an information website for

- depression: 12-month outcomes. . Br J Psychiatry 2008;192(2):130-4. PMID:18245031
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996;41(3):201-10. PMID:8988452
Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Maes M, Vandoolaeghe E, van Hunsel F, et al. Immune disturbances in treatment-resistant depression: Modulation by antidepressive treatments. Hum Psychopharmacol 1997;12(2):153-62.
Exclude: For study design, OVID-Embase.
- Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharm 1999;19(2):177-82. PMID:10211920
Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Maes M, Verkerk R, Vandoolaeghe E, et al. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998;97(4):302-8.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Mahmoud RA, Pandina GJ, Turkoz I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. [summary for patients in Ann Intern Med. 2007 Nov 6;147(9):I34; PMID: 17975178]. Ann Intern Med 2007;147(9):593-602. PMID:17975181
Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Mahoney,S.H. Depression, anxiety, and stress among the elderly: A comparison of treatment outcome between two cognitive-behavioral interventions Mahoney. 1998
Exclude: For study design, OVID-PsycINFO.
- Maina G, Rosso G, Bogetto F. Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: Long-term results. J Affect Disord 2009;114(1-3):200-7.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Maina G, Rosso G, Crespi C, et al. Combined brief dynamic therapy and pharmacotherapy in the treatment of major depressive disorder: a pilot study. Psychother Psychosom 2007;76(5):298-305. PMID:17700050
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Malhi GS, Ng F, Berk M. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression. Aust NZ J Psychiatry 2008;42(4):346-9. PMID:18330778
Exclude: For study design, OVID-Medline.
- Malison RT, Anand A, Pelton GH, et al. Limited efficacy of ketoconazole in treatment-refractory major depression. J Clin Psychopharm 1999;19(5):466-70.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Malt UF, Robak OH, Madsbu HP, et al. The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: randomised double blind study. . BMJ 1999;318(7192):1180-4. PMID:10221945
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Manber R, Schnyer RN, Allen JJ, et al. Acupuncture: a promising treatment for depression during pregnancy. J Affect Disord 2004;83(1):89-95. PMID:15546651
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Manber R, Edinger JD, Gress JL, et al. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. . Sleep 2008;31(4):489-95. PMID:18457236
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Manber R, Kraemer HC, Arnow BA, et al. Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. J Consult Clin Psychol 2008;76(3):459-67. PMID:18540739
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Manber R, Arnow B, Blasey C, et al. Patient's therapeutic skill acquisition and response to psychotherapy, alone or in combination with medication. Psychol Med 2003;33(4):693-702. PMID:12785471
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Manber R, Rush AJ, Thase ME, et al. The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. . Sleep: Journal of Sleep and Sleep Disorders Research 2003;26(2):130-6.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Mancini C, Van Ameringen M, Folvolden P. Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive-compulsive disorder? J Affect Disord 2002;68(1):59-65. PMID:11869783
Exclude: For study design, OVID-Medline.
- Manger TA, Motta RW. The impact of an exercise program on posttraumatic stress disorder, anxiety, and depression. International Journal of Emergency Mental Health 2005;7(1):49-57. PMID:15869081
Exclude: For study design, OVID-Medline.

- Manschreck TC, Redmond DA, Beaudette SM. Clozapine in the back wards. *Ann Clin Psychiatry* 1994;6(4):215-25.
Exclude: For study design, OVID-PsycINFO.
- Manson, Spero M. Depression and related mental illnesses among American Indians: The current state of the art in treatment. 1992:81-91. 1992.
Exclude: For study design, OVID-PsycINFO.
- Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. *Am J Psychiatry* 2003;160(5):996-8. PMID:12727707
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Marangell LB, George MS, Callahan AM, et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. *Arch Gen Psychiatry* 1997;54(3):214-22. PMID:9075462
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. *JAMA* 2004;292(7):807-20. PMID:15315995
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- March J, Silva S, Vitiello B, et al. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. *J Am Acad Child Adolesc Psychiatry* 2006;45(12):1393-403. PMID:17135984
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- March J, Silva S, Curry J, et al. The treatment for adolescents with depression study (TADS): Outcomes over 1 year of naturalistic follow-up. *Am J Psychiatry* 2009;166(10):1141-9.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- March JS, Silva S, Petrycki S, et al. Fluoxetine plus cognitive behavioural therapy was most effective for adolescents with major depressive disorder. *Evidence-Based Medicine* 2005;10(2):46
Exclude: For study design, OVID-Embase.
- March JS. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. *JAMA* 2004;292(7):807-20.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. [erratum appears in *Arch Gen Psychiatry*. 2008 Jan;65(1):101]. *Arch Gen Psychiatry* 2007;64(10):1132-43. PMID:17909125
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Marchioro G, Azzarello G, Checchin F, et al. The impact of a psychological intervention on quality of life in non-metastatic breast cancer. *Eur J Cancer* (1996;32A(9):1612-5.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Marco EJ, Wolkowitz OM, Vinogradov S, et al. Double-blind antigluocorticoid treatment in schizophrenia and schizoaffective disorder: a pilot study. *World J Biol Psychiatry* 2002;3(3):156-61. PMID:12478881
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychopharm* 2008;28(2):156-65. PMID:18344725
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Marcus SC, Hassan M, Olfson M. Antidepressant switching among adherent patients treated for depression. *Psychiatr Serv* 2009;60(5):617-23. PMID:19411348
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Markopoulou K, Papadopoulos A, Juruena MF, et al. The ratio of cortisol/DHEA in treatment resistant depression. *Psychoneuroendocrinology* 2009;34(1):19-26. PMID:18805642
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Markowitz JC, Kocsis JH, Bleiberg KL, et al. A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. *J Affect Disord* 2005;89(1-3):167-75. PMID:16263177
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Markowitz JC, Spielman LA, Sullivan M, et al. An exploratory study of ethnicity and psychotherapy outcome among HIV-positive patients with depressive symptoms. *J Psychother Pract Res* 2000;9(4):226-31.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. *Arch Gen Psychiatry* 1998;55(5):452-7. PMID:9596048
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Markowitz JC, Kocsis JH, Christos P, et al. Pilot study of interpersonal psychotherapy versus supportive psychotherapy for dysthymic patients with secondary alcohol abuse or dependence. *J Nerv Ment Dis* 2008;196(6):468-74.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

- Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. *Arch Gen Psychiatry* 1998;55(5):452-7.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Marks IM, Mataix-Cols D, Kenwright M, et al. Pragmatic evaluation of computer-aided self-help for anxiety and depression. *Br J Psychiatry* 2003;183(7):57-65.
Exclude: For study design, OVID-Embase.
- Marmar CR, Gaston L, Gallagher D, et al. Alliance and outcome in late-life depression. *J Nerv Ment Dis* 1989;177(8):464-72.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Maron E, Eller T, Vasar V, et al. Effects of bupropion augmentation in escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study. *J Clin Psychiatry* 2009;70(7):1054-6. PMID:19653982
Exclude: For study design, OVID-Medline.
- Marquez-Gonzalez M, Losada A, Izal M, et al. Modification of dysfunctional thoughts about caregiving in dementia family caregivers: description and outcomes of an intervention programme. *AGING MENT HEALTH* 2007;11(6):616-25. PMID:18074249
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Marriott M, Kellett S. Evaluating a cognitive analytic therapy service; practice-based outcomes and comparisons with person-centred and cognitive-behavioural therapies. *Psychology & Psychotherapy: Theory, Research & Practice* 2009;82(Pt:1):1-72. PMID:18759998
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Marsden CA, Tyrer P, Casey P, et al. Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. *J Psychopharmacol* 1987;1(4):244-50.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Marshall TK, Mazie AS. A cognitive approach to treating depression. *Social Casework* 1987;68(9):540-5.
Exclude: For study design, OVID-PsycINFO.
- Martin E, Martin S. IPT for treatment-resistant depression. In *Cochrane* 2006. **Exclude:** For study design, Wiley-CCTR.
- Martin LM, Fleming KC, Evans JM. Recognition and management of anxiety and depression in elderly patients. *Mayo Clinic Proceedings* 1995;70(10):999-1006.
Exclude: For systematic review before 2005, OVID-Embase.
- Martinsen EW, Hoffart A, Solberg O. Comparing aerobic with nonaerobic forms of exercise in the treatment of clinical depression: A randomized trial. *Comp Psychiatry* 1989;30(4):324-31.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Martinsen EW, Medhus A, Sandvik L. Effects of aerobic exercise on depression: A controlled study. *BMJ* 1985;291(6488):109
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
- OVID-Embase.
- Martinsen EW. Therapeutic implications of exercise for clinically anxious and depressed patients. *Int J Sport Psychol* 1993;24(2):185-99.
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Martiny K. Adjunctive bright light in non-seasonal major depression. . *Acta Psychiatrica Scandinavica, Supplementum* 2004;(425):7-28. PMID:15527426
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Martiny K, Lunde M, Unden M, et al. Adjunctive bright light in non-seasonal major depression: results from clinician-rated depression scales. *Acta Psychiatr Scand* 2005;112(2):117-25. PMID:15992393
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Martiny K, Lunde M, Unden M, et al. Adjunctive bright light in non-seasonal major depression: results from patient-reported symptom and well-being scales. *Acta Psychiatr Scand* 2005;111(6):453-9. PMID:15877712
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Martiny K, Lunde M, Unden M, et al. The lack of sustained effect of bright light, after discontinuation, in non-seasonal major depression. [erratum appears in *Psychol Med*. 2006 Sep;36(9):1336]. *Psychol Med* 2006;36(9):1247-52. PMID:16756691
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Masand P, Peindl K, Hooper-Wood C and others. A randomized, double-blind, placebo-controlled, flexible-dose trial of augmentation with OROS methylphenidate in treatment-resistant depression. In 2006. **Exclude:** For study design, Wiley-CCTR.
- Mason, R.A. Efficacy of prosocial behavior as an adjunct to short-term psychotherapy in treating clinically depressed college students Mason. 2004
Exclude: For study design, OVID-PsycINFO.
- Masuda A, Nakazato M, Kihara T, et al. Repeated thermal therapy diminishes appetite loss and subjective complaints in mildly depressed patients. *Psychosom Med* 2005;67(4):643-7.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Mathe G, Lopez MD, Frechet M, et al. A comparative trial of a MAOI, iproniazide, and a polycyclic agent, mianserine, for the search of the most rapidly and frequently active treatment of depressive syndromes in

- an oncology service. *Biomed Pharmacother* 1987;41(1):13-26. PMID:3300808
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mather AS, Rodriguez C, Guthrie MF, et al. Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder: randomised controlled trial. *Br J Psychiatry* 2002;180:411-5. PMID:11983637
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Matinsen EW, Medhus A. Adherence to exercise and patients' evaluation of physical exercise in a comprehensive treatment programme for depression. *Nordisk Psykiatrisk Tidsskrift* 1989;43(5):411-5.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Mattes JA. Pergolide to augment the effectiveness of antidepressants: clinical experience and a small double-blind study. *Ann Clin Psychiatry* 1997;9(2):87-8. PMID:9242894
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Mattingly G, Ilivicky H, Canale J and others. Quetiapine augmentation for treatment-resistant depression. In *Cochrane* 2006. **Exclude:** For study design, Wiley-CCTR.
- Matussek N, Angst J, Benkert O, et al. The effect of L-5-hydroxytryptophan alone and in combination with a decarboxylase inhibitor (Ro-4-4602) in depressive patients. *Adv Biochem Psychopharmacol* 1974;11(0):399-404.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Mayers AG, Baldwin DS, Dyson R, et al. Use of St. John's wort (*Hypericum perforatum* L) in members of a depression self-help organisation: A 12-week open prospective pilot study using the HADS scale. *Primary Care Psychiatry* 2003;9(1):15-20.
Exclude: For study design, OVID-Embase.
- Maynard CK. Comparison of effectiveness of group interventions for depression in women. *Arch Psychiatr Nurs* 1993;7(5):277-83.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Mayur PM, Gangadhar BN, Subbakrishna DK, et al. Discontinuation of antidepressant drugs during electroconvulsive therapy: a controlled study. *J Affect Disord* 2000;58(1):37-41. PMID:10760556
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mazeh D, Shahal B, Saraf R, et al. Venlafaxine for the treatment of depressive episode during the course of schizophrenia. *J Clin Psychopharm* 2004;24(6):653-5.
Exclude: For study design, OVID-Embase.
- Mbaya P. Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression. *Hum Psychopharmacol* 2002;17(7):335-9. PMID:12415551
Exclude: For study design, OVID-Medline.
- McCabe MP, McGillivray JA, Newton DC. Effectiveness of treatment programmes for depression among adults with mild/moderate intellectual disability. *J Intellect Disabil Res* 2006;50(Pt:4):4-47. PMID:16507028
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- McCaffrey R. The effect of healing gardens and art therapy on older adults with mild to moderate depression. *Holistic Nurs Pract* 2007;21(2):79-84.
Exclude: For study design, EBSCO-CINAHL.
- McCann IL, Holmes DS. Influence of aerobic exercise on depression. *J Pers Soc Psychol* 1984;46(5):1142-7.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Mcclanahan, T.M. A comparative evaluation of cognitive-behavioral therapy and insight-oriented psychotherapy in the treatment of comorbid substance abuse, anxiety, and depression in substance abusing females 2001
Exclude: For study design, OVID-PsycINFO.
- McClellan JM, Werry JS. Evidence-based treatments in child and adolescent psychiatry: an inventory. [Review] [187 refs]. *J Am Acad Child Adolesc Psychiatry* 2003;42(12):1388-400. PMID:14627873
Exclude: For systematic review before 2005, OVID-Medline.
- McClermon FJ, Hiott FB, Westman EC, et al. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. *Psychopharmacology* 2006;189(1):125-33. PMID:16977477
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- McCrone P, Knapp M, Proudfoot J, et al. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. *Br J Psychiatry* 2004;185:55-62. PMID:15231556
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- McCue RE, Aronowitz J. Accelerated antidepressant response in geriatric inpatients. *Am J Geriatr Psychiatry* 1994;2(3):244-6.
Exclude: For study design, OVID-Embase.
- McCusker J, Cole M, Keller E, et al. Effectiveness of treatments of depression in older ambulatory patients. *Arch Intern Med* 1998;158(7):705-12. PMID:9554676
Exclude: For systematic review before 2005, OVID-Medline.
- McCusker J, Cole M, Yaffe M, et al. Project direct: Pilot study of a collaborative intervention for depressed seniors. *Can J Community Ment Health* 2008;27(2):201-18.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

- McDowell DM, Levin FR, Seracini AM, et al. Venlafaxine treatment of cocaine abusers with depressive disorders. *Am J Drug Alcohol Abuse* 2000;26(1):25-31. PMID:10718161
Exclude: For study design, OVID-Medline.
- McEnany GW, Lee KA. Effects of light therapy on sleep, mood, and temperature in women with nonseasonal major depression. *Issues Ment Health Nurs* 2005;26(7):781-94. PMID:16126652
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- McEvoy PM, Nathan P. Effectiveness of cognitive behavior therapy for diagnostically heterogeneous groups: a benchmarking study. *J Consult Clin Psychol* 2007;75(2):344-50. PMID:17469892
Exclude: For study design, OVID-Medline.
- McGillivray JA, McCabe MP, Kershaw MM. Depression in people with intellectual disability: an evaluation of a staff-administered treatment program. *Res Dev Disabil* 2008;29(6):524-36. PMID:17981010
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- McGillivray JA, McCabe MP, Kershaw MM. Depression in people with intellectual disability: An evaluation of a staff-administered treatment program. *Res Dev Disabil* 2008;29(6):524-36.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. *Am J Psychiatry* 1993;150(1):118-23. PMID:8417553
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- McGrath PJ, Khan AY, Trivedi MH, et al. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. *J Clin Psychiatry* 2008;69(12):1847-55. PMID:19026268
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- McGrath PJ, Stewart JW, Harrison W, et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. *Psychopharmacol Bull* 1987;23(1):169-72.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- McGrath PJ, Stewart JW, Nunes EN, et al. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant. *J Clin Psychiatry* 1994;55(8):336-9. PMID:8071301
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. *Depress Anxiety* 2007;24(7):487-94. PMID:17177199
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- McIntyre RS, O'Donovan C. The human cost of not achieving full remission in depression. *Can J Psychiatry* 2004;49(3:Suppl 1):Suppl-16S
PMID:15147032
Exclude: For systematic review before 2005, OVID-Medline.
- McKnight DL, Nelson RO, Hayes SC, et al. Importance of treating individually assessed response classes in the amelioration of depression. *Behav Ther* 1984;15(4):315-35.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
- McLean P, Taylor S. Severity of unipolar depression and choice of treatment. *Behav Res Ther* 1992;30(5):443-51. PMID:1520230
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- McLean PD, Hakstian AR. Clinical depression: comparative efficacy of outpatient treatments. *J Consult Clin Psychol* 1979;47(5):818-36.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- McLean PD, Hakstian AR. Relative endurance of unipolar depression treatment effects: longitudinal follow-up. *J Consult Clin Psychol* 1990;58(4):482-8. PMID:2212186
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. *Am J Hum Genet* 2006;78(5):804-14. PMID:16642436
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- McMahon L, Foran KM, Forrest SD, et al. Graduate mental health worker case management of depression in UK primary care: A pilot study. *British Journal of General Practice* 2007;57(544):880-5.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- McNamara K, Horan JJ. Experimental construct validity in the evaluation of cognitive and behavioral treatments for depression. *Journal of Counseling Psychology* 1986;33(1):23-30.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- McNeil JK, LeBlanc EM, Joyner M. The effect of exercise on depressive symptoms in the moderately depressed elderly. *Psychol Aging* 1991;6(3):487-8.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- McPherson S, Walker C, Caryle JA. Primary care counsellors' experiences of working with treatment resistant depression: A qualitative pilot study. *Counsel PsychotherRes* 2006;6(4):250-7.
Exclude: For study design, OVID-PsycINFO.

- McShane G, Mihalich M, Walter G, et al. Outcome of patients with unipolar, bipolar and psychotic disorders admitted to a specialist child and adolescent mental health service. *Australas Psychiatry* 2006;14(2):198-201. PMID:16734650
Exclude: For study design, OVID-Medline.
- Mead N, MacDonald W, Bower P, et al. The clinical effectiveness of guided self-help versus waiting-list control in the management of anxiety and depression: A randomized controlled trial. *Psychol Med* 2005;35(11):1633-43.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Means KM, O'Sullivan PS, Rodell DE. Psychosocial effects of an exercise program in older persons who fall. *Journal of Rehabilitation Research and Development* 2003;40(1):49-58.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Medhus A, Heskestad S, Tjemsland L. Mianserin added to tricyclic antidepressants in depressed patients not responding to a tricyclic antidepressant alone: A randomized, placebo-controlled, double-blind study. *Nord J Psychiatry* 1994;48(5):355-8.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Meeks S, Looney SW, Van Haitsma K, et al. BE-ACTIV: a staff-assisted behavioral intervention for depression in nursing homes. *Gerontologist* 2008;48(1):105-14. PMID:18381837
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mehdi PR, Sen AK, Sen Mazumdar DP. The usefulness of psychodrama in the treatment of depressed patients. *Indian J Clin Psychol* 1997;24(1):82-92.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Meier RM. Group treatment of depression and withdrawal at a day-treatment center. *Int J Partial Hosp* 1982;1(4):349-53.
Exclude: For study design, OVID-PsycINFO.
- Melvin GA, Tonge BJ, King NJ, et al. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. *J Am Acad Child Adolesc Psychiatry* 2006;45(10):1151-61. PMID:17003660
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mendels J, Stinnett JL, Burns D, et al. Amine precursors and depression. *Arch Gen Psychiatry* 1975;32(1):22-30.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Mendes De Leon CF, Czajkowski SM, Freedland KE, et al. The effect of a psychosocial intervention and quality of life after acute myocardial infarction: The Enhancing Recovery in Coronary Heart Disease (ENRICH) clinical trial. *J Cardiopulm Rehabil* 2006;26(1):9-15.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Mendez Carrillo FX, Moreno PJ, Sanchez-Meca J, et al. Effectiveness of psychological treatment for child and adolescent depression: A qualitative review of two decades of research. *Psicologia Conductual* 2000;8(3):487-510.
Exclude: For systematic review before 2005, OVID-Embase.
- Mendlewicz J, Youdim MB. Antidepressant potentiation of 5-hydroxytryptophan by L-deprenil in affective illness. *J Affect Disord* 1980;2(2):137-46. PMID:6448885
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mendlewicz J, Kriwin P, Oswald P, et al. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. *Int Clin Psychopharmacol* 2006;21(4):227-31. PMID:16687994
Exclude: For study design, OVID-Medline.
- Mendlowitz SL, Manassis K, Bradley S, et al. Cognitive-behavioral group treatments in childhood anxiety disorders: the role of parental involvement. *J Am Acad Child Adolesc Psychiatry* 1999;38(10):1223-9.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Mendoza RJ, Pittenger DJ, Weinstein CS. Unit management of depression of patients with multiple sclerosis using cognitive remediation strategies: a preliminary study. *Neurorehabil Neural Repair* 2001;15(1):9-14. PMID:11527284
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Merrill KA, Tolbert VE, Wade WA. Effectiveness of cognitive therapy for depression in a community mental health center: a benchmarking study. *J Consult Clin Psychol* 2003;71(2):404-9. PMID:12699035
Exclude: For study design, OVID-Medline.
- Merrill RM, Taylor P, Aldana SG. Coronary Health Improvement Project (CHIP) is associated with improved nutrient intake and decreased depression. *Nutrition* 2008;24(4):314-21. PMID:18296026
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Meyer B, Berger T, Caspar F, et al. Effectiveness of a novel integrative online treatment for depression (Deprexis): randomized controlled trial. *J Med Internet Res* 2009;11(2):e15. PMID:19632969
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Michael KD, Crowley SL. How effective are treatments for child and adolescent depression? A meta-analytic review. *Clinical Psychology Review* 2002;22(2):247-69.
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Milak MS, Parsey RV, Lee L, et al. Pretreatment regional brain glucose uptake in the midbrain on PET

- may predict remission from a major depressive episode after three months of treatment. *Psychiatry Res* 2009;173(1):63-70. PMID:19446443
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Milani RV, Lavie CJ, Cassidy MM. Effects of cardiac rehabilitation and exercise training programs on depression in patients after major coronary events. *Am Heart J* 1996;132(4):726-32. PMID:8831359
Exclude: For study design, OVID-Medline.
- Milani RV, Lavie CJ. Impact of Cardiac Rehabilitation on Depression and Its Associated Mortality. *Am J Med* 2007;120(9):799-806.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Miljkovic BR, Pokrajac M, Timotijevic I, et al. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy. *Int Clin Psychopharmacol* 1997;12(4):207-12. PMID:9347381
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Miller FE. Strategies for the rapid treatment of depression. *Hum Psychopharmacol* 2001;16(2):125-32.
Exclude: For systematic review before 2005, OVID-Embase.
- Miller IW, Norman WH, Keitner GI. Cognitive-behavioral treatment of depressed inpatients: Six- and twelve-month follow-up. *Am J Psychiatry* 1989;146(10):1274-9.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Miller IW, Norman WH, Keitner GI, et al. Cognitive-behavioral treatment of depressed inpatients. *Behav Ther* 1989;20(1):25-47.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Miller IW, Bishop SB, Norman WH, et al. Cognitive/behavioural therapy and pharmacotherapy with chronic, drug-refractory depressed inpatients: A note of optimism. *Behavioural Psychotherapy* 1985;13(4):320-7.
Exclude: For study design, OVID-Embase
- OVID-Embase.
- Miller IW, Norman WH, Keitner GI. Combined treatment for patients with double depression. *Psychother Psychosom* 1999;68(4):180-5.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Miller IW, Keitner GI, Ryan CE, et al. Treatment matching in the posthospital care of depressed patients. *Am J Psychiatry* 2005;162(11):2131-8. PMID:16263854
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Miller IW, Norman WH, Keitner GI. Treatment response of high cognitive dysfunction depressed inpatients. *Comp Psychiatry* 1990;31(1):62-71. PMID:2404660
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Miller MD, Pollock BG, Rifai AH, et al. Longitudinal analysis of nortriptyline side effects in elderly depressed patients. *J Geriatr Psychiatry Neurol* 1991;4(4):226-30. PMID:1789911
Exclude: For study design, OVID-Medline.
- Miller MD, Paradis CF, Houck PR, et al. Chronic medical illness in patients with recurrent major depression. *The Am J Geriatr Psychiatry* 1996;4(4):281-90.
Exclude: For study design, OVID-PsycINFO.
- Mindham R H. Continuation therapy with tricyclic antidepressants in relapsing depressive illness. In 1981. p.49-55.**Exclude:** For study design, Wiley-CCTR.
- Mino Y, Babazono A, Tsuda T, et al. Can stress management at the workplace prevent depression? A randomized controlled trial. *Psychother Psychosom* 2006;75(3):177-82. PMID:16636633
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Miranda J, Munoz R. Intervention for minor depression in primary care patients. *Psychosom Med* 1994;56(2):136-41. PMID:8008800
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Miranda J, Green BL, Krupnick JL, et al. One-year outcomes of a randomized clinical trial treating depression in low-income minority women. *J Consult Clin Psychol* 2006;74(1):99-111. PMID:16551147
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Miranda J, Chung JY, Green BL, et al. Treating depression in predominantly low-income young minority women: a randomized controlled trial. *JAMA* 2003;290(1):57-65. PMID:12837712
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Miranda J, Azocar F, Organista KC, et al. Treatment of depression among impoverished primary care patients from ethnic minority groups. *Psychiatr Serv* 2003;54(2):219-25. PMID:12556604
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Miranda VC, Trufelli DC, Santos J, et al. Effectiveness of guaraní (Paullinia cupana) for postradiation fatigue and depression: results of a pilot double-blind randomized study. *J Altern Complement Med* 2009;15(4):431-3. **Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Mischoulon D, Best-Popescu C, Laposata M, et al. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. *European Neuropsychopharmacol* 2008;18(9):639-45. PMID:18539007
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Mischoulon D, Best-Popescu C, Laposata M, et al. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. *Eur Neuropsychopharmacol* 2008;18(9):639-45.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Mischoulon D, Opitz G, Kelly K, et al. A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment. *Depress Anxiety* 2004;19(1):43-50. PMID:14978785
Exclude: For study design, OVID-Medline.
- Miser WF. Exercise as an effective treatment option for major depression in older adults. *J Fam Prac* 2000;49(2):109-10. PMID:10718684
Exclude: For study design, OVID-Medline.
- Mishra M, Sinha RK. Effect of yogic practices on depression and anxiety. *Journal of Projective Psychology & Mental Health* 2001;8(1):23-7.
Exclude: For study design, OVID-PscINFO.
- Mitchell N, Dunn K. Pragmatic evaluation of the viability of CCBT self-help for depression in higher education. *Counsel Psychother Res* 2007;7(3):144-50.
Exclude: For study design, OVID-PscINFO.
- Mitchell PB, Schweitzer I, Burrows G, et al. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. *J Clin Psychopharm* 2000;20(4):483-7. PMID:10917411
Exclude: For study design, OVID-Medline.
- Mitchell PH, Veith RC, Becker KJ, et al. Brief psychosocial-behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial. *Stroke* (00392499) 2009;40(9):3073-8. PMID:19661478
Exclude: For population/diagnosis, OVID-Medline.
- Mitchell PH, Teri L, Veith R, et al. Living well with stroke: design and methods for a randomized controlled trial of a psychosocial behavioral intervention for poststroke depression. *J Stroke Cerebrovasc Dis* 2008;17(3):109-15. PMID:18436150
Exclude: For population/diagnosis, OVID-Medline.
- Mitchell P. The pharmacological treatment of tricyclic-resistant depression: Review and management guidelines. *Aust N Z J Psychiatry* 1987;21(4):442-51.
Exclude: For Guideline published before 2005, OVID-PscINFO.
- Mittelman MS, Brodaty H, Wallen AS, et al. A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression. *Am J Geriatr Psychiatry* 2008;16(11):893-904.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Miyasaki JM, Shannon K, Voon V, et al. Appendix F: Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (evidenced-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Continuum Lifelong Learning in Neurology* 2007;13(1):193-9.
Exclude: For guideline, not a population of interest, OVID-Embase.
- Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2006;66(7):996-1002. PMID:16606910
Exclude: For Guideline focus on diagnosis or screening rather than treatment, OVID-Medline.
- Moak DH, Anton RF, Latham PK, et al. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. *J Clin Psychopharm* 2003;23(6):553-62. PMID:14624185
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. *J Consult Clin Psychol* 2001;69(6):942-9. PMID:11777121
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mohr DC, Likosky W, Bertagnolli A, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. *J Consult Clin Psychol* 2000;68(2):356-61. PMID:10780138
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mohr DC, Hart SL, Julian L, et al. Telephone-administered psychotherapy for depression. *Arch Gen Psychiatry* 2005;62(9):1007-14. PMID:16143732
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mohr DC, Hart SL, Marmar C. Telephone administered cognitive-behavioral therapy for the treatment of depression in a rural primary care clinic. *Cogn Ther Res* 2006;30(1):29-37.
Exclude: For study design, OVID-Embase.
- Moldenhauer, Z. Adolescent depression: A primary care pilot intervention study Moldenhauer. 2004
Exclude: For study design, OVID-PscINFO.
- Moleiro C, Beutler LE. Clinically significant change in psychotherapy for depressive disorders. *J Affect Disord* 2009;115(1-2):220-4.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Molenaar PJ, Dekker J, Van R, et al. Does adding psychotherapy to pharmacotherapy improve social

- functioning in the treatment of outpatient depression? *Depress Anxiety* 2007;24(8):553-62. PMID:17131302
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Moller HJ, Bottlender R, Grunze H, et al. Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? *J Affect Disord* 2001;67(1-3):141-6. PMID:11869761
Exclude: For study design, OVID-Medline.
- Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression.[update of *Cochrane Database Syst Rev.* 2001;(2):CD003012; PMID: 11406060]. *Cochrane Database of Systematic Reviews* 2004;(1):CD003012 PMID:14974002
Exclude: For systematic review before 2005, OVID-Medline.
- Moncrieff J, Wessely S, Hardy R. Antidepressants using active placebos.[update in *Cochrane Database Syst Rev.* 2004;(1):CD003012; PMID: 14974002]. *Cochrane Database of Systematic Reviews* 2001;(2):CD003012 PMID:11406060
Exclude: For systematic review before 2005, OVID-Medline.
- Montes JM, Ferrando L, Saiz-Ruiz J. Remission in major depression with two antidepressant mechanisms: results from a naturalistic study. *J Affect Disord* 2004;79(1-3):229-34. PMID:15023499
Exclude: For study design, OVID-Medline.
- Montgomery SA, Djarv L. The antidepressant efficacy of citalopram. *Int Clin Psychopharmacol* 1996;11:Suppl-33 PMID:8732442
Exclude: For systematic review before 2005, OVID-Medline.
- Montoya A, Weiss AP, Price BH, et al. Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease. *Neurosurgery* 1049;50(5):1043-9. PMID:11950407
Exclude: For study design, OVID-Medline.
- Moore, J.D. The effectiveness of bright light treatment on depression in an HIV population. 2009
Exclude: For study design, OVID-PsycINFO.
- Moore RG, Blackburn I-M. Cognitive therapy in the treatment of non-responders to antidepressant medication: A controlled pilot study. *Behav Cogn Psychother* 1997;25(3):251-9.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.
- Moorey S, Cort E, Kapari M, et al. A cluster randomized controlled trial of cognitive behaviour therapy for common mental disorders in patients with advanced cancer. *Psychol Med* 2009;39(5):713-23. PMID:18761755
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Moreno FA, Gelenberg AJ, Bachar K, et al. Pindolol augmentation of treatment-resistant depressed patients. *J Clin Psychiatry* 1997;58(10):437-9. PMID:9375594
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Moreno RA, Teng CT, Almeida KM, et al. *Hypericum perforatum* versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. *Revista Brasileira de Psiquiatria* 2006;28(1):29-32. PMID:16612487
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Moreno R, Cunningham AC, Gatchel RJ, et al. Functional restoration for chronic low back pain: Changes in depression, cognitive distortion, and disability. *Journal of Occupational Rehabilitation* 1991;1(3):207-16.
Exclude: For study design, OVID-PsycINFO.
- Morgan ML, Cook IA, Rapkin AJ, et al. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. *J Clin Psychiatry* 2005;66(6):774-80. PMID:15960574
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Morgan ML, Cook IA, Rapkin AJ, et al. Neurophysiologic changes during estrogen augmentation in perimenopausal depression. *Maturitas* 2007;56(1):54-60. PMID:16835012
Exclude: For study design, OVID-Medline.
- Morishita S, Sawamura J, Ishigooka J. Characteristics associated with response to clonazepam augmentation therapy in patients with protracted depression. *Int Med J* 2009;16(1):9-12.
Exclude: For study design, OVID-Embase.
- Morishita S, Aoki S. Clonazepam augmentation of antidepressants: does it distinguish unipolar from bipolar depression? *J Affect Disord* 2002;71(1-3):217-20. PMID:12167520
Exclude: For study design, OVID-Medline.
- Morishita S, Arita S. Clonazepam augmentation of antidepressants: Which is the suitable combined antidepressant? *Int Med J* 2007;14(3):195-7.
Exclude: For study design, OVID-Embase.
- Morishita S, Aoki S. Clonazepam in the treatment of prolonged depression. *J Affect Disord* 1999;53(3):275-8. PMID:10404714
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Morishita S, Arita S. Possible predictors of response to clonazepam augmentation therapy in patients with protracted depression. *Hum Psychopharmacol* 2007;22(1):27-31. PMID:17191267
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Morishita S, Arita S. Prophylactic effect of clonazepam augmentation on protracted depression as a mood stabilizer. *Int Med J* 2002;9(4):261-4.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Morishita S, Arita S. Response period of combined fluvoxamine and milnacipran treatment for depression.

- Int Med J 2005;12(1):25-6.
Exclude: For study design, OVID-Embase.
- Morishita S, Arita S. The Period of Onset of Action of Clonazepam Augmentation as a Mood Stabilizer for Protracted Depression. *Int Med J* 2003;10(1):3-6.
Exclude: For study design, OVID-PsycINFO.
- Morris RG, Morris LW. Cognitive and behavioural approaches with the depressed elderly. *Int J Geriatr Psychiatry* 1991;6(6):407-13.
Exclude: For study design, OVID-Embase
OVID-Embase.
- Moscovici L, Kotler M. A multistage chronobiologic intervention for the treatment of depression: a pilot study. *J Affect Disord* 2009;116(3):201-7.
PMID:19232745
Exclude: For study design, OVID-Medline.
- Moshiri E, Basti AA, Noorbala AA, et al. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. *Phytomedicine* 2006;13(9-10):607-11. PMID:16979327
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Motl RW, Konopack JF, McAuley E, et al. Depressive symptoms among older adults: Long-term reduction after a physical activity intervention. *J Behav Med* 2005;28(4):385-94.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Mow KE. Treatment of psychoneurosis and depression with medical hypnoanalysis: San Antonio Conference September 22-25, 1994. *Medical Hypnoanalysis Journal* 1994;9(4):167-76.
Exclude: For study design, OVID-AMED.
- Möller HJ, Kissling W, Herberger B, et al. Controlled trial on the possible advantages of a combined therapy with maprotiline and haloperidol in endogenous depression. *Pharmacopsychiatry* 1986;19(5):362-4.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Mueller BM. St. John's Wort for depressive disorders: results of an outpatient study with the Hypericum preparation HYP 811. *Advances in Therapy* 1998;15(2):109-16. PMID:10180997
Exclude: For study design, OVID-Medline.
- Mulcahy, K.A. Beck's cognitive therapy and aerobic exercise for the treatment of depression Mulcahy. 1998
Exclude: For study design, OVID-PsycINFO.
- Mulder RT, Joyce PR, Frampton CM, et al. Antidepressant treatment is associated with a reduction in suicidal ideation and suicide attempts. *Acta Psychiatr Scand* 2008;118(2):116-22.
PMID:18384467
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Muller-Oerlinghausen B, Rao ML, Stieglitz RD, et al. Fluvoxamine challenge test, phototherapy, and successive fluvoxamine treatment in patients with non-seasonal depression. *Pharmacopsychiatry* 1989;22(5):209-10.
Exclude: For study design, OVID-Embase.
- Muller-Siecheneder F, Muller MJ, Hillert A, et al. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. *J Clin Psychopharm* 1998;18(2):111-20. PMID:9555596
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Muller D, Pfeil T, von dD, V. Treating depression comorbid with anxiety--results of an open, practice-oriented study with St John's wort WS 5572 and valerian extract in high doses. *Phytomedicine* 2003;10:Suppl-30 PMID:12807339
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Muller MJ, Seifritz E, Hatzinger M, et al. Side effects of adjunct light therapy in patients with major depression. *Eur Arch Psychiatry Clin Neurosci* 1997;247(5):252-8. PMID:9444494
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Mulrow CD, Williams JW, Jr., Trivedi M, et al. Evidence report on: Treatment of depression - Newer pharmacotherapies. *Psychopharmacol Bull* 1998;34(4):409-795.
Exclude: For systematic review before 2005, OVID-Embase.
- Mulrow CD, Williams JW, Jr., Trivedi M, et al. Treatment of depression--newer pharmacotherapies. *Psychopharmacol Bull* 1998;34(4):409-795.
PMID:10513454
Exclude: For systematic review before 2005, OVID-Medline.
- Mulsant BH, Alexopoulos GS, Reynolds CF, III, et al. Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. *Int J Geriatr Psychiatry* 2001;16(6):585-92.
PMID:11424167
Exclude: For Guideline published before 2005, OVID-Medline.
- Murck H, Fava M, Alpert J, et al. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. *Int J Neuropsychopharmacol* 2005;8(2):215-21.
PMID:15458612
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Murck H, Held K, Ziegenbein M, et al. Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. *Psychoneuroendocrinology* 2004;29(9):1205-11.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Muris P, Bogie N, Hoogsteder A. Effects of an early intervention group program for anxious and depressed adolescents: a pilot study. *Psychol Rep* 2001;88(2):481-2. PMID:11351893
Exclude: For study design, OVID-Medline.

- Murphy BE, Dhar V, Ghadirian AM, et al. Response to steroid suppression in major depression resistant to antidepressant therapy. *J Clin Psychopharm* 1991;11(2):121-6. PMID:1829098
Exclude: For study design, OVID-Medline.
- Murphy BE, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU 486. *J Psychiatry Neurosci* 1993;18(5):209-13.
Exclude: For study design, OVID-PsycINFO.
- Murphy BP, Dhar V, Ghadirian AM, et al. Response to steroid suppression in major depression resistant to antidepressant therapy. *J Clin Psychopharm* 1991;11(2):121-6.
Exclude: For study design, OVID-PsycINFO.
- Murphy DL, Baker M, Goodwin FK, et al. L-tryptophan in affective disorders: indoleamine changes and differential clinical effects. *Psychopharmacologia* 1974;34(1):11-20.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Murphy GE, Carney RM, Knesevich MA, et al. Cognitive behavior therapy, relaxation training, and tricyclic antidepressant medication in the treatment of depression. *Psychol Rep* 1995;77(2):403-20. PMID:8559866
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Murphy GE, Simons AD, Wetzel RD, et al. Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression. *Arch Gen Psychiatry* 1984;41(1):33-41.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
- OVID-Embase.
- Muscettola G, Galzenati M, Balbi A. SAME versus placebo: a double blind comparison in major depressive disorders. *Adv Biochem Psychopharmacol* 1982;32:151-6. PMID:7046362
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: Epidemiology, biology, and treatment. *Biol Psychiatry* 2003;54(3):317-29.
Exclude: For systematic review before 2005, OVID-Embase.
- Mussini M, Agricola R, Coletti MG, et al. A preliminary study on the use of calcitonin in clinical psychopathology. *J Int Med Res* 1984;12(1):23-9. PMID:6141115
Exclude: For study design, OVID-Medline.
- Müller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. *Molecular Psychiatry* 2006;11(7):680-4.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Mynatt S, Wicks M, Bolden L. Pilot study of INSIGHT therapy in African American women. *Arch Psychiatr Nurs* 2008;22(6):364-74. PMID:19026925
Exclude: For study design, OVID-Medline.
- Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, et al. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. *BMJ* 1995;310(6977):441-5.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Mynors-Wallis LM, Gath DH, Day A, et al. Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. *BMJ* 2000;320(7226):26-30. PMID:10617523
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Myskja A, Nord PG. "The day the music died": a pilot study on music and depression in a nursing home. *Nordic J Music Ther* 2008;17(1):30-40.
Exclude: For study design, EBSCO-CINAHL.
- Nabkasorn C, Miyai N, Sootmongkol A, et al. Effects of physical exercise on depression, neuroendocrine stress hormones and physiological fitness in adolescent females with depressive symptoms. *Eur J Public Health* 2006;16(2):179-84.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Nagata H, Nozaki M, Nakano H. Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies. *J Obstet Gynaecol Res* 2005;31(2):107-14. PMID:15771635
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Nahas Z, Kunik ME, Orengo CA, et al. Depression in male geropsychiatric inpatients with and without dementia: a naturalistic study. *J Affect Disord* 1997;46(3):243-6. PMID:9547120
Exclude: For study design, OVID-Medline.
- Nahunek K, Svestka J, Rysanek R, et al. Full therapeutic success of repeated treatment in most "drug resistant" cases of endogenous depression. *Acta Nerv Super* 1986;28(4):302-3.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Nahunek K, Svestka J, Rysanek R, et al. Further clinical experience with maprotiline in endogenous depressions. *Acta Nerv Super* 1981;23(3):214-5.
Exclude: For study design, OVID-PsycINFO.
- Nakajima S, Ishida T, Akaishi R, et al. Impacts of switching antidepressants after successful electroconvulsive therapy on the maintenance of clinical remission in patients with treatment-resistant depression: A chart review. *Journal of ECT* 2009;25(3):178-81.
Exclude: For study design, OVID-Embase.

- Nalini NR, Kumaraiah V, Subbakrishna DK. Cognitive behaviour therapy in the treatment of neurotic depression. *Nimhans Journal* 1996;14(1):31-5.
Exclude: For study design, OVID-PsycINFO.
- Nangia M, Syed W, Doraiswamy PM. Efficacy and safety of St. John's wort for the treatment of major depression. [Review] [52 refs]. *Public Health Nutr* 2000;3(4A):487-94. PMID:11276296
Exclude: For systematic review before 2005, OVID-Medline.
- Nardini M, De Stefano R, Iannuccelli M, et al. Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study. *Int J Clin Pharmacol Res* 1983;3(4):239-50. PMID:6381336
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- National clinical practice, guideline. Depression: Management of depression in primary and secondary care. national clinical practice guideline number 23 2009;23:1-363.
Exclude: For Guideline published before 2005.
- Naylor EV, Antonuccio DO, Johnson G, et al. A pilot study investigating behavioral prescriptions for depression. *J Clin Psych in Medical Settings* 2007;14(2):152-9.
Exclude: For study design, OVID-Embase.
- Naylor,E.V. A five-minute bibliotherapy prescription as a physician-delivered treatment for depression Naylor. 2008
Exclude: For study design, OVID-PsycINFO.
- Neidig,J.L. Aerobic exercise training: effects on depressive symptoms in HIV-infected adults Ohio State University. 1998
Exclude: For study design, EBSCO-CINAHL.
- Neidig JL, Smith BA, Brashers DE. Aerobic exercise training for depressive symptom management in adults living with HIV infection. *J Assoc Nurses AIDS Care* 2003;14(2):30-40. PMID:12698764
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Neimeyer RA, Baker KD, Haykal RF, et al. Patterns of symptomatic change in depressed patients in a private inpatient mood disorders program. *Bulletin of the Menninger Clinic* 1995;59(4):460-71. PMID:8535385
Exclude: For study design, OVID-Medline.
- Nelson-Gray RO, Herbert JD, Herbert DL, et al. Effectiveness of matched, mismatched, and package treatments of depression. *J Behav Ther Exp Psychiatry* 1989;20(4):281-94. PMID:2636233
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Nelson EL, Barnard M, Cain S. Treating childhood depression over videoconferencing. *Telemedicine Journal & E-Health* 2003;9(1):49-55. PMID:12699607
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Nelson,E.L. Cognitive behavioral therapy for childhood depression: A comparison of face-to-face and interactive televideo settings Nelson. 2004
Exclude: For study design, OVID-PsycINFO.
- Nelson EL, Barnard M, Cain S. Feasibility of telemedicine intervention for childhood depression. *Counsel Psychother Res* 2006;6(3):191-5.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Nelson JC, Mazure CM, Bowers MB, Jr., et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. *Arch Gen Psychiatry* 1991;48(4):303-7. PMID:2009031
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Nelson JC, Docherty JP, Henschen GM, et al. C. Algorithms for the treatment of subtypes of unipolar major depression. *Psychopharmacol Bull* 1995;31(3):475-83.
Exclude: For study design, OVID-Embase.
- Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. *Biol Psychiatry* 2004;55(3):296-300. PMID:14744472
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Nelson JC, Jatlow P, Quinlan DM, et al. Desipramine plasma concentration and antidepressant response. *Arch Gen Psychiatry* 1982;39(12):1419-22. PMID:7149903
Exclude: For study design, OVID-Medline.
- Nelson JC, Mazure CM, Jatlow PI. Desipramine treatment of major depression in patients over 75 years of age. *J Clin Psychopharm* 1995;15(2):99-105. PMID:7782495
Exclude: For study design, OVID-Medline.
- Nelson,M.K. Meta-analysis: Hypnotherapy/cognitive-behavioral therapy and its efficacy on depression compared to pharmacotherapy Nelson. 2002
Exclude: For study design, OVID-PsycINFO.
- Nemeroff CB, Heim CM, Thase ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.[erratum appears in *Proc Natl Acad Sci U S A*. 2005 Nov 8;102(45):16530]. *Proc Natl Acad Sci U S A*. 2003;100(24):14293-6. PMID:14615578
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. *Am J Psychiatry* 2002;159(3):477-9. PMID:11870016
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Nemets H, Nemets B, Apter A, et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. *Am J Psychiatry*

- 2006;163(6):1098-100. PMID:16741212
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Neuberger GB, Aaronson LS, Gajewski B, et al. Predictors of exercise and effects of exercise on symptoms, function, aerobic fitness, and disease outcomes of rheumatoid arthritis. *Arthritis Rheum* 2007;57(6):943-52.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Neumeister A, Goessler R, Lucht M, et al. Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. *Biol Psychiatry* 1996;39(1):16-21. PMID:8719121
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Neumeister A, Praschak-Rieder N, Hesselmann B, et al. Effects of tryptophan depletion in drug-free depressed patients who responded to total sleep deprivation. *Arch Gen Psychiatry* 1998;55(2):167-72. PMID:9477931
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Nezu AM, Perri MG. Social problem-solving therapy for unipolar depression: An initial dismantling investigation. *J Consult Clin Psychol* 1989;57(3):408-13.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Nguyen, S.D. Simultaneous technique of exercise and psychotherapy (STEP) as an adjunct to multidisciplinary treatment in acute inpatient psychiatric hospitalized older adults with depressive symptoms. 2008
Exclude: For study design, OVID-PsycINFO.
- Nickel MK, Nickel C, Lahmann C, et al. Changes in instrumental activities of daily living disability after treatment of depressive symptoms in elderly women with chronic musculoskeletal pain: A double-blind, placebo-controlled trial. *Aging Clin Exp Res* 2005;17(4):293-6.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Nierenberg AA, Price LH, Charney DS, et al. After lithium augmentation: a retrospective follow-up of patients with antidepressant-refractory depression. *J Affect Disord* 1990;18(3):167-75. PMID:2139061
Exclude: For study design, OVID-Medline.
- Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. *J Clin Psychopharm* 2003;23(1):92-5. PMID:12544380
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. *J Clin Psychopharm* 1994;14(6):419-23. PMID:7884023
Exclude: For study design, OVID-Medline.
- Nilforooshan P, Ahmadi A, Abedi MR, et al. Studying the effect of cognitive-behavioral counseling based on interacting cognitive subsystems on depression of infertile couples. *Middle East Fertility Society Journal* 2006;11(1):43-7.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Ninan PT, Hassman HA, Glass SJ, et al. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. *J Clin Psychiatry* 2004;65(3):414-20. PMID:15096082
Exclude: For study design, OVID-Medline.
- Nisbet Wallis DA. Depression, anxiety and self-esteem: A clinical field study. *Behav Change* 2002;19(2):112-20.
Exclude: For study design, OVID-Embase.
- Nitkin-Kaner, Y. Relationships between expressive writing about traumatic events and reduction in depressive symptomatology Nitkin-Kaner. 2009
Exclude: For study design, OVID-PsycINFO.
- No ai. Adjunctive Aripiprazole Effective for Treatment-Resistant Depression. *Prim Psychiatry* 2005;12(1):19
Exclude: For study design, OVID-PsycINFO.
- No ai. Getting fitter, improving depression. *Journal of Sport & Exercise Psychology* 2008;30(3):435
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- No ai. The effect of sequential antidepressant treatment on geriatric depression: Erratum. *J Affect Disord* 1996;41(1):77
Exclude: For study design, OVID-PsycINFO.
- Nolen WA, Haffmans PMJ, Bouvy PF, et al. Hypnotics as concurrent medication in depression. A placebo-controlled, double-blind comparison of flunitrazepam and lormetazepam in patients with major depression, treated with a (tri)cyclic antidepressant. *J Affect Disord* 1993;28(3):179-88.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Nolen WA, van de Putte JJ, Dijken WA, et al. L-5HTP in depression resistant to re-uptake inhibitors. An open comparative study with tranlycypromine. *Br J Psychiatry* 1985;147:16-22. PMID:3933601
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Nolen WA, Haffmans PM, Bouvy PF, et al. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranlycypromine in patients resistant to tricyclic antidepressants. *J Affect Disord* 1993;28(3):189-97. PMID:8408980
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Nolen WA, Hoencamp E, Bouvy PF, et al. Reversible monoamine oxidase-A inhibitors in resistant major depression. *Clin Neuropharmacol* 1993;16(Suppl 2):1993, pp-1993,S76.

Exclude: For systematic review before 2005, OVID-PsycINFO.

Nolen WA. Tranylcypromine in depression resistant to cyclic antidepressants. *Prog Neuropsychopharmacol Biol Psychiatry* 1989;13(1-2):155-8. PMID:2664883

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. *Acta Psychiatr Scand* 1988;78(6):676-83. PMID:3146891

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. I. Non-tricyclic and selective reuptake inhibitors in resistant depression: a double-blind partial crossover study on the effects of oxaprotiline and fluvoxamine. *Acta Psychiatr Scand* 1988;78(6):668-75. PMID:3146890

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Noorbala AA, Ramazanzadeh F, Malekafzali H, et al. Effects of a psychological intervention on depression in infertile couples. *Int J Gynaecol Obstet* 2008;101(3):248-52. PMID:18321515

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, et al. Hydro-alcoholic extract of *Crocus sativus* L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. *J Ethnopharmacol* 2005;97(2):281-4. PMID:15707766

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Norman J, Lowry CE. Evaluating inpatient treatment for women with clinical depression. *Research on Social Work Practice* 1995;5(1):10-9.

Exclude: For study design, OVID-PsycINFO.

Normann C, Hummel B, Scharer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. *J Clin Psychiatry* 2002;63(4):337-44. PMID:12000208

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

North TC, McCullagh P, Tran ZV. Effect of exercise on depression. *Exerc Sport Sci Rev* 1990;18:379-415. PMID:2141567

Exclude: For systematic review before 2005, OVID-Medline.

Nowak G, Siwek M, Dudek D, et al. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. *Pol J Pharmacol* 2003;55(6):1143-7. PMID:14730113

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Nunes DF, Rodriguez AL, da Silva HF, et al. Relaxation and guided imagery program in patients

with breast cancer undergoing radiotherapy is not associated with neuroimmunomodulatory effects. *J Psychosom Res* 2007;63(6):647-55. PMID:18061756

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Nurnberg HG, Thompson PM, Hensley PL. Antidepressant medication change in a clinical treatment setting: A comparison of the effectiveness of selective serotonin reuptake inhibitors. *J Clin Psychiatry* 1999;60(9):574-9.

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.

Nutzinger DO, Cayiroglu S, Sachs G, et al. Emotional problems during weight reduction: Advantages of a combined behavior therapy and antidepressive drug therapy for obesity. *J Behav Ther and Experimental Psychiatry* 1985;16(3):217-21.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Nystrom C, Hallstrom T. Comparison between a serotonin and a noradrenaline reuptake blocker in the treatment of depressed outpatients. A cross-over study. *Acta Psychiatr Scand* 1987;75(4):377-82. PMID:3035878

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

O'Brien S, McKeon P, O'Regan M. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. *Br J Psychiatry* 1993;162:363-8. PMID:8453432

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

O'Brien SM, Scully P, Fitzgerald P, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. *J Psychiatr Res* 2007;41(3-4):326-31. PMID:16870211

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

O'Dwyer AM, Lightman SL, Marks MN, et al. Treatment of major depression with metyrapone and hydrocortisone. *J Affect Disord* 1995;33(2):123-8.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

O'Kearney R, Kang K, Christensen H, et al. A controlled trial of a school-based Internet program for reducing depressive symptoms in adolescent girls. *Depress Anxiety* 2009;26(1):65-72. PMID:18828141

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

O'Kearney R, Gibson M, Christensen H, et al. Effects of a cognitive-behavioural internet program on depression, vulnerability to depression and stigma in adolescent males: a school-based controlled trial. *Cognitive Behaviour Therapy* 2006;35(1):43-54. PMID:16500776

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

O'Kearney, Richard, Kang, Kanwal, Gibson, Malcolm et al. A CBT internet program for depression in

- adolescents (MoodGYM): Effects on depressive symptoms, attributional style, self-esteem and beliefs about depression. *J Affect Disord* 2007;117(2):197-204. 2007.
Exclude: For study design, OVID-PsycINFO.
- O'Laoire S. An experimental study of the effects of distant, intercessory prayer on self-esteem, anxiety, and depression. *Altern Ther Health Med* 1997;3(6):38
Exclude: For study design, EBSCO-CINAHL.
- O'Leary D, Costello F, Gormley N, et al. Remission onset and relapse in depression: An 18-month prospective study of course for 100 first admission patients. *J Affect Disord* 2000;57(1-3):159-71.
Exclude: For study design, OVID-Embase.
- O'Leary KD, Beach SR. Marital therapy: a viable treatment for depression and marital discord. *Am J Psychiatry* 1990;147(2):183-6. PMID:2301656
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. *Biol Psychiatry* 2002;51(3):253-60.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Odeberg H, Rodriguez-Silva B, Salander P, et al. Individualized continuation electroconvulsive therapy and medication as a bridge to relapse prevention after an index course of electroconvulsive therapy in severe mood disorders: A naturalistic 3-year cohort study. *Journal of ECT* 2008;24(3):183-90.
Exclude: For study design, OVID-Embase.
- Oei TP, Bullbeck K, Campbell JM. Cognitive change process during group cognitive behaviour therapy for depression. *J Affect Disord* 2006;92(2-3):231-41. PMID:16542734
Exclude: For study design, OVID-Medline.
- Oei TP, Yeoh AE. Pre-existing antidepressant medication and the outcome of group cognitive-behavioural therapy. *Aust NZ J Psychiatry* 1999;33(1):70-6. PMID:10197887
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Oei TPS, Free ML. Do cognitive behaviour therapies validate cognitive models of mood disorders? A review of the empirical evidence. *International Journal of Psychology* 1995;30(2):145-80.
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Oh H, Seo W. Decreasing pain and depression in a health promotion program for people with rheumatoid arthritis. *J Nurs Scholarsh* 2003;35(2):127-32.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Okamoto A, Kuriyama H, Watanabe S, et al. The effect of aromatherapy massage on mild depression: a pilot study. *Psychiatry & Clinical Neurosciences* 2005;59(3):363 PMID:15896234
Exclude: For study design, OVID-Medline.
- Okumura K, Furukawa TA. Remission rates with milnacipran 100 mg/day and 150 mg/day in the long-term treatment of major depression. *Clinical Drug Investigation* 2006;26(3):135-42. PMID:17163244
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Oliwenstein L. Lifting moods by losing sleep: an adjunct therapy for treating depression. *Alternative & Complementary Therapies* 2006;12(2):66-70.
Exclude: For study design, EBSCO-CINAHL.
- Olver JS, Cryan JF, Burrows GD, et al. Pindolol augmentation of antidepressants: A review and rationale. *Aust N Z J Psychiatry* 2000;34(1):71-9.
Exclude: For systematic review before 2005, OVID-Embase.
- Olver JS, Ignatiadis S, Maruff P, et al. Quetiapine augmentation in depressed patients with partial response to antidepressants. *Hum Psychopharmacol* 2008;23(8):653-60. PMID:18816504
Exclude: For study design, OVID-Medline.
- Onder E, Tural U. Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone. *J Affect Disord* 2003;76(1-3):223-7. PMID:12943952
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Ontiveros A, Fontaine R, Elie R. Refractory depression: the addition of lithium to fluoxetine or desipramine. *Acta Psychiatr Scand* 1991;83(3):188-92. PMID:1903237
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. *J Geriatr Psychiatry Neurol* 2005;18(1):20-4. PMID:15681624
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Organista KC, Munoz RF, Gonzalez G. Cognitive-behavioral therapy for depression in low-income and minority medical outpatients: Description of a program and exploratory analyses. *Cogn Ther Res* 1994;18(3):241-59.
Exclude: For study design, OVID-PsycINFO.
- Osgood-Hynes DJ, Greist JH, Marks IM, et al. Self-administered psychotherapy for depression using a telephone-accessed computer system plus booklets: An open U.S.-U.K. study. *J Clin Psychiatry* 1998;59(7):358-65.
Exclude: For study design, OVID-PsycINFO.
- Oslin DW, Sayers S, Ross J, et al. Disease Management for Depression and At-Risk Drinking Via Telephone in an Older Population of Veterans. *Psychosom Med* 2003;65(6):931-7.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Oslin DW. Treatment of late-life depression complicated by alcohol dependence. *Am J Geriatr Psychiatry* 2005;13(6):491-500. PMID:15956269
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Ostacher, Michael J., Huffman, Jeffrey, Perlis, Roy et al. Evidence-based pharmacotherapy of major depressive disorder. . 2005:1-21. 2005.
Exclude: For study design, OVID-PsycINFO.
- Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. *J Clin Psychiatry* 1999;60(4):256-9. PMID:10221288
Exclude: For study design, OVID-Medline.
- Otero FJ, Hernandez-Herrero C, Martinez-Arevalo M-J, et al. Fluoxetine/benzazepam combination in the treatment of dysthymic disorders. *Curr Ther Res Clin Exp* 1994;55(5):519-31.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Overall JE, Brown D, Williams JD, et al. Drug treatment of anxiety and depression in detoxified alcoholic patients. *Arch Gen Psychiatry* 1973;29(2):218-25.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Overholser JC, Schubert DS. Cognitive-behavioral treatment of depression, Part VI: Integrating the use of antidepressant medications. *Journal of Contemporary Psychotherapy* 1996;26(3):235-50.
Exclude: For Guideline published before 2005, OVID-PsycINFO.
- Oxman TE, Barrett JE, Sengupta A, et al. Status of minor depression or dysthymia in primary care following a randomized controlled treatment. *Gen Hosp Psychiatry* 2001;23(6):301-10. PMID:11738460
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Oxman TE, Barrett JE, Sengupta A, et al. Status of minor depression or dysthymia in primary care following a randomized controlled treatment. . *Gen Hosp Psychiatry* 2001;23(6):301-10.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Ozmenler NK, Karlidere T, Bozkurt A, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. *Hum Psychopharmacol* 2008;23(4):321-6. PMID:18278806
Exclude: For study design, OVID-Medline.
- Pace TM, Dixon DN. Changes in depressive self-schemata and depressive symptoms following cognitive therapy. . *Journal of Counseling Psychology* 1993;40(3):288-94.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. . *Am J Psychiatry* 2007;164(8):1181-8. PMID:17671280
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Pae CU, Patkar AA, Jun TY, et al. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. *Depress Anxiety* 2007;24(7):522-6. PMID:17111388
Exclude: For study design, OVID-Medline.
- Page AC, Hooke GR. Outcomes for depressed and anxious inpatients discharged before or after group cognitive behavior therapy: a naturalistic comparison. *J NERV MENT DIS* 2003;191(10):653-9. PMID:14555867
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Pagoto S, Bodenlos JS, Schneider KL, et al. Initial investigation of behavioral activation therapy for comorbid major depressive disorder and obesity. *Psychotherapy* 2008;45(3):410-5.
Exclude: For study design, OVID-Embase.
- Paleacu D, Shutzman A, Giladi N, et al. Effects of pharmacological therapy on gait and cognitive function in depressed patients. *Clin Neuropharmacol* 2007;30(2):63-71.
Exclude: For study design, OVID-Embase.
- Palleschi L, De Gennaro E, Sottosanti G, et al. The role of exercise training in aged subjects with anxiety-depression syndrome. *Archives of Gerontology and Geriatrics* 1998;27(SUPPL. 6):381-4.
Exclude: For study design, OVID-Embase.
- Palmer J, Vacc N, Epstein J. Adult inpatient alcoholics: Physical exercise as a treatment intervention. *Journal of Studies on Alcohol* 1988;49(5):418-21.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Palmer JA, Palmer LK, Michiels K, et al. Effects of type of exercise on depression in recovering substance abusers. *Perceptual and Motor Skills* 1995;80(2):523-30.
Exclude: For population/not failed to respond to an SSRI, OVID-AMED.
- Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. . [Review] [52 refs]. *Arch Gen Psychiatry* 2004;61(7):714-9. PMID:15237083
Exclude: For systematic review before 2005, OVID-Medline.
- Pancheri P, Scapicchio P, Chiaie RD. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAME) versus imipramine in patients with major depressive disorder. *Int J Neuropsychopharmacol* 2002;5(4):287-94. PMID:12466028
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Papadimitriou GN, Christodoulou GN, Katsouyanni K, et al. Therapy and prevention of affective illness by total sleep deprivation. *J Affect Disord* 1993;27(2):107-16. PMID:8440806
Exclude: For study design, OVID-Medline.
- Papakostas GI, Petersen T, Worthington JJ, et al. A pilot, open study of sertraline in outpatients with

- treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. *Int Clin Psychopharmacol* 2003;18(5):293-6. PMID:12920390
Exclude: For study design, OVID-Medline.
- Papakostas GI, Petersen TJ, Burns AM, et al. Adjunctive atomoxetine for residual fatigue in major depressive disorder. *J Psychiatr Res* 2006;40(4):370-3. PMID:15978621
Exclude: For study design, OVID-Medline.
- Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. *J Clin Psychiatry* 2005;66(10):1326-30. PMID:16259548
Exclude: For study design, OVID-Medline.
- Papakostas GI, Petersen T, Pava J, et al. Hopelessness and suicidal ideation in outpatients with treatment-resistant depression: prevalence and impact on treatment outcome. *J NERV MENT DIS* 2003;191(7):444-9. PMID:12891091
Exclude: For study design, OVID-Medline.
- Papakostas GI, Petersen TJ, Farabaugh AH, et al. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. *J Clin Psychiatry* 2003;64(11):1357-61. PMID:14658951
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Papakostas GI, Worthington JJ, III, Iosifescu DV, et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. *Depress Anxiety* 2006;23(3):178-81. PMID:16528701
Exclude: For study design, OVID-Medline.
- Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. *J Clin Psychiatry* 2004;65(2):217-21. PMID:15003076
Exclude: For study design, OVID-Medline.
- Papakostas GI, Petersen T, Sonawalla SB, et al. Serum cholesterol in treatment-resistant depression. *Neuropsychobiology* 2003;47(3):146-51.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Pappas GP, Golin S, Meyer DL. Reducing symptoms of depression with exercise. *Psychosomatics: Journal of Consultation Liaison Psychiatry* 1990;31(1):112-3.
Exclude: For study design, OVID-PsycINFO.
- Parker G, Crawford J. Atypical depression: Retrospective self-reporting of treatment effectiveness. *Acta Psychiatr Scand* 2009;120(3):213-21.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Parker G, Brotchie H, Parker K. Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? *Am J Psychiatry* 2005;162(4):796-8. PMID:15800157
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Parker JC, Smarr KL, Slaughter JR, et al. Management of depression in rheumatoid arthritis: a combined pharmacologic and cognitive-behavioral approach. *Arthritis & Rheumatism* 2003;49(6):766-77. PMID:14673962
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Parker KL, Mittmann N, Shear NH, et al. Lithium augmentation in geriatric depressed outpatients: A clinical report. *Int J Geriatr Psychiatry* 1994;9(12):995-1002.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Parrish BP, Cohen LH, Gunthert KC, et al. Effects of cognitive therapy for depression on daily stress-related variables. *Beh Res Ther* 2009;47(5):444-8.
Exclude: For study design, OVID-Embase.
- Pasquini M, Picardi A, Specia A, et al. Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: An open study. *Clin Pract Epidemiol Ment Health* 2007;3, 2007. Article Number: 3. Date of Publication: 2007.:
Exclude: For study design, OVID-Embase.
- Passeri M, Cucinotta D, Abate G, et al. Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. *Aging-Clinical & Experimental Research* 1993;5(1):63-71. PMID:8257478
Exclude: For population/diagnosis, OVID-Medline.
- Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. *J Clin Psychopharm* 2006;26(6):653-6. PMID:17110825
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Patkar AA, Peindl K, Mago R, et al. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. *Primary Care Companion to the J Clin Psychiatry* 2006;8(2):82-7.
Exclude: For study design, OVID-Embase.
- Patten SB, Lupin DA, Boucher SA, et al. Pharmacologic management of refractory depression. [Review] [19 refs]. *CMAJ* 1992;146(4):483-7. PMID:1737312
Exclude: For systematic review before 2005, OVID-Medline.
- Paykel ES, Scott J, Cornwall PL, et al. Duration of relapse prevention after cognitive therapy in residual depression: follow-up of controlled trial. *Psychol Med* 2005;35(1):59-68. PMID:15842029
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. *Arch Gen Psychiatry* 1999;56(9):829-35. PMID:12884889

- Exclude:**For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Payne DL. Antidepressant therapies in the elderly. *CLIN GERONTOL* 1987;7(2):31-41.
Exclude: For study design, OVID-Embase.
- Payne JK, Held J, Thorpe J, et al. Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. *Oncol Nurs Forum* 2008;Online.(4):635-42. PMID:18591167
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Paz-Diaz H, Montes dO, Lopez JM, et al. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. *AM J PHYS MED REHABIL* 2007;86(1):30-6. PMID:17304686
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Pecheur DR, Edwards KJ. A comparison of secular and religious versions of cognitive therapy with depressed Christian college students. *Journal of Psychology & Theology* 1984;12(1):45-54.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Peden AR, Rayens MK, Hall LA. A community-based depression prevention intervention with low-income single mothers. *J Am Psychiatr Nurses Assoc* 2005;11(1):18-25. **Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Peden AR, Rayens MK, Hall LA, et al. Testing an intervention to reduce negative thinking, depressive symptoms, and chronic stressors in low-income single mothers. *J Nurs Scholarsh* 2005;37(3):268-74. PMID:16235869
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. *Arch Gen Psychiatry* 2002;59(10):913-9. PMID:12365878
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Peet M. Essential fatty acids: Theoretical aspects and treatment implications for schizophrenia and depression. *Advances in Psychiatric Treatment* 2002;8(3):223-9.
Exclude: For study design,
- Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. *Arch Gen Psychiatry* 2002;59(10):913-20.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Pelham TW, Campagna PD, Ritvo PG, et al. The effects of exercise therapy on clients in a psychiatric rehabilitation program. *Psychosoc Rehab Jour* 1993;16(4):75-84.
Exclude: For study design, OVID-PsycINFO.
- Pelton GH, Harper OL, Tabert MH, et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. *Int J Geriatr Psychiatry* 2008;23(7):670-6. PMID:18088076
Exclude: For population/diagnosis, OVID-Medline.
- Pendola,D.P. Effects of scientific weight training and muscle building nutrition on self-reports of mild to moderate depression Pendola. 1996
Exclude: For study design, OVID-PsycINFO.
- Peniston EG, Hughes RB, Kulkosky PJ. EMG biofeedback-assisted relaxation training in the treatment of reactive depression in chronic pain patients. *Psychol Rec* 1986;36(4):471-81.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Penninx BW, Rejeski WJ, Pandya J, et al. Exercise and depressive symptoms: a comparison of aerobic and resistance exercise effects on emotional and physical function in older persons with high and low depressive symptomatology. *J Gerontol B Psychol Sci Soc Sci* 2002;57(2):124-32. PMID:11867660
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Perahia DG, Quail D, Gandhi P, et al. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression. *J Affect Disord* 2008;108(1-2):33-41. PMID:17905442
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Perez V, Puiigdemont D, Gilaberte I, et al. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. *J Clin Psychopharm* 2001;21(1):36-45. PMID:11199945
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Perez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. *Lancet* 1997;349(9065):1594-7. PMID:9174562
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Perez V, Soler J, Puidgemont D, et al. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. *Arch Gen Psychiatry* 1999;56(4):375-9.
Exclude:For Mixed antidepressants; some failed on SSRI , OVID-PsycINFO.
- Perini S, Titov N, Andrews G. Clinician-assisted Internet-based treatment is effective for depression: randomized controlled trial. *Aust NZ J Psychiatry* 2009;43(6):571-8. PMID:19440890
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Perino C, Rago R, Cicolini A, et al. Mood and behavioural disorders following traumatic brain

- injury: clinical evaluation and pharmacological management. *Brain Inj* 2001;15(2):139-48. PMID:11260764
Exclude: For study design, OVID-Medline.
- Perlis RH, Purcell S, Fava M, et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. *Arch Gen Psychiatry* 2007;64(6):689-97. PMID:17548750
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Perlis RH, Nierenberg AA, Alpert JE, et al. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. *J Clin Psychopharm* 2002;22(5):474-80. PMID:12352270
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Perry PJ. Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. *J Affect Disord* 1996;39(1):1-6.
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Persons JB, Roberts NA, Zalecki CA, et al. Naturalistic outcome of case formulation-driven cognitive-behavior therapy for anxious depressed outpatients. *Behav Res Ther* 2006;44(7):1041-51. PMID:16209865
Exclude: For study design, OVID-Medline.
- Persons JB, Bostrom A, Bertagnolli A. Results of randomized controlled trials of cognitive therapy for depression generalize to private practice. *Cogn Ther Res* 1999;23(5):535-48.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Persons JB, Burns DD, Perloff JM. Predictors of dropout and outcome in cognitive therapy for depression in a private practice setting. *Cogn Ther Res* 1988;12(6):557-75.
Exclude: For study design, OVID-PsycINFO.
- Peselow ED, Sanfilippo MP, DiFiglia C, et al. Melancholic/endogenous depression and response to somatic treatment and placebo. *Am J Psychiatry* 1992;149(10):1324-34.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Peter K, Kuhne GE, Kowalik A. Bright light: Therapy in endogenous depression. *Psychiatria Danubina* 1992;4(3-4):289-93.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Peterson AL, Halstead TS. Group cognitive behavior therapy for depression in a community setting: A clinical replication series. *Behav Ther* 1998;29(1):3-18.
Exclude: For study design, OVID-Embase.
- Petty F, Trivedi MH, Fulton M, et al. Benzodiazepines as antidepressants: does GABA play a role in depression? *Biol Psychiatry* 1995;38(9):578-91. PMID:8573660
Exclude: For systematic review before 2005, OVID-Medline.
- Pérez V, Puiigdemont D, Gilaberte I, et al. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. *J Clin Psychopharm* 2001;21(1):36-45.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Pérez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. *Lancet* 1997;349(9065):1594-7.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Pfeiffer E, Baxter D, Candelora E, et al. Finding and treating depression in Alzheimer's patients: A study of the effects on patients and caregivers. *Psychopharmacol Bull* 1997;33(4):721-9.
Exclude: For study design, OVID-Embase.
- Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. *Biol Psychiatry* 2009;65(2):181-4. PMID:18996507
Exclude: For study design, OVID-Medline.
- Philip NS, Carpenter LL, Tyrka AR, et al. Varenicline augmentation in depressed smokers: an 8-week, open-label study. *J Clin Psychiatry* 2009;70(7):1026-31. PMID:19323966
Exclude: For study design, OVID-Medline.
- Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. [erratum appears in *BMJ* 2000 Feb 5;320(7231):361]. *BMJ* 1999;319(7224):1534-8. PMID:10591711
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Philp F, Lucock MP, Wilson AR. Primary care-based guided self-help for depression provided by a nurse practitioner: A pilot evaluation. *Prim Care Ment Health* 2006;4(3):159-64.
Exclude: For study design, OVID-Embase.
- Pierre OJ, Kasper S. Efficacy of agomelatine, a MT₁/MT₂ receptor agonist with 5-HT_{2C} antagonistic properties, in major depressive disorder. *Int J Neuropsychopharmacol* 2007;10(5):661-73.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Pierson K, Addington D, Addington J, et al. Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication. *Can J Psychiatry* 2006;51(11):715-8. PMID:17121171

- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Pilu A, Sorba M, Hardoy MC, et al. Efficacy of physical activity in the adjunctive treatment of major depressive disorders: Preliminary results. *Clin Pract Epidemiol Ment Health* 2007;3, 2007. Article Number: 8. Date of Publication: 09 Jul 2007.:
Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Embase.
- Pinquart M, Sorensen S. How effective are psychotherapeutic and other psychosocial interventions with older adults? A meta-analysis. *Prof Psychol Res Pr* 2001;7(2):207-43.
Exclude: For systematic review before 2005, OVID-Embase.
- Piper WE, Debbane EG, Garant J. An outcome study of group therapy. *Arch Gen Psychiatry* 1977;34(9):1027-32.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Piper WE, Azim HF, McCallum M, et al. Patient suitability and outcome in short-term individual psychotherapy. *J Consult Clin Psychol* 1990;58(4):475-81. PMID:2212185
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Pitts J. Combination drug therapy in depression. *J Clin Psychiatry* 1985;46(6):205
Exclude: For study design, OVID-Embase
- OVID-Embase.
- Platania-Solazzo A, Field TM, Blank J, et al. Relaxation therapy reduces anxiety in child and adolescent psychiatric patients. *Acta Paedopsychiatrica* 1992;55(2):115-20. PMID:1585802
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Plotkin BJ, Rodos JJ, Kappler R, et al. Adjunctive osteopathic manipulative treatment in women with depression: a pilot study. *J Am Osteopath Assoc* 2001;101(9):517-23. PMID:11575038
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Pohl A, Nordin C. Clinical and biochemical observations during treatment of depression with electroacupuncture: a pilot study. *Hum Psychopharmacol* 2002;17(7):345-8. PMID:12415553
Exclude: For study design, OVID-Medline.
- Poirier M-F, Boyer P. "Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison": Erratum. *Br J Psychiatry* 1999;175:394
Exclude: For study design, OVID-PsycINFO.
- Poirier M-F, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. *Br J Psychiatry* 1999;175(JUL.):12-6.
Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Embase.
- Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. [erratum appears in *Br J Psychiatry* 1999 Oct;175:394]. *Br J Psychiatry* 1999;175:12-6. PMID:10621762
Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Pons G, Rey E, Matheson I. Excretion of psychoactive drugs into breast milk. Pharmacokinetic principles and recommendations. *Clinical Pharmacokinetics* 1994;27(4):270-89.
Exclude: For Guideline published before 2005, OVID-Embase.
- Pope HG, Cohane GH, Kanayama G, et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. *Am J Psychiatry* 2003;160(1):105-11.
Exclude:For Mixed antidepressants; some failed on SSRI , Wiley-CCTR.
- Popkin MK, Callies AL, MacKenzie TB. The outcome of antidepressant use in the medically ill. *Arch Gen Psychiatry* 1985;42(12):1160-3. PMID:4074108
Exclude: For study design, OVID-Medline.
- Portella MJ, Diego-Adelino J, Puigdemont D, et al. Pindolol augmentation enhances response outcomes in first depressive episodes. *European Neuropsychopharmacol* 2009;19(7):516-9. PMID:19419845
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Possel P, Horn AB, Groen G, et al. School-based prevention of depressive symptoms in adolescents: a 6-month follow-up. *J Am Acad Child Adolesc Psychiatry* 2004;43(8):1003-10. PMID:15266195
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Posternak M, Novak S, Stern R, et al. A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. *Int J Neuropsychopharmacol* 2008;11(1):15-25. PMID:17352847
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. *J Clin Psychiatry* 143;62(2):135-42. PMID:11247104
Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Potkin SG, Bell K, Plon L, et al. Rapid antidepressant response with SAME. A double-blind study.[erratum appears in *Ala J Med Sci* 1988 Oct;25(4):496]. *Alabama Journal of Medical Sciences* 1988;25(3):313-6. PMID:3052140
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Powers DV, Thompson LW, Gallagher-Thompson D. The Benefits of Using Psychotherapy Skills Following Treatment for Depression: An Examination of

"Afterwork" and a Test of the Skills Hypothesis in Older Adults. *Cognitive and Behavioral Practice* 2008;15(2):194-202.

Exclude: For study design, OVID-Embase.

Pöldinger W, Reinhardt B. Neurotropic drugs as co-medication to psychotropics. Combined administration of a neurotropic drug and a tetracyclic antidepressant. *International Pharmacopsychiatry* 1980;15(3):137-42.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Pössel P, Horn AB, Groen G, et al. School-based prevention of depressive symptoms in adolescents: a 6-month follow-up. *J Am Acad Child Adolesc Psychiatry* 2004;43(8):1003-10.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Prasko J, Horacek J, Klaschka J, et al. Bright light therapy and/or imipramine for inpatients with recurrent non-seasonal depression. *Neuroendocrinology Letters* 2002;23(2):109-13. PMID:12011795

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Prasko J, Horacek J, Klaschka J, et al. Bright light therapy and/or imipramine for inpatients with recurrent non-seasonal depression. *Neuroendocrinology letters* 2002;23(2):109-13.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Price CS, Taylor FB. A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. *Depress Anxiety* 2005;(29):149-53.

Exclude: For population/not failed to respond to an SSRI,

Price LH, Charney DS, Heninger GR. Effects of tranlycypromine treatment on neuroendocrine, behavioral, and autonomic responses to tryptophan in depressed patients. *Life Sciences* 1985;37(9):809-18. PMID:4033356

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Price LH, Charney DS, Heninger GR. Efficacy of lithium-tranlycypromine treatment in refractory depression. *Am J Psychiatry* 1985;142(5):619-23.

Exclude: For study design, OVID-Embase.

Price LH, Charney DS, Delgado PL, et al. Fenfluramine augmentation in tricyclic-refractory depression. *J Clin Psychopharm* 1990;10(5):312-7.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Price LH, Charney DS, Heninger GR. Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects. *Psychopharmacology* 1987;92(4):431-7.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Price LH, Charney DS, Heninger GR. Variability of response to lithium augmentation in refractory depression. *Am J Psychiatry* 1986;143(11):1387-92.

Exclude:For Mixed antidepressants; some failed on SSRI , Wiley-CCTR.

Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. *Biol Psychiatry* 2009;66(5):522-6. PMID:19545857

Exclude: For study design, OVID-Medline.

Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. *Arch Gen Psychiatry* 1984;41(11):1096-104. PMID:6437366

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Procter A. Enhancement of recovery from psychiatric illness by methylfolate. . *Br J Psychiatry* 1991;159:271-2. PMID:1773245

Exclude: For study design, OVID-Medline.

Propst LR, Ostrom R, Watkins P, et al. Comparative efficacy of religious and nonreligious cognitive-behavioral therapy for the treatment of clinical depression in religious individuals. *J Consult Clin Psychol* 1992;60(1):94-103. PMID:1556292

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Proudfoot J, Ryden C, Everitt B, et al. Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. *Br J Psychiatry* 2004;185:46-54. PMID:15231555

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Proudfoot J, Goldberg D, Mann A, et al. Computerized, interactive, multimedia cognitive-behavioural program for anxiety and depression in general practice. . *Psychol Med* 2003;33(2):217-27. PMID:12622301

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Prusoff BA, Williams DH, Weissman MM, et al. A controlled clinical trial of amitriptyline added to perphenazine in the treatment of depressed schizophrenics [proceedings]. *Psychopharmacol Bull* 1979;15(2):80-1.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Prusoff BA, Williams DH, Weissman MM, et al. Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine. *Arch Gen Psychiatry* 1979;36(5):569-75.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Pyne JM, Smith J, Fortney J, et al. Cost-effectiveness of a primary care intervention for depressed females. *J Affect Disord* 2003;74(1):23-32. PMID:12646296

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Qaseem A, Snow V, Shekelle P, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians. . *Ann Intern Med* 2008;148(2):141-6. PMID:18195338

Exclude: For guideline, not a population of interest, OVID-Medline.

Qu F, Cai X, Gu Y, et al. Chinese medicinal herbs in relieving perimenopausal depression: A randomized, controlled trial. *J Altern Complement Med* 2009;15(1):93-100.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Qu W, Qin Y-Y. Improvement of sleep and anxiety in patients of major depression with fluoxetine combined with small dose of olanzapine. *Chinese Journal of Clinical Rehabilitation* 2005;9(8):254-6.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Qu W, Meng P. Relationship between blood glucose levels in patients with type 2 diabetes mellitus, depression and anxiety and the anti-depression/anxiety intervention. *Chinese Journal of Clinical Rehabilitation* 2005;9(24):213-5.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Quadbeck H, Lehmann E, Tegeler J. Comparison of the antidepressant action of tryptophan, tryptophan/5-hydroxytryptophan combination and nomifensine. *Neuropsychobiology* 1984;11(2):111-5. PMID:6384815

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Quah-Smith JI, Tang WM, Russell J. Laser acupuncture for mild to moderate depression in a primary care setting--a randomised controlled trial. *ACUPUNCTURE MED* 2005;23(3):103-11. PMID:16259308

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Quitkin FM, McGrath PJ, Stewart JW, et al. Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. *J Clin Psychiatry* 2005;66(6):670-6. PMID:15960558

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Rabin AS, Kaslow NJ, Rehm LP. Changes in symptoms of depression during the course of therapy. *Cogn Ther Res* 1984;8(5):479-87.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. *J Clin Psychiatry* 1994;55(3):92-7. PMID:7915270

Exclude: For study design, OVID-Medline.

Ragan, J.D. Excessive reassurance-seeking, interpersonal rejection, rejection sensitivity and depressive symptoms: An intervention focusing on mediating mechanisms Ragan. 2006

Exclude: For study design, OVID-PsycINFO.

Raisi F, Habibi N, Nasehi AA, et al. Combination of citalopram and nortriptyline in the treatment of severe major depression: A double-blind, placebo-controlled trial. *Therapy* 2007;4(2):187-92.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Ramana R, Paykel ES, Cooper Z, et al. Remission and relapse in major depression: A two-year prospective follow-up study. *Psychol Med* 1995;25(6):1161-70.

Exclude: For study design, OVID-Embase.

Ramasubbu R. Treatment of resistant depression by adding noradrenergic agents to lithium augmentation of SSRIs. *Ann Pharmacother* 2002;36(4):634-40. PMID:11918513

Exclude: For study design, OVID-Medline.

Ramos L. SAME as a supplement: can it really help treat depression and arthritis? . *J AM DIET ASSOC* 2000;100(4):414 PMID:10767892

Exclude: For study design, OVID-Medline.

Rampello L, Alvano A, Chiechio S, et al. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. . *Neuropsychobiology* 2004;50(4):322-8. PMID:15539864

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Randall, F. Differences between Christian Cognitive Behavioral Therapy and cognitive behavioral therapy as measured by depression and resiliency Randall. 2004

Exclude: For study design, OVID-PsycINFO.

Randlov C, Mehlsen J, Thomsen CF, et al. The efficacy of St. John's Wort in patients with minor depressive symptoms or dysthymia--a double-blind placebo-controlled study. *Phytomedicine* 2006;13(4):215-21. PMID:16423519

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Rani NJ, Rao PVK. Impact of yoga training on body image and depression. . *Psychological Studies* 2005;50(1):98-100.

Exclude: For study design, OVID-PsycINFO.

Rapaport MH, Gharabawi GM, Canuso CM, et al. Corrigendum: "Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation". *Neuropsychopharmacol* 2007;32(5):1208

Exclude: For study design, OVID-PsycINFO.

Rapp, S.L. A cognitive-behavioral treatment of older medical inpatients with depressive symptoms Rapp. 1998

Exclude: For study design, OVID-PsycINFO.

- Rasanen P, Hakko H, Tiihonen J, Mitchell B, Balter Award--1998. Pindolol and major affective disorders: a three-year follow-up study of 30,485 patients. *J Clin Psychopharm* 1999;19(4):297-302. PMID:10440455
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rasanen P, Hakko H, Jokelainen J, et al. Outcome of different types of long-term antidepressant treatments: a 3-year follow-up study of 14182 patients. *J Affect Disord* 1999;55(1):67-71. PMID:10512609
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rasanen P, Hakko H, Tiihonen J. Pindolol and major affective disorders: A three-year follow-up study of 30,485 patients. *J Clin Psychopharm* 1999;19(4):297-302.
Exclude: For study design, OVID-Embase.
- Rasgon NL, Dunkin J, Fairbanks L, et al. Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study. *J Psychiatr Res* 2007;41(3-4):338-43. PMID:16697413
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rasgon NL, Altshuler LL, Fairbanks LA, et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. *J Clin Psychiatry* 2002;63:Suppl-8 PMID:11995778
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Raskin A. High dosage chlorpromazine alone and in combination with an antiparkinsonian agent (procyclidine) in the treatment of hospitalized depressions. *J Nerv Ment Dis* 1968;147(2):184-95.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Rasmussen N-A, Schroder P, Olsen LR, et al. Modafinil augmentation in depressed patients with partial response to antidepressants: A pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92). *Nord J Psychiatry* 2005;59(3):173-8.
Exclude: For study design, OVID-Embase.
- Ravindran AV, Kennedy SH, O'Donovan MC, et al. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. *J Clin Psychiatry* 2008;69(1):87-94. PMID:18312042
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Ravindran AV, Anisman H, Merali Z, et al. Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. *Am J Psychiatry* 1999;156(10):1608-17. PMID:10518174
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Ravindran L, Lam R, Chaput Y and others. Impact of low vs. high dose olanzapine or risperidone on outcome and side effects in non-psychotic treatment resistant depression. In 2006. **Exclude:** For study design, Wiley-CCTR.
- Razani J, White KL, White J, et al. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment. A controlled trial. *Arch Gen Psychiatry* 1983;40(6):657-61. PMID:6342565
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Ree MJ, Craigie MA. Outcomes following mindfulness-based cognitive therapy in a heterogeneous sample of adult outpatients. *Behav Change* 2007;24(2):70-86.
Exclude: For study design, OVID-PsycINFO.
- Reed C, Monz BU, Perahia DG, et al. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. *J Affect Disord* 2009;113(3):296-302. PMID:18603303
Exclude: For study design, OVID-Medline.
- Reeves H, Batra S, May RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. *J Clin Psychiatry* 2008;69(8):1228-336. PMID:18681749
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Reinecke MA, Ryan NE, DuBois DL. Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: a review and meta-analysis. *J Am Acad Child Adolesc Psychiatry* 1998;37(1):26-34. PMID:9444896
Exclude: For systematic review before 2005, OVID-Medline.
- Reinecke MA, Ryan NE, DuBois DL. Cognitive-behavioral therapy of depression and depressive symptoms during adolescence: A review and meta-analysis. *J Am Acad Child Adolesc Psychiatry* 1998;37(1):26-34.
Exclude: For systematic review before 2005, OVID-PsycINFO.
- Rektorová I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. *European journal of neurology : the official journal of the European Federation of Neurological Societies* 2003;10(4):399-406.
Exclude: For population/diagnosis, Wiley-CCTR.
- Remick RA. Diagnosis and management of depression in primary care: a clinical update and review. *CMAJ* 2002;167(11):1253-60. **Exclude:** For systematic review before 2005, EBSCO-CINAHL.
- Rene, R. The efficacy of a portable HRV feedback device in conjunction with mental health treatment of clients with major depressive disorder enrolled in a county welfare-to-work program Rene. 2008
Exclude: For study design, OVID-PsycINFO.
- Replogle WH, Eicke FJ. Megavitamin therapy in the reduction of anxiety and depression among alcoholics.

- Journal of Orthomolecular Medicine 1989;4(4):221-4.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Resick PA, Nishith P, Weaver TL, et al. A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol 2002;70(4):867-79.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Revicki DA, Siddique J, Frank L, et al. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Arch Gen Psychiatry 2005;62(8):868-75. PMID:16061764
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Revicki DA, Simon GE, Chan K, et al. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Prac 1998;47(6):446-52.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Reynaert-Dupuis C, Zdanowicz N, Leyman S, et al. Efficacy and tolerance of venlafaxine in depressed patients switched from prior antidepressant treatment. Primary Care Psychiatry 2002;8(2):63-8.
Exclude: For study design,
- Reynaert C, Parent M, Mirel J, et al. Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology 1995;118(2):183-7. PMID:7617806
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Reynolds CF, III, Smith GS, Dew MA, et al. Accelerating symptom-reduction in late-life depression: a double-blind, randomized, placebo-controlled trial of sleep deprivation. Am J Geriatr Psychiatry 2005;13(5):353-8. PMID:15879583
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Reynolds CF, III, Frank E, Perel JM, et al. Combined pharmacotherapy and psychotherapy in the acute and continuation treatment of elderly patients with recurrent major depression: a preliminary report. Am J Psychiatry 1992;149(12):1687-92. PMID:1443245
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Reynolds CF, III, Frank E, Perel JM, et al. High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. Am J Psychiatry 1996;153(11):1418-22. PMID:8890674
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Reynolds CF, III, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N ENGL J MED 2006;354(11):1130-8. PMID:16540613
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Reynolds CF, III, Kupfer DJ, Hoch CC, et al. Sleep deprivation effects in older endogenous depressed patients. Psychiatry Res 1987;21(2):95-109. PMID:3615695
Exclude: For study design, OVID-Medline.
- Reynolds CF, III, Frank E, Kupfer DJ, et al. Treatment outcome in recurrent major depression: a post hoc comparison of elderly ("young old") and midlife patients. Am J Psychiatry 1996;153(10):1288-92. PMID:8831436
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Reynolds, Charles F. I., Schneider, Lon S., Lebowitz, Barry D. et al. Treatment of depression in elderly patients: Guidelines for primary care. 1994:463-90. 1994.
Exclude: For study design, OVID-PsycINFO.
- Reynolds WM, Coats KI. A comparison of cognitive-behavioral therapy and relaxation training for the treatment of depression in adolescents. J Consult Clin Psychol 1986;54(5):653-60. PMID:3534032
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Richards A, Barkham M, Cahill J, et al. PHASE: a randomised, controlled trial of supervised self-help cognitive behavioural therapy in primary care. British Journal of General Practice 2003;53(495):764-70. PMID:14601351
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Richelson E. Treatment of acute depression. PSYCHIATR CLIN NORTH AM 1993;16(3):461-78.
Exclude: For Guideline published before 2005, OVID-PsycINFO.
- Rickels K, Csanalosi I, Werblowsky J, et al. Amitriptyline-perphenazine and doxepin in depressed outpatients: a controlled double-blind study. J Clin Psychiatry 1982;43(10):419-22. PMID:6749826
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rickels K, Schweizer E, Case WG, et al. Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability. J Clin Psychopharm 1998;18(2):145-53. PMID:9580369
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Riedel WJ, Schoenmakers E, Vermeeren A, et al. The influence of trazodone treatment on cognitive functions in outpatients with major depressive disorder. Hum Psychopharmacol 1999;14(7):499-508.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Riemann D, Konig A, Hohagen F, et al. How to preserve the antidepressive effect of sleep deprivation: A comparison of sleep phase advance and sleep phase delay. Eur Arch Psychiatry Clin Neurosci

- 1999;249(5):231-7. PMID:10591988
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Ries RK, Wittkowsky AK. Synergistic action of alprazolam with tranylcypramine in drug-resistant atypical depression with panic attacks. *Biol Psychiatry* 1986;21(5-6):522-6. PMID:3697440
Exclude: For study design, OVID-Medline.
- Riggs PD, Mikulich-Gilbertson SK, Davies RD, et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. *ARCH PEDIATR ADOLESC MED* 2007;161(11):1026-34. PMID:17984403
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rihmer Z, Satori M, Pestaloty P. Selegiline-citalopram combination in patients with Parkinson's disease and major depression. *Int J Psychiatry Clin Pract* 2000;4(2):123-5.
Exclude: For study design, OVID-Embase.
- Riise IS, Holm P. Concomitant isocarboxazid/mianserin treatment of major depressive disorder. *J Affect Disord* 1984;6(2):175-9. PMID:6233349
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Ritchie, L.G. Group telepsychotherapy for reducing depression: An exploratory study Ritchie. 2008
Exclude: For study design, OVID-PsycINFO.
- Robb SL, Ebberts AG. Songwriting and digital video production interventions for pediatric patients undergoing bone marrow transplantation, part I: an analysis of depression and anxiety levels according to phase of treatment. *J PEDIATR ONCOL NURS* 2003;20(1):2-15.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Robbins DR, Alessi NE, Colfer MV. Treatment of adolescents with major depression: Implications of the DST and the melancholic clinical subtype. *J Affect Disord* 1989;17(2):99-104.
Exclude: For study design, OVID-PsycINFO.
- Robertson L, Smith M, Castle D, et al. Using the Internet to enhance the treatment of depression. *AUSTRALAS PSYCHIATRY* 2006;14(4):413-7. PMID:17116083
Exclude: For study design, OVID-Medline.
- Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy. A double-blind trial. *J Affect Disord* 1985;9(2):127-36. PMID:2932485
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Robinson RG, Jorge RE, Clarence-Smith K. Double-blind randomized treatment of poststroke depression using nefiracetam. *The Journal of Neuropsychiatry and Clinical Neurosciences* 2008;20(2):178-84.
Exclude: For population/diagnosis, Wiley-CCTR.
- Rocco PL, Pacella G, Giavedoni A. Major depression in medical inpatients: A preliminary report on a tentative therapeutic approach with S-adenosyl-L-methionine. *Curr Ther Res Clin Exp* 1993;54(2):177-85.
Exclude: For study design, OVID-Embase.
- Rocha FL, Hara C. Lamotrigine augmentation in unipolar depression. *Int Clin Psychopharmacol* 2003;18(2):97-9. PMID:12598821
Exclude: For study design, OVID-Medline.
- Roepke S, Merkl A, Dams A, et al. Preliminary evidence of improvement of depressive symptoms but not impulsivity in cluster B personality disorder patients treated with quetiapine: an open label trial. *Pharmacopsychiatry* 2008;41(5):176-81. PMID:18763219
Exclude: For study design, OVID-Medline.
- Rofey DL, Szigethy EM, Noll RB, et al. Cognitive-behavioral therapy for physical and emotional disturbances in adolescents with polycystic ovary syndrome: a pilot study. *Journal of Pediatric Psychology* 2009;34(2):156-63. PMID:18556675
Exclude: For study design, OVID-Medline.
- Rogers DR, Ei S, Rogers KR, et al. Evaluation of a multi-component approach to cognitive-behavioral therapy (CBT) using guided visualizations, cranial electrotherapy stimulation, and vibroacoustic sound. *COMPLEMENT THER CLIN PRACT* 2007;13(2):95-101. PMID:17400144
Exclude: For study design, OVID-Medline.
- Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. *BR J NUTR* 2008;99(2):421-31. PMID:17956647
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rogoz Z, Skuza G, Daniel WA, et al. Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. *Pharmacological Reports: PR* 2007;59(6):778-84. PMID:18195470
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Rogoz Z, Skuza G, Wojcikowski J, et al. Effect of metyrapone supplementation on imipramine therapy in patients with treatment-resistant unipolar depression. *Pol J Pharmacol* 2004;56(6):849-55. PMID:15662100
Exclude: For study design, OVID-Medline.
- Rogoz Z, Dziedzicka-Wasylewska M, Daniel WA, et al. Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression. *Pol J Pharmacol* 2004;56(6):735-42. PMID:15662086
Exclude: For study design, OVID-Medline.
- Roh YS, Cho H, Oh JO, et al. Effects of skin rehabilitation massage therapy on pruritus, skin status, and depression in burn survivors. *Daehan Ganho Haghoeji* 2007;37(2):221-6. PMID:17435407
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Rohde P, Silva SG, Tonev ST, et al. Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy. *Arch Gen Psychiatry* 2008;65(4):447-55. PMID:18391133
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rohde P, Clarke GN, Mace DE, et al. An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder. *J Am Acad Child Adolesc Psychiatry* 2004;43(6):660-8. PMID:15167082
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rohde P, Clarke GN, Mace DE, et al. An Efficacy/Effectiveness Study of Cognitive-Behavioral Treatment for Adolescents With Comorbid Major Depression and Conduct Disorder. *J Am Acad Child Adolesc Psychiatry* 2004;43(6):660-8.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Rohde P, Lewinsohn PM, Seeley JR. Response of depressed adolescents to cognitive-behavioral treatment: Do differences in initial severity clarify the comparison of treatments? *J Consult Clin Psychol* 1994;62(4):851-4.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Rohen, N.A. Analysis of efficacy and mediators of outcome in minimal-contact cognitive bibliotherapy used in the treatment of depressive symptoms Rohen. 2003
Exclude: For study design, OVID-PsycINFO.
- Roijen LHV, van Straten A, Maiwenn A, et al. Cost-utility of brief psychological treatment for depression and anxiety. *Br J Psychiatry* 2006;188(APR.):323-9.
Exclude: For population/not failed to respond to an SSRI, OVID-Embse.
- Roitman S, Green T, Osher Y, et al. Creatine monohydrate in resistant depression: a preliminary study. *Bipolar Disorders* 2007;9(7):754-8. PMID:17988366
Exclude: For study design, OVID-Medline.
- Rokke PD, Tomhave JA, Jovic Z. The role of client choice and target selection in self-management therapy for depression in older adults. *Psychology & Aging* 1999;14(1):155-69. PMID:10224639
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rolland Y, Pillard F, Klapouszczak A, et al. Exercise program for nursing home residents with Alzheimer's disease: a 1-year randomized, controlled trial. *J AM GERIATR SOC* 2007;55(2):158-65.
Exclude: For population/diagnosis, Wiley-CCTR.
- Romano SJ, Amsterdam JD, Shelton RC, Hassman H and others. Adjunctive ziprasidone in treatment-resistant depression: Pilot study. In 2003. **Exclude:** For study design, Wiley-CCTR.
- Roose SP, Glassman AH, Walsh BT, et al. Tricyclic nonresponders: phenomenology and treatment. *Am J Psychiatry* 1986;143(3):345-8. PMID:3953869
Exclude: For study design, OVID-Medline.
- Roschke J, Wolf C, Muller MJ, et al. The benefit from whole body acupuncture in major depression. *J Affect Disord* 2000;57(1-3):73-81. PMID:10708818
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rosenbaum JF, Fava M, Falk WE, et al. An open-label pilot study of oral S-adenosylmethionine in major depression. An interim report. *Alabama Journal of Medical Sciences* 1988;25(3):301-6. PMID:3052138
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rosenbaum JF, Fava M, Falk WE, et al. An open-label pilot study of oral S-adenosyl-L-methionine in major depression: interim results. *Psychopharmacol Bull* 1988;24(1):189-94. PMID:3387521
Exclude: For study design, OVID-Medline.
- Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-L-methionine. *Acta Psychiatr Scand* 1990;81(5):432-6. PMID:2113347
Exclude: For study design, OVID-Medline.
- Ross EA, Hollen TL, Fitzgerald BM. Observational study of an Arts-in-Medicine Program in an outpatient hemodialysis unit. *AM J KIDNEY DIS* 2006;47(3):462-8.
Exclude: For study design, EBSCO-CINAHL.
- Rossello J, Bernal G, Rivera-Medina C. Individual and group CBT and IPT for Puerto Rican adolescents with depressive symptoms. *Cultural Diversity & Ethnic Minority Psychology* 2008;14(3):234-45. PMID:18624588
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rossello J, Bernal G. The efficacy of cognitive-behavioral and interpersonal treatments for depression in Puerto Rican adolescents. *J Consult Clin Psychol* 1999;67(5):734-45. PMID:10535240
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Rossello, Jeannette, Bernal, Guillermo. Adapting cognitive-behavioral and interpersonal treatments for depressed Puerto Rican adolescents. 1996:157-85. 1996.
Exclude: For Guideline published before 2005, OVID-PsycINFO.
- Rossello JM, Jimenez-Chafey MI. Cognitive-Behavioral Group Therapy for Depression in Adolescents with Diabetes: A Pilot Study. *Revista Interamericana de Psicologia* 2006;40(2):219-26.
Exclude: For study design, OVID-PsycINFO.
- Rossini D, Magri L, Lucca A, et al. Does rTMS hasten the response to escitalopram, sertraline, or venlafaxine in patients with major depressive disorder? A double-blind, randomized, sham-controlled trial. *J Clin Psychiatry* 2005;66(12):1569-

75.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Roth D, Covi L. Cognitive group psychotherapy of depression: The open-ended group. *International Journal of Group Psychotherapy* 1984;34(1):67-82.
Exclude: For study design, OVID-Embase

OVID-Embase.

Rothschild AJ. The diagnosis and treatment of late-life depression. *J Clin Psychiatry* 1996;57(Suppl 5):1996, pp-11.

Exclude: For Guideline published before 2005, OVID-PsycINFO.

Rounsaville BJ, Sholomskas D, Prusoff BA. Chronic mood disorders in depressed outpatient--diagnosis and response to pharmacotherapy. *J Affect Disord* 1980;2(2):73-88. PMID:6448886

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Röschke J, Wolf C, Müller MJ, et al. The benefit from whole body acupuncture in major depression. *J Affect Disord* 2000;57(1-3):73-81.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Rubio G, San L, Lopez-Munoz F, et al. Reboxetine adjunct for partial or nonresponders to antidepressant treatment. *J Affect Disord* 2004;81(1):67-72. PMID:15183602

Exclude: For study design, OVID-Medline.

Rubio G, San L, Lopez-Munoz F, et al. Reboxetine adjunct for partial or nonresponders to antidepressant treatment. *J Affect Disord* 2004;81(1):67-72.

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-PsycINFO.

Rudas S, Schmitz M, Pichler P, et al. Treatment of refractory chronic depression and dysthymia with high-dose thyroxine. *Biol Psychiatry* 1999;45(2):229-33. PMID:9951571

Exclude: For study design, OVID-Medline.

Ruffolo MC, Fischer D. Using an evidence-based CBT group intervention model for adolescents with depressive symptoms: lessons learned from a school-based adaptation. *CHILD FAM SOC WORK* 2009;14(2):189-97.

Exclude: For study design, EBSCO-CINAHL.

Rumi DO, Gattaz WF, Rigonatti SP, et al. Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. *Biol Psychiatry* 2005;57(2):162-6. PMID:15652875

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. *Am J Psychiatry* 2006;163(11):1905-17. PMID:17074942

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Rush AJ, Bose A, Heydorn WE. Naturalistic study of the early psychiatric use of citalopram in the United States. *Depress Anxiety* 2002;16(3):121-7.

PMID:12415537

Exclude: For study design, OVID-Medline.

Rush AJ, Trivedi M, Carmody TJ, et al. One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. *Biol Psychiatry* 2004;56(1):46-53. PMID:15219472

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Rush AJ. Comparison of the effects of cognitive therapy and pharmacotherapy on hopelessness and self-concept. *Am J Psychiatry* 1982;139(7):862-6.

Exclude: For study design, OVID-PsycINFO.

Rutherford B, Sneed J, Miyazaki M, et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. *Int J Geriatr Psychiatry* 2007;22(10):986-91. PMID:17340654

Exclude: For study design, OVID-Medline.

Ryan ND, Meyer V, Dachille S, et al. Lithium antidepressant augmentation in TCA-refractory depression in adolescents. *J Am Acad Child Adolesc Psychiatry* 1988;27(3):371-6. PMID:3379022

Exclude: For study design, OVID-Medline.

Ryan ND, Puig-Antich J, Rabinovich H, et al. MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. *J Am Acad Child Adolesc Psychiatry* 1988;27(6):755-8.

Exclude: For study design, OVID-Embase.

Rybakowski J, Matkowski K. Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. *European Neuropsychopharmacol* 1992;2(2):161-5. PMID:1633434

Exclude: For study design, OVID-Medline.

Rybakowski JK, Suwalska A, Chlopocka W. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. *Neuropsychobiology* 1999;40(3):134-9.

Exclude: For Mixed antidepressants; some failed on SSRI, Wiley-CCTR.

Rymaszewska J, Ramsey D, Chladzinska-Kiejna S. Whole-body cryotherapy as adjunct treatment of depressive and anxiety disorders. *Archivum Immunologiae et Therapiae Experimentalis* 2008;56(1):63-8. PMID:18250970

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Saab PG, Bang H, Williams RB, et al. The impact of cognitive behavioral group training on event-free survival in patients with myocardial infarction: the ENRICH experience. *J Psychosom Res* 2009;67(1):45-56. PMID:19539818

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sabelli H, Fink P, Fawcett J, et al. Sustained antidepressant effect of PEA replacement. *Journal of Neuropsychiatry & Clinical Neurosciences* 1996;8(2):168-71. PMID:9081552

Exclude: For study design, OVID-Medline.

Sackeim HA, Roose SP, Lavori PW. Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD). *Biol Psychiatry* 2006;59(6):483-92. PMID:16517241

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sacristan JA, Gilaberte I, Boto B, et al. Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial. *Int Clin Psychopharmacol* 2000;15(2):107-13. PMID:10759342

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sado M, Knapp M, Yamauchi K, et al. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. *Aust N Z J Psychiatry* 2009;43(6):539-47.

Exclude: For study design, OVID-Embase.

Safren SA, O'Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. *HEALTH PSYCHOL* 2009;28(1):1-10. PMID:19210012

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sagud M, Mihaljevic-Peles A, Muck-Seler D, et al. Quetiapine augmentation in treatment-resistant depression: a naturalistic study. *Psychopharmacology* 2006;187(4):511-4. PMID:16802162

Exclude: For study design, OVID-Medline.

Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. *Prog Neuropsychopharmacol Biol Psychiatry* 2002;26(6):1129-34. PMID:12452535

Exclude: For study design, OVID-Medline.

Saiz-Ruiz J, Ibaez A, Diaz-Marsa M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. *Progress in Neuro-Prog Neuropsychopharmacol Biol Psychiatry* 2002;26(6):1129-34.

Exclude: For study design,

Sajatovic M, DiGiovanni S, Fuller M, et al. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity. *Clinical Therapeutics* 1999;21(4):733-40. PMID:10363738

Exclude: For study design, OVID-Medline.

Saletu B, Gruenberger J. Changes in clinical symptomatology and psychometric assessments in depressed patients during mianserin and combined amitriptyline/chlordiazepoxide therapy: A double-blind comparison. *Current Medical Research and Opinion* 1980;6(Suppl. 7):52-62.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Salin-Pascual RJ, Rosas M, Jimenez-Genchi A, et al. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. *J Clin Psychiatry* 1996;57(9):387-9. PMID:9746444

Exclude: For study design, OVID-Medline.

Salin-Pascual RJ, de IF, Jr., Galicia-Polo L, et al. Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients. *Psychopharmacology* 1995;121(4):476-9. PMID:8619011

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Salin-Pascual RJ. Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients. *Revista de Investigacion Clinica* 2002;54(1):36-40. PMID:11995405

Exclude: For study design, OVID-Medline.

Salin-Pascual RJ, Rosas M, Jimenez-Genchi A, et al. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. *J Clin Psychiatry* 1996;57(9):387-9.

Exclude: For study design, OVID-PsycINFO.

Salkovskis PM, Atha C, Storer D. Cognitive-behavioural problem solving in the treatment of patients who repeatedly attempt suicide. A controlled trial. *Br J Psychiatry* 1990;157(DEC.):871-6.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase
OVID-Embase.

Sallis JF. Anxiety and depression management for the elderly. *International Journal of Behavioral Geriatrics* 1983;1(4):3-12.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Salmaggi P, Bressa GM, Nicchia G, et al. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. *Psychother Psychosom* 1993;59(1):34-40. PMID:8441793

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Salminen JK, Karlsson H, Hietala J, et al. Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study. *Psychother Psychosom* 2008;77(6):351-7. PMID:18701831

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sanacora G, Berman RM, Cappiello A, et al. Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. *Neuropsychopharmacol* 2004;29(6):1166-71. PMID:15010697

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. *Biol*

- Psychiatry 2007;61(6):822-5. PMID:17141740
Exclude: For study design, OVID-Medline.
- Sanders MR, McFarland M. Treatment of depressed mothers with disruptive children: A controlled evaluation of cognitive behavioral family intervention. *Behav Ther* 2000;31(1):89-112.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Sanford M, Boyle M, McCleary L, et al. A pilot study of adjunctive family psychoeducation in adolescent major depression: feasibility and treatment effect. *J Am Acad Child Adolesc Psychiatry* 2006;45(4):386-495. PMID:16601642
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Sanger MD. The treatment of anxiety and depression in the allergic patient. *Annals of allergy* 1969;27(10):506-10.
Exclude: For study design, Wiley-CCTR.
- Santor DA, Kusumakar V. Open trial of interpersonal therapy in adolescents with moderate to severe major depression: Effectiveness of novice IPT therapists. *J Am Acad Child Adolesc Psychiatry* 2001;40(2):236-40.
Exclude: For study design, OVID-Embase.
- Santos MA, Rocha FL, Hara C. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: A randomized, placebo-controlled, double-blind study. *Primary Care Companion to the J Clin Psychiatry* 2008;10(3):187-90.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Saran AS. Depression after minor closed head injury: role of dexamethasone suppression test and antidepressants. *J Clin Psychiatry* 1985;46(8):335-8. PMID:4019422
Exclude: For study design, OVID-Medline.
- Sarris J, Kavanagh DJ, Deed G, et al. St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. *Hum Psychopharmacol* 2009;24(1):41-8. PMID:19090505
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Sarris J, Kavanagh DJ, Byrne G, et al. The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum. *Psychopharmacology* 2009;205(3):399-407.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Sato Y, Yasui-Furukori N, Nakagami T, et al. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2009;33(3):416-8. PMID:19166896
Exclude: For study design, OVID-Medline.
- Satterfield JM. Cognitive behavioral group therapy for depressed, low-income minority clients: Retention and treatment enhancement. *Cognitive and Behavioral Practice* 1998;5(1):65-80.
Exclude: For study design, OVID-PsycINFO.
- Sava FA, Yates BT, Lupu V, et al. Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial. *J Clin Psych* 2009;65(1):36-52. PMID:19051275
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Savard J, Laberge B, Gauthier JG, et al. Combination of fluoxetine and cognitive therapy for the treatment of major depression among people with HIV infection: A time-series analysis investigation. *Cogn Ther Res* 1998;22(1):21-46.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Savard J, Simard S, Giguere I, et al. Randomized clinical trial on cognitive therapy for depression in women with metastatic breast cancer: psychological and immunological effects. *PALLIAT SUPPORT CARE* 2006;4(3):219-37. PMID:17066964
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Sawka AM, Gerstein HC, Marriott MJ, et al. Does a combination regimen of thyroxine (T4) and 3,5,3'-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. *Journal of Clinical Endocrinology & Metabolism* 2003;88(10):4551-5. PMID:14557420
Exclude: For population/diagnosis, OVID-Medline.
- Saxby E, Peniston EG. Alpha-theta brainwave neurofeedback training: An effective treatment for male and female alcoholics with depressive symptoms. *J Clin Psych* 1995;51(5):685-93.
Exclude: For study design, OVID-Embase.
- Sayyah M, Sayyah M, Kamalinejad M. A preliminary randomized double blind clinical trial on the efficacy of aqueous extract of *Echium amoenum* in the treatment of mild to moderate major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2006;30(1):166-9. PMID:16309809
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Schaeffer P, Poirier F M, Boyer P. Double-blind trial of venlafaxine and paroxetine for treatment-resistant depression CONFERENCE ABSTRACT. In 1998; 1998. **Exclude:** For study design, Wiley-CCTR.
- Schatzberg AF, Rush AJ, Arnow BA, et al. Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. *Arch Gen Psychiatry* 2005;62(5):513-20. PMID:15867104
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Schene AH, Koeter MW, Kikkert MJ, et al. Adjuvant occupational therapy for work-related major depression works: randomized trial including economic evaluation. *Psychol Med* 2007;37(3):351-62. PMID:17112401

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Schening,L.J. Refractory depression treatment options: A meta-analysis Schening. 2004

Exclude: For study design, OVID-PsycINFO.

Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. *Am J Psychiatry* 1990;147(11):1493-7. PMID:2221162

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Schimmel-Spreuw A, Linssen AC, Heeren TJ. Coping with depression and anxiety: preliminary results of a standardized course for elderly depressed women. *INT PSYCHOGERIATR* 2000;12(1):77-86. PMID:10798455

Exclude: For study design, OVID-Medline.

Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. *Int Clin Psychopharmacol* 2007;22(3):179-82. PMID:17414745

Exclude:For Mixed antidepressants; some failed on SSRI , OVID-Medline.

Schloredt K, Varley CK. Current perspectives on the diagnosis and treatment of adolescent depression in the primary care setting. *JCOM* 2005;12(5):260-74.

Exclude: For study design, OVID-Embase.

Schmauss M, Kapfhammer HP, Meyr P, et al. Combined MAO-inhibitor and tri- (tetra) cyclic antidepressant treatment in therapy resistant depression. *Prog Neuropsychopharmacol Biol Psychiatry* 1988;12(4):523-32. PMID:3406429

Exclude: For study design, OVID-Medline.

Schmauss M, Kapfhammer HP, Meyr P, et al. Combined MAO-inhibitor and tri- (tetra) cyclic antidepressant treatment in therapy resistant depression. *Progress in Neuro-Prog Neuropsychopharmacol Biol Psychiatry* 1988;12(4):523-32.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Schmauss M, Laakmann G, Dieterle D. Effects of alpha 2-receptor blockade in addition to tricyclic antidepressants in therapy-resistant depression. *J Clin Psychopharm* 1988;8(2):108-11. PMID:3372705

Exclude: For study design, OVID-Medline.

Schmauss M, Laakmann G, Dieterle D. Nomifensine: A double-blind comparison of intravenous versus oral administration in therapy - Resistant depressed patients. *Pharmacopsychiatry* 1985;18(1):88-90.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Schmauss M, Laakmann G, Dieterle D. Yohimbine in combination with tricyclic antidepressants in the treatment of therapy-resistant depressed patients. *Pharmacopsychiatry* 1986;19(4):264-5.

Exclude: For study design, OVID-Embase

OVID-Embase.

Schmidt MM, Miller WR. Amount of therapist contact and outcome in a multidimensional depression treatment program. *Acta Psychiatr Scand* 1983;67(5):319-32.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Schmidt MM, Miller WR. Amount of therapist contact and outcome in a multidimensional depression treatment program. *Acta Psychiatr Scand* 1983;67(5):319-32.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Schmitt L, Tonnoir B, Arbus C. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder. *Neuropsychobiology* 2006;54(4):201-7. PMID:17337913

Exclude: For study design, OVID-Medline.

Schmitz JM, Averill P, Stotts AL, et al. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. *DRUG ALCOHOL DEPENDENCE* 2001;63(3):207-14. PMID:11418225

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Schmitz JP. Focus of attention in the treatment of depression. *Psychotherapy* 1983;20(4):457-63.

Exclude: For study design, OVID-Embase

OVID-Embase.

Schneider CM, Hsieh CC, Sprod LK, et al. Cancer treatment-induced alterations in muscular fitness and quality of life: the role of exercise training. *Annals of Oncology* 2007;18(12):1957-62. PMID:17804476

Exclude: For study design, OVID-Medline.

Schneider LS, Small GW, Clary CM. Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. *Am J Geriatr Psychiatry* 2001;9(4):393-9. PMID:11739065

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Schneider LS, Martinez RA, Lebowitz BD. Clinical psychopharmacology research in geriatrics: An agenda for research. *Int J Geriatr Psychiatry* 1993;8(1):89-93.

Exclude: For Guideline published before 2005, OVID-PsycINFO.

Schneider LS, Small GW, Hamilton SH, et al. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. *The Am J Geriatr Psychiatry* 1997;5(2):97-106.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Schoenbaum M, Miranda J, Sherbourne C, et al. Cost-effectiveness of interventions for depressed Latinos. *Journal of Mental Health Policy and Economics* 2004;7(2):69-76.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Scholz U, Knoll N, Sniehotta FF, et al. Physical activity and depressive symptoms in cardiac rehabilitation: long-term effects of a self-management intervention. *SOC SCI MED* 2006;62(12):3109-20. PMID:16388882

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Schopf J, Baumann P, Lemarchand T, et al. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. *Pharmacopsychiatry* 1989;22(5):183-7. PMID:2682692

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Schou M. Lithium and treatment-resistant depressions: A review. *Lithium* 1990;1(1):3-8.

Exclude: For systematic review before 2005, OVID-PsycINFO.

Schou M. Lithium treatment: A refresher course. *Br J Psychiatry* 1986;149(NOV.):541-7.

Exclude: For Guideline published before 2005, OVID-Embase

OVID-Embase.

Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. *Int Clin Psychopharmacol* 2000;15(2):61-8. PMID:10759336

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Schrader E, Meier B, Brattstrom A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study. *Hum Psychopharmacol* 1998;13(3):163-9.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Schramm E, van Calker D, Dykierk P, et al. An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: acute and long-term results. *Am J Psychiatry* 2007;164(5):768-77. PMID:17475736

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Schramm E, Schneider D, Zobel I, et al. Efficacy of Interpersonal Psychotherapy plus pharmacotherapy in chronically depressed inpatients. *J Affect Disord* 2008;109(1-2):65-73. PMID:18067973

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Schroer S, MacPherson H. Acupuncture, or non-directive counselling versus usual care for the treatment of depression: a pilot study. *Trials [Electronic Resource]* 2009;10:3 PMID:19134170

Exclude: For study design, OVID-Medline.

Schulberg HC, Post EP, Raue PJ, et al. Treating late-life depression with interpersonal psychotherapy in the

primary care sector. *Int J Geriatr Psychiatry* 2007;22(2):106-14. PMID:17096458

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Schulberg HC, Katon W, Simon GE, et al. Treating major depression in primary care practice: An update of the agency for health care policy and research practice guidelines. *Arch Gen Psychiatry* 1998;55(12):1121-7.

Exclude: For Guideline published before 2005, OVID-Embase.

Schule C, Baghai TC, Eser D, et al. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. *World J Biol Psychiatry* 2007;8(2):112-22. PMID:17455104

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Schultz, C.L. The effect of cognitive group therapy in the treatment of depression among residents of senior communities Schultz. 1996

Exclude: For study design, OVID-PsycINFO.

Schulz V. Clinical trials with Hypericum extracts in patients with depression -- results, comparisons, conclusions for therapy with antidepressant drugs. *Phytomedicine* 2002;9(5):468-74.

Exclude: For systematic review before 2005, EBSCO-CINAHL.

Schwartz TL, Azhar N, Cole K, et al. An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. *J Clin Psychiatry* 2004;65(9):1223-7. PMID:15367049

Exclude: For study design, OVID-Medline.

Schwartz TL, Nasra GS, Chilton M, et al. Aripiprazole augmentation of selective serotonin or serotonin norepinephrine reuptake inhibitors in the treatment of major depressive disorder. *Prim Psychiatry* 2007;14(1):67-9.

Exclude: For study design, OVID-Embase.

Schweitzer I, Burrows G, Tuckwell V, et al. Sustained response to open-label venlafaxine in drug-resistant major depression. *J Clin Psychopharm* 2001;21(2):185-9. PMID:11270915

Exclude: For study design, OVID-Medline.

Schweizer E, Rynn M, Mandos LA, et al. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. *Int Clin Psychopharmacol* 2001;16(3):137-43. PMID:11354235

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Schweizer E, Rickels K, Amsterdam JD, et al. What constitutes an adequate antidepressant trial for fluoxetine? *J Clin Psychiatry* 1990;51(1):8-11. PMID:2403998

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Scogin F, Jamison C, Gochneaur K. Comparative efficacy of cognitive and behavioral bibliotherapy for

- mildly and moderately depressed older adults. *J Consult Clin Psychol* 1989;57(3):403-7. PMID:2738212
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Scogin F, McElreath L. Efficacy of psychosocial treatments for geriatric depression: A quantitative review. *J Consult Clin Psychol* 1994;62(1):69-74.
Exclude: For systematic review before 2005, OVID-Embase.
- Scogin F, Jamison C, Davis N. Two-year follow-up of bibliotherapy for depression in older adults. *J Consult Clin Psychol* 1990;58(5):665-7. PMID:2254516
Exclude: For study design, OVID-Medline.
- Scogin F, Hamblin D, Beutler L. Bibliotherapy for depressed older adults: A self-help alternative. *The Gerontologist* 1987;27(3):383-7.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Scogin F, Jamison C, Davis N. Two-year follow-up of bibliotherapy for depression in older adults. *J Consult Clin Psychol* 1990;58(5):665-7.
Exclude: For study design, OVID-PsycINFO.
- Scott AI, Freeman CP. Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks. *BMJ* 1992;304(6831):883-7. PMID:1392754
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Scott C, Tacchi MJ, Jones R, et al. Acute and one-year outcome of a randomised controlled trial of brief cognitive therapy for major depressive disorder in primary care. *Br J Psychiatry* 1997;171:131-4. PMID:9337947
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Scott CS, Scott JL, Tacchi MJ, et al. Abbreviated cognitive therapy for depression: A pilot study in primary care. *Behavioural Psychotherapy* 1994;22(1):57-64.
Exclude: For study design, OVID-Embase.
- Scott J, Moon CA, Blacker CV, et al. A. I. F. Scott & C. P. L. Freeman's "Edinburgh Primary Care Depression Study. *Br J Psychiatry* 1994;164(3):410-5. PMID:8199795
Exclude: For study design, OVID-Medline.
- Scott J. Chronic depression: Can cognitive therapy succeed when other treatments fail? *Behavioural Psychotherapy* 1992;20(1):25-36.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Scott J, Teasdale JD, Paykel ES, et al. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. *Br J Psychiatry* 2000;177:440-6. PMID:11059998
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Scott J, Palmer S, Paykel E, et al. Use of cognitive therapy for relapse prevention in chronic depression. Cost-effectiveness study. *Br J Psychiatry* 2003;182:221-7. PMID:12611785
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Scott MJ, Stradling SG. Group cognitive therapy for depression produces clinically significant reliable change in community-based settings. *Behavioural Psychotherapy* 1990;18(1):1-19.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Scott, T.M. Treating adult depression in rural areas through videoconferencing Scott. 2009
Exclude: For study design, OVID-PsycINFO.
- Segal ZV, Kennedy SH, Cohen NL, et al. Clinical guidelines for the treatment of depressive disorders. V. Combining psychotherapy and pharmacotherapy. *Can J Psychiatry* 2001;46:Suppl-62S PMID:11441772
Exclude: For Guideline published before 2005, OVID-Medline.
- Segal ZV, Whitney DK, Lam RW, et al. Clinical guidelines for the treatment of depressive disorders. III. Psychotherapy. *Can J Psychiatry* 2001;46:Suppl-37S PMID:11441770
Exclude: For Guideline published before 2005, OVID-Medline.
- Segar ML, Katch VL, Roth RS, et al. The effect of aerobic exercise on self-esteem and depressive and anxiety symptoms among breast cancer survivors. *Oncol Nurs Forum* 1998;25(1):107-13.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. *J Affect Disord* 1998;48(2-3):157-61. PMID:9543205
Exclude: For study design, OVID-Medline.
- Seligman ME, Schulman P, Tryon AM. Group prevention of depression and anxiety symptoms. *Behav Res Ther* 2007;45(6):1111-26. PMID:17074301
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Selmi PM, Klein MH, Greist JH, et al. Computer-administered cognitive-behavioral therapy for depression. *Am J Psychiatry* 1990;147(1):51-6. PMID:2403473
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Selmi PM, Klein MH, Greist JH, et al. Computer-administered therapy for depression. *MD Computing* 1991;8(2):98-102. PMID:2038242
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Semla TP, Watanabe MD. ASHP therapeutic position statement on the recognition and treatment of depression in older adults. *AM J HEALTH SYST PHARM AJHP* 1998;55(23):2514-8.
Exclude: For Guideline published before 2005, OVID-Embase.
- Seo HJ, Jung YE, Woo YS, et al. Effect of augmented atypical antipsychotics on weight change in patients

with major depressive disorder in a naturalistic setting. *Hum Psychopharmacol* 2009;24(2):135-43.

PMID:19156709

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sephton SE, Salmon P, Weissbecker I, et al. Mindfulness meditation alleviates depressive symptoms in women with fibromyalgia: results of a randomized clinical trial. *Arthritis & Rheumatism: Arthritis Care & Research* 2007;57(1):77-85.

Exclude: For population/not failed to respond to an SSRI, EBSICO-CINAHL.

Seppälä T, Linnola M, Mattila MJ. Psychomotor skills in depressed out-patients treated with L-tryptophan, doxepin, or chlorimipramine. *Annals of clinical research* 1978;10(4):214-21.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Serre C, Clerc G, Escande M. An early clinical trial of midalcipran, 1-phenyl-1-diethyl aminocarbonyl 2-aminomethyl cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant. *Curr Ther Res Clin Exp* 1986;39(1):156-64.

Exclude: For study design, OVID-Embase

OVID-Embase.

Serretti A, Calati R, Massat I, et al. Cytochrome p450 cyp1a2, cyp2c9, cyp2c19 and cyp2d6 genes are not associated with response and remission in a sample of depressive patients. *Int Clin Psychopharmacol* 2009;24(5):250-6. PMID:19593158

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. *Br J Psychiatry* 1992;161:562-5. PMID:1327396

Exclude: For study design, OVID-Medline.

Sevar R. Audit of outcome in 455 consecutive patients treated with homeopathic medicines. *Homeopathy* 2005;94(4):215-21.

Exclude: For study design, OVID-Embase.

Shahal B, Piel E, Mecz L, et al. Lack of advantage for imipramine combined with lithium versus imipramine alone in the treatment of major depression--a double-blind controlled study. *Biol Psychiatry* 1996;40(11):1181-3.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Shamsaei F, Rahimi A, Zarabian MK, et al. Efficacy of pharmacotherapy and cognitive therapy, alone and in combination in major depressive disorder. *HONG KONG J PSYCHIATRY* 2008;18(2):76-80.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Shapira B, Kindler S, Lerer B. Medication outcome in ECT-resistant depression. *Convulsive Therapy* 1988;4(3):192-8.

Exclude: For study design, OVID-Embase.

Shapira B. Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. *Biol Psychiatry* 1985;20(5):576-9.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Shapiro D, Cook IA, Davydov DM, et al. Yoga as a complementary treatment of depression: Effects of traits and moods on treatment outcome. *Evidence-based Complementary and Alternative Medicine* 2007;4(4):493-502.

Exclude: For study design, OVID-Embase.

Shapiro DA, Barkham M, Rees A, et al. Effects of treatment duration and severity of depression on the effectiveness of cognitive-behavioral and psychodynamic-interpersonal psychotherapy. *J Consult Clin Psychol* 1994;62(3):522-34.

PMID:8063978

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Shapiro DA, Firth J. Prescriptive v. exploratory psychotherapy: Outcomes of the Sheffield Psychotherapy Project. *Br J Psychiatry* 1987;151:790-9.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Shapiro J, Sank LI, Shaffer CS, et al. Cost effectiveness of individual vs. group cognitive behavior therapy for problems of depression and anxiety in an HMO population. *J Clin Psych* 1982;38(3):674-7.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Sharma V, Persad E, Kueneman K, et al. Lithium augmentation of valproic acid in treatment resistant depression. *Lithium* 1994;5(2):99-103.

Exclude: For study design, OVID-Embase.

Sharpe L, Sensky T, Timberlake N, et al. A blind, randomized, controlled trial of cognitive-behavioural intervention for patients with recent onset rheumatoid arthritis: Preventing psychological and physical morbidity. *Pain* 2001;89(2-3):275-83.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Sharpe M, Strong V, Allen K, et al. Management of major depression in outpatients attending a cancer centre: A preliminary evaluation of a multicomponent cancer nurse-delivered intervention. *British Journal of Cancer* 2004;90(2):310-3.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Sharpley AL, Attenburrow ME, Hafizi S, et al. Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients. *J Clin Psychiatry* 2005;66(4):450-4. PMID:15816787

Exclude: For study design, OVID-Medline.

Shaw DM. L-tryptophan in depression. *Lancet* 1970;1(7656):1111

Exclude: For study design, Wiley-CCTR.

- Shaw DM, Johnson AL, MacSweeney DA. Tricyclic antidepressants and tryptophan in unipolar affective disorder. *Lancet* 1972;2(7789):1245
Exclude: For study design, Wiley-CCTR.
- Shaw K, Turner J, Del Mar C. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. *Aust NZ J Psychiatry* 2002;36(4):488-91. PMID:12169147
Exclude: For systematic review before 2005, OVID-Medline.
- Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression.[update of Cochrane Database Syst Rev. 2001;(3):CD003198; PMID: 11687048]. [Review] [87 refs]. *Cochrane Database of Systematic Reviews* 2002;(1):CD003198 PMID:11869656
Exclude: For systematic review before 2005, OVID-Medline.
- Shea MT, Elkin I, Imber SD, et al. Course of depressive symptoms over follow-up. Findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. *Arch Gen Psychiatry* 1992;49(10):782-7. PMID:1417430
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Sheffield JK, Spence SH, Rapee RM, et al. Evaluation of universal, indicated, and combined cognitive-behavioral approaches to the prevention of depression among adolescents. *J Consult Clin Psychol* 2006;74(1):66-79. PMID:16551144
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Sheffrin M, Driscoll HC, Lenze EJ, et al. Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. *J Clin Psychiatry* 2009;70(2):208-13. PMID:19210951
Exclude: For study design, OVID-Medline.
- Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. *JAMA* 2001;285(15):1978-86. PMID:11308434
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Shelton RC, Addington S, Thakkar V. Risperidone vs. Bupropion Combined with SSRIs in Treatment Resistant Unipolar Major Depression. *Neuropsychopharmacol* 2005;30 Suppl 1:S238
Exclude: For study design, Wiley-CCTR.
- Shelton RC, Loosen PT. Sleep deprivation accelerates the response to nortriptyline. *Prog Neuropsychopharmacol Biol Psychiatry* 1993;17(1):113-23. PMID:8416598
Exclude: For study design, OVID-Medline.
- Shelton RC, Tohen M, Stahl S, et al. The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features. *Schizophrenia Research* 2000;Number 1 - Special Issue:
Exclude: For study design, Wiley-CCTR.
- Sher TG, Baucom DH, Larus JM. Communication patterns and response to treatment among depressed and nondepressed maritally distressed couples. *Journal of Family Psychology* 1990;4(1):63-79.
Exclude: For study design, OVID-PsycINFO.
- Sherbourne CD, Edelen MO, Zhou A, et al. How a therapy-based quality improvement intervention for depression affected life events and psychological well-being over time: a 9-year longitudinal analysis. *MED CARE* 2008;46(1):78-84.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Shergill SS, Robertson MM, Stein G, et al. Outcome in refractory depression. *J Affect Disord* 1999;54(3):287-94. PMID:10467973
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Shippy RA, Mendez D, Jones K, et al. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. *BMC Psychiatry* 2004;4:38 PMID:15538952
Exclude: For study design, OVID-Medline.
- Shirk SR, Kaplinski H, Gudmundsen G. School-based cognitive-behavioral therapy for adolescent depression: a benchmarking study. *Journal of Emotional & Behavioral Disorders* 2009;17(2):106-17.
Exclude: For study design, EBSCO-CINAHL.
- Shore AG. Long-term effects of energetic healing on symptoms of psychological depression and self-perceived stress. *Altern Ther Health Med* 2004;10(3):42-8. **Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Siepmann M, Aykac V, Unterdorfer J, et al. A pilot study on the effects of heart rate variability biofeedback in patients with depression and in healthy subjects. *Applied Psychophysiology & Biofeedback* 2008;33(4):195-201. PMID:18807175
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Silvers KM, Woolley CC, Hamilton FC, et al. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. *Prostaglandins Leukotrienes & Essential Fatty Acids* 2005;72(3):211-8. PMID:15664306
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Silvers KM, Woolley CC, Hamilton FC, et al. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. *Prostaglandins, leukotrienes, and essential fatty acids* 2005;72(3):211-8.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Simeon J, Milin R, Walker S. A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders. *Progress in Neuro-Prog Neuropsychopharmacol Biol Psychiatry* 2002;26(2):267-75.
Exclude: For study design, OVID-Embase.

- Simeon J, Nixon MK, Milin R, et al. Open-label pilot study of St. John's wort in adolescent depression. *Journal of Child & Adolescent Psychopharmacology* 2005;15(2):293-301. PMID:15910213
Exclude: For study design, OVID-Medline.
- Simeon J, Nixon MK, Milin R, et al. Open-Label Pilot Study of St. John's Wort in Adolescent Depression. *Journal of Child and Adolescent Psychopharmacology* 2005;15(2):293-301.
Exclude: For study design, OVID-PsycINFO.
- Simko A. Guidelines for the use of psychopharmaca in geriatric cases. *Therapia Hungarica* 1989;37(4):187-98.
Exclude: For Guideline published before 2005, OVID-Embase.
- Simon GE, Von Korff M, Lin E. Clinical and functional outcomes of depression treatment in patients with and without chronic medical illness. *Psychol Med* 2005;35(2):271-9.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Simon GE, Manning WG, Katzelnick DJ, et al. Cost-effectiveness of systematic depression treatment for high utilizers of general medical care. *Arch Gen Psychiatry* 2001;58(2):181-7.
Exclude: For study design, OVID-Embase.
- Simon GE, Ludman EJ, Rutter CM. Incremental benefit and cost of telephone care management and telephone psychotherapy for depression in primary care. *Arch Gen Psychiatry* 2009;66(10):1081-9. PMID:19805698
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Simon GE, Lin EHB, Katon W, et al. Outcomes of 'inadequate' antidepressant treatment. *J Gen Intern Med* 1995;10(12):663-70.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Simon GE, Ludman EJ, Operskalski BH. Randomized trial of a telephone care management program for outpatients starting antidepressant treatment. *Psychiatr Serv* 2006;57(10):1441-5. PMID:17035563
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. *Gen Hosp Psychiatry* 2000;22(3):153-62.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Simon GE, Ludman EJ, Tutty S, et al. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized controlled trial. *JAMA* 2004;292(8):935-42. PMID:15328325
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Simon J, Pilling S, Burbeck R, et al. Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. *Br J Psychiatry* 2006;189:494-501. PMID:17139032
Exclude: For guideline, not a population of interest, OVID-Medline.
- Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. *J Clin Psychiatry* 2005;66(10):1216-20. PMID:16259533
Exclude: For study design, OVID-Medline.
- Simons AD, Murphy GE, Levine JL, et al. Cognitive therapy and pharmacotherapy for depression. Sustained improvement over one year. *Arch Gen Psychiatry* 1986;43(1):43-8.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
- OVID-Embase.
- Simons AD, Garfield SL, Murphy GE. The process of change in cognitive therapy and pharmacotherapy for depression. Changes in mood and cognition. *Arch Gen Psychiatry* 1984;41(1):45-51.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase
- OVID-Embase.
- Simpson GM, Amin M, Angus JW, et al. Role of antidepressants and neuroleptics in the treatment of depression. *Arch Gen Psychiatry* 1972;27(3):337-45.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Simpson S, Corney R, Beecham J. A randomized controlled trial to evaluate the effectiveness and cost-effectiveness of psychodynamic counselling for general practice patients with chronic depression. *Psychol Med* 2003;33(2):229-39.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Simpson SW, Jackson A, Baldwin RC, et al. Subcortical hyperintensities in late-life depression: Acute response to treatment and neuropsychological impairment. *INT PSYCHOGERIATR* 1997;9(3):257-75.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Simpson S, Baldwin RC, Jackson A, et al. Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. *Psychol Med* 1998;28(5):1015-26.
Exclude: For study design, OVID-PsycINFO.
- Sims J, Hill K, Davidson S, et al. Exploring the feasibility of a community-based strength training program for older people with depressive symptoms and its impact on depressive symptoms. *BMC Geriatrics* 2006;6:18. PMID:17134517
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Sims J, Galea M, Taylor N, et al. Regenerate: assessing the feasibility of a strength-training program to enhance the physical and mental health of chronic

- post stroke patients with depression. *Int J Geriatr Psychiatry* 2009;24(1):76-83. PMID:18613281
Exclude: For population/diagnosis, OVID-Medline.
- Sinclair JM, Walsh MR, Valle-Jones JC, et al. Treatment of anxiety/depressive conditions in the elderly: a double-blind comparative study of Motival and amitriptyline. *Age and Ageing* 1975;4(4):226-31.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Singh NA, Clements KM, Fiatarone MA. A randomized controlled trial of progressive resistance training in depressed elders. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences* 1997;52(1):M27-M35 PMID:9008666
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Singh NA, Stavrinou TM, Scarbek Y, et al. A randomized controlled trial of high versus low intensity weight training versus general practitioner care for clinical depression in older adults. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences* 2005;60(6):768-76.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Singh NA, Clements KM, Singh MAF. The efficacy of exercise as a long-term antidepressant in elderly subjects: A randomized, controlled trial. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences* 2001;56(8):M497-M504
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Singh NA, Clements KM, Fiatarone MA. A randomized controlled trial of the effect of exercise on sleep. *Sleep: Journal of Sleep Research & Sleep Medicine* 1997;20(2):95-101.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Siris SG, Cutler J, Owen K, et al. Adjunctive imipramine maintenance treatment in schizophrenic patients with remitted postpsychotic depression. *Am J Psychiatry* 1989;146(11):1495-7. PMID:2817126
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Siris SG, Rifkin A, Reardon GT, et al. Comparative side effects of imipramine, benzotropine, or their combination in patients receiving fluphenazine decanoate. *Am J Psychiatry* 1983;140(8):1069-71. PMID:6346910
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Siwek M, Dudek D, Paul IA, et al. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: A double blind, placebo-controlled study. *J Affect Disord* 2009;118(1-3):187-95.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Skevington SM, Wright A. Changes in the quality of life of patients receiving antidepressant medication in primary care: validation of the WHOQOL-100. *Br J Psychiatry* 2001;178(3):261-7.
Exclude: For study design, OVID-AMED.
- Slooman R. Relaxation and imagery for anxiety and depression control in community patients with advanced cancer. *CANCER NURS* 2002;25(6):432-5. PMID:12464834
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Small JG, Kellams JJ, Dennis JL, et al. Comparison of molindone and tranylcypromine in the treatment of refractory depression. *J CLIN PHARMACOL* 1981;21(8-9):351-8.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. *J Affect Disord* 1998;48(1):47-56. PMID:9495601
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Smit A, Kluiters H, Conradi HJ, et al. Short-term effects of enhanced treatment for depression in primary care: Results from a randomized controlled trial. *Psychol Med* 2006;36(1):15-26.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Smit F, Willemse G, Koopmanschap M, et al. Cost-effectiveness of preventing depression in primary care patients: randomised trial. *Br J Psychiatry* 2006;188:330-6. PMID:16582059
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Smith Fawzi MC, Kaaya SF, Mbwambo J, et al. Multivitamin supplementation in HIV-positive pregnant women: impact on depression and quality of life in a resource-poor setting. *HIV Medicine* 2007;8(4):203-12. PMID:17461847
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Smith A, Graham L, Senthinathan S. Mindfulness-based cognitive therapy for recurring depression in older people: a qualitative study. *AGING MENT HEALTH* 2007;11(3):346-57. PMID:17558586
Exclude: For study design, OVID-Medline.
- Smith CE, Leenerts MH, Gajewski BJ. A systematically tested intervention for managing reactive depression. *Nurs Res* 2003;52(6):401-9. PMID:14639087
Exclude: For systematic review before 2005, OVID-Medline.
- Smith C A, Hay Phillipa P J. Acupuncture for depression. In 2004. **Exclude:** For systematic review before 2005, Wiley-CDSR.
- Smith DF, Stromgren E, Petersen HN. Lack of effect of tryptophan treatment in demented gerontopsychiatric patients. A double-blind, crossover-controlled study. *Acta Psychiatr Scand* 1984;70(5):470-7.
Exclude: For population/diagnosis, OVID-Embase.

OVID-Embase.

Smith GS, Reynolds CF, III, Houck PR, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: a randomized, placebo-controlled study. *Psychiatry Res* 2009;171(1):1-9. PMID:19087899

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Smith NM, Floyd MR, Scogin F, et al. Three-year follow-up of bibliotherapy for depression. *J Consult Clin Psychol* 1997;65(2):324-7. PMID:9086697

Exclude: For study design, OVID-Medline.

Smith PJ, Blumenthal JA, Babyak MA, et al. Effects of exercise and weight loss on depressive symptoms among men and women with hypertension. *J Psychosom Res* 2007;63(5):463-9.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Smith PS, Thompson M. Treadmill training post stroke: are there any secondary benefits? A pilot study. *CLIN REHABIL* 2008;22(10-11):997-1002.

Exclude: For population/diagnosis, Wiley-CCTR.

Smith WT, Lønborg PD, Glaudin V, et al. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? *J Affect Disord* 2002;70(3):251-9. PMID:12128237

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Smith WT, Lønborg PD, Glaudin V, et al. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. *Am J Psychiatry* 1998;155(10):1339-45. PMID:9766764

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Smith WT, Lønborg PD, Glaudin V, et al. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? *J Affect Disord* 2002;70(3):251-9.

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-PsycINFO.

Smits JA, Minhajuddin A, Jarrett RB. Cognitive therapy for depressed adults with comorbid social phobia. *J Affect Disord* 2009;114(1-3):271-8. PMID:18804285

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Snow V, Lascher S, Mottur-Pilson C. Pharmacologic treatment of acute major depression and dysthymia. American College of Physicians-American Society of Internal Medicine. *Ann Intern Med* 2000;132(9):738-42. PMID:10787369

Exclude: For Guideline published before 2005, OVID-Medline.

Soares CN, Poitras JR, Prouty J, et al. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and

vasomotor symptoms. *J Clin Psychiatry* 2003;64(4):473-9. PMID:12716252

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Soden K, Vincent K, Craske S, et al. A randomized controlled trial of aromatherapy massage in a hospice setting. *PALLIAT MED* 2004;18(2):87-92. PMID:15046404

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sokolski KN, Reist C, Chen CC, et al. Antidepressant responses and changes in visual adaptation after sleep deprivation. *Psychiatry Res* 1995;57(3):197-207. PMID:7501729

Exclude: For study design, OVID-Medline.

Solomon DA, Leon AC, Mueller TI, et al. Tachyphylaxis in unipolar major depressive disorder. *J Clin Psychiatry* 2005;66(3):283-90.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Solomon JL. A clinical study of the effect of the introduction of antidepressant medication on the psychoanalytic process in an analysis of long duration. *Journal of Clinical Psychoanalysis* 1995;4(2):169-84.

Exclude: For study design, OVID-Embase.

Sommer H, Harrer G. Placebo-controlled double-blind study examining the effectiveness of an hypericum preparation in 105 mildly depressed patients. *J Geriatr Psychiatry Neurol* 1994;7:Suppl-11. PMID:7857516

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sondergaard MP, Jarden JO, Martiny K, et al. Dose response to adjunctive light therapy in citalopram-treated patients with post-stroke depression. A randomised, double-blind pilot study. *Psychother Psychosom* 2006;75(4):244-8. PMID:16785774

Exclude: For population/diagnosis, OVID-Medline.

Song Y, Zhou D, Fan J, et al. Effects of electroacupuncture and fluoxetine on the density of GTP-binding-proteins in platelet membrane in patients with major depressive disorder. *J Affect Disord* 2007;98(3):253-7. PMID:16919758

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sood JR, Cisek E, Zimmerman J, et al. Treatment of depressive symptoms during short-term rehabilitation: An attempted replication of the DOUR project. *REHABIL PSYCHOL* 2003;48(1):44-9.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Sorensen L, Nielsen B, Stage KB, et al. Implementation of a rational pharmacotherapy intervention for inpatients at a psychiatric department. *Nord J Psychiatry* 2008;62(3):242-9.

Exclude: For study design, OVID-Embase.

Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. *J Clin Psychiatry* 2007;68(7):1062-70. PMID:17685743

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Søgaard J, Lane R, Latimer P, et al. A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. *Journal of psychopharmacology (Oxford, England)* 1999;13(4):406-14.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Søndergaard MP, Jarden JO, Martiny K, et al. Dose response to adjunctive light therapy in citalopram-treated patients with post-stroke depression. A randomised, double-blind pilot study. *Psychother Psychosom* 2006;75(4):244-8.

Exclude: For population/diagnosis, Wiley-CCTR.

Spek V, Nyklicek I, Smits N, et al. Internet-based cognitive behavioural therapy for subthreshold depression in people over 50 years old: a randomized controlled clinical trial. *Psychol Med* 2007;37(12):1797-806. PMID:17466110

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Spek V, Cuijpers P, Nyklicek I, et al. One-year follow-up results of a randomized controlled clinical trial on internet-based cognitive behavioural therapy for subthreshold depression in people over 50 years. *Psychol Med* 2008;38(5):635-9. PMID:18205965

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Spier SA. Use of bupropion with SRIs and venlafaxine. *Depress Anxiety* 1998;7(2):73-5. PMID:9614595

Exclude: For study design, OVID-Medline.

Splevins K, Smith A, Simpson J. Do improvements in emotional distress correlate with becoming more mindful? A study of older adults. *AGING MENT HEALTH* 2009;13(3):328-35. PMID:19484596

Exclude: For study design, OVID-Medline.

Spoov J, Lahdelma L. Should thyroid augmentation precede lithium augmentation--a pilot study. *J Affect Disord* 1998;49(3):235-9. PMID:9629954

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Sporn J, Ghaemi SN, Sambur MR, et al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. *Ann Clin Psychiatry* 2000;12(3):137-40. PMID:10984002

Exclude: For study design, OVID-Medline.

Stabl M, Kasas A, Blajev B, et al. A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression.[erratum appears in *J Clin Psychopharmacol* 1995 Oct;15(5):360]. *J Clin Psychopharm* 1995;15(4:Suppl 2):Suppl-45S PMID:7593730

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Stamm TJ, Adli M, Kirchheiner J, et al. Serotonin transporter gene and response to lithium augmentation in depression. *Psychiatric Genetics* 2008;18(2):92-7.

PMID:18349701

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Stant AD, Ten Vergert EM, den Boer PC, et al. Cost-effectiveness of cognitive self-therapy in patients with depression and anxiety disorders. *Acta Psychiatr Scand* 2008;117(1):57-66. PMID:18005369

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Steel JL, Nadeau K, Olek M, et al. Preliminary results of an individually tailored psychosocial intervention for patients with advanced hepatobiliary carcinoma. *Journal of Psychosocial Oncology* 2007;25(3):19-42.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Steffen AM, Futterman A, Gallagher-Thompson D. Depressed caregivers: Comparative outcomes of two interventions. *Clinical Gerontologist: The Journal of Aging and Mental Health* 1998;19(4):3-15.

Exclude: For systematic review before 2005, OVID-PscINFO.

Steffens DC, Doraiswamy PM, McQuoid DR. Bupropion SR in the naturalistic treatment of elderly patients with major depression. *Int J Geriatr Psychiatry* 2001;16(9):862-5. PMID:11571765

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Stein BD, Jaycox LH, Kataoka SH, et al. A mental health intervention for schoolchildren exposed to violence: a randomized controlled trial. *JAMA* 2003;290(5):603-11. PMID:12902363

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. *Br J Psychiatry* 1993;162:634-40. PMID:8149115

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Stein MD, Solomon DA, Anderson BJ, et al. Persistence of antidepressant treatment effects in a pharmacotherapy plus psychotherapy trial for active injection drug users. *American Journal on Addictions* 2005;14(4):346-57. PMID:16188715

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Stein MD, Solomon DA, Herman DS, et al. Pharmacotherapy plus psychotherapy for treatment of depression in active injection drug users.[erratum appears in *Arch Gen Psychiatry*. 2005 Feb;62(2):224]. *Arch Gen Psychiatry* 2004;61(2):152-9. PMID:14757591

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Stein PN, Motta RW. Effects of aerobic and nonaerobic exercise on depression and self-concept. *Perceptual and Motor Skills* 1992;74(1):79-89.

Exclude: For population/not failed to respond to an SSRI, OVID-PscINFO.

- Steinacher L, Vandel P, Zullino DF, et al. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. *European Neuropsychopharmacology* 2002;12(3):255-60. PMID:12007677
Exclude: For study design, OVID-Medline.
- Stella SG, Vilar AP, Lacroix C, et al. Effects of type of physical exercise and leisure activities on the depression scores of obese Brazilian adolescent girls. *Brazilian Journal of Medical and Biological Research* 2005;38(11):1683-9.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Stern MJ, Gorman PA, Kaslow L. The group counseling v exercise therapy study. A controlled intervention with subjects following myocardial infarction. *Arch Intern Med* 1983;143(9):1719-25.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Stern WC, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclic-resistant or intolerant patients. *J Clin Psychiatry* 1983;44(5:Pt 2):t:52 PMID:6406447
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Stevinson C. Preliminary results suggest that yoga can alleviate depression. *Focus on Alternative and Complementary Therapies* 2001;6(1):27-8.
Exclude: For study design, OVID-AMED.
- Stewart JW, Quitkin F, Fyer A, et al. Efficacy of desipramine in endogenomorphically depressed patients. *J Affect Disord* 1980;2(3):165-76. PMID:6210722
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Stewart JW, Mercier MA, Agosti V, et al. Imipramine is effective after unsuccessful cognitive therapy: sequential use of cognitive therapy and imipramine in depressed outpatients. *J Clin Psychopharm* 1993;13(2):114-9. PMID:8463443
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Stewart NJ, McMullen LM, Rubin LD. Movement therapy with depressed inpatients: a randomized multiple single case design. *Arch Psychiatr Nurs* 1994;8(1):22-9. PMID:8203940
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Stice E, Rohde P, Seeley JR, et al. Brief cognitive-behavioral depression prevention program for high-risk adolescents outperforms two alternative interventions: a randomized efficacy trial. *J Consult Clin Psychol* 2008;76(4):595-606. PMID:18665688
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Stice E, Burton E, Bearman SK, et al. Randomized trial of a brief depression prevention program: an elusive search for a psychosocial placebo control condition. *Behav Res Ther* 2007;45(5):863-76. PMID:17007812
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Stimpson N, Agrawal N, Lewis G. Randomised controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression. Systematic review. . [Review] [43 refs]. *Br J Psychiatry* 2002;181:284-94. PMID:12356654
Exclude: For systematic review before 2005, OVID-Medline.
- Stinson CK, Kirk E. Structured reminiscence: an intervention to decrease depression and increase self-transcendence in older women. *J CLIN NURS* 2006;15(2):208-18. PMID:16422738
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Stinson D, Thompson C. Clinical experience with phototherapy. *J Affect Disord* 1990;18(2):129-35. PMID:2137470
Exclude: For study design, OVID-Medline.
- Story TJ, Potter GG, Attix DK, et al. Neurocognitive correlates of response to treatment in late-life depression. *Am J Geriatr Psychiatry* 2008;16(9):752-9.
Exclude: For study design, OVID-Embase.
- Stoudemire A, Hill CD, Lewison BJ, et al. Lithium intolerance in a medical-psychiatric population. *Gen Hosp Psychiatry* 1998;20(2):85-90. PMID:9582592
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Stoudemire A, Hill CD, Marquardt M, et al. Recovery and relapse in geriatric depression after treatment with antidepressants and ECT in a medical-psychiatric population. *Gen Hosp Psychiatry* 1998;20(3):170-4. PMID:9650035
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Strachowski D, Khaylis A, Conrad A, et al. The effects of cognitive behavior therapy on depression in older patients with cardiovascular risk. *Depress Anxiety* 2008;25(8):E1-10. PMID:17377961
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Strauman TJ, Vieth AZ, Merrill KA, et al. Self-system therapy as an intervention for self-regulatory dysfunction in depression: a randomized comparison with cognitive therapy. *J Consult Clin Psychol* 2006;74(2):367-76. PMID:16649881
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Strauss W H. Combined Cognitive-Behavioral and Pharmacotherapy in Refractory Depression CONFERENCE ABSTRACT. In 1996; 1996.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Strauss W H. Combined cognitive-behavioral and pharmacotherapy in refractory depression. In 2002.
Exclude: For study design, Wiley-CCTR.
- Stravynski A, Shahar A, Verreault R. A pilot study of the cognitive treatment of dysthymic disorder. *Behavioural Psychotherapy* 1991;19(4):369-72.

- Exclude:** For study design, OVID-Embase
OVID-Embase.
- Stravynski A, Greenberg D. The psychological management of depression. *Acta Psychiatr Scand* 1992;85(6):407-14.
- Exclude:** For systematic review before 2005, OVID-PsycINFO.
- Stravynski A, Verreault R, Gaudette G, et al. The treatment of depression with group behavioural-cognitive therapy and imipramine. *Can J Psychiatry* 1994;39(7):387-90. PMID:7987780
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Strickland TL, Stein R, Lin KM, et al. The pharmacologic treatment of anxiety and depression in African Americans. Considerations for the general practitioner. [Review] [43 refs]. *Archives of Family Medicine* 1997;6(4):371-5. PMID:9225711
- Exclude:** For systematic review before 2005, OVID-Medline.
- Strober M, Freeman R, Rigali J, et al. The pharmacotherapy of depressive illness in adolescence: II. Effects of lithium augmentation in nonresponders to imipramine. *J Am Acad Child Adolesc Psychiatry* 1992;31(1):16-20. PMID:1537769
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Strober M, DeAntonio M, Schmidt-Lackner S, et al. The pharmacotherapy of depressive illness in adolescents: an open-label comparison of fluoxetine with imipramine-treated historical controls. *J Clin Psychiatry* 1999;60(3):164-9. PMID:10192591
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Strong DR, Kahler CW, Leventhal AM, et al. Impact of bupropion and cognitive-behavioral treatment for depression on positive affect, negative affect, and urges to smoke during cessation treatment. *Nicotine and Tobacco Research* 2009;11(10):1142-53.
- Exclude:** For population/not failed to respond to an SSRI, OVID-Embase.
- Stryjer R, Strous RD, Shaked G, et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. *Int Clin Psychopharmacol* 2003;18(2):93-6. PMID:12598820
- Exclude:** For study design, OVID-Medline.
- Stuart S, Bowers WA. Cognitive therapy with inpatients: Review and meta-analysis. *Journal of Cognitive Psychotherapy: An International Quarterly* 1995;9(2):85-92.
- Exclude:** For systematic review before 2005, OVID-Embase.
- Stump, J.E.L. Efficacy and process of cognitive bibliotherapy for the treatment of depression in prison Stump. 2004
- Exclude:** For study design, OVID-PsycINFO.
- Stuppaeck C, Barnas C, Miller C, et al. Carbamazepine in the prophylaxis of mood disorders. *J Clin Psychopharm* 1990;10(1):39-42. PMID:2307735
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Stuppaeck CH, Barnas C, Schwitzer J, et al. Carbamazepine in the prophylaxis of major depression: a 5-year follow-up. *J Clin Psychiatry* 1994;55(4):146-50. PMID:8071258
- Exclude:** For study design, OVID-Medline.
- Su KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial.[erratum appears in *Eur Neuropsychopharmacol*. 2004 Mar;14(2):173]. *European Neuropsychopharmacol* 2003;13(4):267-71. PMID:12888186
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Sudweeks, C. Effects of cognitive group hypnotherapy in the alteration of depressogenic schemas Sudweeks. 1998
- Exclude:** For study design, OVID-PsycINFO.
- Suffin S C, Gutierrez N M, Karan S and others. Neurometric EEG Predicts Pharmacotherapeutic Outcome in Depressed Outpatients: A Prospective Trial CONFERENCE ABSTRACT. In 1997; 1997.
- Exclude:** For study design, Wiley-CCTR.
- Suija K, Pechter U, Kalda R, et al. Physical activity of depressed patients and their motivation to exercise: Nordic walking in family practice. *INT J REHABIL RES* 2009;32(2):132-8.
- Exclude:** For study design, OVID-Embase.
- Sullivan MJ, Adams H, Tripp D, et al. Stage of chronicity and treatment response in patients with musculoskeletal injuries and concurrent symptoms of depression. *Pain* 2008;135(1-2):151-9. PMID:17646052
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Sullivan MJ, Wood L, Terry J, et al. The Support, Education, and Research in Chronic Heart Failure Study (SEARCH): a mindfulness-based psychoeducational intervention improves depression and clinical symptoms in patients with chronic heart failure. *Am Heart J* 2009;157(1):84-90. PMID:19081401
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Sumaya IC, Rienzi BM, Deegan JF, et al. Bright light treatment decreases depression in institutionalized older adults: a placebo-controlled crossover study. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences* 2001;56(6):M356-M360 PMID:11382795
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Sund KP, Huang SY, Chiu CC, et al. Omega-3 fatty acids in major depressive disorder A preliminary double-blind, placebo-controlled trial. . *European Neuropsychopharmacol* 2003;13(4):267-71.
- Exclude:** For population/not failed to respond to an SSRI, OVID-PsycINFO.

- Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. *Arch Gen Psychiatry* 1994;51(8):607-15. PMID:7519005
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Sutherland JE, Sutherland SJ, Hoehns JD. Achieving the best outcome in treatment of depression. *The J Fam Prac* 2003;52(3):201-9.
Exclude: For Guideline published before 2005, OVID-PsycINFO.
- Suwalska A, Rybakowski J. Potentiation of antidepressants with lithium or carbamazepine CONFERENCE ABSTRACT. In 1996; 1996.
Exclude: For study design, Wiley-CCTR.
- Suwalska A, Rybakowski J. Potentiation of antidepressants with lithium or carbamazepine: Factors associated with therapeutic efficacy CONFERENCE ABSTRACT. In 1998; 1998.
Exclude: For study design, Wiley-CCTR.
- Svanborg C, Wistedt AA, Svanborg P. Long-term outcome of patients with dysthymia and panic disorder: a naturalistic 9-year follow-up study. *Nord J Psychiatry* 2008;62(1):17-24. PMID:18389421
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Svartberg M, Stiles TC. Comparative effects of short-term psychodynamic psychotherapy: A meta-analysis. *J Consult Clin Psychol* 1991;59(5):704-14.
Exclude: For systematic review before 2005, OVID-Embase.
- Swan J, Sorrell E, MacVicar B, et al. "Coping with depression": an open study of the efficacy of a group psychoeducational intervention in chronic, treatment-refractory depression. *J Affect Disord* 2004;82(1):125-9. PMID:15465585
Exclude: For study design, OVID-Medline.
- Swartz HA, Frank E, Shear MK, et al. A pilot study of brief interpersonal psychotherapy for depression among women. *Psychiatr Serv* 2004;55(4):448-50. PMID:15067162
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Swartz HA, Frank E, Zuckoff A, et al. Brief interpersonal psychotherapy for depressed mothers whose children are receiving psychiatric treatment. *Am J Psychiatry* 2008;165(9):1155-62.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Szanto K, Mulsant BH, Houck P, et al. Occurrence and course of suicidality during short-term treatment of late-life depression. *Arch Gen Psychiatry* 2003;60(6):610-7. PMID:12796224
Exclude: For systematic review before 2005, OVID-Medline.
- Szegedi A, Kohnen R, Dienel A, et al. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. [erratum appears in *BMJ*. 2005 Apr 2;330(7494):759 Note: dosage error in text]. *BMJ* 2005;330(7490):503 PMID:15708844
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Szegedi A, Wetzel H, Leal M, et al. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. *J Clin Psychiatry* 1996;57(6):257-64. PMID:8666564
Exclude: For study design, OVID-Medline.
- Szigethy E, Whitton SW, Levy-Warren A, et al. Cognitive-behavioral therapy for depression in adolescents with inflammatory bowel disease: a pilot study. *J Am Acad Child Adolesc Psychiatry* 2004;43(12):1469-77. PMID:15564816
Exclude: For study design, OVID-Medline.
- Szigethy E, Kenney E, Carpenter J, et al. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. *J Am Acad Child Adolesc Psychiatry* 2007;46(10):1290-8. PMID:17885570
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Szigethy E, Craig AE, Iobst EA, et al. Profile of depression in adolescents with inflammatory bowel disease: implications for treatment. *Inflammatory Bowel Diseases* 2009;15(1):69-74. PMID:18831071
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Szigethy E, Whitton SW, Levy-Warren A, et al. Cognitive-Behavioral Therapy for Depression in Adolescents With Inflammatory Bowel Disease: A Pilot Study. *J Am Acad Child Adolesc Psychiatry* 2004;43(12):1469-77.
Exclude: For study design, OVID-PsycINFO.
- Szigethy E, Kenney E, Carpenter J, et al. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. *J Am Acad Child Adolesc Psychiatry* 2007;46(10):1290-8.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Takahashi H, Kamata M, Yoshida K, et al. Augmentation with olanzapine in TCA-refractory depression with melancholic features: A consecutive case series. *Hum Psychopharmacol* 2008;23(3):217-20.
Exclude: For study design, OVID-Embase.
- Tang SW, Remington G, Persad E, et al. Coadministration of a beta-adrenergic antagonist and a tricyclic antidepressant: a pilot study. *Psychiatry Res* 1990;33(2):101-6.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Tang SW, Remington G, Persad E, et al. Coadministration of a beta-adrenergic antagonist and a tricyclic antidepressant: A pilot study. *Psychiatry Res* 1990;33(2):101-6.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Tanghe A, Steeman J, Bollen E, et al. Moclobemide and amitriptyline, alone or in combination, in therapy

resistant depression. *Hum Psychopharmacol* 1997;12(5):509-10.

Exclude: For study design, OVID-PsycINFO.

Taragano FE, Bagnatti P, Allegri RF. A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of "vascular depression". *INT PSYCHOGERIATR* 2005;17(3):487-98. PMID:16252380

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Taragano FE, Allegri R, Vicario A, et al. A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression'. *Int J Geriatr Psychiatry* 2001;16(3):254-60. PMID:11288158

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Targ EF, Karasic DH, Diefenbach PN, et al. Structured group therapy and fluoxetine to treat depression in HIV-positive persons. *Psychosomatics* 1994;35(2):132-7. PMID:8171171

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Tarrier N, Maguire P, Kincey J. Locus of control and cognitive behaviour therapy with mastectomy patients: A pilot study. *British Journal of Medical Psychology* 1983;56(3):265-70.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Tavoni A, Vitali C, Bombardieri S, et al. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. *Am J Med* 1987;83(5 A):107-10.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Taylor CB, Houston-Miller N, Ahn DK, et al. The effects of exercise training programs on psychosocial improvement in uncomplicated postmyocardial infarction patients. *J Psychosom Res* 1986;30(5):581-7.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. [Review] [38 refs]. *Br J Psychiatry* 1995;167(5):575-80. PMID:8564311

Exclude: For systematic review before 2005, OVID-Medline.

Taylor DJ, Lichstein KL, Weinstock J, et al. A pilot study of cognitive-behavioral therapy of insomnia in people with mild depression. *Behav Ther* 2007;38(1):49-57. PMID:17292694

Exclude: For study design, OVID-Medline.

Taylor FB, Prather MR. The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder. *Depress Anxiety* 2003;18(2):83-8. PMID:12964175

Exclude: For study design, OVID-Medline.

Taylor MJ, Carney S, Geddes J, et al. Folate for depressive disorders. [Review] [39 refs]. *Cochrane Database of Systematic Reviews* 2003;(2):CD003390 PMID:12804463

Exclude: For systematic review before 2005, OVID-Medline.

Taylor MJ, Carney SM, Goodwin GM, et al. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. [Review] [28 refs]. *J Psychopharmacol* 2004;18(2):251-6. PMID:15260915

Exclude: For systematic review before 2005, OVID-Medline.

Taylor MJ, Wilder H, Bhagwagar Z, et al. Inositol for depressive disorders. [Review] [23 refs]. *Cochrane Database of Systematic Reviews* 2004;(2):CD004049 PMID:15106232

Exclude: For systematic review before 2005, OVID-Medline.

Taylor MP, Reynolds CF, III, Frank E, et al. Which elderly depressed patients remain well on maintenance interpersonal psychotherapy alone?: report from the Pittsburgh study of maintenance therapies in late-life depression. *Depress Anxiety* 1999;10(2):55-60. PMID:10569127

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Taylor M J, Carney S M, Geddes J and others. Folate for depressive disorders. In 2003. **Exclude:** For systematic review before 2005, Wiley-CDSR.

Taylor M J, Wilder H, Bhagwagar Z and others. Inositol for depressive disorders. In 2004. **Exclude:** For systematic review before 2005, Wiley-CDSR.

Taylor WD, Steffens DC, Macfall JR, et al. White Matter Hyperintensity Progression and Late-Life Depression Outcomes. *Arch Gen Psychiatry* 2003;60(11):1090-6.

Exclude: For study design, OVID-Embase.

Teasdale JD, Fennell MJV, Hibbert GA, et al. Cognitive therapy for major depressive disorder in primary care. *Br J Psychiatry* 1984;144(4):400-6.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Teasdale JD, Fennell MJV. Immediate effects on depression of cognitive therapy interventions. *Cogn Ther Res* 1982;6(3):343-52.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

OVID-Embase.

Teasdale JD, Segal ZV, Williams JM, et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. *J Consult Clin Psychol* 2000;68(4):615-23. PMID:10965637

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Teichman Y, Bar-El Z, Shor H, et al. Changes in cognitions, emotions, and behaviors in depressed

patients and their spouses following marital cognitive therapy, traditional cognitive therapy, pharmacotherapy, and no intervention. *Journal of Psychotherapy Integration* 1998;8(1):27-53.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Tempesta E, Casella L, Pirrongelli C, et al. L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. *Drugs Under Experimental & Clinical Research* 1987;13(7):417-23. PMID:3308388

Exclude: For study design, OVID-Medline.

Terao T. Lack of urinary side-effects with nefazodone as compared to other newer antidepressants. *Hum Psychopharmacol* 1998;13(4):245-6.

Exclude: For study design, OVID-PsycINFO.

Teusch L, Bohme H, Finke J, et al. Antidepressant medication and the assimilation of problematic experiences in psychotherapy. *Psychotherapy Research* 2003;13(3):307-22.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Teusch L, Bohme H, Finke J, et al. Effects of client-centered psychotherapy for personality disorders alone and in combination with psychopharmacological treatment: An empirical follow-up study. *Psychother Psychosom* 2001;70(6):328-36.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Tew JD, Mulsant BH, Haskett RF, et al. Relapse during continuation pharmacotherapy after acute response to ECT: A comparison of usual care versus protocolized treatment. *Ann Clin Psychiatry* 2007;19(1):1-4.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Tew JD, Jr., Mulsant BH, Houck PR, et al. Impact of prior treatment exposure on response to antidepressant treatment in late life. *Am J Geriatr Psychiatry* 2006;14(11):957-65. PMID:17068318

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Thase M, Kremer C, Rodrigues H. Mirtazapine versus sertraline after SSRI non-response. In Annual meeting of the new clinical drug evaluation unit (NCDEU) of the national institute of mental health. 2001. **Exclude:** For study design,

Thase ME, Feighner MD, Lydiard RB. Citalopram Treatment of Fluoxetine Nonresponders. *J Clin Psychiatry* 2001;62(9):683-7.

Exclude: For study design,

Thase ME, Ferguson JM, Lydiard RB, et al. Citalopram treatment of paroxetine-intolerant depressed patients. *Depress Anxiety* 2002;16(3):128-33. PMID:12415538

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Thase ME, Bowler K, Harden T. Cognitive behavior therapy of endogenous depression: Part 2: Preliminary findings in 16 unmedicated inpatients. *Behav Ther* 1991;22(4):469-77.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Thase ME, Simons AD, Cahalane JF, et al. Cognitive behavior therapy of endogenous depression: Part 1: An outpatient clinical replication series. *Behav Ther* 1991;22(4):457-67.

Exclude: For study design, OVID-Embase.

Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. *Arch Gen Psychiatry* 2002;59(3):233-9. PMID:11879161

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Thase ME, Trivedi MH, Nelson JC, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: A pooled analysis of 2 studies. *Primary Care Companion to the J Clin Psychiatry* 2008;10(6):440-7.

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.

Thase ME, Friedman ES, Berman SR, et al. Is cognitive behavior therapy just a 'nonspecific' intervention for depression? A retrospective comparison of consecutive cohorts treated with cognitive behavior therapy or supportive counseling and pill placebo. *J Affect Disord* 2000;57(1-3):63-71. PMID:10708817

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. *Cns Spectrums* 2006;11(2):93-102. PMID:16520686

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Thase ME, Reynolds Iii CF, Frank E, et al. Response to cognitive-behavioral therapy in chronic depression. *J Psychother Pract Res* 1994;3(3):204-14.

Exclude: For study design, OVID-Embase.

Thase ME, Kupfer DJ, Frank E, et al. Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation. *J Clin Psychiatry* 1989;50(11):413-7. PMID:2509437

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine. *J Clin Psychiatry* 1989;50(10):385-8. PMID:2676995

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. *J Clin Psychiatry* 1992;53(1):5-11. PMID:1737741

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

- Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. *Arch Gen Psychiatry* 1997;54(11):1009-15. PMID:9366657
Exclude: For systematic review before 2005, OVID-Medline.
- Thase ME, Friedman ES, Fasiczka AL, et al. Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. *J Clin Psychiatry* 2000;61(7):466-72. PMID:10937603
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Thompson LW, Coon DW, Gallagher-Thompson D, et al. Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression. *Am J Geriatr Psychiatry* 2001;9(3):225-40. PMID:11481130
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Thompson LW, Gallagher D, Breckenridge JS. Comparative effectiveness of psychotherapies for depressed elders. *J Consult Clin Psychol* 1987;55(3):385-90.
Exclude: For study design, OVID-PsycINFO.
- Thompson LW, Gallagher D. Depression and its treatment in the elderly. *Aging* 1985;348:14-8.
Exclude: For study design, OVID-PsycINFO.
- Thompson SB. Cognitive therapy in cognitive rehabilitation: eight region study of older adults. *Journal of Cognitive Rehabilitation* 2002;19(4):4-7.
Exclude: For study design, OVID-AMED.
- Thomson J, Rankin H, Ashcroft GW, et al. The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. *Psychol Med* 1982;12(4):741-51. PMID:7156248
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Thorpe L, Whitney DK, Kutcher SP, et al. Special populations. *Canadian Journal of Psychiatry* 2001;46(SUPPL. 1):63S-76S.
Exclude: For Guideline published before 2005, OVID-Embase.
- Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. *Arch Gen Psychiatry* 1997;54(11):1009-15.
Exclude: For systematic review before 2005, OVID-Embase.
- Tiller JW, Johnson GF, Burrows GD. Moclobemide for depression: an Australian psychiatric practice study. *J Clin Psychopharm* 1995;15(4:Suppl 2):Suppl-34S PMID:7593727
Exclude: For study design, OVID-Medline.
- Tiller JW, Mitchell P, Burrows GD. Monoamine oxidase inhibitors (MAOI) or reversible inhibitors of monoamine oxidase (RIMA)/tricyclic antidepressant (TCA) combination therapy. *Aust NZ J Psychiatry* 1992;26(2):327-9. PMID:1642632
Exclude: For study design, OVID-Medline.
- Timotijevic I, Zdravkovic M, Pokrajac M, et al. Correlation of mono and combined amitriptyline/lithium therapy with therapeutic and side effects. *Romanian Journal of Physiology (Bucuresti)* 1994;31(1-4):103-11. PMID:8640362
Exclude: For study design, OVID-Medline.
- Titievsky J, Seco G, Barranco M, et al. Doxepin as adjunctive therapy for depressed methadone maintenance patients: a double-blind study. *J Clin Psychiatry* 1982;43(11):454-6. PMID:7174622
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Tollefson G D, Shelton R, Tohen M and others. Efficacy of olanzapine, fluoxetine and combination therapy in treatment-resistant major depressive disorder without psychotic features. In 1998; 1998.
Exclude: For study design, Wiley-CCTR.
- Tollefson G D, Shelton R C, Tohen M F and others. The study of olanzapine plus fluoxetine in treatment-resistant MDD without psychotic features. In 1999 May 15; 1999.
Exclude: For study design, Wiley-CCTR.
- Tome MB, Isaac MT. Cost effectiveness study of a year follow-up of selective serotonin reuptake inhibitor (SSRI) and augmentor combination compared with SSRI and placebo. *Int Clin Psychopharmacol* 1998;13(4):175-82. PMID:9727728
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Tome MB, Isaac MT. One year real world prospective follow-up study of a major depressive episode of patients treated with paroxetine and pindolol or paroxetine for 6 weeks. *Int Clin Psychopharmacol* 1998;13(4):169-74. PMID:9727727
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. *Int Clin Psychopharmacol* 1997;12(2):81-9. PMID:9219043
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Tome MB, Cloninger CR, Watson JP, et al. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol. *J Affect Disord* 1997;44(2-3):101-9. PMID:9241570
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Tondo L, Masia M, Silvetti F, et al. Fluoxetine in depressive episodes during prophylactic lithium treatment. *European Neuropsychopharmacol*

1993;3(3):326

Exclude: For study design, OVID-Embase.

Trapp, M.D.C. The interaction of cognitive-behavioral therapy with integrated couple therapy for the treatment of depression in women Trapp. 1998

Exclude: For study design, OVID-PsycINFO.

Trautmann-Sponsel RD. St. John's Wort extract in the treatment of depression -- an effective and well-tolerated antidepressant. *European Phytojournal* 2001;(1):44-9. **Exclude:** For study design, EBSCO-CINAHL.

Treatment for Adolescents With Depression Study (TADS) Team, March J, Silva S, et al. The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up. *Am J Psychiatry* 2009;166(10):1141-9. PMID:19723787

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas medication algorithm project. *Arch Gen Psychiatry* 2004;61(7):669-80.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Trivedi MH, Greer TL, Grannemann BD, et al. Exercise as an augmentation strategy for treatment of major depression. *J Psychiatr Pract* 2006;12(4):205-13. PMID:16883145

Exclude: For study design, OVID-Medline.

Trivedi MH, Corey-Lisle PK, Guo Z, et al. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. *Int Clin Psychopharmacol* 2009;24(3):133-8. PMID:19318972

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Trivedi MH, Morris DW, Grannemann BD, et al. Symptom clusters as predictors of late response to antidepressant treatment. *J Clin Psychiatry* 2005;66(8):1064-70. PMID:16086624

Exclude: For study design, OVID-Medline.

Trivedi MH, Greer TL, Grannemann BD, et al. TREAD: Treatment with Exercise Augmentation for Depression: study rationale and design. *Clinical Trials* 2006;3(3):291-305. PMID:16895046

Exclude: For study design, OVID-Medline.

Truax P. The cognitive behavioural analysis system of psychotherapy prevented recurrence in chronic major depression. *Evidence-Based Medicine* 2005;10(3):85

Exclude: For study design, OVID-Embase.

Tsai YF, Wong TK, Tsai HH, et al. Self-worth therapy for depressive symptoms in older nursing home residents. *J ADV NURS* 2008;64(5):488-94. PMID:19146517

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Tsai YF, Wong TK, Juang YY, et al. The effects of light therapy on depressed elders. *Int J Geriatr Psychiatry* 2004;19(6):545-8. PMID:15211533

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Tsang HWH, Fung KMT, Chan ASM, et al. Effect of a qigong exercise programme on elderly with depression. *Int J Geriatr Psychiatry* 2006;21(9):890-7.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Tsay SL, Cho YC, Chen ML. Acupressure and Transcutaneous Electrical Acupoint Stimulation in improving fatigue, sleep quality and depression in hemodialysis patients. *AM J CHINESE MED* 2004;32(3):407-16. PMID:15344424

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Turk DC, Zaki HS, Rudy TE. Effects of intraoral appliance and biofeedback/stress management alone and in combination in treating pain and depression in patients with temporomandibular disorders. *Journal of Prosthetic Dentistry* 1993;70(2):158-64. PMID:8371179

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Turvey CL, Klein DM. Remission from Depression Comorbid with Chronic Illness and Physical Impairment. *Am J Psychiatry* 2008;165(5):569-74. **Exclude:** For study design, OVID-Embase.

Tutty S, Simon G, Ludman E. Telephone counseling as an adjunct to antidepressant treatment in the primary care system. A pilot study. *Effective Clinical Practice* 2000;3(4):170-8. PMID:11183432

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Tutty, S. Evaluating the effectiveness of teletherapy in rural depressed adults Tutty. 2008

Exclude: For study design, OVID-PsycINFO.

Tuunainen A, Kripke DF, Endo T. Light therapy for non-seasonal depression. [Review] [93 refs]. *Cochrane Database of Systematic Reviews* 2004;(2):CD004050 PMID:15106233

Exclude: For systematic review before 2005, OVID-Medline.

Tuunainen A, Kripke D F, Endo T. Light therapy for non-seasonal depression. In 2004. **Exclude:** For systematic review before 2005, Wiley-CDSR.

Tyrer P, Marsden CA, Casey P, et al. Clinical efficacy of paroxetine in resistant depression. *J Psychopharmacol* 1987;1(4):251-7.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Tyrer P, Seivewright N, Murphy S, et al. The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. *Lancet* 1988;2(8605):235-40. PMID:2899234

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Uchida H, Takeuchi H, Suzuki T, et al. Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. *J Clin Psychopharm* 2005;25(6):545-51. PMID:16282835

- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Udabe RU, Marquez CA, Traballi CA, et al. Double-blind comparison of moclobemide, imipramine and placebo in depressive patients. *Acta Psychiatrica Scandinavica, Supplement* 1990;82(360):54-6.
- Exclude:** For population/not failed to respond to an SSRI, OVID-Embase
- OVID-Embase.
- Udry EM. Interventions for the anxious and depressed: Suggested links between control theory and exercise therapy. *Journal of Reality Therapy* 1992;12(1):32-6.
- Exclude:** For Guideline published before 2005, OVID-PsycINFO.
- Uebelhack R, Gruenwald J, Graubaum HJ, et al. Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial. *Advances in Therapy* 2004;21(4):265-75. PMID:15605620
- Exclude:** For study design, OVID-Medline.
- Uehlinger C, Nil R, Amey M, et al. Citalopram-lithium combination treatment of elderly depressed patients: A pilot study. *Int J Geriatr Psychiatry* 1995;10(4):281-7.
- Exclude:** For study design, OVID-Embase.
- Unutzer J, Hantke M, Powers D, et al. Care management for depression and osteoarthritis pain in older primary care patients: A pilot study. *Int J Geriatr Psychiatry* 2008;23(11):1166-71.
- Exclude:** For study design, OVID-Embase.
- Unutzer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: A randomized controlled trial. *JAMA* 2002;288(22):2836-45.
- Exclude:** For population/not failed to respond to an SSRI, OVID-Embase.
- Ushiroyama T, Ikeda A, Sakuma K, et al. Chai-hu-gui-zhi-gan-jiang-tang regulates plasma interleukin-6 and soluble interleukin-6 receptor concentrations and improves depressed mood in climacteric women with insomnia. *AM J CHINESE MED* 2005;33(5):703-11. PMID:16265982
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Valliant PM, Asu ME. Exercise and its effects on cognition and physiology in older adults. *Perceptual and Motor Skills* 1985;61(3 II):1031-8.
- Exclude:** For population/not failed to respond to an SSRI, OVID-Embase
- OVID-Embase.
- van Bastelaar KM, Pouwer F, Cuijpers P, et al. Web-based cognitive behavioural therapy (W-CBT) for diabetes patients with co-morbid depression: design of a randomised controlled trial. *BMC Psychiatry* 2008;8:9 PMID:18284670
- Exclude:** For study design, OVID-Medline.
- van Calker D, Zobel I, Dykierck P, et al. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. *J Affect Disord* 2009;114(1-3):243-53. PMID:18849079
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- Van de Vliet P, Knapen J, Fox KR, et al. Changes in psychological well-being in female patients with clinically diagnosed depression: an exploratory approach in a therapeutic setting. *Psychology, Health & Medicine* 2003;8(4):399-408. **Exclude:** For study design, EBSCO-CINAHL.
- Van Den Berg S, Shapiro DA, Bickerstaffe D, et al. Computerized cognitive-behaviour therapy for anxiety and depression: A practical solution to the shortage of trained therapists. *Journal of Psychiatric and Mental Health Nursing* 2004;11(5):508-13.
- Exclude:** For study design, OVID-PsycINFO.
- van den Hout JH, Arntz A, Kunkels FH. Efficacy of a self-control therapy program in a psychiatric day-treatment center. *Acta Psychiatr Scand* 1995;92(1):25-9. PMID:7572244
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- van den Hout M, Brouwers C, Oomen J. Clinically Diagnosed Axis II Co-Morbidity and the Short Term Outcome of CBT for Axis I Disorders. *Clinical Psychology & Psychotherapy* 2006;13(1):56-63.
- Exclude:** For study design, OVID-PsycINFO.
- van den BW, Bouhuys AL, van den Hoofdakker RH, et al. Sleep deprivation in bright and dim light: antidepressant effects on major depressive disorder. *J Affect Disord* 1990;19(2):109-17. PMID:2142697
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- van der Kolk BA, Spinazzola J, Blaustein ME, et al. A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. *J Clin Psychiatry* 2007;68(1):37-46. PMID:17284128
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- van der Merwe I, Naude S. Exercise and depression: a treatment manual. *Health SA Gesondheid* 2004;9(4):28-41.
- Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- van Gurp G, Meterissian GB, Haiek LN, et al. St John's wort or sertraline? Randomized controlled trial in primary care. *CAN FAM PHYSICIAN* 2002;48:905-12. PMID:12053635
- Exclude:** For population/not failed to respond to an SSRI, OVID-Medline.
- van Hiele LJ. l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with 'therapy-resistant' depressions. *Neuropsychobiology* 1980;6(4):230-40. PMID:6967194
- Exclude:** For study design, OVID-Medline.

- Van Houdenhove B, Onghena P, Floris M, et al. An open study of sertraline in acute and continuation treatment of depressed out-patients. *J Int Med Res* 1997;25(6):340-53. PMID:9427167
Exclude: For study design, OVID-Medline.
- van Marwijk HW, Bekker FM, Nolen WA, et al. Lithium augmentation in geriatric depression. *J Affect Disord* 1990;20(4):217-23. PMID:2149727
Exclude: For study design, OVID-Medline.
- van Marwijk HW, Ader H, de Haan M, et al. Primary care management of major depression in patients aged > or =55 years: outcome of a randomised clinical trial. *British Journal of General Practice* 58(555):680-6. PMID:18826778
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. *Br J Psychiatry* 2007;190(JUNE):460-6.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- van Moffaert M, Bartholome F, Cosyns P, et al. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. *Hum Psychopharmacol* 1995;10(5):393-405.
Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Embase.
- van Moffaert M, Dierick M, De Meulemeester F, et al. Treatment of depressive anxiety states associated with psychosomatic symptoms. A double-blind multicentre clinical study: mianserin versus melitracen-flupentixol. *Acta Psychiatrica Belgica* 1983;83(5):525-39. PMID:6670581
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- van Os TW, van den Brink RH, Tiemens BG, et al. Communicative skills of general practitioners augment the effectiveness of guideline-based depression treatment. *J Affect Disord* 2005;84(1):43-51. PMID:15620384
Exclude: For study design, OVID-Medline.
- van Praag H, de Hann S. Depression vulnerability and 5-hydroxytryptophan prophylaxis. *Psychiatry Res* 1980;3(1):75-83. PMID:6160599
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Van Praag HM, de Haan S. Chemoprophylaxis of depressions. An attempt to compare lithium with 5-hydroxytryptophan. *Acta Psychiatrica Scandinavica, Supplementum* 1981;290:191-201. PMID:6164250
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- van Rooijen LH, van Straten A, Al M, et al. Cost-utility of brief psychological treatment for depression and anxiety. *Br J Psychiatry* 2006;188:323-9. PMID:16582058
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Van Voorhees BW, Fogel J, Reinecke MA, et al. Randomized clinical trial of an Internet-based depression prevention program for adolescents (Project CATCH-IT) in primary care: 12-week outcomes. *Journal of Developmental & Behavioral Pediatrics* 2009;30(1):23-37. PMID:19194326
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Van HL, Dekker J, Koelen J, et al. Patient preference compared with random allocation in short-term psychodynamic supportive psychotherapy with indicated addition of pharmacotherapy for depression. *Psychotherapy Research* 2009;19(2):205-12. PMID:19396651
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Vanelle JM, Attar-Levy D, Poirier MF, et al. Controlled efficacy study of fluoxetine in dysthymia. *Br J Psychiatry* 1997;170:345-50. PMID:9246253
Exclude: For Mixed antidepressants; some failed on SSRI , OVID-Medline.
- Vanelle JM, Attar-Levy D, Poirier MF, et al. Controlled efficacy study of fluoxetine in dysthymia. *Br J Psychiatry* 1997;170(4):345-50.
Exclude: For Mixed antidepressants; some failed on SSRI , OVID-PscINFO.
- Varney NR, Garvey MJ, Cook BL, et al. Identification of treatment-resistant depressives who respond favorably to carbamazepine. *Ann Clin Psychiatry* 1993;5(2):117-22. PMID:8348203
Exclude: For study design, OVID-Medline.
- Veale D, Le Fevre K, Pantelis C, et al. Aerobic exercise in the adjunctive treatment of depression: a randomized controlled trial. *Journal of the Royal Society of Medicine* 1992;85(9):541-4. PMID:1433121
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Verduyn C, Barrowclough C, Roberts J, et al. Maternal depression and child behaviour problems. Randomised placebo-controlled trial of a cognitive-behavioural group intervention. *Br J Psychiatry* 2003;183:342-8. PMID:14519613
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Vergouwen AC, Bakker A, Burger H, et al. A cluster randomized trial comparing two interventions to improve treatment of major depression in primary care. *Psychol Med* 2005;35(1):25-33. PMID:15842026
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Verhoeven WMA. Antidepressive effects of the selective MAO-inhibitor brofaromine: An open trial. *Eur Psychiatry* 1992;7(5):243-7.
Exclude: For study design, OVID-Embase.
- Vezmar S, Miljkovic B, Vucicevic K, et al. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. *Journal of Pharmacological Sciences* 2009;110(1):98-104. PMID:19444001

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Viinamaki H, Hintikka J, Tanskanen A, et al. Partial remission in major depression: A two-phase, 12-month prospective study. *Nord J Psychiatry* 2002;56(1):33-7.

Exclude: For study design,

Vinar O, Dvorak A, Obrovská V, et al. Does sodium valproate increase clinical effects of antidepressants? *Acta Nerv Super* 1989;31(2):103-5.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Vinar O, Vinarova E. Tianeptine helps depressed patients resistant to serotonin function enhancing drugs. *Homeostasis in Health and Disease* 1997;38(4):170-2.

Exclude: For study design, OVID-PsycINFO.

Vinar O. Tranylcypromine in treatment of resistant depression. *Acta Nerv Super* 1984;26(4):239-41.

Exclude: For study design, OVID-Embase

OVID-Embase.

Vitiello B, Brent DA, Greenhill LL, et al. Depressive Symptoms and Clinical Status During the Treatment of Adolescent Suicide Attempters (TASA) Study. *J Am Acad Child Adolesc Psychiatry* 2009;48(10):997-1004.

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.

Vitiello B, Rohde P, Silva S, et al. Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). *J Am Acad Child Adolesc Psychiatry* 2006;45(12):1419-26. PMID:17135987

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Vitiello B. The Treatment of Resistant Depression in Adolescents (TORDIA) Study: A research update. In 2006. **Exclude:** For study design, Wiley-CCTR.

Vittengl JR, Clark LA, Jarrett RB. Continuation-phase cognitive therapy's effects on remission and recovery from depression. *J Consult Clin Psychol* 2009;77(2):367-71. PMID:19309197

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Volz HP, Faltus F, Magyar I, et al. Brofaromine in treatment-resistant depressed patients--a comparative trial versus tranylcypromine. *J Affect Disord* 1994;30(3):209-17. PMID:8006247

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Volz HP, Mackert A, Stieglitz RD, et al. Effect of bright white light therapy on non-seasonal depressive disorder. Preliminary results. *J Affect Disord* 1990;19(1):15-21. PMID:2140842

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Volz HP, Laux P. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine. [Review] [34 refs]. *Comp*

Psychiatry 2000;41(2:Suppl 1):Suppl-7
PMID:10746915

Exclude: For systematic review before 2005, OVID-Medline.

Von Korff M, Katon W, Bush T, et al. Treatment costs, cost offset, and cost-effectiveness of collaborative management of depression. *Psychosom Med* 1998;60(2):143-9.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Voon V, Lang AE. Antidepressant treatment outcomes of psychogenic movement disorder. *J Clin Psychiatry* 2005;66(12):1529-34. PMID:16401153

Exclude: For study design, OVID-Medline.

Vorbach EU, Hubner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. *J Geriatr Psychiatry Neurol* 1994;7:Suppl-23 PMID:7857502

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. *Pharmacopsychiatry* 1997;30:Suppl-5 PMID:9342765

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Vos T, Corry J, Haby MM, et al. Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression. *Aust NZ J Psychiatry* 2005;39(8):683-92. PMID:16050922

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Vostanis P, Feehan C, Grattan E, et al. A randomised controlled out-patient trial of cognitive-behavioural treatment for children and adolescents with depression: 9-month follow-up. *J Affect Disord* 1996;40(1-2):105-16. PMID:8882920

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Vostanis P, Feehan C, Grattan E. Two-year outcome of children treated for depression. *EUR CHILD ADOLESC PSYCHIATRY* 1998;7(1):12-8. PMID:9563808

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Vostanis P, Feehan C, Grattan E, et al. Treatment for children and adolescents with depression: Lessons from a controlled trial. *Clinical Child Psychology and Psychiatry* 1996;1(2):199-212.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Wagner, J.J. A meta-analysis/literature review comparing the effectiveness of SSRI antidepressants, cognitive behavioral therapy, and placebo for the treatment of depression Wagner. 2005

Exclude: For study design, OVID-PsycINFO.

Waldkoetter RO, Sanders GO. Auditory brainwave stimulation in treating alcoholic depression.

PERCEPT MOTOR SKILLS 1997;84(1):226
PMID:9132712

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Walinder J, Carlsson A, Persson R. 5-HT reuptake inhibitors plus tryptophan in endogenous depression. *Acta Psychiatrica Scandinavica, Supplementum* 1981;290:179-90. PMID:6452791

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Walinder J, Skott A, Carlsson A, et al. Potentiation of the antidepressant action of clomipramine by tryptophan. *Arch Gen Psychiatry* 1976;33(11):1384-9.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Walinder J, Carlsson A, Persson R, et al. Potentiation of the effect of antidepressant drugs by tryptophan. *Acta Psychiatrica Scandinavica, Supplementum* 1980;280:243-9. PMID:6447432

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Walker CE, Elliott C, Koehn R. Nitrous oxide: A potential unconditioned positive stimulus in cognitive therapy for depression. *the Behavior Therapist* 1987;10(4):90-2.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Walker R. Electroconvulsive therapy during high-risk pregnancy. *Gen Hosp Psychiatry* 1994;16(5):348-53.
Exclude: For Guideline published before 2005, OVID-Embase.

Wallis DAN. Depression, anxiety and self-esteem: A clinical field study. *Behav Change* 2002;19(2):112-20.

Exclude: For study design, OVID-PsycINFO.

Walter M, Hanni B, Haug M, et al. Humour therapy in patients with late-life depression or Alzheimer's disease: a pilot study. *Int J Geriatr Psychiatry* 2007;22(1):77-83. PMID:16977676

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Wampold BE, Minami T, Baskin TW, et al. A meta-(re)analysis of the effects of cognitive therapy versus 'other therapies' for depression. *J Affect Disord* 2002;68(2-3):159-65. PMID:12063144

Exclude: For systematic review before 2005, OVID-Medline.

Wan DD, Kundhur D, Solomons K, et al. Mirtazapine for treatment-resistant depression: a preliminary report. *J Psychiatry Neurosci* 2003;28(1):55-9. PMID:12587851

Exclude: For study design, OVID-Medline.

Wang H. Acupuncture treatment of depressive syndromes after cerebral vascular accidents. *J Tradit Chin Med* 2002;22(4):274-5. PMID:16579090

Exclude: For study design, OVID-Medline.

Wang L, Li J. Role of educational intervention in the management of comorbid depression and hypertension. *Blood Pressure* 2003;12(4):198-202.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Wang PS, Simon GE, Avorn J, et al. Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial. *JAMA* 2007;298(12):1401-11. PMID:17895456

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. *International Journal of Methods in Psychiatric Research* 2003;12(1):22-33.

Exclude: For systematic review before 2005, OVID-Embase.

Ward E, King M, Lloyd M, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: clinical effectiveness. *BMJ* 2000;321(7273):1383-8. PMID:11099284

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Warden D, Rush AJ, Wisniewski SR, et al. What predicts attrition in second step medication treatments for depression?: a STAR*D Report. *Int J Neuropsychopharmacol* 2009;12(4):459-73. PMID:18611293

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.

Warden DL, Gordon B, McAllister TW, et al. Guidelines for the pharmacologic treatment of neurobehavioral sequelae of traumatic brain injury. *Journal of Neurotrauma* 2006;23(10):1468-501.

Exclude: For Guideline focus on diagnosis or screening rather than treatment, OVID-Embase.

Warmerdam L, van Straten A, Twisk J, et al. Internet-based treatment for adults with depressive symptoms: Randomized controlled trial. *J Med Internet Res* 2008;10(4):-December

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Warnock JK, Bundren JC, Morris DW. Sertraline in the treatment of depression associated with gonadotropin-releasing hormone agonist therapy. *Biol Psychiatry* 1998;43(6):464-5. PMID:9532352

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Waslick BD, Walsh BT, Greenhill LL, et al. Open trial of fluoxetine in children and adolescents with dysthymic disorder or double depression. *J Affect Disord* 1999;56(2-3):227-36. PMID:10701482

Exclude: For study design, OVID-Medline.

Watkins ER, Baeyens CB, Read R. Concreteness training reduces dysphoria: proof-of-principle for repeated cognitive bias modification in depression. *Journal of Abnormal Psychology* 2009;118(1):55-64. PMID:19222314

Exclude: For population/diagnosis, OVID-Medline.

Watkins JT, Leber WR, Imber SD, et al. Temporal course of change of depression. *J Consult Clin*

- Psychol 1993;61(5):858-64. PMID:8245283
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Watson HJ, Nathan PR. Role of gender in depressive disorder outcome for individual and group cognitive-behavioral treatment. *J Clin Psych* 2008;64(12):1323-37. PMID:18825696
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Watson JC, Gordon LB, Stermac L, et al. Comparing the effectiveness of process-experiential with cognitive-behavioral psychotherapy in the treatment of depression. *J Consult Clin Psychol* 2003;71(4):773-81. PMID:12924682
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Watson JC, Gordon LB, Stermac L, et al. Comparing the effectiveness of process-experiential with cognitive-behavioral psychotherapy in the treatment of depression. *J Consult Clin Psychol* 2003;71(4):773-81.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Watt LM, Cappeliez P. Integrative and instrumental reminiscence therapies for depression in older adults: Intervention strategies and treatment effectiveness. *Aging and Mental Health* 2000;4(2):166-77.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Weber BA, Roberts BL, Resnick M, et al. The effect of dyadic intervention on self-efficacy, social support, and depression for men with prostate cancer. *Psycho Oncol* 2004;13(1):47-60.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Weersing VR, Weisz JR. Community clinic treatment of depressed youth: benchmarking usual care against CBT clinical trials. *J Consult Clin Psychol* 2002;70(2):299-310. PMID:11952188
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Weersing VR, Iyengar S, Kolko DJ, et al. Effectiveness of cognitive-behavioral therapy for adolescent depression: a benchmarking investigation. *Behav Ther* 2006;37(1):36-48. PMID:16942959
Exclude: For study design, OVID-Medline.
- Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. *J Clin Psychiatry* 1989;50(12):447-9. PMID:2600061
Exclude: For study design, OVID-Medline.
- Weilburg JB, Rosenbaum JF, Meltzer-Brody S, et al. Tricyclic augmentation of fluoxetine. *Ann Clin Psychiatry* 1991;3(3):209-13.
Exclude: For study design, OVID-Embase.
- Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. *J Clin Psychiatry* 1989;50(12):447-9.
Exclude: For study design, OVID-PsycINFO.
- Weintraub D, Streim JE, Datto CJ, et al. Effect of increasing the dose and duration of sertraline trial in the treatment of depressed nursing home residents. *J Geriatr Psychiatry Neurol* 2003;16(2):109-11. PMID:12801161
Exclude: For study design, OVID-Medline.
- Weiss BD, Francis L, Senf JH, et al. Literacy education as treatment for depression in patients with limited literacy and depression: A randomized controlled trial. *J Gen Intern Med* 2006;21(8):823-8.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Weiss, J.C. A comparison of cognitive group therapy to life review group therapy with older adults Weiss. 1994
Exclude: For study design, OVID-PsycINFO.
- Weiss M, Nordlie JW, Siegel EP. Mindfulness-based stress reduction as an adjunct to outpatient psychotherapy. *Psychother Psychosom* 2005;74(2):108-12. PMID:15741760
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Weissman MM, Prusoff B, Sholomskas AJ, et al. A double-blind clinical trial of alprazolam, imipramine, or placebo in the depressed elderly. *J Clin Psychopharm* 1992;12(3):175-82. PMID:1629383
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Weissman MM, Klerman GL, Prusoff BA, et al. Depressed outpatients. Results one year after treatment with drugs and/or interpersonal psychotherapy. *Arch Gen Psychiatry* 1981;38(1):51-5.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Weist MD, Paskewitz DA, Warner BS, et al. Treatment outcome of school-based mental health services for urban teenagers. *Community Ment Health J* 1996;32(2):149-57. PMID:8777871
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Weisz JR, Southam-Gerow MA, Gordis EB, et al. Cognitive-behavioral therapy versus usual clinical care for youth depression: an initial test of transportability to community clinics and clinicians. *J Consult Clin Psychol* 2009;77(3):383-96. PMID:19485581
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Weisz JR, Thurber CA, Sweeney L, et al. Brief treatment of mild-to-moderate child depression using primary and secondary control enhancement training. *J Consult Clin Psychol* 1997;65(4):703-7.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Weisz JR, Southam-Gerow MA, Gordis EB, et al. Cognitive-behavioral therapy versus usual clinical care for youth depression: An initial test of

- transportability to community clinics and clinicians. *J Consult Clin Psychol* 2009;77(3):383-96.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Wells A, Fisher P, Myers S, et al. Metacognitive therapy in recurrent and persistent depression: A multiple-baseline study of a new treatment. *Cogn Ther Res* 2009;33(3):291-300.
Exclude: For study design, OVID-Embase.
- Wells BG, Evans RL, Ereshefsky L, et al. Clinical outcome and adverse effect profile associated with concurrent administration of alprazolam and imipramine. *J Clin Psychiatry* 1988;49(10):394-9. PMID:3049560
Exclude: For study design, OVID-Medline.
- Werneke U, Horn O, Taylor DM. How effective is St John's wort? The evidence revisited. *J Clin Psychiatry* 2004;65(5):611-7. PMID:15163246
Exclude: For systematic review before 2005, OVID-Medline.
- Wheatley D. An adrenergic drug in depression. *Arch Gen Psychiatry* 1975;32(5):653-5.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
- Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients--a controlled 6-week clinical trial. *Pharmacopsychiatry* 1997;30:Suppl-80 PMID:9342764
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Wheatley D. Side-effects are no problem with St John's wort in depression. *Primary Care Psychiatry* 2002;8(1):31-3.
Exclude: For study design,
- Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of *Hypericum perforatum* in depression: a comprehensive clinical review. [Review] [80 refs]. *Int Clin Psychopharmacol* 2001;16(5):239-52. PMID:11552767
Exclude: For systematic review before 2005, OVID-Medline.
- White K, Pistole T, Boyd JL. Combined monoamine oxidase inhibitor-tricyclic antidepressant treatment: a pilot study. *Am J Psychiatry* 1980;137(11):1422-5. PMID:7435677
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- White K, Wykoff W, Tynes LL, et al. Fluvoxamine in the treatment of tricyclic-resistant depression. *Psychiatric Journal of the University of Ottawa* 1990;15(3):156-8. PMID:2123039
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Whitehead C, Moss S, Cardno A, et al. Antidepressants for people with both schizophrenia and depression. [Review] [70 refs]. *Cochrane Database of Systematic Reviews* 2002;(2):CD002305 PMID:12076447
Exclude: For systematic review before 2005, OVID-Medline.
- Whitehead C, Moss S, Cardno A, et al. Antidepressants for the treatment of depression in people with schizophrenia: A systematic review. *Psychol Med* 2003;33(4):589-99.
Exclude: For systematic review before 2005, OVID-Embase.
- Whitfield G, Hinshelwood R, Pashely A, et al. The impact of a novel computerized CBT CD Rom (overcoming depression) offered to patients referred to clinical psychology. *Behav Cogn Psychother* 2006;34(1):1-11.
Exclude: For study design, OVID-Embase.
- Whiting M, Leavey G, Scammell A, et al. Using acupuncture to treat depression: a feasibility study. *COMPLEMENT THER MED* 2008;16(2):87-91. PMID:18514910
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Whyte EM, Basinski J, Farhi P, et al. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. *J Clin Psychiatry* 2004;65(12):1634-41. PMID:15641868
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Whyte EM, Mulsant BH. Post stroke depression: Epidemiology, pathophysiology, and biological treatment. *Biol Psychiatry* 2002;52(3):253-64.
Exclude: For systematic review before 2005,
- Wiegand MH, Lauer CJ, Schreiber W. Patterns of response to repeated total sleep deprivations in depression. *J Affect Disord* 2001;64(2-3):257-60. PMID:11313092
Exclude: For study design, OVID-Medline.
- Wiegand MH, Lauer CJ, Schreiber W. Patterns of response to repeated total sleep deprivations in depression. *J Affect Disord* 2001;64(2-3):257-60.
Exclude: For study design, OVID-PsycINFO.
- Wiersma JE, van Schaik DJ, van Oppen P, et al. Treatment of chronically depressed patients: a multisite randomized controlled trial testing the effectiveness of 'Cognitive Behavioral Analysis System of Psychotherapy' (CBASP) for chronic depressions versus usual secondary care. *BMC Psychiatry* 2008;8:18 PMID:18366729
Exclude: For study design, OVID-Medline.
- Wierzbicki M, Bartlett TS. The efficacy of group and individual cognitive therapy for mild depression. *Cogn Ther Res* 1987;11(3):337-42.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Wignall A. Evaluation of a Group CBT Early Intervention Program for Adolescents With Comorbid Depression and Behaviour Problems. *Australian Journal of Guidance & Counselling* 2006;16(1):119-32.
Exclude: For study design, OVID-PsycINFO.
- Wiles NJ, Hollinghurst S, Mason V, et al. A randomized controlled trial of cognitive behavioural

therapy as an adjunct to pharmacotherapy in primary care based patients with treatment resistant depression: A pilot study. *Behav Cogn Psychother* 2008;36(1):21-33.

Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.

Wilhelm K, Niven H, Mitchell P, et al. Actions taken to cope with depression in patients seeking specialist care. *Aust NZ J Psychiatry* 2006;40(3):239-44.

Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.

Wilkie MJ, Smith G, Day RK, et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy.

Pharmacogenomics Journal 2009;9(1):61-70. PMID:18253134

Exclude: For study design, OVID-Medline.

Wilkinson D, Holmes C, Woolford J, et al. Prophylactic therapy with lithium in elderly patients with Unipolar Major Depression. *Int J Geriatr Psychiatry* 2002;17(7):619-22.

Exclude: For population/not failed to respond to an SSRI,

Wilkinson P, Alder N, Juszczak E, et al. A pilot randomised controlled trial of a brief cognitive behavioural group intervention to reduce recurrence rates in late life depression. *Int J Geriatr Psychiatry* 2009;24(1):68-75. PMID:18615497

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Wilkinson PO, Goodyer IM. The effects of cognitive-behavioural therapy on mood-related ruminative response style in depressed adolescents. *Child and Adolescent Psychiatry and Mental Health* 2008;2, 2008. Article Number: 3. Date of Publication: 29 Jan 2008.:

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Wilkinson SM, Love SB, Westcombe AM, et al. Effectiveness of aromatherapy massage in the management of anxiety and depression in patients with cancer: a multicenter randomized controlled trial. *J CLIN ONCOL* 2007;25(5):532-9. PMID:17290062

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Willemsse GRWM, Smit F, Cuijpers P, et al. Minimal-contact psychotherapy for sub-threshold depression in primary care: Randomised trial. *Br J Psychiatry* 2004;185(NOV.):416-21.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Williams CL, Tappen RM. Exercise training for depressed older adults with Alzheimer's disease. *AGING MENT HEALTH* 2008;12(1):72-80. PMID:18297481

Exclude: For population/diagnosis, OVID-Medline.

Williams J, Graham C. Acupuncture for older adults with depression-a pilot study to assess acceptability and feasibility. *Int J Geriatr Psychiatry*

2006;21(6):599-600. PMID:16783799

Exclude: For study design, OVID-Medline.

Williams JW, Jr., Mulrow CD, Chiquette E, et al. Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. *Ann Intern Med* 2000;132(9):743-56.

Exclude: For Guideline published before 2005, EBSCO-CINAHL.

Williams JW, Jr., Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults. *JAMA* 2000;284(12):1519-26. PMID:11000645

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Williams JM, Getty D. Effect of levels of exercise on psychological mood states, physical fitness, and plasma beta-endorphin. *Perceptual and Motor Skills* 1986;63(3):1099-105.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Williams LS, Kroenke K, Bakas T, et al. Care management of poststroke depression: a randomized, controlled trial. *Stroke* (00392499) 2007;38(3):998-1003. PMID:17303771

Exclude: For population/diagnosis, OVID-Medline.

Wilson GL. Psychotherapy with depressed incarcerated felons: a comparative evaluation of treatments. *Psychol Rep* 1990;67(3:Pt 1):t-41 PMID:2287655

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Wilson KC, Scott M, Abou-Saleh M, et al. Long-term effects of cognitive-behavioural therapy and lithium therapy on depression in the elderly. *Br J Psychiatry* 1995;167(5):653-8. PMID:8564323

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Wilson PH. Cognitive-behaviour therapy for depression: Empirical findings and methodological issues in the evaluation of outcome. *Behav Change* 1989;6(2):85-95.

Exclude: For study design, OVID-Embase.

Wilson PH. Combined pharmacological and behavioural treatment of depression. *Beh Res Ther* 1982;20(2):173-84.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase

Wilson PH, Goldin JC, Charbonneau-Powis M. Comparative efficacy of behavioral and cognitive treatments of depression. *Cogn Ther Res* 1983;7(2):111-24.

Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.

Wilz G, Barskova T. Evaluation of a cognitive behavioral group intervention program for spouses of stroke patients. *Beh Res Ther* 2007;45(10):2508-17.

Exclude: For population/not failed to respond to an SSRI, OVID-Embase.

Winkler D, Willeit M, Wolf R, et al. Clonazepam in the long-term treatment of patients with unipolar

- depression, bipolar and schizoaffective disorder. *European Neuropsychopharmacol* 2003;13(2):129-34. PMID:12650958
Exclude: For study design, OVID-Medline.
- Winkler D, Willeit M, Wolf R, et al. Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. *European Neuropsychopharmacol* 2003;13(2):129-34.
Exclude: For study design, OVID-PsycINFO.
- Winningham RG, Anunsen R, Hanson LM, et al. MemAerobics: A Cognitive Intervention to Improve Memory Ability and Reduce Depression in Older Adults. *Prof Psychol Res Pr* 2003;9(3):183-92.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Woelk H, Burkard G, Grunwald J. Benefits and risks of the hypericum extract LI 160: drug monitoring study with 3250 patients. *J Geriatr Psychiatry Neurol*1994;7:Suppl-8 PMID:7857506
Exclude: For study design, OVID-Medline.
- Woelk H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. *BMJ* 2000;321(7260):536-9. PMID:10968813
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Wohlreich MM, Martinez JM, Mallinckrodt CH, et al. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. *J Clin Psychopharm* 2005;25(6):552-60. PMID:16282837
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Medline.
- Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. *Ann Clin Psychiatry* 2005;17(4):259-68. PMID:16402760
Exclude: For study design, OVID-Medline.
- Wolfe HL. Electroacupuncture compared to maprotiline in the treatment of depression. *Townsend Letter for Doctors and Patients* 2003;235-236:168-9.
Exclude: For population/not failed to respond to an SSRI, OVID-AMED.
- Wolkowitz OM, Reus VI. Treatment of depression with antigluco-corticoid drugs. *Psychosom Med* 1999;61(5):698-711.
Exclude: For systematic review before 2005, OVID-Embase.
- Wollersheim JP, Wilson GL. Group treatment of unipolar depression: A comparison of coping, supportive, bibliotherapy, and delayed treatment groups. *Prof Psychol Res Pr* 1991;22(6):496-502.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
- Wong DF. Cognitive and health-related outcomes of group cognitive behavioural treatment for people with depressive symptoms in Hong Kong: randomized wait-list control study. *Aust NZ J Psychiatry* 2008;42(8):702-11. PMID:18622778
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Wong DF. Cognitive behavioral treatment groups for people with chronic depression in Hong Kong: a randomized wait-list control design. *Depress Anxiety* 2008;25(2):142-8. PMID:17340612
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Wong FKD. A six-month follow-up study of cognitive-behavioural treatment groups for Chinese people with depression in Hong Kong. *Behav Change* 2009;26(2):130-40.
Exclude: For study design, OVID-Embase.
- Wood A, Harrington R, Moore A. Controlled trial of a brief cognitive-behavioural intervention in adolescent patients with depressive disorders. *J Child Psychol Psychiatry* 1996;37(6):737-46. PMID:8894955
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Woods SW, Rizzo JA. Cost effectiveness of antidepressant treatment reassessed. *Br J Psychiatry* 1997;170(MAR.):257-63.
Exclude: For study design, OVID-Embase.
- Woody S, McLean PD, Taylor S, et al. Treatment of major depression in the context of panic disorder. *J Affect Disord* 1999;53(2):163-74. PMID:10360411
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Woolery A, Myers H, Sternlieb B, et al. A yoga intervention for young adults with elevated symptoms of depression. *Altern Ther Health Med* 2004;10(2):60-3. **Exclude:** For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Worthington JJ, III, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. *Int Clin Psychopharmacol* 2005;20(1):9-11. PMID:15602109
Exclude: For study design, OVID-Medline.
- Wright JH, Wright AS, Albano AM, et al. Computer-assisted cognitive therapy for depression: maintaining efficacy while reducing therapist time. *Am J Psychiatry* 2005;162(6):1158-64. PMID:15930065
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Wu HS, Lin LC, Wu SC, et al. The psychologic consequences of chronic dyspnea in chronic pulmonary obstruction disease: the effects of acupuncture on depression. *J Altern Complement Med* 2007;13(2):253-61. PMID:17388769
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Wuerth D, Finkelstein SH, Finkelstein FO. The identification and treatment of depression in patients maintained on dialysis. *Seminars in Dialysis* 2005;18(2):142-6. PMID:15771659
Exclude: For study design, OVID-Medline.
- Xia Q, Wang J, Zheng K. Rehabilitative therapy for the elderly chronic somatic disease complicated with depression. *Chinese J Clin Rehabil* 2006;10(14):166-

8.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
 Yamada K, Yagi G, Kanba S. Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial. *Psychiatry & Clinical Neurosciences* 2003;57(2):183-7. PMID:12667165
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
 Yamada K, Yagi G, Kanba S. Effectiveness of herbal medicine (Rokumigan and Hachimijiogan) for fatigue or loss of energy in patients with partial remitted major depressive disorder. *Psychiatry & Clinical Neurosciences* 2005;59(5):610-2. PMID:16194267
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
 Yamada N, Martin-Iverson MT, Daimon K, et al. Clinical and chronobiological effects of light therapy on nonseasonal affective disorders. *Biol Psychiatry* 1995;37(12):866-73. PMID:7548461
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
 Yang TT, Hsiao FH, Wang KC, et al. The effect of psychotherapy added to pharmacotherapy on cortisol responses in outpatients with major depressive disorder. *J Nerv Ment Dis* 2009;197(6):401-6. PMID:19525739
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
 Yang X, Liu X, Luo H, et al. Clinical observation on needling extrachannel points in treating mental depression. *J Tradit Chin Med* 1994;14(1):14-8. PMID:8196410
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
 Yargic LI, Corapcioglu A, Kocabasoglu N, et al. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. *Int J Psychiatry Clin Pract* 2004;8(4):205-11.
Exclude: For population/not failed to respond to an SSRI, OVID-PsycINFO.
 Yasmin, S. Adjunctive Gabapentin in Treatment Resistant Depression: A retrospective chart review. Carpenter, L. L., Leon, Z, Siniscalchi, J. M., and Price, L. H. *J Affect Disord* 2001;63:243-7. 2001.
Exclude: For study design,
 Yazicioglu B, Akkaya C, Sarandol A, et al. A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: a randomized, open-labeled clinical trial. *Prog Neuropsychopharmacol Biol Psychiatry* 2006;30(7):1271-6. PMID:16820257
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
 Yerevanian BI, Anderson JL, Grota LJ, et al. Effects of bright incandescent light on seasonal and nonseasonal major depressive disorder. *Psychiatry* Res 1986;18(4):355-64. PMID:3749392
Exclude: For study design, OVID-Medline.
 Yoshimura R, Umene-Nakano W, Ueda N, et al. Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline. *Hum Psychopharmacol* 2008;23(8):707-13. PMID:18803170
Exclude: For study design, OVID-Medline.
 Yoshino A, Sawamura T, Kobayashi N, et al. Algorithm-guided treatment versus treatment as usual for major depression: Regular Article. *Psychiatry and Clinical Neurosciences* 2009;63(5):652-7.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.
 Young JP, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. *BMJ* 1979;2(6201):1315-7.
Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.
 Yuan R, Peng Q, Liao Q, et al. Efficacy of hormone replacement plus antidepressant for anxiety and depression in patients with menopause syndrome. *Chinese Journal of Clinical Rehabilitation* 2006;10(2):162-3.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
 Yury, C.A. Analysis of empirical research on augmentation strategies for unipolar depression Yury. 2009
Exclude: For study design, OVID-PsycINFO.
 Yyldyz A, Sachs GS. Administration of antidepressants. Single versus split dosing: a meta-analysis. *J Affect Disord* 2001;66(2-3):199-206. PMID:11578673
Exclude: For systematic review before 2005, OVID-Medline.
 Zajecka JM, Jeffriess H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: A retrospective analysis. *J Clin Psychiatry* 1995;56(8):338-43.
Exclude: For study design, OVID-Embase.
 Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. *European Neuropsychopharmacol* 2006;16(4):281-7. PMID:16316746
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
 Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? *J Clin Psychopharm* 1997;17(6):446-50. PMID:9408806
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
 Zanardi R, Rossini D, Magri L, et al. Response to SSRIs and role of the hormonal therapy in post-menopausal depression. *European*

- Neuropsychopharmacol 2007;17(6-7):400-5. PMID:17196795
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Zaninelli R, Bauer M, Jobert M, et al. Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline. J Clin Psychopharm 2001;21(2):190-8. PMID:11270916
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Zaninelli R, Meister W. The treatment of depression with paroxetine in psychiatric practice in Germany: the possibilities and current limitations of drug monitoring. Pharmacopsychiatry 1997;30(1:Suppl):Suppl-20 PMID:9035223
Exclude: For study design, OVID-Medline.
- Zapletalek M, Zbytovsky J, Kudrma K. Clinical experience with maprotilin and maprotilin/clomipramine infusions in resistant depression. Act Nerv Super 1982;24(2):73-6. PMID:7102227
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Zarate CA, Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-64. PMID:16894061
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Zarate CA, Jr., Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161(1):171-4. PMID:14702270
Exclude: For study design, OVID-Medline.
- Zarate CA, Kando JC, Tohen M, et al. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996;57(2):67-71.
Exclude: For study design, OVID-PsycINFO.
- Zarate J, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63(8):856-64.
Exclude: For Mixed antidepressants; some failed on SSRI, OVID-Embase.
- Zarate J, Payne JL, Quiroz J, et al. An Open-Label Trial of Riluzole in Patients with Treatment-Resistant Major Depression. Am J Psychiatry 2004;161(1):171-4.
Exclude: For study design, OVID-Embase.
- Zarate J, Kando JC, Tohen M, et al. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996;57(2):67-71.
Exclude: For study design, OVID-Embase.
- Zautra AJ, Davis MC, Reich JW, et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J Consult Clin Psychol 2008;76(3):408-21. PMID:18540734
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Zerhusen JD, Boyle K, Wilson W. Out of the darkness: group cognitive therapy for depressed elderly. J Psychosoc Nurs Ment Health Serv 1991;29(9):16-21. PMID:1941727
Exclude: For population/not failed to respond to an SSRI, OVID-Medline.
- Zerka Yoo, C. Hapkido vs. yoga: Analysis of choice, persistence and psychological benefits Zerka Yoo. 2008
Exclude: For study design, OVID-PsycINFO.
- Zettle RD, Herring EL. Treatment utility of the sociotropy/autonomy distinction: Implications for cognitive therapy. J Clin Psych 1995;51(2):280-9.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Zhang C. The brain-resuscitation acupuncture method for treatment of post wind-stroke mental depression--a report of 45 cases. J Tradit Chin Med 2005;25(4):243-6. PMID:16447661
Exclude: For population/diagnosis, OVID-Medline.
- Zhang G-J, Shi Z-Y, Liu S, et al. Clinical observation on treatment of depression by electro-acupuncture combined with paroxetine. Chin J Integr Med 2007;13(3):228-30.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Zhang W, Yang X, Zhong B. Combination of acupuncture and fluoxetine for depression: a randomized, double-blind, sham-controlled trial. J Altern Complement Med 2009;15(8):837-44.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Zhang Z-J, Kang W-H, Li Q, et al. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: Double-blind, placebo-controlled studies. J Psychiatr Res 2007;41(10):828-36.
Exclude: For population/not failed to respond to an SSRI, OVID-Embase.
- Zhao L, Gan A. Clinical and psychological assessment on Xinwei decoction for treating functional dyspepsia accompanied with depression and anxiety. AM J CHINESE MED 2005;33(2):249-57.
Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.
- Zimmer B, Rosen J, Thornton JE, et al. Adjunctive lithium carbonate in nortriptyline-resistant elderly depressed patients. J Clin Psychopharm 1991;11(4):254-6. PMID:1918424
Exclude: For study design, OVID-Medline.
- Zisook S, Peterkin J, Goggin KJ, et al. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 1998;59(5):217-24. PMID:9632030

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Zmilacher K, Battegay R, Gastpar M. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. *Neuropsychobiol* 1988;20(1):28-35. PMID:3265988

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Zohar J, Drummer D, Edelstein ED, et al. Effect of lysine vasopressin in depressed patients on mood and 24-hour rhythm of growth hormone, cortisol, melatonin and prolactin. *Psychoneuroendocrinol* 1985;10(3):273-9. PMID:3903821

Exclude: For population/not failed to respond to an SSRI, OVID-Medline.

Zubenko GS, Mulsant BH, Rifai AH, et al. Impact of acute psychiatric inpatient treatment on major depression in late life and prediction of response. *Am J Psychiatry* 1994;151(7):987-94.

Exclude: For study design, OVID-PsycINFO.

Zusky PM, Biederman J, Rosenbaum JF, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. *J Clin Psychopharm* 1988;8(2):120-4.

Exclude: For population/not failed to respond to an SSRI, Wiley-CCTR.

Zust BL. Effect of cognitive therapy on depression in rural, battered women. *Arch Psychiatr Nurs* 2000;14(2):51-63.

Exclude: For population/not failed to respond to an SSRI, EBSCO-CINAHL.